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Multiple	  sclerosis	  (MS)	  affects	  around	  2.5	  million	  people	  worldwide,	  making	  it	  one	  of	  the	  
most	   common	   neurological	   conditions	   in	   young	   adults.	   	   Experimental	   autoimmune	  
encephalomyelitis	  (EAE)	  has	  been	  the	  standard	  animal	  model	  for	  MS	  where	  antigens	  are	  
introduced	  alongside	  powerful	  T	  cell	  polarising	  adjuvants	  to	  induce	  disease.	  	  This	  general	  
protocol	  has	  been	  both	  helpful	  and	  sometimes	  limiting	  in	  modelling	  T	  cell	  events	  as	  the	  
immune	  adjuvants	  make	  interpretation	  of	  mechanism	  more	  difficult.	  There	  is	  a	  need	  for	  
more	   relevant	   mouse	   models	   lacking	   the	   inherent	   biases	   of	   immune	   adjuvants	   and	  
providing	  a	  human	  context	  for	  disease	  initiation	  and	  progression.	  	  For	  this	  thesis,	  I	  have	  
characterized	   the	   disease	   and	   cellular	   dynamics	   in	   a	   humanized,	   T	   cell	   receptor	   (TCR)	  
transgenic	   mouse	   model,	   termed	   Line7.	   	   The	   mice	   develop	   spontaneous,	   ascending	  
paralysis.	   	   T	   cell	   responses	   defined	   in	   these	   transgenics	   have	   direct	   relevance	   to	   the	  
human	   setting	   since	   they	   are	   by	   definition	   HLA-­‐DR15	   restricted	   and	   are	   allowed	   to	  
progress	  without	  interference	  from	  modifying	  adjuvants.	  	  I	  have	  focused	  on	  the	  dynamics	  
of	  Th1	  and	  Th17	  cells	  in	  both	  the	  initiation	  and	  progressive	  phase	  of	  disease	  and	  the	  role	  
that	   regulatory	   T	   cells	   play	   in	   affecting	   this	   balance.	   	   Initial	   observation	   of	   naturally	  
progressing	   disease	   showed	   that	   in	   this	   model	   IFNγ+	   cells	   dominate	   through	   disease	  
initiation	   and	   IL-­‐17+	   cells	   are	   only	   observed	   in	   the	   affected	   tissue	   once	   disease	   is	  
established.	   	   The	   cytokine	   milieu	   favours	   Treg	   differentiation	   over	   Th17	   cells	   and	  
regulatory	  T	  cells	  accumulate	   in	  the	  central	  nervous	  system	  (CNS)	  but	  are	   ineffective	  at	  
halting	   progression	   or	   initiating	   recovery.	   	   Through	   removal	   of	   the	   Tregs,	   severe	  





the	  CNS.	  	  IFNγ	  production	  by	  CD4	  and	  CD8	  cells	  is	  upregulated	  at	  the	  expense	  of	  IL-­‐17	  but	  
reconstitution	  of	   the	  Treg	  population	  halts	  disease	  progression,	   illustrating	   the	   roles	  of	  
Tregs	   in	   regulating	  autoreactive	  T	  cell	  activity	  and	  controlling	  cellular	   infiltration	  across	  
immunological	  barriers.	  	  Therefore	  the	  use	  of	  this	  model,	  without	  the	  introduced	  biases	  
of	  immune	  adjuvants,	  has	  highlighted	  the	  importance	  of	  the	  Th1/Treg	  balance	  in	  disease	  
initiation	   over	   Th17	   cells	   whilst	   underlining	   the	   critical	   role	   for	   Tregs	   in	   preventing	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  Single-­‐Stranded	  RNA	  Oligonucleotide	  
STAT	   Signal	  Transducers	  and	  Activators	  of	  Transcription	  
TBE	   Tris/Borate/EDTA	  
T-­‐BET	   T-­‐box	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8 Introduction	  	  
8.1 Multiple	  sclerosis	  
8.1.1 Clinical	  Presentation	  
Multiple	  sclerosis	   (MS)	   is	   the	  most	  common	  neurological	  condition	   in	  young	  adults	  and	  
one	  of	  the	  many	  diseases	  lacking	  a	  clear	  causative	  agent	  or	  mechanism.	  	  At	  present,	  it	  is	  
thought	  to	  be	  an	  autoimmune	  disease	  triggered	  in	  susceptible	  individuals	  by	  some	  form	  
of	  environmental	  interaction	  which	  leads	  to	  an	  autoimmune	  attack	  on	  the	  myelin	  sheath	  
and	   consequently,	   damage	   to	   central	   nervous	   system	   (CNS)	   axons	   (Compston	   2002).	  	  
Many	  factors	  have	  been	  thought	  to	  contribute	  to	  disease	  initiation	  and	  progression	  but	  
none	  have	  been	  shown	  to	  be	  solely	  responsible.	  	  There	  is	  even	  debate	  as	  to	  whether	  MS	  
is	   one	   condition	   or	   rather	   a	   collective	   syndrome,	   as	   there	   is	   a	   great	   deal	   of	   clinical	  
heterogeneity	  (Lucchinetti	  2000).	  	  This	  would	  impact	  greatly	  on	  selection	  and	  assessment	  
of	  therapies	  as	  some	  may	  be	  effective	  in	  a	  subset	  of	  patients	  but	  not	  in	  others.	  	  	  
The	  characteristic	  pathology	  of	  MS	  is	  the	  presence	  of	  many	  large	  demarcated	  lesions	  or	  
plaques	   throughout	   the	   CNS	   white	   matter	   and	   these	   tend	   to	   be	   located	   within	   the	  
periventricular	  regions,	  optic	  nerve,	  brain	  stem	  and	  spinal	  cord.	  	  Around	  10	  years	  ago	  an	  
attempt	  was	  made	  to	  classify	  the	  pathology	  of	  MS	  lesions	  into	  4	  categories	  based	  on	  the	  
severity	   of	   tissue	   injury,	   extent	   of	   demyelination	   and	   inflammation	   (Lucchinetti	   2000).	  	  
Pattern	   I	   and	   II	   lesions	   were	   described	   as	   presenting	   with	   perivascular	   myelin	   loss,	  
infiltration	  of	  lymphoid	  cells	  but	  relative	  sparing	  of	  oligodendrocytes.	  	  Patterns	  III	  and	  IV	  
involve	   oligodendrocyte	   cell	   death	   either	   as	   a	   result	   of	   apoptosis	   (III)	   or	   necrosis	   (IV)	  





formed	  though	  only	  one	  mechanism	  in	  each	  patient.	  	  However	  this	  has	  been	  shown	  to	  be	  
inaccurate	   and	   rather	   a	   homogeneous	   pattern	   of	   demyelination	   occurs	   in	   all	   patients	  
with	  established	  disease.	  	  This	  demyelination	  forms	  pattern	  II	  lesions	  and	  the	  formation	  
of	  other	  lesion	  patterns	  is	  very	  rarely	  seen	  (Breij	  2008).	  	  	  	  	  
While	   inter-­‐individual	   variation	   in	   clinical	   presentation	   is	   substantial,	   there	   are	   three	  
general,	  clinical	  forms	  often	  used	  to	  classify	  MS,	  varying	  in	  the	  pattern	  of	  symptoms	  and	  
time	   course.	   	   The	   most	   severe	   is	   primary	   progressive	   (PP)	   where	   disease	   severity	  
increases	  unabated	  and	  results	  in	  extensive	  neuronal	  disability	  without	  clear	  attacks.	  	  The	  
most	  common	  in	  around	  85%	  of	  cases	  is	  relapsing-­‐remitting	  (RR)	  where	  periodic	  episodes	  
of	   disease	   are	   broken	   by	   periods	   of	   recovery.	   	   This	   can	   develop	   into	   secondary	  
progressive	  (SP)	  disease	  where	  there	  is	  further	  neuronal	  degeneration	  and	  no	  period	  of	  
remission	   between	   relapses.	   	   Symptoms	   of	   MS	   are	   wide	   ranging,	   representing	   the	  
integral	   role	   the	   CNS	   plays	   in	   controlling	   all	   aspects	   of	   the	   human	   body.	   	   Muscular	  
weakness	   and/or	   control	   of	  movement,	   visual	   and	   speech	   problems,	   acute	   or	   chronic	  
pain	   syndromes	   and	   other	   cognitive	   impairment	   are	   some	   potential	   symptoms	   but	  
diagnosis	   is	   very	  difficult,	   particularly	   during	   the	  early	   stages	  of	   disease.	   	   RR	  disease	   is	  
especially	  hard	  to	  diagnose	  as	  MS	  given	  the	  period	  of	  time	  between	  relapses	  and	  early	  
attacks	  are	  often	  diagnosed	  in	  hindsight	  (McFarland	  2007).	  	  	  
A	  major	  factor	  in	  determining	  the	  long-­‐term	  disability	  of	  a	  patient	  is	  the	  degree	  of	  axonal	  
loss.	   	   The	   use	   of	   magnetic	   resonance	   imaging	   (MRI)	   as	   a	   diagnostic	   tool	   has	   greatly	  
improved	   our	   understanding	   and	   recognition	   of	   this	   disease.	   	   MRI	   has	   allowed	  
longitudinal	  studies	  of	  RR-­‐MS	  patients	  and	  has	  highlighted	  the	  importance	  of	  permanent	  





and	   as	   a	   positive	   correlate	   for	   subsequent	   disability	   (Rudick	   1999,	   Fisher	   2002).	   	   MRI	  
studies	   on	   progressive	   patients	   have	   not	   been	   able	   to	   place	   demyelination	   as	   primary	  
before	  neuronal	  damage	  (Rudick	  1999,	  Miller	  2002).	  	  The	  improvement	  of	  MRI	  to	  image	  
metabolites	  (MRSI)	  has	  highlighted	  some	  early	  checkpoints	   in	  neuronal	   loss	  such	  as	  the	  
reduction	   of	   the	   glutamate	  metabolite	  N-­‐actetyl	   aspartate	   (NAA).	   	   This	   is	   indicative	   of	  
neuronal	  damage	  and	  it	  seems	  that	  a	  non-­‐reversible	  NAA	  reduction	  in	  the	  white	  matter	  
lesions	  occurs	  (De	  Stefano	  1999)	  highlighting	  axonal	  loss	  and	  which	  could	  act	  as	  an	  early	  
diagnostic	  tool.	  	  As	  it	  happens	  early	  in	  disease,	  and	  before	  overt	  lesions	  can	  be	  observed,	  
it	  indicates	  that	  axonal	  loss	  is	  not	  necessarily	  a	  consequence	  of	  demyelination	  but	  could	  
be	  a	  result	  of	  a	  separate	  immune	  attack.	  	  Indeed	  axonal	  pathology	  is	  seen	  in	  both	  normal	  
appearing	   white	   matter	   and	   demyelinated	   lesions	   (Arnold	   1992,	   Narayanan	   1997,	   De	  
Stefano	  1998).	   	  Observation	  of	  precursor	  proteins	  characteristic	  of	  axonal	   loss	   in	  active	  
inflammatory	  lesions	  of	  early	  biopsy	  material	  from	  MS	  patients	  (Kuhlmann	  2002)	  support	  
the	   use	   of	  metabolites	   as	   early	   checkpoints	   and	  may	   pave	   the	  way	   for	  more	   accurate	  
early	  diagnostic	  tools	  before	  lesions	  can	  be	  seen	  on	  MRI.	  	  	  	  
The	  different	  types	  of	  MS	  seem	  to	  also	  present	  different	  CNS	  pathology.	  	  In	  early	  disease	  
there	  are	   low	  degrees	  of	  cortical	  demyelination,	   this	  only	  becoming	  prominent	  at	   later	  
stages	  of	  disease	  (Kutzelnigg	  2005).	  	  The	  progressive	  stages	  of	  the	  disease,	  both	  primary	  
and	  secondary	  show	  few	  classic	  active	  plaque	  white-­‐matter	  lesions	  and	  a	  dominance	  for	  
diffuse	   inflammation	   and	   extensive	   cortical	   demyelination	   (Koyanagi	   1993,	   Bo	   2003,	  
Kutzelnigg	  2005).	  	  Increased	  numbers	  of	  Na+	  channels	  and	  reduced	  ATP	  production	  along	  
demyelinated	  axons	   in	  MS	   lesions	   (Craner	  2004,	  Mahad	  2009)	   indicate	   that	   the	   loss	  of	  





findings,	  it	  has	  also	  been	  shown	  that	  inhibition	  of	  remyelination	  in	  an	  animal	  model	  leads	  
to	   increased	   axonal	   degeneration	   (Irvine	   2008).	   	   The	   degree	   of	   axon	   and	   neuronal	  
degeneration	  has	  been	  shown	  in	  MS	  patients	  to	  be	  linked	  to	  the	  numbers	  of	  activated	  T	  
cells	   and	   macrophages/microglia	   (Ferguson	   1997,	   Kuhlmann	   2002)	   which	   both	   are	  
thought	   to	  be	  directly	   involved	   in	  mediating	  neuronal	  damage.	   	  The	   roles	  of	   these	  and	  
other	  immune	  cells	  in	  the	  pathogenesis	  of	  MS	  will	  be	  introduced	  in	  a	  later	  section.	  
	  
8.1.2 	  Genetic	  and	  Environmental	  Influence	  
The	  mean	  age	  of	  onset	  is	  approximately	  30	  years	  of	  age	  and	  there	  is	  a	  clear	  gender	  bias	  
of	   the	   condition,	   with	   females	   being	  more	   frequently	   affected	   than	  males	   (Compston	  
2002).	  	  There	  is	  a	  clear	  genetic	  link	  of	  MS	  as	  the	  concordance	  rate	  in	  monozygotic	  twins	  is	  
around	  30%	  compared	  to	  less	  than	  5%	  in	  dizygotic	  twins	  (Ebers	  1986,	  Dyment	  2004a)	  and	  
the	   incidence	  of	  disease	   in	   first-­‐degree	  relatives	   is	   reported	  to	  be	  20	  times	  higher	  than	  
the	   general	   population	   (Dyment	   2004b).	   	   An	   association	   with	   the	   major	  
histocompatibility	  complex	  (MHC)	  region	  of	  the	  genome	  was	  first	  shown	  almost	  30	  years	  
ago	   (Jersild	   1972)	   and	   has	   been	   since	   focused	   by	   genome	   wide	   association	   studies	  
(GWAS)	   to	   show	   a	   link	   between	   the	   HLA-­‐DRB1*15:01-­‐B5*01:01	   (originally	   called	   DR2)	  
and	  HLA-­‐DQA1*01:02-­‐B1*06:02	  haplotype	  and	  MS	  (Dyment	  2004a,	  Hafler	  2007).	  	  Several	  
GWAS	   have	   been	   carried	   out	   to	   identify	   susceptibility	   loci	   for	  many	   complex	   diseases,	  
including	  MS.	  	  They	  utilise	  chip-­‐based	  technology	  to	  efficiently	  genotype	  several	  hundred	  
thousand	   single	   nucleotide	   polymorphisms	   (SNPs)	   throughout	   the	   genome	  





DRB1*15:01	  but	  have	  also	   identified	  16	  non-­‐HLA	   loci	  with	  genome	  wide	  significance	  as	  
MS	  risk	  factors	  (Kemppinen	  2011).	  	  	  
The	   first	   published	  MS	   related	  GWAS	  used	   trios	   (affected	   individual	   and	  both	  parents)	  
from	  the	  UK	  and	  USA,	  and	  reported	  an	  association	  with	  a	  non-­‐synonymous	  coding	  SNP	  in	  
the	   IL7RA	  gene	  and	  2	  SNPs	  in	  intron	  2	  of	  the	   IL2RA	   (CD25)	  gene	  (Dyment	  2004a,	  Hafler	  
2007).	   	   Both	   of	   these	   associations	   have	   been	   confirmed	   by	   candidate	   gene	   studies	  
(Gregory	  2007,	  Lundmark	  2007,	  Rubio	  2008,	  Weber	  2008,	  Akkad	  2009,	  Perera	  2009)	  and	  
due	  to	  their	  important	  roles	  in	  the	  life-­‐cycle	  of	  a	  T	  cell	  and	  function,	  their	  association	  re-­‐
affirms	   the	   importance	   of	   the	   T	   cell	   in	   MS	   disease.	   	   As	   an	   extension,	   the	   proximal	  
promoter	  of	  the	  IL7RA	  gene	  has	  been	  shown	  to	  include	  interferon	  beta	  (IFN-­‐β)	  response	  
elements	   and	   so	   is	   thought	   to	  have	  a	   role	   in	  patients’	   responses	   to	   therapy	  as	  well	   as	  
individual	  immune	  responses	  (Cunningham	  2005).	  	  	  
The	  original	  GWAS	  also	   found	  associations	   for	  a	  SNP	   in	   intron	  19	  of	  CLEC16A,	   a	  C-­‐type	  
lectin,	   and	   a	   SNP	   in	   CD58	   (Hafler	   2007).	   	   The	   association	   of	   CLEC16A	   was	   confirmed	  
through	  a	   replication	   cohort	   (IMSGC	  2009),	  within	   Sardinian	  populations	   (Zoledziewska	  
2009)	  showing	  the	  same	  SNP	  association,	  from	  a	  meta-­‐analysis	  (Hoppenbrouwers	  2009)	  
and	  in	  an	  African-­‐American	  population	  (Johnson	  2010).	  	  CD58	  has	  shown	  both	  protective	  
(De	  Jager	  2009b)	  and	  susceptibility	  (Hafler	  2007)	  associations	  with	  different	  SNPs.	  	  CD58	  
is	  involved	  in	  co-­‐stimulation	  of	  T	  cells	  and	  CD58	  mRNA	  is	  elevated	  in	  MS	  patients	  during	  
remission	  (De	  Jager	  2009a)	  suggesting	  a	  protective	  role	  although	  an	  association	  from	  an	  
Australian	  GWAS	  and	  in	  a	  recent	  meta-­‐analysis	  reaffirmed	  its	  role	  as	  a	  risk	  gene	  for	  MS	  
(ANZgene	   2009,	   Hoppenbrouwers	   2009).	   	   However,	   for	   CD58	   unlike	   CLEC16A,	   no	  





Other	  non-­‐HLA	  genes	  implicated	  in	  MS	  from	  GWAS	  include	  TYK2	  (Ban	  2009,	  Mero	  2010),	  
MMEL1	  (ANZgene	  2009,	  Ban	  2010),	  CD6,	  IRF8	  and	  TNFRSF1A	  (De	  Jager	  2009b)	  and	  CD40	  
(ANZgene	  2009)	  whilst	  follow-­‐up	  studies	  on	  the	  original	  GWAS	  identified	  the	  TMEM39A	  
and	  KIF21B	  genes	  as	  having	  risk	  variants	  for	  MS	  (IMSGC	  2010).	  	  Interestingly,	  associations	  
with	   IL12A,	  MPHOSPH9,	   RGS1	   and	   STAT3	   have	   also	   been	   confirmed	   recently	   (IMSGC	  
2010,	  Jakkula	  2010)	  providing	  a	  direct	  link	  to	  T	  helper	  cell	  involvement	  in	  MS.	  
These	  genes	  and	  all	  others	  found	  in	  this	  manner	  confer	  very	  small	  increased	  risk	  of	  MS	  as	  
measured	  by	  odds	  ratios	  (<1.4)	  (Kemppinen	  2011)	  suggesting	  that	  the	  genetic	  model	  of	  
MS	   could	   be	   polygenic,	   as	   suggested	   originally	   by	   Fisher	   (Fisher	   1918).	   	   In	   this,	   a	  
combination	  of	   risk	   allele	   variants	  will	   all	   exert	  weak	  effects	   and	   their	   interaction	  with	  
the	   environment	   could	   provide	   an	   additional	   tipping	   point	   for	   development	   of	   MS.	  	  
Further	  genetic	  and	  functional	  analysis	  should	  be	  carried	  out	  in	  co-­‐ordination	  with	  GWAS	  
to	   help	   provide	   a	  much	  more	   detailed	   picture	   of	   genetic	   pre-­‐disposition	   and	   risk	   and	  
understand	  the	  relevance	  of	  the	  highlighted	  pathways	  in	  disease	  pathology.	  	  	  
	  	  
In	  conjunction	  with	  the	  genetic	  risk,	  environmental	  factors	  impact	  on	  both	  susceptibility	  
and	   progression	   of	   MS.	   	   Latitude	   is	   the	   factor	   most	   strongly	   associated	   with	   MS	   risk	  
represented	  by	  higher	  frequencies	  of	  MS	  in	  countries	  at	  higher	  latitudes	  and	  in	  patients	  
with	   west	   European	   ancestry	   (Ebers	   1993).	   	   In	   New	   Zealand	   the	   first	   admission	   to	  
hospital	   for	  MS	   on	   the	   south	   island	  was	  much	   higher	   than	   on	   the	   north	   island	   (Skegg	  
1987,	  Fawcett	  1988),	  and	  a	  similar	  pattern	  was	  seen	  in	  Europe	  and	  North	  America	  (Ebers	  
1993)	   representing	   the	   association	   of	   MS	   with	   latitude.	   	   The	   Viking	   theory	   has	   been	  





Scandinavian	  genes	  initially	  by	  the	  Vikings	  and	  then	  by	  further	  migration	  (Poser	  1995)	  but	  
twin	   concordance	   rates	   also	   differ	   by	   latitude	   of	   birth	   suggesting	   important	  
environmental	  effects	  also	  determine	  MS	   risk	   (Islam	  2006).	   	   Levels	  of	   sunlight	   follow	  a	  
pattern	  similar	  to	  MS	  and	  so	  have	  implicated	  vitamin	  D	  levels	  to	  be	  a	  key	  environmental	  
factor	  (Goldberg	  1986).	  	  High	  serum	  levels	  of	  the	  Vitamin	  D	  precursor	  2,5-­‐hydroxyvitamin	  
D	   have	   been	   shown	   to	   be	   protective	   against	  MS	   (Munger	   2006)	   and	   Vitamin	   D	   levels	  
during	   pregnancy	   are	   thought	   to	   affect	   likelihood	   of	  MS	   as	   babies	   born	   in	  May	   in	   the	  
Northern	  Hemisphere	  are	  more	  susceptible	  than	  those	  born	  in	  November,	  reflecting	  the	  
exposure	  to	  sunlight	  during	  pregnancy	  (Willer	  2005).	  	  	  
Vitamin	  D	   levels	  throughout	   life,	  both	   in	  childhood	  and	  adulthood	  may	  be	   important	   in	  
mediating	  the	  risk	  of	  MS	  but	  the	  difficulty	  in	  excluding	  reverse	  causation	  and	  correcting	  
for	  recall	  bias	  in	  studies	  makes	  any	  conclusions	  very	  difficult	  to	  prove.	  	  Equally,	  Vitamin	  D	  
is	  not	  solely	  derived	   from	  sunlight	  and	  dietary	   intake	  will	   influence	  serum	   levels.	   	  Both	  
provide	   similar	   immunomodulatory	   effects	   (Munger	   2006,	   Smolders	   2008),	   increasing	  
the	   difficulty	   of	   control	  within	   studies.	   	  Modern	   advances	   in	   sun	   cream	   and	   increased	  
ability	   to	   travel	   throughout	   the	  world	   could	   average	   out	   regional	   differences,	  masking	  
the	  more	  subtle	  regional	  differences	  but	  the	  identification	  of	  a	  vitamin	  D	  binding	  element	  
in	   the	   promoter	   of	   the	   HLA-­‐DRB1*15:01	   gene	   adds	   support	   to	   the	   hypothesis	   that	  
vitamin	  D	  levels	  affect	  MS	  susceptibility	  and	  progression	  (Ramagopalan	  2009a).	  
The	   intrauterine	   environment	   has	   also	   been	   implicated	   from	   both	   the	  month	   of	   birth	  
observations	  and	  also	  from	  concordance	  rates	  between	  full	  siblings	  and	  dizygotic	  twins	  in	  





concordance	  in	  dizygotic	  twins	  (5.4%	  compared	  to	  2.9%)	  and	  concordant	  dizygotic	  twins	  
tend	  to	  develop	  MS	  at	  the	  same	  age	  (Bulman	  1991,	  Willer	  2003).	  	  	  
These	  results	  add	  weight	  to	  the	  importance	  of	  environmental	  factors	  over	  genetics	  and	  
indeed	   migration	   of	   individuals	   from	   high-­‐risk	   to	   low-­‐risk	   areas	   has	   been	   shown	   to	  
provide	  some	  protection	  from	  acquiring	  MS	  (Kurtzke	  1993),	  although	  the	  critical	  age	  for	  
this	  migration	  however	  is	  unknown.	  	  Studies	  have	  ranged	  from	  suggesting	  that	  migration	  
must	   be	   before	   the	   age	   of	   15	   (Dean	   1997)	   to	   those	   that	   suggest	   it	   may	   extend	   into	  
adulthood,	  as	  far	  as	  the	  third	  decade	  of	  life	  (Hammond	  2000).	  	  More	  general	  studies	  have	  
shown	  that	  the	  MS	  rate	  among	  genetically	  comparable	  UK	  migrants	  to	  Tasmania	  or	  the	  
south	  island	  of	  New	  Zealand	  resemble	  those	  remaining	  in	  the	  UK	  whereas	  they	  are	  five	  to	  
six-­‐fold	   lower	   in	   Queensland	   or	   the	   Northern	   Territory	   (Pugliatti	   2002),	   further	  
emphasizing	  the	  importance	  of	  environmental	  factors.	  	  	  	  
Alongside	  latitude,	  Epstein-­‐Barr	  Virus	  (EBV)	  seropositivity	  is	  also	  strongly	  associated	  with	  
MS	   risk.	   	   Almost	   all	   MS	   patients	   are	   EBV	   seropositive	   compared	   to	   a	   rate	   of	   90%	   of	  
healthy	  people	  (Ascherio	  2007),	  both	  implicating	  EBV	  as	  important	  to	  MS	  progression	  but	  
also	  demonstrating	  that	  it	  is	  not	  solely	  responsible.	  	  Individuals	  developing	  EBV-­‐induced	  
infectious	   mononucleosis	   have	   a	   higher	   risk	   of	   MS	   (Goldacre	   2004,	   Sundstrom	   2004,	  
Ramagopalan	  2009b),	  and	  those	  developing	  adult-­‐onset	  MS	  have	  elevated	  levels	  of	  EBV	  
antibodies	  is	  early	  adult	  life	  (Levin	  2005,	  DeLorenze	  2006)	  suggesting	  a	  pre-­‐disposing	  role	  
of	   infection.	   	   Viral	   infections,	   more	   specifically	   of	   the	   respiratory	   tract,	   have	   been	  
associated	   with	   triggering	   relapses	   and	   new-­‐onset	   MS	   in	   adulthood	   (Sibley	   1985,	  
Edwards	   1998,	   Marrie	   2000,	   Kriesel	   2005),	   and	   high	   EBV	   antibody	   titres	   can	   act	  





be	   however	   too	   far	   to	   say	   that	   EBV	   infection	   is	   a	   step	   in	  MS	  development,	   despite	   its	  
candidacy	  as	  a	  risk	  factor.	  	  	  
Other	  environmental	   risk	   factors	   considered	   important	   include	   smoking.	   	  Many	   studies	  
have	   shown	   an	   association	   between	   smoking	   and	   MS,	   independent	   of	   latitude	   and	  
ancestry,	  with	  preliminary	  studies	  suggesting	  causality	  although	  not	  fully	  confirmed	  (De	  
Jager	  2008).	  	  After	  clinically	  isolated	  syndrome	  (CIS),	  the	  risk	  of	  developing	  definite	  MS	  is	  
increased	   if	   the	   patient	   is	   a	   smoker	   and	   the	   likelihood	   of	   developing	   secondary	  
progressive	   MS	   from	   relapsing-­‐remitting	   also	   increases	   (Hernan	   2005,	   Di	   Pauli	   2008,	  
Healy	  2009).	  	  	  	  
	  	  	  
8.1.3 Therapies	  
The	   lack	  of	   a	   clear	  mechanism	  of	  MS	  pathology,	   the	  differing	   clinical	   varieties	   and	   the	  
challenge	   in	   targeting	   the	   drug	   to	   the	   correct	   location,	   has	  made	   the	   development	   of	  
effective	   therapeutics	   very	   difficult.	   	   Immunosuppressants	   were	   first	   used	   in	  MS	   over	  
twenty	  years	  ago	  and	  have	  showed	  minor	  successes	  but	  not	  sufficient	   to	  outweigh	  the	  
risk	   of	   side	   effects	   including	   serious	   infections	   (Yudkin	   1991).	   	   The	   advance	   from	  
immunosuppressants	  was	  made	  through	  the	  use	  of	  disease	  modifying	  therapies,	  aiming	  
to	   prevent	   relapses	   and	   disability	   progression	  without	   the	   immunosuppressive	   effects.	  	  
At	  present,	  therapeutic	  intervention	  for	  MS	  is	  limited	  in	  most	  centres	  to	  three	  classes	  of	  
compounds	  that	  act	  as	  disease	  modifying	  therapies.	   	  These	  are	   interferon	  beta	  (1a	  and	  
1b),	   glatiramer	   acetate	   (GA)	   and	   natalizumab	   although	   mitoxantrone	   is	   licensed	   for	  





IFN-­‐β1a	  and	  1b	  are	  both	  type	  one	   interferons	  and	  have	  antiviral	  and	  anti-­‐inflammatory	  
properties	  although	  they	  differ	   in	  their	  pharmacodynamics	  and	  pharmacokinetics	  (Alam	  
1997).	   	  On	   average,	   in	  RR-­‐MS,	   relapse	   rates	   are	   reduced	  by	   approximately	   a	   third	   and	  
severe	  attacks	  are	  cut	  by	  almost	  half	  through	  use	  of	  IFNβ	  and	  it	  has	  been	  shown	  to	  slow	  
the	  rate	  of	  disease	  progression	  by	  around	  1	  year	   in	   the	  short	   term	  (Jacobs	  1996).	   	  The	  
mechanism	  of	  IFNβ	  action	  appears	  to	  be	  wide	  ranging.	  	  T	  cell	  activation	  is	  downregulated	  
through	  a	  reduction	  in	  expression	  of	  MHC	  class	  II	  antigens	  and	  co-­‐stimulatory	  molecules,	  
impairing	   antigen	   recognition	   (Jiang	   1995,	   Teleshova	   2000).	   	   At	   the	   same	   time,	   an	  
upregulation	   of	   cytotoxic	   T	   lymphocyte	   antigen	   4	   (CTLA-­‐4)	   and	   Fas	   promotes	   the	  
apoptosis	   of	   autoreactive	   cells	   (Hallal-­‐Longo	   2007).	   	   IFNβ	   administration	   causes	   a	   shift	  
from	  pro-­‐inflammatory	  to	  anti-­‐inflammatory	  cytokine	  production	  and	  has	  been	  shown	  to	  
decrease	  the	  responsiveness	  of	  both	  human	  peripheral	  blood	  mononuclear	  cells	  (PBMCs)	  
and	  myelin	   specific	   T	   cells	   to	   IL-­‐12	   (Wang	   2000).	   	   The	   permeability	   of	   the	   blood	   brain	  
barrier	  (BBB)	  is	  reduced	  through	  the	  downregulation	  of	  very	  large	  antigen	  4	  (VLA-­‐4)	  and	  
upregulation	  of	   soluble	   vascular	   cell	   adhesion	  molecules	   (VCAMs)	   to	  block	  adhesion	  of	  
cells	   to	   the	  BBB	   (Muraro	   2000,	  Graber	   2005)	   and	  CD73	   to	   increase	   endothelial	   barrier	  
function	  (Airas	  2007).	  	  The	  final	  mechanism	  that	  IFNβ	  is	  thought	  to	  aid	  neuroprotection	  is	  
by	   impairing	  macrophage	   and	  dendritic	   cell	   (DC)	   uptake	  of	   antigen.	   	   This	  would	   act	   to	  
slow	  or	  prevent	  epitope	  spread,	  a	  mechanism	  implicated	  in	  progression	  of	  RR-­‐MS	  (Axtell	  
2008).	  	  
Glatiramer	   acetate	   is	   a	   synthetic	   co-­‐polymer	   composed	   of	   four	   amino	   acids	   found	   in	  
MBP.	  	   It	  was	  designed	  to	  simulate	  MBP	  and	  identify	  immune	  response	  gene	  effects	  but	  





efficacies	   as	   IFNβ	   in	  human	  disease	   (Mikol	   2008)	   and	  promotes	   similar	  mechanisms	   to	  
mediate	   neuroprotection.	   	   A	   shift	   in	   cytokine	   production	   from	   a	   pro-­‐inflammatory	   to	  
anti-­‐inflammatory	  signature	  has	  been	  observed	  after	  GA	  administration	  (Miller	  1998)	  as	  
well	  as	  an	  increase	  in	  forkhead	  box	  P3	  (Foxp3)	  expression	  that	  would	  act	  to	  increase	  Treg	  
function	   (Hong	  2005).	   	  GA	  also	   increased	  production	  of	  neuroprotective	   factors,	  which	  
directly	  act	  to	  promote	  recovery	  from	  autoimmune	  damage	  in	  the	  CNS	  (Ziemssen	  2005).	  	  	  
	  
Natalizumab	   is	   a	   humanized	  monoclonal	   antibody	   directed	   to	   the	   α4	   subunit	   of	   α4β1	  
integrin	   (VLA-­‐4)	   and	   prevents	   the	   trafficking	   of	   lymphocytes	   across	   the	   blood	   brain	  
barrier	   by	   blocking	   the	   interaction	   between	   VLA-­‐4	   and	   VCAM-­‐1	   required	   for	   this	  
transmigration	   (Steinman	  2005a).	   	   It	   is	   generally	   recommended	   for	  patients	  with	  more	  
aggressive	  RR-­‐MS	  and	  those	  who	  failed	  to	  respond	  to	  other	  disease	  modifying	  therapies,	  
and	   in	   trials	   showed	   a	   68%	   reduction	   in	   relapse	   rate	   and	   42%	   reduction	   in	   disability	  
progression	  over	  2	  years	  (Polman	  2006).	   	  Although	  it	  was	  briefly	  withdrawn	  over	  safety	  
fears	  linked	  to	  the	  development	  of	  progressive	  multifocal	  leucoencephalopathy	  (PML),	  it	  
was	  reapproved	  as	  a	  therapy	  for	  MS	  in	  2006.	  	  The	  risk	  of	  PML	  developing	  was	  originally	  
estimated	   to	  be	  1:1000,	  and	   is	  now	  thought	   to	  be	  even	   lower	   than	   that,	  with	   the	   risk-­‐
benefit	  analysis	  supporting	  its	  use	  (Thompson	  2008).	  	  	  
The	   final	   approved	   therapy	   is	   mitoxantrone,	   along	   with	   IFNβ,	   licensed	   for	   use	   in	  
secondary	  progressive	  MS	  cases.	   	   It	  belongs	   to	   the	  anthracenedione	  group	  of	  aromatic	  
organic	  compounds	  and	  is	  also	  used	  to	  treat	  some	  forms	  of	  cancer	  (Shenkenberg	  1986).	  	  
In	   EAE,	   mitoxantrone	   suppresses	   disease	   activity	   (Lublin	   1987,	   Watson	   1991)	   and	   in	  





made	   up	   of	   expanded	   disability	   status	   scale	   (EDSS),	   relapse	   rates,	   ambulation	   and	  
neurological	   status	   (Hartung	  2002).	   	  However,	   less	   significant	   changes	  were	   seen	   from	  
MRI	  observation	  in	  the	  same	  trials	  (Krapf	  2005).	  	  Its	  mechanism	  of	  action	  is	  thought	  to	  be	  
wide-­‐ranging,	   suppressing	   proliferation	   of	   T	   cells,	   B	   cells	   and	   macrophages,	   inhibiting	  
activation	  of	  T	   cells	   and	  production	  of	  pro-­‐inflammatory	   cytokines	  whilst	   also	   reducing	  
antigen	   presentation	   and	   macrophage-­‐mediated	   demyelination	   (Fidler	   1986a,	   Fidler	  
1986b,	  Fox	  2004).	  	  	  
Other	   depleting	   antibodies	   have	   also	   been	   used,	   including	   the	   humanized	   anti-­‐CD52	  
monoclonal	   antibody,	   alemtuzumab	  which	   depletes	   both	   CD4	   and	  CD8	   T	   lymphocytes,	  
anti-­‐CD20	   monoclonal	   antibody,	   rituximab	   which	   depletes	   B	   lymphocytes	   (Reff	   1994),	  
and	   anti-­‐IL-­‐2R	   (CD25)	   humanized	  monoclonal	   antibody,	   daclizumab	   which	   limits	   T	   cell	  
expansion	   (Waldmann	   2007).	   	   Alemtuzumab	   has	   been	   shown	   to	   significantly	   reduce	  
relapses	  and	  new	  lesion	  formation	  in	  the	  short	  term	  (Coles	  2008)	  although	  side	  effects	  of	  
CAMPATH-­‐1H	  are	   idiopathic	  thrombocytopaenia	  purpura,	  thyroiditis	  and	  Goodpasture’s	  
syndrome	  (Moreau	  1996,	  Coles	  1999).	  	  The	  effectiveness	  of	  alemtuzumab	  was	  highest	  if	  
given	  early	  in	  the	  disease	  course,	  leading	  to	  the	  inference	  by	  the	  authors	  that	  secondary	  
progressive	  neurodegeneration	  occurred	  independently	  of	  inflammation	  (Coles	  2004).	  	  	  	  
Rituximab	  therapy	  led	  to	  a	  reduction	  in	  both	  clinical	  disease	  and	  MRI	  markers	  in	  a	  phase	  
II	   trial	   (Hauser	   2008)	   and	   has	   been	   trialled	   in	   neuromyelitis	   optica,	   an	   autoimmune	  
condition	  similar	  but	  distinct	  from	  MS,	  mediated	  by	  autoimmune	  B	  cells	  where	  it	  showed	  
beneficial	   effects	   and	   an	   improvement	   in	   relapse	   rate	   and	   recovery	   (Cree	   2005,	   Jacob	  
2008).	   	   The	   contribution	   of	   B	   lymphocytes	   in	  MS	   however	   is	   not	   clear	   but	   these	   trials	  





of	   daclizumab	   leads	   to	   improved	  disease	   conditions	   through	  measurement	  of	  MRI	   and	  
disability	   scores	   (Bielekova	   2004,	   Rose	   2004,	   Rose	   2007,	   Bielekova	   2009).	   	   There	   is	   an	  
expansion	  of	   CD56bright	   natural	   killer	   (NK)	   cells	   and	   these	   are	   thought	   to	   bring	   about	   a	  
reduction	  in	  CNS	  inflammation	  through	  inhibition	  of	  peripheral	  T	  cell	  survival	  (Bielekova	  
2006).	   	   	   CD56bright	   NK	   cells	   appear	   to	   be	   able	   to	   maintain	   IL-­‐2	   signalling	   despite	   the	  
administration	   of	   daclizumab,	   and	   it	   appears	   that	   the	   reduced	   levels	   of	   IL-­‐2	   act	   to	  
increase	  the	  cytotoxic	  potential	  of	  the	  NK	  cells	   (Martin	  2010).	   	   In	  addition,	  recent	  work	  
has	  shown	  a	  potential	  explanation	  for	  the	  increased	  efficacy	  of	  daclizumab	  at	  reducing	  T	  
cell	   proliferation	   with	   higher	   doses,	   despite	   achieving	   saturation	   of	   CD25	   in	   blood	  
lymphocytes.	   	  The	  identification	  of	  a	  mechanism	  whereby	  myeloid	  DCs	  can	  present	  IL-­‐2	  
in	   trans	   to	   T	   cells	   and	   ‘lend’	   their	   CD25	   to	   T	   cells	   to	   facilitate	   expansion	   offers	   an	  
explanation	   for	   how	   lymphoproliferation	   can	   be	   inhibited	   by	   daclizumab	   whilst	   also	  
diminishing	  the	  Treg	  population	  (Wuest	  2011).	  	  
Oral	   immunomodulators	   have	   also	   shown	   promise	   as	   therapeutics	   in	   MS	   patients.	  	  
FTY720	   (fingolimod),	   a	   sphingosine-­‐1-­‐phosphate	   receptor	   modulator,	   inhibits	   T	   cell	  
migration	   from	   lymphoid	   to	   peripheral	   organs	   thereby	   limiting	   inflammation	   without	  
affecting	   function	   (Brinkmann	   2004)	   and	   protects	   against	   experimental	   autoimmune	  
encephalomyelitis	   (EAE)	   and	   showed	   protection	   in	   a	   phase	   III	   trial	   (Cohen	   2010a).	   	   In	  
oligodendrocyte	  progenitor	  cells	  treated	   in	  vitro,	   it	  also	  promoted	  survival	  but	  inhibited	  
differentiation,	   having	   potentially	   both	   positive	   and	   negative	   effects	   on	   the	  
remyelination	   process	   (Miron	   2008).	   	   It	  was	   licensed	   for	   use	   in	   Russia	   and	   the	  USA	   in	  
2010,	   and	   by	   the	   EU	   in	   2011,	   for	   use	   in	   patients	   with	   highly	   active	   RR-­‐MS	   who	   had	  





immunomodulators	   have	   demonstrated	   encouraging	   results	   from	   animal	   studies	   or	   in	  
clinical	  trials.	  	  The	  only	  other	  licensed	  oral	  therapy	  is	  Cladribine,	  approved	  in	  2010	  for	  use	  
in	   the	   USA	   and	   Russia.	   	   Cladribine	   leads	   to	   the	   depletion	   of	   T	   cells	   (Carson	   1983),	  
teriflunomide	  works	  by	  inhibiting	  of	  lymphocyte	  expansion	  and	  differentiation	  (Tallantyre	  
2008)	   and	   laquinimod	   prevents	   lymphocyte	   migration	   (Brunmark	   2002).	   	   Dimethyl	  
fumarate	  activates	  neuronal	  protection	  and	   the	  maintenance	  of	  CNS	  myelin	   (Calabrese	  
2005,	   Hubbs	   2007)	  whilst	   also	   inhibiting	   pro-­‐inflammatory	   cytokines	   and	   cell	   adhesion	  
molecules	  (de	  Jong	  1996,	  Vandermeeren	  1997)	  and	  firategrast,	  like	  natalizumab,	  acts	  on	  
α4	   integrins	   to	  block	   cell	  migration	   (Jackson	  2002).	   	   This	   class	  of	   therapeutic	   approach	  
have	  the	  advantage	  of	  an	  easier	  mode	  of	  delivery	  and	  reduced	  costs	  and	  so	  may	  end	  up	  
being	   the	   front	   line	   treatment	   regime	   for	   long-­‐term	   disease	   if	   they	   succeed	   in	   clinical	  
trials.	  	  	  	  	  
	  
8.1.4 One	  Disease?	  
The	   idea	   that	   multiple	   sclerosis	   is	   a	   spectrum	   of	   diseases	   based	   upon	   clinical	  
considerations	  has	  been	  put	  forward	  (Weinshenker	  1999).	  	  Schilder’s	  disease,	  Marburg’s	  
disease,	  Balό’s	  disease,	  Devic’s	  disease	  and	  disseminated	  encephalomyelitis	  (DEM)	  are	  all	  
described	   forms	   of	   demyelinated	   lesions	   in	   the	   CNS.	   	   However,	   rather	   than	   being	  
considered	  forms	  of	  MS,	  they	  differ	  from	  MS	  in	  both	  presentation	  and	  location	  of	  lesions.	  	  
In	  the	  case	  of	  Devic’s	  disease,	  a	  different	   immune	  mechanism	  has	  been	  identified,	  with	  
demyelination	   mediated	   by	   autoantibodies	   to	   aquaporin-­‐4	   (Lennon	   2004).	   	   Therefore	  
there	   is	   a	   clear	   separation	   of	   these	   conditions	   from	  MS,	   rather	   than	   classifying	   them	  





determination	  to	  the	  different	  demyelinating	  conditions	  have	  been	  put	  forward	  based	  on	  
ethnicity	  of	  patients	  (Poser	  2004b)	  and	  splitting	  the	  inflammatory	  demyelinating	  diseases	  
into	   two	   groups,	   those	   of	  MS	   and	   DEM	   has	   been	   proposed	   as	   the	   simplest	  means	   of	  
characterising	   the	   CNS	   demyelinating	   conditions	   (Poser	   2004a).	   	   As	   more	   research	   is	  
done,	   the	   individual	   similarities	   and	   differences	   between	   conditions	   will	   be	   fully	  
described	  which	  should	  help	  to	  clarify	  the	  relationships	  between	  these	  conditions.	  	  There	  
is	  an	  obvious	  requirement	  for	  the	  correct	  determination	  of	  which	  syndrome	  is	  affecting	  
the	   patient.	   	   Although	   different	   mechanisms	   can	   lead	   to	   a	   similar	   phenotype	  
characterized	   by	   demyelination	   in	   the	   CNS,	   each	   will	   display	   differential	   responses	   to	  
therapies	  and	  proper	  identification	  of	  condition	  can	  lead	  to	  improved	  treatment	  regimes.	  	  	  
	  
	  
8.2 Animal	  Models	  of	  MS	  
8.2.1 EAE	  
A	  major	  difficulty	  with	  studying	  MS	  is	  the	  limited	  access	  to	  early	  stage	  and	  active	  tissue	  
samples	  and	  the	  inability	  to	  causally	  relate	  autoimmune	  responses	  to	  attacks.	  	  Therefore,	  
animal	  models	  have	  been	  used	  to	  try	  and	  fill	   this	  void	  and	  allow	  researchers	   to	  dissect	  
immunological	  mechanisms	   that	  may	   be	   active	   in	   human	  MS.	   	   There	   are	   three	  major	  
types	  of	   animal	  model	   for	  MS:	   EAE,	   virally	   induced	   chronic	  demyelinating	  disease,	   and	  
toxin-­‐induced	   demyelination.	   	   Of	   these,	   EAE	   has	   been	   the	  most	   widely	   used	   and	   has,	  
despite	   limitations,	   been	   very	   informative	   and	   has	   directly	   led	   to	   the	   development	   of	  
approved	  treatments	  for	  MS	  namely	  glatiramer	  acetate,	  mitoxantrone,	  natalizumab	  and	  





success	   in	   EAE	   but	   have	   proved	   to	   be	   ineffective	   in	   treating	   human	   disease	   e.g.	  
administration	   of	   IFNγ	   and	   blockade	   of	   tumor	   necrosis	   factor	   alpha	   (TNFα)	   (Feldmann	  
2005).	   	  This	  mixed	  success	  is	  due	  to	  the	  limitations	  of	  EAE	  as	  a	  representative	  model	  of	  
MS,	   unable	   to	   reproduce	   all	   facets	   of	   the	   human	   condition	   (Sriram	   2005,	   Steinman	  
2005b,	  2006).	  	  Individual	  models	  of	  EAE	  can	  be	  made	  to	  model	  all	  clinical	  forms	  of	  MS	  but	  
therefore	  aspects	  of	  each	  of	  these	  models	  are	  unrepresentative.	  	  Toxicity	  of	  new	  drugs	  is	  
rarely	  tested	  in	  EAE	  models	  and	  EAE	  experiments	  generally	  run	  for	  too	  short	  a	  time,	  and	  
under	   conditions	   designed	   to	   limit	   pathogen	   interference,	   to	   detect	   infectious	  
complications.	   	  Most	   therapies	   for	   the	  human	  condition	  would	  be	  used	  once	  disease	   is	  
established	  rather	  than	  administering	  alongside	  or	  shortly	  after	  the	  initial	  attack.	  	  The	  use	  
of	   knockout	   mice	   to	   study	   autoimmunity	   also	   creates	   problems	   of	   translation	   into	  
therapies	  as	  cytokines	  etc	  often	  have	  diverse	  biological	  activities	  that	  may	  be	  replaced	  by	  
other	   proteins,	   as	   there	   is	   large	   redundancy	   in	   most	   physiological	   processes.	   	   Many	  
knockout	  mice	  show	  altered	   lymphoid	  architecture,	   leading	  to	  conclusions	  being	  drawn	  
from	   unrealistic	   physiological	   conditions	   (Steinman	   1997).	   	   EAE	   is	   induced	   by	   the	  
introduction	   of	   an	   autoantigen	   alongside	   powerful	   immune	   adjuvants	   to	   initiate	   an	  
immune	  response	  that	  overcomes	  self-­‐tolerance	  to	  a	  self-­‐peptide.	  	  Similar	  to	  MS,	  EAE	  is	  
heterogeneous,	  influenced	  by	  the	  selected	  autoantigen,	  species,	  and	  genetic	  background	  
used.	   	   It	   was	   discovered	   in	   the	   1930s	   by	   Rivers	   et	   al	   (Rivers	   1933)	   investigating	  
neurological	  conditions	  observed	  after	   rabies	  vaccinations.	   	  Work	  had	  been	  carried	  out	  
over	   the	   previous	   38	   years	   investigating	   an	   observation	   by	   Pasteur	   in	   attempting	   to	  
vaccinate	   against	   rabies	   virus,	   that	   patients	   injected	   with	   dried	   spinal	   cord	   of	   rabies-­‐





encephalomyelitis	   (PVE)	   (Balaguer	   1888,	   Baxter	   2007),	   rather	   than	   immunity	   to	   the	  
rabies	  virus.	  	  The	  initial	  version	  of	  the	  model	  involved	  immunizing	  rhesus	  monkeys	  with	  
homogenised	  normal	   rabbit	   brain	   but	   this	  was	   cumbersome,	   involving	  many	   injections	  
per	  animal	  over	  long	  time	  spans	  (Rivers	  1935).	  	  	  
The	   model	   was	   improved	   by	   Elvin	   Kabat,	   by	   combining	   the	   brain	   extracts	   with	   the	  
adjuvant	  recently	  developed	  by	  Jules	  Freund	  (Kabat	  1946)	  originally	  designed	  to	  increase	  
antibody	   production	   against	   horse	   serum	   in	   guinea	   pigs	   (Freund	   1942).	   	   This	   method	  
allowed	   induction	   of	   disease	   with	   only	   one	   injection,	   saving	   a	   great	   deal	   of	   time	   but	  
arguably	  masking	   some	  of	   the	  more	   subtle	   initiating	  events.	   	   The	   similarities	  of	  EAE	   to	  
human	  demyelinating	  diseases	  was	  noted	  at	  this	  same	  time	  (Wolf	  1947)	  and	  since	  then	  it	  
has	  been	  induced	  in	  a	  wide	  range	  of	  mammals	  and	  now,	  the	  mouse	  and	  rat	  are	  the	  main	  
species	  used.	  	  	  
The	  importance	  of	  T	  cells	  in	  driving	  the	  disease	  was	  highlighted	  initially	  by	  the	  ability	  of	  
adoptively	  transferred	  spleen	  cells	  from	  an	  EAE	  donor	  to	  induce	  EAE	  in	  naïve	  recipients.	  	  
This	   observation	  was	   further	   specialised	   to	  myelin-­‐specific	   CD4+	   T	   cells	   through	   similar	  
adoptive	  transfer	  experiments	  of	  these	  specific	  cells	  inducing	  EAE	  in	  all	  animals	  (Ben-­‐Nun	  
1981,	  Pettinelli	  1981).	  	  	  
The	  usefulness	  of	  EAE	  as	  a	  model	  of	  MS	  has	  been	  questioned	  with	  some	  groups	  sighting	  a	  
CD4-­‐mediated	  mechanism	  as	  evidence	  for	  their	  scepticism.	  	  Whilst	  EAE	  is	  certainly	  a	  CD4+	  
T	   cell	   mediated	   disease	   with	   the	   predominant	   cell	   type	   present	   in	   CNS	   lesions	   being	  
CD4+,	  there	  is	  not	  such	  clear	  evidence	  for	  the	  same	  importance	  in	  the	  human	  condition,	  





However,	   its	   usefulness	   in	   leading	   to	   disease	   modifying	   therapies	   is	   without	   doubt	  
(Steinman	  2006).	  	  	  
EAE	  is	  not	  a	  complete	  model	  of	  human	  MS,	  but	  rather	  replicates	  distinct	  characteristics	  
of	   the	   human	   condition	   with	   each	   individual	   model	   reproducing	   a	   different	   clinical	  
manifestation	   allowing	   isolated	   investigation.	   	   Relapsing-­‐remitting,	   chronic	   and	   acute	  
disease	   can	   be	  modelled	   by	   using	   a	   different	   combination	   of	  mouse	   strain	   and	  myelin	  
peptide,	   immunized	   alongside	   Complete	   Freund’s	   Adjuvant	   (CFA)	   and	   Bordetella	  
pertussis	   toxin.	   	   SJL	   (H-­‐2s)	   and	   Biozzi	   ABH	   (H-­‐2dql)	   (Colombani	   1979,	   Baker	   1990)	  mice	  
typically	   develop	   a	   relapsing-­‐remitting	   clinical	   profile,	   B10.PL	   or	   PL/J	   (H-­‐2u)	   an	   acute	  
monophasic	  disease	  (Waxman	  1980),	  and	  C57BL/6	  (H-­‐2b)	  mice	  develop	  chronic	  paralysis	  
although	   they	   may	   also	   show	   acute	   attacks	   followed	   by	   resolution	   (McRae	   1992,	  
Tompkins	  2002).	  	  These	  different	  profiles	  are	  due	  largely	  but	  not	  exclusively	  to	  the	  MHC	  
class	  II	  antigens	  of	  the	  strains	  used,	  determining	  which	  myelin	  peptides	  the	  mouse	  strains	  
are	  susceptible	  to.	  	  	  
SJL,	  PL/J	  and	  B10.PL	  mice	  can	  be	   induced	   to	  develop	  EAE	  with	  MBP	   (Zamvil	  1986),	  PLP	  
(Tuohy	  1989,	  Greer	  1992,	  McRae	  1992)	  and	  MOBP	  (Kaye	  2000)	  peptides.	  	  PL/J	  and	  B10.PL	  
mice	  are	  however	  resistant	  to	  EAE	  induced	  by	  MOG	  peptides	  whereas	  SJL,	  Biozzi	  ABH	  and	  
C57BL/6	  mice	  are	  susceptible	  (Amor	  1994,	  Mendel	  1995).	  	  C57BL/6	  and	  Biozzi	  ABH	  mice	  
are	   also	   susceptible	   to	   PLP	   induced	   EAE	   (Amor	   1993,	   Tompkins	   2002)	   but	   only	   show	  
limited	   susceptibility	   to	  MBP.	   	   It	   is	   a	  minor	  encephalitogen	   in	  Biozzi	  mice	   (Amor	  1996)	  
and	  only	  acts	  as	  a	  successful	  antigen	   in	  C57BL/6	  mice	  when	  bovine	  MBP	   is	  used	  rather	  





As	   relapsing-­‐remitting	  MS	   is	   the	  most	   common	   form	   of	   the	   human	   condition,	   the	   SJL	  
model	  appears	  the	  most	  relevant	  for	  direct	  comparisons	  with	  human	  disease.	   	   It	  shows	  
histopathological	  similarities	  to	  MS,	  with	  areas	  of	  cellular	  infiltration	  linked	  to	  regions	  of	  
demyelination	   (Brown	   1982,	   Paterson	   1988).	   	   Biozzi	   ABH	  mice	   share	   these	   similarities	  
(Baker	  1990)	  and	  along	  with	  SJL	  mice	  show	  reactivity	  to	  a	  wide	  range	  of	  myelin-­‐derived	  
peptides,	   likely	   to	   be	   the	   source	   of	   the	   remitting	   disease.	   	   It	   is	   thought	   that	   the	  
scavenging	   and	   subsequent	   re-­‐presentation	   of	   myelin	   peptides	   from	   an	   initial	  
demyelinating	  event	  can	   lead	  to	  epitope	  spread	  and	  new	   inflammatory	  attacks	   (McRae	  
1995).	   	   The	   Biozzi	   ABH	  mice	   can	   also	   be	   used	   to	   study	   neurological	   inflammation	   in	   a	  
variety	   of	   models	   including	   virally-­‐induced	   (Amor	   2005),	   and	   EAE	   induced	   with	   CNS-­‐
derived	  non-­‐myelin	  peptides	  e.g.	  αBcrystallin	  and	  GFAP	  (Thoua	  2000),	  which	  have	  been	  
shown	   to	  elicit	   T	   cell	   reactivity	   in	  MS	  patients	   (van	  Noort	  1995).	   	   They	  have	  also	  been	  
used	   to	  model	   secondary	  progressive	  MS	   (Hampton	  2008),	   a	   clinical	   form	  neglected	   in	  
most	  EAE	  studies.	   	  Despite	  the	  strengths	  of	  these	  models,	  both	  are	  still	  primarily	  CD4+-­‐
mediated	   conditions,	   at	   a	   scale	   much	   higher	   than	   MS	   and	   so	   do	   not	   provide	   a	  
comprehensive	  representation	  of	  human	  disease.	  	  	  
The	   recent	  development	  of	   a	  MBP-­‐PLP	   fusion	  protein	   (MP4)	   to	   induce	  EAE	   in	  C57BL/6	  
mice	   (Kuerten	   2006)	   provides	   an	   improvement	   in	   diversity	   of	   C57BL/6	  models	   but	   the	  
most	   commonly	   used	   EAE	   model	   is	   a	   MOG-­‐induced	   disease	   in	   mouse	   strains	   on	   the	  
C57BL/6	   background	   (Mendel	   1995).	   	   This	   chronic	   progressive	   EAE	   model	   does	   not	  
represent	  the	  largest	  clinical	  form	  of	  human	  MS,	  rather	  models	  primary	  progressive	  MS,	  
but	  still	  provides	   important	   information	  regarding	  CNS	   inflammation.	   	  Tissue	  damage	   is	  





absence	  of	   a	  demyelinating	  autoantibody	   response,	  which	   is	  blocked	  by	   the	  H-­‐2b	  MHC	  
haplotype,	  when	   rat	   or	  mouse	  MOG	   is	   used	   (Bourquin	   2003).	   	   Therefore	  human	  MOG	  
must	   be	   used	   to	   induce	   an	   autoantibody	   response	   (Oliver	   2003),	   to	   elicit	   axonal	   and	  
neuronal	  damage	  (Bourquin	  2003).	  	  Lesions	  in	  MOG-­‐specific	  models	  form	  in	  the	  forebrain	  
and	   optic	   nerve,	   in	   a	   similar	  way	   to	  MS,	   suggesting	   that	  MOG	  may	   be	   involved	   in	   the	  
development	  of	  optic	  neuritis	  but	  as	  the	  clinical	  score	  is	  measure	  by	  paralysis,	  the	  degree	  
of	   CNS	   damage	   does	   not	   always	   directly	   correlate	   with	   achieved	   score	   (Berger	   1997).	  	  
Despite	   these	   limitations,	   the	   C57BL/6	   strain	   is	   widely	   used	   because	   of	   the	   ease	   of	  
generating	  transgenic	  lines.	  	  There	  is	  a	  large	  availability	  of	  knockout	  mice	  on	  the	  C57BL/6	  
background	   and	   so	   using	   this	  model	   allows	   the	   comparison	   of	   congenic	   strains	  where	  
they	  differ	  in	  only	  one	  locus,	  necessary	  for	  mechanistic	  studies	  (Owens	  2001).	  	  The	  speed	  
of	  disease	  induction	  allows	  rapid	  pre-­‐clinical	  testing	  of	  potential	  therapeutic	  compounds	  
increasing	   its	   popularity	   and	   this	   further	   accelerates	   its	   use	   but	   to	   the	   potential	  
detriment	  of	  the	  human	  condition	  as	  the	  variety	  of	  models	  is	  neglected	  over	  ease	  of	  use	  
when	  it	  is	  clear	  how	  large	  an	  impact	  genetic	  diversity	  can	  have	  on	  disease	  outcome.	  	  
	  
8.2.2 Other	  Animal	  Models	  
There	   are	   two	   other	   animal	   models	   of	   MS,	   namely	   virally	   induced	   demyelination	   by	  
Theiler’s	   murine	   encephalomyelitis	   virus	   (TMEV)	   and	   toxin-­‐induced	   demyelination.	  	  
TMEV	   is	  a	   single-­‐stranded	  RNA	  picornavirus	  and	  was	   initially	  described	   to	  cause	   flaccid	  
paralysis	   in	  mice	  but	  not	  monkeys	   (Theiler	  1934).	   	   Intracereberal	   injection	  of	   the	  virus,	  
mice	   develop	   transient	   meningo-­‐encephalomyelitis	   peaking	   at	   around	   day	   7	   after	  





and	   demyelinating	   lesions	   appear	   in	   the	   spinal	   cord	   (Dal	   Canto	   1996).	   	   A	   less	   virulent	  
strain	   of	   the	   virus	   is	   used	   to	   model	   MS	   as	   the	   more	   virulent	   strains	   cause	   fatal	  
encephalitis	   (Zoecklein	   2003).	   	   TMEV	   infection	   is	   an	   attractive	   model	   for	   MS	   as	   the	  
pathology	  resembles	  MS	  (Lipton	  1975,	  Dal	  Canto	  1977)	  and	  it	  is	  a	  model	  for	  a	  viral	  CNS	  
infection,	  thought	  to	  be	  a	  potential	  cause	  of	  MS	  (Rodriguez	  1987).	   	   It	  has	  been	  claimed	  
that	  TMEV	  may	  be	  a	  more	  accurate	  predictor	  of	  therapeutic	  potential	  than	  EAE	  (Nelson	  
2004)	  but	  until	   all	   potential	   therapies	   for	  MS	  and	  EAE	  have	  been	   tried,	   then	   the	   claim	  
cannot	  be	  validated.	  	  	  
Toxin–induced	   demyelination	   is	   a	   model	   for	   investigating	   mechanisms	   of	   focal	  
demyelination	  and	  remyelination	  and	  those	  cells	  involved	  (Blakemore	  2008).	  	  Injection	  of	  
lysolecithin	   into	   the	   spinal	   cord	   radidly	   induces	   areas	   of	   non-­‐immune	   mediated	  
demyelination	   with	   complete	   relmyelination	   within	   5-­‐6	   weeks	   (Shields	   1999,	   Bieber	  
2003).	  	  Cuprizone	  added	  to	  the	  diet	  of	  the	  animal	  however	  leads	  to	  the	  development	  of	  
spongiform	  encephalopathy	  (Carlton	  1969,	  Suzuki	  1969)	  and	  pathology	  develops	  due	  to	  a	  
depletion	   of	   oligodendrocytes,	   induced	   to	   undergo	   apoptosis.	   	   Removal	   of	   cuprizone	  
from	  the	  diet	  allows	  remyelination	  as	  homeostasis	  returns	  (Matsushima	  2001).	  	  	  	  	  
There	  is	  no	  one	  mouse	  model	  that	  can	  recapitulate	  all	  the	  immune	  events	  involved	  in	  the	  
human	   disease,	   especially	   given	   the	   heterogeneity	   of	   the	   condition.	   	   However,	  mouse	  
models	   should	   be	   made	   as	   relevant	   and	   faithful	   to	   the	   human	   condition	   as	   possible	  







8.3 Immune	  Mechanisms	  in	  MS	  
8.3.1 CD4	  T	  cell	  subset	  divisions	  
8.3.1.1 Historical	  –	  Th1	  and	  Th2	  
It	  would	  seem	  logical	  that	  in	  such	  a	  complex	  immune	  system	  such	  as	  the	  one	  evolved	  in	  
mammals	   to	   react	   to	   a	   wide	   variety	   of	   pathogens	   should	   be	   formed	   of	   many	  
interconnected	   but	   yet	   distinct	   subsets	   of	   cells.	   	   Each	   has	   their	   own	   specificity	   and	  
armoury	   to	   protect	   the	   host	   from	   a	   group	   of	   pathogens	   or	   threats,	  whether	   these	   be	  
from	  outside	  or	  from	  the	  host	  itself.	  	  	  It	  has	  been	  this	  rationale	  that	  has	  lead	  people	  to	  try	  
and	  classify	  cellular	  subsets,	  assuming	  that	  through	  classification,	  our	  knowledge	  of	  the	  
system	  and	  diseases	  will	  simplify,	  and	  aid	  advances	  in	  therapy.	  	  	  
The	  first	  division	  of	  the	  CD4+	  T	  cell	  lineage	  was	  made	  by	  Mossmann	  and	  Coffman	  in	  1986	  
based	   initially	   upon	   functional	   characteristics.	   	   They	   proposed	   that	   two	   mutually	  
exclusive	  subsets	  could	  be	  described	  called	  Th1	  and	  Th2,	  and	  this	  paradigm	  survived	  for	  
almost	   twenty	   years.	   	   Th1	   cells	   were	   described	   as	   producing	   large	   amounts	   of	   IFNγ	  
enabling	  them	  to	  kill	  intracellular	  pathogens	  whereas	  Th2	  cells	  produced	  IL-­‐4,	  IL-­‐5,	  IL-­‐13	  
and	   IL-­‐25	   to	   control	   extracellular	   pathogens	   mainly	   by	   promoting	   antibody	   class	  
switching	  (Mosmann	  1986,	  Mosmann	  1989,	  Fort	  2001).	  	  Cytokine	  release	  however	  is	  not	  
sufficient	  to	  classify	  cell	  fate	  determination	  and	  it	  was	  ten	  years	  later	  that	  transcriptional	  
signatures	   were	   identified	   for	   Th1	   and	   Th2	   cells.	   	   T-­‐bet	   (Tbx21)	   a	   TATA	   box	   binding	  
protein	   and	   GATA3,	   a	  member	   of	   the	   GATA	   binding	   family	   were	   shown	   to	   be	   lineage	  
specific	  for	  Th1	  and	  Th2	  CD4+	  T	  cells	  respectively	  (Zhang	  1997b,	  Zheng	  1997,	  Szabo	  2000).	  	  





transcription	   (STAT)	   proteins	   also	   act	   in	   a	   lineage	   specific	   fashion.	   	   They	   are	   signaling	  
molecules	   of	   cytokine	   receptors;	   STAT4	   is	   activated	   after	   IL-­‐12R	   ligation	   and	   STAT6	  
activated	   after	   IL-­‐4R	   ligation	   (Kaplan	   1996,	   Thierfelder	   1996).	   	   The	   activity	   of	   these	  
proteins	   is	  determined	  not	   just	  by	  expression	  as	   in	  the	  case	  of	  the	  master	  transcription	  
factors	  but	  by	  post-­‐transcriptional	  modification	   in	   response	   to	   cytokine	   release.	   	   Some	  
STAT	  proteins	  are	  directly	  responsible	  for	  controlling	  the	  expression	  of	  master	  regulator	  
transcription	   factors	   whilst	   others	   act	   directly	   on	   cytokine	   genes	   and	   therefore	   work	  
alongside	   the	  master	   transcription	   factors	   to	  polarise	  T	  cells.	   	   It	  was	  shown	  that	  STAT4	  
works	  with	  T-­‐bet	  in	  Th1	  cells	  and	  STAT6	  is	  active	  in	  Th2	  cells.	  
From	   this	   simple	   division,	   many	   human	   conditions	   could	   be	   put	   in	   the	   perspective	   of	  
aberrant	   T	   cell	   activity.	   	   Uncontrolled	   Th1	   cell	   activity	   was	   assumed	   to	   lead	   to	  
autoimmune	   inflammatory	   conditions	   (e.g.	   MS,	   RA)	   and	   over-­‐reactive	   Th2	   responses	  
were	  thought	  to	  be	  responsible	  for	  allergic	  reactions.	  	  	  
Support	  for	  Th1	  cells	  being	  important	  in	  autoimmune	  conditions	  came	  from	  observations	  
in	  multiple	  sclerosis	  and	  its	  animal	  model	  EAE.	  	  Myelin	  specific	  Th1	  cells	  producing	  IFNγ	  
upon	   in	   vitro	   restimulation	   were	   identified	   at	   higher	   frequencies	   in	   blood	   and	  
cerebrospinal	  fluid	  (CSF)	  of	  MS	  patients	  (Olsson	  1990,	  Link	  1992)	  and	  accumulate	  in	  CNS	  
lesions	  of	  MS	  patients	  (Traugott	  1988)	  and	  mice	  (Merrill	  1992).	  	  Th1	  cells	  were	  shown	  to	  
require	  the	  presence	  of	  α4	  integrins	  on	  their	  surface	  to	  enter	  the	  brain	  parenchyma,	  and	  
despite	  maintaining	  their	  response	  to	  antigen	  and	  cytokine	  production,	  those	  cells	  with	  
low	   levels	   of	   α4	   integrins	  were	   non-­‐encephalitogenic	   (Baron	   1993).	   	   Treatment	   of	  MS	  
patients	  with	  IFNγ	  exacerbated	  disease	  (Panitch	  1987)	  and	  mice	  lacking	  p40,	  a	  subunit	  of	  





However,	   several	   observations	   including	   more	   severe	   EAE	   in	   IFNγ-­‐/-­‐	   and	   STAT1-­‐/-­‐	   mice	  
that	   lack	  Th1	  cells	   (Ferber	  1996,	  Bettelli	  2004)	  and	  the	  ability	  of	  MBP	  specific	  Th2	  cells	  
that	   lack	   IFNγ	   production	   to	   cause	   EAE	   in	   immunodeficient	   animals,	   probably	   through	  
TNFα	   (Lafaille	   1997)	   confused	   the	   issue	   and	   suggested	   that	   the	   situation	   was	   more	  
complicated	  than	  just	  Th1	  and	  Th2.	  
	  
8.3.1.2 Paradigm	  Revision	  
The	   discovery	   of	   IL-­‐23	   partially	   resolved	   these	   confused	   results.	   	   IL-­‐23	   shares	   a	   p40	  
subunit	  with	  IL-­‐12	  but	  has	  a	  specific	  p19	  subunit	  as	  compared	  to	  the	  p35	  subunit	  of	  IL-­‐12.	  	  
p19-­‐/-­‐	  mice	  were	  resistant	  to	  EAE	  whereas	  p35-­‐/-­‐	  mice	  remained	  susceptible	  (Gran	  2002)	  
illustrating	   that	   it	   was	   not	   IL-­‐12	   that	   was	   important	   for	   EAE	   induction	   but	   IL-­‐23	   (Cua	  
2003).	   	   IL-­‐23R	   knockout	   mice	   are	   also	   resistant	   to	   EAE	   induction	   (Awasthi	   2009,	  
McGeachy	   2009).	   	   IL-­‐23	  was	   shown	   to	   be	   necessary	   for	   the	   induction	   or	   expansion	   of	  
CD4+	  cells	  expressing	  IL-­‐17,	  which	  were	  called	  Th17	  cells.	  	  
	  Since	  then	  there	  has	  been	  a	  great	  deal	  of	  focus	  on	  Th17	  cells	  and	  they	  have	  been	  shown	  
to	   be	   a	   distinct	   subset	   of	   pro-­‐inflammatory	   cells	   alongside	   classical	   Th1	   and	   Th2	   cells,	  
releasing	   IL-­‐17A,	   IL-­‐17F,	   IL-­‐21,	   IL-­‐9	  and	  TNFα	  and	  being	   independent	  of	  T-­‐bet	  or	  GATA3	  
transcription	   factors	   (Harrington	   2005,	   Park	   2005).	   	   Retinoid-­‐related	   orphan	   receptor	  
gamma	   second	   isoform	   (RORγt)	   and	   alpha	   (RORα)	   were	   shown	   to	   be	   the	   master	  
transcription	   factors	   related	   to	   this	   subset	   and	   initially	   differentiating	   conditions	   of	  
transforming	  growth	  factor	  beta	  (TGFβ)	  and	  IL-­‐6	  reinforced	  that	  idea	  (Ivanov	  2006,	  Yang	  
2008b)	  with	   IL-­‐23	   considered	   vital	   for	   their	   expansion	   (Mangan	   2006)	   and	  maintaining	  





discovery,	  TGFβ	  has	  been	  shown	  to	  be	  dispensable	  for	  Th17	  differentiation	  and	  is	  more	  
likely	   to	   function	  by	  suppressing	  Th1	  and	  Th2	  cells,	  and	  therefore	   their	  products	  which	  
inhibit	   Th17	   differentiation	   (Das	   2009,	   Santarlasci	   2009).	   	   IL-­‐1	   has	   been	   shown	   to	   be	  
required	  for	  Th17	  differentiation	  as	  IL-­‐1RI-­‐/-­‐	  mice	  are	  resistant	  to	  EAE	  and	  show	  defective	  
Th17	  responses	  (Sutton	  2006),	  and	  a	  role	  for	  IL-­‐21	  in	  differentiation	  of	  human	  Th17	  cells	  
has	  been	  suggested	  although	  this	  has	  only	  been	  shown	  in	  vitro	  (Yang	  2008a).	  	  	  
Th17	   cells	  were	   therefore	   thought	   to	   be	   the	  most	   important	   subset	   in	  mediating	   EAE.	  	  
PLP-­‐specific,	   IL-­‐23	   induced	   Th17	   cells	   induced	   EAE	   in	   naïve	   SJL	   mice	   whereas	   IL-­‐12	  
induced	   Th1	   cells	   did	   not	   and	   neutralizing	   anti-­‐IL-­‐17	   antibody	   reduced	   severity	   of	   EAE	  
whereas	  anti-­‐IFNγ	  exacerbated	   it	   (Langrish	  2005).	   	   Studies	   inducing	  EAE	   in	   IL-­‐17-­‐/-­‐	  mice	  
resulted	   in	   very	  mild	   disease	  with	   delayed	   onset	   and	   early	   recovery	   (Komiyama	   2006)	  
and	  neutralizing	   IL-­‐17	   in	   a	  MOG-­‐induced	  EAE	  model	   improved	   clinical	   signs	   (Hofstetter	  
2005).	  RORγt-­‐/-­‐	  mice	  also	  developed	  a	  much	  milder	  EAE	  later	  than	  wildtype	  mice	  (Ivanov	  
2006)	   and	   studies	   showing	   that	   adoptive	   transfer	   of	  MOG35-­‐55	   primed	   Th17	   cells	   could	  
initiate	  EAE	  (Jager	  2009)	  have	  all	  provided	  further	  evidence	  for	  their	  importance.	  
Increased	   expression	   of	   IL-­‐17	   mRNA	   has	   been	   detected	   in	   the	   CSF	   and	   lesions	   of	  MS	  
patients	  where	  there	  is	  also	  an	  increase	  in	  IL-­‐6	  mRNA	  (Lock	  2002).	  	  CD4+	  T	  cells	  producing	  
IL-­‐17	  at	  both	  the	  mRNA	  and	  protein	  level	  have	  been	  detected	  in	  active	  lesions	  alongside	  
both	  IL-­‐23	  subunits	  (p19	  and	  p40)	  (Li	  2007)	  and	  the	  borders	  of	  chronically	  active	  lesions	  
(Tzartos	  2008).	  
The	  discovery	  of	  Th17	  cells	  has	  lead	  to	  greater	  acceptance	  of	  the	  possibility	  of	  new	  CD4	  
subsets.	  	  In	  the	  last	  few	  years,	  new	  CD4+	  T	  cell	  subsets	  have	  been	  touted,	  including	  Th9	  





upon	  their	  production	  of	  IL-­‐9,	  a	  cytokine	  initially	  thought	  to	  be	  derived	  from	  Th2	  or	  even	  
Th17	  cells	  (Nowak	  2009)	  but	  now	  shown	  to	  not	  be	  expressed	  with	  IL-­‐4,	  IL-­‐5,	  IL-­‐13,	  IL-­‐17	  
or	  IL-­‐22.	  	  Th22	  cells	  have	  been	  described	  in	  the	  human	  setting	  as	  skin-­‐homing	  cells	  that	  
do	  not	  produce	  IL-­‐17	  or	  RORγt,	  but	  as	  with	  Th9	  cells,	  at	  present	  the	  evidence	  is	  only	   in	  
vitro	   and	   without	   the	   identification	   of	   a	   master	   transcription	   factor,	   it	   is	   not	   clear	  
whether	  they	  are	  a	  new	  subset	  or	  just	  an	  adaption	  of	  another.	  	  	  
This	  openness	  to	  new	  subsets	  should	  however	  be	  approached	  with	  caution.	  	  Just	  as	  the	  
Th1	  and	  Th2	  paradigm	  simply	  provided	  simple	  guidelines,	   recent	  evidence	   is	  muddying	  
the	  waters	  and	  confusing	  the	  issue	  of	  whether	  terminal	  differentiation	  of	  cells	  exists	  or	  if	  
it	  is	  just	  a	  convenient	  method	  of	  classification.	  
	  
8.3.1.3 Inconsistencies	  
With	   the	   discovery	   of	   Th17	   cells	   and	   their	   importance	   to	   EAE	   brought	   an	  
ignorance/dismissal	  of	  the	  role	  of	  Th1	  cells	  in	  EAE	  and	  MS.	  	  However	  some	  observations	  
opened	  the	  door	   to	   the	   fact	   that	   it	  may	  not	  be	  that	  simple.	   	  Purified	  Th17	  populations	  
devoid	   of	   IFNγ	   producing	   cells	  were	   reported	   to	   be	   unable	   to	   induce	   EAE	   by	   adoptive	  
transfer	  whereas	  purified	  Th1	  populations	  could,	  and	  Th17	  cells	  seemed	  to	  require	  prior	  
Th1	  access	  to	  the	  CNS	  to	  infiltrate	  (O'Connor	  2008).	  	  The	  plasticity	  between	  these	  subsets	  
poses	  a	  major	  caveat,	  particularly	  the	  ease	  with	  which	  Th17	  polarised	  cells	  can	  switch	  to	  
Th1	   cells	   (Abromson-­‐Leeman	   2009,	   Bending	   2009,	   Nurieva	   2009,	   Domingues	   2010).	  	  
Using	  Rosa26	  fate	  reporter	  mice,	  it	  was	  shown	  that	  in	  the	  MOG/C57BL/6	  EAE	  model,	  the	  
majority	  of	  CNS-­‐infiltrating	  CD4	  cells	  are	  ex-­‐Th17,	  Th1	  cells	  (Hirota	  2011).	  Conversely,	  it	  is	  





transfer	   of	   Th1	   cells	   contained	   a	   contaminating	   population	   of	   Th17	   cell	   because	   the	  
length	  of	  in	  vitro	  stimulation	  with	  IL-­‐12	  was	  not	  long	  enough	  to	  suppress	  Th17	  cells	  (Jager	  
2009).	   	   It	   has	   been	   shown	   that	   EAE	   induced	   by	   Th1	   and	   Th17	   cells	   differ	   in	   both	   the	  
clinical	   and	   pathological	   features	   and	   is	   determined	   by	   the	   Th1:Th17	   ratio	   (Stromnes	  
2008).	  	  IL-­‐12	  polarized	  cells	  promoted	  expression	  of	  monocyte	  attracting	  chemokines	  and	  
the	   infiltrating	  cell	  populations	   into	  the	  spinal	  cord	  were	  rich	   in	  macrophages	  but	   IL-­‐23	  
polarized	   cells	   promoted	   neutrophil	   infiltration	   into	   the	   brain	   and	   their	   attracting	  
chemokines	   (Kroenke	  2008).	   In	  addition,	  T-­‐bet+RORγt+	  cells	  have	  also	  been	  observed	   in	  
the	   infiltrating	  population	   in	  EAE	  and	  Th17	   cells	   can	   switch	   to	  produce	   IFNγ	   (Shi	   2008,	  
Abromson-­‐Leeman	   2009)	   unlike	   Th1	   cell	   switching	   to	   a	   Th17	   phenotype.	   	   There	   are	  
repressive	  histone	  methylation	  marks	  in	  both	  the	  RORc	  and	  IL-­‐17	  loci	  in	  Th1	  cells	  making	  
it	  unlikely	  that	  Th1	  cells	  can	  switch	  to	  becoming	  Th17	  cells	  (Wei	  2009).	  	  In	  fact	  it	  has	  been	  
suggested	   that	   T-­‐bet	   expression	   defines	   encephalitogenicity	   of	   T	   cells	   (Yang	   2009b)	  
backed	  up	  as	   inhibition	  of	  T-­‐bet	  ameliorates	  EAE	  by	   inhibiting	  both	  Th1	  and	  Th17	  cells	  
(Bettelli	   2004,	  Nath	   2006,	  Gocke	   2007)	   raising	   the	   question	   of	   just	   how	  defined	   these	  
subsets	  are.	  	  T	  cells	  expressing	  both	  IFNγ	  and	  IL-­‐17	  have	  been	  observed	  in	  the	  MS	  brain	  
(Kebir	   2009)	   and	   although	   IL-­‐17	   and	   IFNγ	   are	   elevated	   during	   very	   early	   disease,	   it	   is	  
enhancement	   of	   IFNγ	   alone	   which	   is	   associated	   with	   relapses	   (Frisullo	   2008).	   	   IFNγ	  
responsiveness	  is	  also	  thought	  to	  be	  responsible	  for	  lesion	  localisation	  (Lees	  2008a)	  and	  a	  
large	  proportion	  of	  the	  IL-­‐17	  observed	  in	  brain	  lesions	  comes	  from	  host	  cells,	  mainly	  the	  
γδ	  T	  cells	  (Lees	  2008b).	  	  
It	  may	  be	  that	  the	  model	   itself	   is	  skewing	  these	  results	  however.	   	  Pertussis	  toxin,	  given	  





expression	  enhancing	  Th17	  differentiation	  (Chen	  2006)	  whist	  the	  mycobacterium	  within	  
the	  CFA	  can	  stimulate	  IL-­‐17	  production	  (Veldhoen	  2006a,	  Veldhoen	  2006b).	  	  This	  would	  
suggest	   that	   the	   induction	  of	  EAE	   increases	   the	   likelihood	  of	  observing	  Th17	   responses	  
and	   that	   they	   may	   not	   be	   the	   direct	   cause	   to	   the	   pathology	   seen.	   	   Additionally,	   the	  
mouse	  model	  used	  should	  be	  incorporated	  into	  the	  interpretation	  of	  results.	  	  In	  C57BL/6	  
mice	  Th1	  cells	  predominate	  at	  the	  peak	  of	  disease,	  whereas	  in	  the	  SJL	  model,	  more	  Th17	  
cells	  are	  observed	  (Langrish	  2005,	  Korn	  2007a).	  
	  
8.3.1.4 Tregs	  
Th1,	   Th2	   and	   Th17	   cells	   protect	   the	   host	   from	   diverse	   pathogens	   through	   their	   wide	  
repertoire	   of	   T	   cell	   receptor	   (TCR)	   expression.	   	   However,	   a	   number	   of	   them	   will	   be	  
generated	  with	  autoreactive	  TCRs	  and	  any	  that	  are	  not	  negatively	  selected	  in	  the	  thymus	  
must	  be	  inhibited	  in	  the	  periphery	  or	  the	  host	  will	  develop	  autoimmunity.	  	  Tregs	  appear	  
to	   be	   a	   critical	   mechanism	   by	   which	   this	   peripheral	   tolerance	   is	   maintained,	   while	  
retaining	   the	   correct	   scaling	   of	   immune	   responses	   to	   foreign	   antigens	   (Cobbold	   2006,	  
Belkaid	   2007).	   	   They	   were	   originally	   discovered	   after	   experiments	   involving	   the	  
inoculation	  of	  normal	  T	  cells	   into	  thymectomised	  syngeneic	  mice	  were	  able	  to	  suppress	  
the	   development	   of	   autoimmunity	   that	   would	   normally	   develop	   after	   thymectomy	  
(Sakaguchi	   1982).	   	   Therefore	   animals	   possessed	   cells	   capable	   to	  protecting	   themselves	  
from	   autoimmunity	   as	   well	   as	   those	   which	   are	   potentially	   pathogenic.	   	   The	   cell	  
population	   responsible	  was	   initially	   identified	   by	   adoptive	   transfer	   experiments.	   	   CD4+	  
spleen	  cell	  populations	  depleted	  ex	  vivo	  of	  CD5high	  and	  CD45RClow	  were	  transferred	  into	  





These	  initial	  experiments	  identifying	  a	  phenotypic	  marker	  and	  the	  further	  discopvery	  of	  a	  
more	  specific	  marker,	  CD25,	  affirmed	  these	  cells	  as	  an	  individual	  population	  responsible	  
of	  protection	  from	  autoimmunity	  (Sakaguchi	  1995).	  	  	  
Tregs	  include	  both	  natural	  and	  inducible	  Treg	  cells,	  the	  natural	  subset	  classically	  defined	  
as	   CD4+CD25+	   and	   positive	   for	   their	   characteristic	   transcription	   factor	   Foxp3	   (Fontenot	  
2003,	   Hori	   2004).	   	   Inducible	   Tregs	   (Tr-­‐1,	   Th3)	   are	   derived	   from	   naïve	   T	   cells	   in	   the	  
periphery.	  They	  are	  stimulated	  by	  antigen	  in	  the	  presence	  of	  anti-­‐inflammatory	  cytokines	  
e.g.	   IL-­‐10	  and	  TGFβ	  and	  act	  to	  increase	  the	  levels	  of	  these	  cytokines	  in	  the	  local	  milieu.	  	  
nTregs	   on	   the	   other	   hand	   have	   been	   shown	   to	   utilise	   multiple	   mechanisms	   of	   action	  
including	   cell-­‐cell	   contact,	   local	   competition	   for	   growth	   factors	   and	   local	   secretion	   of	  
inhibitory	  cytokines	  (Sojka	  2008).	  	  	  
The	   importance	   of	   Tregs	   is	  most	   apparent	  when	  mutations	   occur	   that	   prevent	   normal	  
function	  of	   these	  cells.	   	  Mutations	   in	   the	  Foxp3	  gene	   lead	  to	  a	  severe	  and	  rapidly	   fatal	  
condition	   called	   Immunodysregulation	   polyendocrinopathy	   enteropathy	   X-­‐linked	  
syndrome	  (IPEX)	  in	  humans	  and	  scurfy	  in	  mice	  (Wildin	  2002,	  Khattri	  2003).	  	  Both	  lead	  to	  
systemic	  autoimmunity	  from	  birth	  and	  human	  patients	  usually	  die	  within	  a	  year	  of	  birth.	  	  
Using	  an	  in	  vivo	  ablation	  model,	  it	  has	  also	  been	  shown	  that	  Tregs	  are	  required	  not	  just	  in	  
neonates	  but	  throughout	  adult	  life	  to	  prevent	  the	  onset	  of	  large-­‐scale	  autoimmunity	  (Kim	  
2007).	  
Therefore	  Tregs	  were	  assumed	  to	  play	  a	  role	   in	  MS.	   	  An	  initial	  study	  reporting	  a	   loss	  of	  
suppressive	  ability	  of	  Tregs	  derived	  from	  patients	  with	  MS	  suggested	  that	  it	  was	  a	  disease	  
of	  aberrant	  regulation	  (Viglietta	  2004),	  but	  since	  there	  have	  been	  mixed	  reports	  on	  the	  





blood	  of	  MS	  patients	  (Haas	  2007,	  Venken	  2008b),	  especially	  those	  that	  have	  recently	  left	  
the	  thymus	  but	  most	  have	  found	  no	  difference	  between	  patients	  and	  controls	  (Hellings	  
2001,	   Haas	   2005,	   Feger	   2007).	   	   However,	   and	   slightly	   paradoxically,	   an	   increased	  
frequency	   of	   nTregs	   was	   found	   in	   the	   CSF	   but	   not	   the	   blood	   of	  MS	   patients	   (Venken	  
2008b).	   	   This	   would	   suggest	   an	   impairment	   in	   the	   function	   of	   Tregs	   rather	   than	   their	  
population	  size	  or	  migration	  potential	  and	  using	  in	  vitro	  suppression	  assays,	  a	  number	  of	  
groups	  have	  found	  impairments	  in	  the	  functionality	  of	  Tregs	  in	  MS	  patients	  (Tsaknaridis	  
2003,	  Viglietta	  2004,	  Haas	  2005,	  Kumar	  2006,	  Feger	  2007,	  Venken	  2008a,	  Frisullo	  2009)	  
but	  this	  may	  be	  reversed	  after	  therapy	  (Hong	  2005,	  de	  Andres	  2007,	  Korporal	  2008).	  	  The	  
complication	   in	   these	   results	  was	   the	   limitation	   in	  being	  able	   to	  sort	  Tregs	  based	  upon	  
CD25hi	   expression.	   	  CD25	   is	  also	  upregulated	  on	  activated	  T	   cells	   and	   so	   some	  effector	  
cells	  may	  also	  have	  been	  sorted	  and	  this	  led	  to	  the	  inconsistent	  results.	  	  However	  in	  two	  
of	  the	  studies,	  the	  functional	  impairments	  of	  the	  Tregs	  was	  associated	  with	  lower	  Foxp3	  
expression	  at	  both	  the	  mRNA	  and	  protein	  level	  (Huan	  2005,	  Venken	  2008b)	  but	  at	  later	  
stages	  of	  the	  disease,	  such	  as	  in	  secondary	  progressive	  forms,	  the	  Tregs	  showed	  a	  normal	  
suppressive	   function	  and	  Foxp3	   levels	  compared	   to	  RR-­‐MS	  patients	   (Venken	  2006).	   	  By	  
observation	  of	  Foxp3+	  by	  immunostaining,	  one	  group	  has	  also	  noted	  an	  absence	  of	  Tregs	  
in	  active	  MS	  lesions	  (Tzartos	  2008)	  throwing	  doubt	  on	  the	  ability	  of	  Tregs	  to	  migrate	  into	  
the	  inflamed	  CNS.	  
In	  mice,	  more	  direct	  evidence	  has	  been	  generated	  that	  Tregs	  have	  an	  important	  role	   in	  
EAE.	   	  An	  early	  study	  showed	  that	   the	  presence	  of	  non-­‐transgenic	  CD4+	  T	  cells	  prevents	  
spontaneous	   autoimmunity	   in	  MBP	   TCR	   transgenic	  mice,	   an	   observation	   subsequently	  





transfer	  of	  CD4+CD25+	  T	  cells	  reduced	  disease	  severity	  in	  MOG-­‐induced	  EAE	  (Kohm	  2002).	  	  
The	   frequency	  of	   antigen-­‐specific	   Tregs	  has	   also	  been	   shown	   to	   correlate	  with	  disease	  
susceptibility	   across	   a	   range	  of	  mouse	   strains	   in	   the	   PLP-­‐induced	  model	   (Reddy	   2004).	  	  
Depletion	  of	  CD25+	  cells	  decreased	  the	  threshold	  of	  antigen	  required	  to	  induce	  EAE	  and	  
prevented	  efficient	   recovery	   (Stephens	  2005,	  Korn	  2007a).	   	   	  Resistant	  B10	  mice	  can	  be	  
made	   susceptible	   to	   EAE	   through	   administration	   of	   anti-­‐CD25	   (Reddy	   2004),	   a	  
component	   of	   this	   dependent	   on	   gender	   as	   the	   susceptibility	   increases	   to	   a	   greater	  
extent	   in	   the	  male	  mice	   compared	   to	   the	   female	   (Reddy	   2005).	   	   Disease	   severity	   and	  
mortality	  were	  increased	  in	  a	  PLP139-­‐151	  induced	  EAE	  model	  following	  Treg	  depletion	  with	  
anti-­‐CD25	  (Zhang	  2004b).	  
As	   in	  humans,	   in	  mice	   it	  has	  been	  seen	   that	  Tregs	  accumulate	   in	   the	  CNS	   through	  EAE	  
although	   they	  were	  mainly	   seen	   during	   the	   recovery	   phase	   of	   the	   disease	   (McGeachy	  
2005,	  Liu	  2006b,	  Korn	  2007b).	  	  Depletion	  of	  the	  Treg	  population	  inhibits	  recovery	  of	  the	  
animals	  (McGeachy	  2005)	  but	  the	  suppressive	  ability	   is	  not	  clear:	  Tregs	  taken	  from	  one	  
model	   at	   peak	   of	   disease	   were	   unable	   to	   suppress	   CNS	   derived	   effector	   T	   cells	   (Korn	  
2007b)	   but	   from	   another	   CNS	   –derived	   Tregs	   taken	   from	   the	   CNS	   during	   the	   recovery	  
phase	  of	  EAE	  could	  suppress	  MOG-­‐specific	   IFNγ	  but	  not	   IL-­‐17	   in	  vitro	   (O'Connor	  2007).	  	  
The	  Tregs	  from	  the	  CNS	  appear	  to	  be	  derived	  from	  proliferation	  of	  host	  Tregs	  rather	  than	  
conversion	  of	   non-­‐Tregs	   (Korn	  2007b,	  O'Connor	   2007)	   and	   the	   inflamed	  CNS	  has	  been	  
shown	  to	  specifically	  drive	  the	  proliferation	  of	  Treg	  cells	  (O'Connor	  2007)	  in	  opposition	  to	  
a	  study	  that	  suggested	  that	  Tregs	  could	  be	  converted	  from	  effector	  cells	  in	  the	  CNS	  (Liu	  





Adoptive	   transfer	   of	   Tregs	   has	   been	   shown	   to	   provide	   protection	   against	   MOG35-­‐55	  
induced	  EAE	  (Kohm	  2002)	  and	  in	  this	  instance	  there	  was	  a	  decreased	  infiltration	  of	  cells	  
into	   the	   CNS.	   	   As	   a	   final	   complication,	   recent	   observations	   are	   that	   Foxp3+	   Tregs	   can	  
produce	  IL-­‐17	  and	  IFNγ	  which	  may	  explain	  the	  difficulties	  in	  showing	  suppressive	  effects,	  
but	  also	  opens	  the	  question	  of	  how	  terminal	  is	  the	  differentiation	  into	  a	  Treg	  phenotype	  
(Koenen	  2008,	  Ayyoub	  2009,	  Beriou	  2009,	  Komatsu	  2009).	  	  
It	  was	   thought	   that	   Tregs	   and	   Th17	   cells	  may	  be	   reciprocally	   differentiated,	   and	   come	  
from	  the	  same	  progenitor	  cells	  (Bettelli	  2006b).	  	  Support	  from	  this	  came	  from	  the	  need	  
for	   TGFβ	   to	  differentiate	  both	   (Oukka	  2007),	  with	   Th17	   cells	   favoured	   in	   inflammatory	  
conditions	   (IL-­‐1,	   IL-­‐6)	   or	   when	   other	   Th17	   cells	   are	   able	   to	   produce	   these	   cytokines	  
(Veldhoen	  2006a).	   	   In	  vitro	   it	  was	  shown	  that	  Tregs	  could	  substitute	  for	  TGFβ	  in	  a	  Th17	  
generating	  cell	  culture	  (Veldhoen	  2006a)	  and	  in	  a	  model	  of	  systemic	  autoimmunity,	  the	  
transfer	   of	   Tregs	   enhanced	   the	   Th17	   population	   (Lohr	   2006).	   	   IL-­‐2	   is	   required	   for	   the	  
maintenance	   of	   the	   Treg	   population	   (Yu	   2006)	   but	   inhibits	   the	   differentiation	   of	   Th17	  
cells	   (and	  Th1,	  Th2)	   (Laurence	  2007)	   so	   it	   could	  be,	   as	  with	   the	  other	   subsets	   that	   the	  
cytokine	  milieu	  in	  fact	  determines	  differentiation	  above	  all	  else.	  Other	  factors	  such	  as	  the	  
aryl	   hydrocarbon	   receptor	  provide	   a	  more	   specific	   developmental	   switch	   incorporating	  
environmental	   stimuli	   in	   the	   form	  of	   ligands	  driving	  one	   lineage	  at	   the	  expense	  of	   the	  
other	   (Quintana	   2008a,	   Veldhoen	   2008a).	   	   Such	   a	   reciprocal	   relationship	   may	   have	  
evolved	   to	   allow	   a	   targeted	   cellular	   function	   in	   response	   to	   the	   environment,	   both	  
internal	  and	  external.	  	  	  	  	  	  
A	   great	   deal	   of	   research	   has	   centred	   on	   the	   role	   immune	   cells	   play	   in	   mediating	   the	  





their	  contribution	  into	  what	  is	  a	  very	  complicated	  set	  of	  events.	  	  Each	  model	  or	  study	  has	  
been	   focused	   on	   a	   different	   aspect	   but	   without	   the	   complete	   model	   it	   is	   hard	   to	   tie	  
together	  observations	   from	  disparate	  settings	  and	   try	   to	   reach	  a	  consensus	  about	  how	  
the	   immune	   pathology	   is	   mediated	   and	   which	   cell	   types	   are	   the	   most	   important	   or	  
limiting.	   	   In	   this	   section	   I	  will	   summarise	  what	   is	   known	  about	  each	  of	   the	  other	   (non-­‐
CD4)	  major	  cell	  types	  and	  their	  hypothesised	  role	  in	  MS,	  coming	  from	  experiments	  with	  
human	  samples	  and	  animal	  models.	  	  	  	  	  
	  
8.3.2 Roles	  of	  Other	  Immune	  Cells	  
8.3.2.1 Mast	  cells	  
Mast	   cells	   are	   present	   in	   the	   parenchyma	   of	   the	   normal	   brain	   and	   at	   the	   blood	   brain	  
barrier	   (Silver	   1996).	   	   They	  have	  been	   seen	   to	   cluster	   in	  CNS	   lesions	  of	  MS	  patients	   in	  
both	  MS	  plaques	  and	  normal	  appearing	  white	  matter	   (Olsson	  1974,	  Toms	  1990,	  Kruger	  
2001)	  and	  mice	  lacking	  mast	  cells	  develop	  a	  milder	  form	  of	  EAE	  (Secor	  2000).	  	  However,	  
the	   role	   of	  mast	   cells	   is	   not	   clear	   as	   a	   recent	   studies	   in	  mast	   cell	   deficient	  mice	   have	  
described	  more	  severe	  EAE	   (Bennett	  2009)	  despite	   their	  usual	   trafficking	   to	   the	  CNS	   in	  
EAE	  (Bennett	  2009)	  and	  a	  significant	  reduction	  in	  mast	  cells	  has	  been	  observed	  in	  brains	  
of	   rats	  with	   EAE	   (Brenner	   1994).	   	   In	   the	   latter	   case,	   a	   higher	   proportion	   of	  mast	   cells	  
appear	  to	  be	  degranulated	  (Brenner	  1994)	  and	  this	  corresponds	  with	  other	  data	  showing	  
that	  mast	  cells	  can	  be	  activated	  by	  myelin	  (Medic	  2008)	  and	  mast	  cell	  derived	  proteases	  
could	   contribute	   to	  MBP	   degradation	   (Johnson	   1988).	   	  Mast	   cells	   are	   also	   thought	   to	  
have	  a	  role	  in	  the	  breakdown	  of	  the	  blood	  brain	  barrier	  as	  molecules	  such	  as	  histamine	  





CNS	   (Lock	   2002,	   Lapilla	   2010).	   	   Roles	   such	   as	   these	   highlight	   the	   importance	   of	   the	  
interplay	  between	  the	  adaptive	  and	   innate	   immune	  systems	   in	  the	  pathogenesis	  of	  MS	  
and	  whilst	   not	   directly	   investigated	   in	   this	   study,	   certainly	   contribute	   to	   the	   variety	   of	  
clinical	  forms	  observed,	  beyond	  the	  directly	  T	  cell	  mediated	  component	  (Pedotti	  2003).	  
	  
8.3.2.2 γδ	  T	  Cells	  
The	  exact	  role	  that	  TCR	  γδ	  T	  cells	  play	  in	  MS	  is	  unclear.	  	  They	  have	  been	  observed	  in	  MS	  
lesions	  (Selmaj	  1991a)	  and	  clonally	  expanded	  cells	  were	  found	  in	  CSF	  taken	  from	  patients	  
with	   recent-­‐onset	  disease	   (Shimonkevitz	  1993)	   along	  with	   increases	   in	   their	  number	   in	  
peripheral	  blood	  (Stinissen	  1995).	  	  Studies	  in	  EAE	  have	  shown	  γδ	  T	  cells	  to	  be	  protective	  
(Kobayashi	  1997,	  Ponomarev	  2004,	  Ponomarev	  2005),	  promote	  EAE	   (Olive	  1995,	  Rajan	  
1996,	  Rajan	  1998,	  Spahn	  1999,	  Odyniec	  2004)	  or	  have	  no	  effect	  (Matsumoto	  1998).	  	  γδ	  T	  
cells	   are	   found	   in	   the	   CNS	   of	   mice	   with	   EAE	   (Sobel	   1992)	   and	   they	   may	   lyse	  
oligodendrocytes	   (Freedman	   1991)	   and	   prevent	   remyelination	   (Selmaj	   1991a)	   or	  
contribute	   to	   recovery	   through	   Fas-­‐FasL	   induced	   apoptosis	   of	   encephalitogenic	   T	   cells	  
(Ponomarev	  2004,	  Ponomarev	  2005).	  
	  
8.3.2.3 Dendritic	  Cells	  
Dendritic	  cells	  are	  implicated	  in	  the	  pathogenesis	  of	  MS	  as	  they	  present	  antigen	  to	  T	  cells	  
and	  so	  can	  therefore	  drive	  an	  autoimmune	  response	  by	  presenting	  self	  peptides	  as	  well	  
as	  shaping	  polarisation	  of	  the	  T	  cell	  response.	  	  DCs	  are	  reported	  to	  be	  found	  in	  elevated	  





some	  of	  which	   are	   seen	   to	  have	   taken	  up	  myelin	   (Serafini	   2006).	   	  DCs	  have	   also	  been	  
shown	  to	  accumulate	   in	  the	  CNS	  and	  either	   initiate	  EAE	  (Dittel	  1999,	  Weir	  2002,	  Bailey	  
2007)	  or	  mediate	   tolerance	   (Khoury	  1995,	  Xiao	  2004)	   in	   studies	   involving	   the	  adoptive	  
transfer	  of	  activated	  myelin	  antigen	  pulsed	  DCs.	  	  	  
Different	   subsets	   of	   DCs	   appear	   to	   behave	   differently	   in	   MS	   patients.	   	   DCs	   from	  
peripheral	  blood	  of	  MS	  patients	  are	  activated,	  with	  expression	  of	  activation	  markers	  and	  
increased	   production	   of	   inflammatory	   cytokines	   whereas	   plasmacytoid	   DCs	   show	  
decreased	  or	   delayed	  expression	  of	   activation	  markers	  when	   isolated	   from	  MS	  patient	  
peripheral	   blood	   (Stasiolek	   2006).	   	   DCs	   are	   also	   likely	   to	   be	   the	   cells	   driving	   epitope	  
spreading	  as	  observed	  in	  MS	  patients.	  	  CNS-­‐invading	  myeloid	  DCs	  have	  been	  reported	  to	  
drive	  this	  spread	  in	  both	  a	  relapsing	  EAE	  and	  TMEV	  model	  of	  demyelination	  (McMahon	  
2005).	  	  	  
Numerous	   attempts	   have	   also	   been	   made	   to	   manipulate	   DCs	   in	   order	   to	   treat	   EAE.	  	  
Severity	  of	  disease	  could	  be	  reduced	  after	  injection	  of	  mature	  DCs	  as	  they	  promoted	  high	  
levels	   of	   IL-­‐10	   production	   at	   the	   expense	   of	   IL-­‐12,	   inhibiting	   the	   pro-­‐inflammatory	  
response	  (Zhang	  2002).	  	  IFNγ	  treated	  DCs	  have	  also	  been	  shown	  to	  reduce	  EAE	  severity	  
somewhat	   paradoxically,	   through	   prevention	   of	   the	   upregulation	   of	   co-­‐stimulatory	  
molecules	  in	  the	  presence	  of	  pro-­‐inflammatory	  cytokines	  (Xiao	  2004),	  and	  DCs	  matured	  
in	  the	  presence	  of	  TNFα	  with	  an	  autoantigenic	  peptide	  lead	  to	  a	  similar	  phenotype	  but	  by	  
an	  opposite	  mechanism,	  through	  an	  up-­‐regulation	  of	  co-­‐stimulatory	  molecules	  but	  weak	  
pro-­‐inflammatory	   cytokine	   response	   (Menges	   2002).	   	   Other	   groups	   promoted	   IL-­‐10	  





with	  SOCS-­‐3	  (suppressor	  of	  cytokine	  signalling	  inhibitor)	  (Li	  2006),	  or	  loaded	  mitomycin	  C	  
treated	  DCs	  with	  MBP	  to	  inhibit	  disease	  induction	  and	  severity	  (Terness	  2008).	  	  	  
	  
8.3.2.4 Macrophages/Microglia	  
Microglia	   are	   considered	   to	   be	   CNS	   resident	   macrophages,	   reflected	   by	   their	   roles	   in	  
antigen	   presentation,	   phagocytosis	   and	   cytokine	   production	   (Benveniste	   1997).	   	   All	  
known	  Toll-­‐like	  receptors	  (TLRs)	  are	  expressed	  by	  microglial	  cells	  and	  their	  expression	  is	  
increased	   in	  CNS	   lesions	   in	  both	  EAE	  and	  human	  disease	   (Bsibsi	  2002).	   	  MS	  patients’	  T	  
cells	   specific	   for	  myelin	  have	  been	  show	  to	  activate	  microglia	  and	  macrophages	  and	  as	  
these	   cells	   have	   been	   shown	   to	   be	   involved	   in	   demyelination	   and	   phagocytosis	   of	  
degraded	  myelin	   (Bauer	   1994).	   	   This	   phagocytosis	   can	   lead	   to	   increased	   expression	   of	  
myeloperoxidases	  (Gray	  2008),	  causing	  neuronal	  damage.	  	  	  
Microglia	  are	  also	  involved	  in	  activating	  T	  cell	  populations	  and	  increasing	  infiltration	  into	  
the	   CNS,	   while	   themselves	   mediating	   damage	   directly.	   	   The	   secretion	   of	   macrophage	  
inflammatory	   protein	   1	   alpha	   (MIP1α)	   and	   monocyte	   chemotactic	   protein	   1	   (MCP1)	  
(Hofmann	  2002)	  and	  upregulation	  of	  their	  receptors	  CCR1	  and	  CCR2	  have	  been	  reported	  
on	  microglia	  (Eltayeb	  2007),	  leading	  to	  increased	  attraction	  for	  leucocytes	  to	  the	  CNS.	  	  In	  
this	  way,	  MCP1	  knock-­‐out	  mice	  or	  those	  treated	  with	  anti-­‐MIP1α	  antibodies	  developed	  
EAE	  with	   lower	   leucocyte	   infiltration	  and	  therefore	   less	  severe	  signs	  of	  disease	   (Karpus	  
1995,	   Izikson	   2000).	   	   CD40	   expression	   on	   brain	   resident	  microglia	   is	   essential	   for	   CNS	  
leucocyte	   infiltration	  and	  EAE	   induction	   (Becher	  2001)	   and	  MHC	  class	   II	  molecules	   and	  
associated	  transcription	  factors	  have	  been	  found	  to	  be	  upregulated	  on	  microglia	  in	  both	  





CD40	  (Windhagen	  1995,	  Gerritse	  1996).	  	  The	  expression	  of	  MHC	  class	  II	  molecules	  could	  
have	  both	   protective	   and	  pathogenic	   roles	   depending	   on	   the	   cells	   expressing	   it.	   	  MHC	  
class	   II	   antigens	   expressed	   on	   microglia	   may	   activate	   Tregs	   (Almolda	   2010)	   favouring	  
remission,	  whereas	  expression	  on	  perivascular	  macrophages	  activates	  pathogenic	  helper	  
T	  cells	  and	  thereby	  promotes	  EAE	  (Hickey	  1988).	  	  In	  EAE,	  macrophages	  have	  been	  seen	  to	  
upregulate	  CD80	  and	  downregulate	  CD86,	  suggesting	  pathogenic	  and	  protective	  roles	  for	  
these	  co-­‐stimulatory	  molecules	  respectively.	  	  By	  blocking	  the	  CD80-­‐CD28	  interaction,	  EAE	  
can	   be	   suppressed	   by	   deletion	   of	   peripheral	   antigen	   specific	   CD4+	   T	   cells	   (Srinivasan	  
2002)	  whereas	  blocking	  of	  CD86	  or	  its	  ligand,	  CTLA-­‐4,	  EAE	  could	  be	  made	  worse	  (Kuchroo	  
1995,	  Hurwitz	  1997).	  	  	  
As	   well	   as	   directly	   activating	   T	   cells,	   microglia	   can	   produce	   factors	   that	   mediate	   CNS	  
damage.	   	   Glutamate	   production	   by	   macrophages/microglia	   correlates	   with	   axonal	  
damage	   in	   EAE	   (Werner	   2001)	   and	   the	   main	   factors	   driving	   glutamate	   degradation,	  
glutamate	  transporters	  and	  degrading	  enzymes	  were	  also	  downregulated	  (Hardin-­‐Pouzet	  
1997,	  Ohgoh	  2002).	  	  Blocking	  of	  the	  glutamate	  receptor	  reduces	  demyelination	  and	  stops	  
disease	   progression	   (Pitt	   2000).	   	   Macrophages/microglia	   are	   also	   potent	   producers	   of	  
inducible	  nitric	  oxide	   synthase	   (iNOS)	   in	  EAE	  which	   can	  be	  mediated	  by	  MBP-­‐primed	  T	  
cells	  (Dasgupta	  2002)	  and	  leads	  to	  the	  production	  of	  the	  free-­‐radical	  NO.	  	  Inhibiting	  NOS	  
suppressed	  the	  disease	  (Zhao	  1996)	  but	  complete	  lack	  of	  NO	  exacerbated	  disease	  (Fenyk-­‐
Melody	  1998)	  so	  there	  must	  be	  a	  minimal	  threshold	  necessary	  for	  homeostasis.	  	  	  
Microglia	  are	   reported	  also	   to	   secrete	  anti-­‐inflammatory	   cytokines	   such	  as	   IL-­‐10	   in	   the	  





neurogenesis,	   such	   as	   brain-­‐derived	   neurotrophic	   factor,	   insulin-­‐like	   growth	   factor	   and	  
neurotropin-­‐3	  (Napoli	  2010).	  	  	  
	  
8.3.2.5 B	  cells	  
B	   cells	   have	   dual	   roles	   in	  mediating	   an	   immune	   response,	   by	   releasing	   antibodies	   and	  
acting	   as	   antigen	   presenting	   cells	   for	   T	   cells.	   	   MS-­‐like	   disease	   is	   not	   transferable	   by	  
antibodies	  (Lassmann	  1983)	  and	  plasmapharesis	  has	  not	  been	  a	  successful	  treatment	  for	  
MS,	  so	  the	  role	  of	  the	  B	  cell	  response	  in	  this	  disease	  has	  been	  difficult	  to	  elucidate.	  One	  
clue	  to	  the	  role	  of	  B	  cells	  came	  from	  characterization	  of	  EAE	   in	   Igµ-­‐null	  mice	  (Kitamura	  
1991).	  	  In	  these	  mice	  the	  development	  of	  B	  cells	  is	  arrested	  at	  the	  pre-­‐B	  cell	  stage	  as	  they	  
are	  unable	  to	  produce	  the	  heavy	  chain	  of	  IgM	  (μ	  chain)	  and	  so	  mice	  are	  generated	  lacking	  
mature	  B	  cells.	  	  Induction	  of	  EAE	  in	  these	  mice	  was	  comparable	  to	  controls	  but	  recovery	  
was	   impaired	   leading	   to	   the	  conclusion	  that	  B	  cells	   influence	  the	   immune	  regulation	   in	  
EAE	  (Wolf	  1996).	  	  A	  key	  study	  by	  Genain	  and	  colleagues	  proposed	  a	  possible	  contributory	  
role	  of	   antibody	   in	   a	  primate	  model	  of	  MOG-­‐induced	  EAE	   (Genain	  1999)	   in	   agreement	  
with	   long	   established	   observations	   from	   rodent	   models	   (Linnington	   1984).	   	   However,	  
many	  of	  the	  myelin	  components	  targeted	  by	  the	  immune	  response	  in	  autoimmunity	  are	  
not	  accessible	  to	  antibody	  on	  the	  surface	  of	  the	  myelin	  sheath.	  
An	   important	   role	   for	   B	   cells	   in	   EAE	   was	   highlighted	   as	   removal	   of	   them	   before	  
immunization	   worsened	   the	   disease	   course.	   	   There	   was	   an	   increase	   in	   leucocyte	  
infiltration	   into	   the	   CNS	   and	  more	   severe	   demyelination	   (Matsushita	   2008)	   probably	   a	  
result	  of	  removing	  a	  regulatory	  B	  cell	  subset	  as	  adoptive	  transfer	  of	  these	  cells	  prior	  to	  





as	   administration	   with	   rituximab	   (anti-­‐CD20)	   during	   disease	   onset	   actually	   reduced	  
leucocyte	   infiltration	   and	   demyelination.	   	   There	   were	   fewer	   and	   less	   active	   T	   cells	  
probably	  as	  a	  result	  of	   lacking	  co-­‐stimulation	  in	  disease	  initiation	  (Matsushita	  2008).	   	   In	  
the	   human	   setting,	   rituximab	   has	   been	   effective	   in	   reducing	   inflammatory	   CNS	   lesions	  
and	  relapses	  over	  48	  weeks	  (Hauser	  2008).	  	  	  
Aggregates	   of	   B	   cells	   in	   the	  meninges	   of	  MS	   patients	  were	   first	   described	   by	   Serafini,	  
present	   in	   40%	   of	   secondary	   progressive	   cases	   (Serafini	   2004).	   	   The	   aggregates	  
resembled	  germinal	  centres	  with	  B	  cells,	  plasma	  cells,	  T	  cells,	  macrophages	  and	  follicular	  
dendritic	  cells.	  	  The	  white	  matter	  lesions	  did	  not	  differ	  but	  these	  patients	  showed	  more	  
severe	  grey	  matter	  lesions	  (Magliozzi	  2007).	  	  However,	  this	  secondary	  lymphoid	  structure	  
has	  been	  observed	   in	  other	  autoimmune	  diseases	  and	   in	  other	  neurological	   conditions	  
(Carragher	  2008).	  	  These	  ectopic	  B	  cell	  structures	  have	  been	  reconstituted	  in	  mice	  to	  an	  
extent	  as	  adoptive	  transfer	  of	  Th17	  cells	  co-­‐cultured	  with	  IL-­‐23	  could	  be	  seen	  to	  form	  B	  
cell	  aggregates	  (Jager	  2009).	  	  	  
When	   MOG-­‐specific	   B	   cells	   are	   present	   to	   act	   as	   APC,	   MOG-­‐specific	   T	   cells	   show	  
enhanced	   proliferation	   and	   secretion	   of	   IFNγ	   in	   response	   to	   the	   recombinant	   protein	  
(Bettelli	  2006a).	  	  It	  has	  also	  been	  shown	  that	  transgenic	  mice	  expressing	  MOG-­‐specific	  B	  
and	  T	  cells	  develop	  spontaneous	  EAE	  and	  the	  B	  and	  T	  cells	  produced	  more	  MOG-­‐specific	  
IgG	  and	  IFNγ	  and	  IL-­‐17	  respectively	  than	  control	  mice	  carrying	  a	  MOG-­‐specific	  B	  or	  T	  cell	  
component	  (Bettelli	  2006a).	  	  	  
Clonally	   expanded	   B	   cells	   have	   been	   found	   in	   the	   CSF	   and	   CNS	   of	   patients.	   	   Positive	  
selection	  based	  on	   the	  matching	   antigen	  was	   suggested	   as	   the	   Ig	   heavy-­‐chain	   variable	  





is	  the	  identification	  of	  oligoclonal	  IgG	  bands	  by	  isoelectric	  focusing	  in	  the	  CSF,	  and	  myelin	  
specific	  antibodies	  have	  been	  detected	   in	   the	  CSF	   reactive	   to	  MBP,	  PLP	   (Warren	  1994)	  
and	  MOG	  where	  they	  often	  bind	  to	  disintegrating	  myelin	  (Genain	  1999).	  	  More	  recently	  
these	  oligoclonal	   Ig	  bands	  have	  been	   linked	   to	   the	   Ig	   transcriptomes	  of	  B	   cells	  derived	  
from	  MS	   patients’	   CSF	   (Obermeier	   2008).	   	   This	  work	   confirmed	   that	   the	   intrathecal	   Ig	  
response	   is	   directly	   relevant	   to	   MS	   pathogenesis	   adding	   retrospective	   support	   to	  
previous	  studies	  of	  CSF	  derived	  B	  cells	  and	  antibodies.	  	  	  
Resistance	   to	   EAE	   by	   early	   removal	   of	   B	   cells	   through	   anti-­‐IgM	   could	   be	   overcome	  
through	   administration	   of	   serum	   containing	  MBP	   or	  MOG	   specific	   antibodies	   although	  
this	  required	  administration	  of	  the	  requisite	  myelin	  peptide	  as	  well	  as	  passive	  transfer	  of	  
serum	  alone	  was	  not	   sufficient	   to	   induce	  EAE	   (Lassmann	  1983,	  Willenborg	  1986,	   Lyons	  
2002).	   	   An	   acceleration	   of	   EAE	   in	   a	   mouse	   overproducing	   MOG-­‐specific	   antibodies	  
irrespective	   of	   the	   myelin	   antigen	   used	   has	   been	   observed	   (Litzenburger	   1998)	   and	  
antibodies	  to	  other	  myelin	  antigens	  have	  been	  implicated	  in	  promotion	  of	  demyelination	  
(Schluesener	  1987,	  Lassmann	  1988).	  	  Therefore	  autoantibodies	  may	  play	  a	  crucial	  role	  in	  
driving	   MS	   pathogenesis	   and	   more	   recently,	   attempts	   have	   been	   made	   to	   identify	   a	  
different	  antibody	  profile	   for	  MS	  patients	  with	  each	  various	   form	  of	   the	  disease	   to	  aid	  
diagnosis	  (Reindl	  2006,	  Quintana	  2008b).	  	  	  
	  
8.3.2.6 iNKT	  cells	  
Invariant	  Natural	  Killer	  T	  cells	  (iNKT)	  are	  considered	  part	  of	  the	  innate	  repertoire	   in	  the	  
sense	   that	   they	   do	   not	   utilise	   clonotypic	   receptors	   and	   express	   immune	  memory,	   but	  





killer	   (NK)	   cells.	   They	   recognise	   glycolipid	   antigens	   presented	   by	   CD1d.	   	   They	   express	  
TCRα	  and	  β	  chains	  but	  have	  a	  highly	  limited	  repertoire	  because	  they	  express	  only	  one	  α	  
chain	  (Vα24-­‐Jα18	  in	  humans	  and	  Vα14-­‐Jα18	  in	  mice)	  that	  couple	  with	  only	  a	  few	  β	  chains	  
(Vβ11	   in	  humans,	  Vβ8.2,	  Vβ2	  and	  Vβ7	   in	  mice).	   	  The	  Vβ	  chains	  show	  a	  degree	  of	  CDR3	  
diversity,	   presumed	   to	   impact	  on	  antigen	  binding	   affinity	   (Matulis	   2010).	   	  A	   consensus	  
regarding	  their	  role	   in	  the	  immune	  system	  is	  still	  a	  matter	  for	  debate.	   	  After	  activation,	  
iNKT	   cells	   have	  been	   shown	   to	  produce	   a	  wide	   array	  of	   cytokines,	   both	  pro-­‐	   and	   anti-­‐
inflammatory	   including	   IL-­‐4,	   IL-­‐6,	   IL-­‐10,	   IL-­‐17A,	   IFNγ	   and	   TGFβ	   (Taniguchi	   2003,	  
Kronenberg	   2005).	   	   Therefore	   iNKT	   cells	   are	   able	   to	   display	   both	   pathogenic	   (e.g.	  
Chlamydia	  muridarum)	   and	   protective	   (e.g.	   Streptococcus	   pneumoniae	   and	   Leishmania	  
major)	  roles	  in	  different	  microbial	   infections	  (Brigl	  2003,	  Ronet	  2005,	  Tupin	  2007).	   	  This	  
variety	   of	   cytokines	   secreted	   implicates	   iNKT	   cells	   in	   both	   protective	   and	   promotional	  
roles	   for	  autoimmune	  conditions	   (Miyamoto	  2001,	   Singh	  2001,	  Wu	  2009,	  Caielli	   2011),	  
whereby	   the	   usual	   Th2	   bias	   would	   lead	   to	   the	   reduction	   of	   symptoms	   but	   the	  
polarisation	   of	   iNKT	   cells	   to	   produce	   Th1	   cytokines	   could	   exacerbate	   existing	  
inflammation	  (Wilson	  2003,	  Kent	  2005).	  	  	  
Overexpression	  of	   invariant	  TCR	   in	  non-­‐obese	  diabetic	   (NOD)	  mice	  was	  seen	   to	   lead	   to	  
protection	  from	  EAE	  by	  reducing	  IFNγ	  release	  (Mars	  2002)	  and	  lower	  numbers	  have	  been	  
detected	  in	  MS	  patients	  (van	  der	  Vliet	  2001),	  most	  specifically	  in	  the	  CD4-­‐	  subpopulation	  
(Araki	  2003).	  	  	  Dysfunctions	  in	  NKT	  activity	  have	  also	  been	  implicated	  in	  susceptibility	  to	  
EAE	   (Gombert	   1996)	   potentially	   by	   inhibiting	   Th17	   differentiation.	   	   EAE	   can	   also	   be	  
prevented	   through	   the	   use	   of	   synthetic	   glycolipids	   to	   stimulate	   iNKT	   cells	   (Miyamoto	  





either	  a	  protective	  or	  pathogenic	  outcome,	  despite	  perhaps	  not	  playing	  a	  direct	   role	   in	  
mediating	  damage.	  	  	  
8.3.2.7 NK	  cells	  
NK	  cells	  are	  another	  form	  of	  lymphocyte	  separate	  from	  the	  B	  and	  T	  cell	  lineage.	  	  They	  do	  
not	   express	   TCRs	   and	   do	   not	   require	   prior	   stimulation	   to	   recognise	   and	   lyse	   cells	  
(Trinchieri	  1989).	  	  The	  major	  target	  for	  NK	  cells	  are	  tumour	  lines	  and	  virally	  infected	  cells	  
which	   are	   directed	   towards	   apoptosis	   through	   the	   release	   of	   perforin	   and	   granzymes	  
(Russell	   2002).	   	   They	   are	   found	   in	   demyelinating	   MS	   lesions	   (Traugott	   1985)	   and	   in	  
autoimmune	  diseases	  have	  been	  thought	  to	  play	  both	  protective	  and	  pathogenic	  roles,	  
as	  evidence	  has	  been	  accumulated	   for	  both.	   	   Initial	  division	  of	  NK	  cells	  on	   the	  basis	  of	  
CD56	  expression	  separates	  the	  CD56dim	  subset	  as	  those	  with	  cytotoxic	  function,	  and	  the	  
CD56bright	   subset	   which	   secrete	   cytokines	   (Cooper	   2001).	   	   This	   division	   has	   also	   been	  
taken	  further,	  separating	  NK	  cells	  based	  upon	  their	  cytokine	  production.	  	  Those	  secreting	  
IFNγ	  and	  IL-­‐10	  called	  NK1,	  and	  those	  secreting	  IL-­‐5	  and	  IL-­‐13	  called	  NK2	  (Peritt	  1998).	  	  	  
The	   first	   indication	   of	   an	   effect	   in	   autoimmune	   disease	   is	   any	   alteration	   in	   disease	  
progression	  after	  depletion	  of	   the	  cell	   type	  of	   interest.	   	  Depletion	  of	  NK	  cells	  has	  been	  
shown	   to	   exacerbate	   EAE	   (Zhang	   1997a,	   Matsumoto	   1998,	   Xu	   2005)	   or	   reduce	   EAE	  
severity	   if	   depletion	   was	   done	   before	   MOG	   immunization	   (Winkler-­‐Pickett	   2008)	  
illustrating	   both	   protective	   and	   pathogenic	   phenotypes.	   	   NK	   cells	   have	   been	   shown	   to	  
have	   cytotoxic	   activity	   directed	   at	   neurons	   (Backstrom	   2003)	   oligodendrocytes,	  
astrocytes	   and	  microglial	   cells	   (Antel	   1998,	  Morse	   2001,	   Saikali	   2007)	   in	   vitro	   through	  
interactions	   with	   NKp46	   and	   NKG2D	   receptors	   and	   subsequent	   release	   of	   perforin	  





cell	  polarization	  (Martin-­‐Fontecha	  2004,	  Morandi	  2006)	  and	  can	  restore	  susceptibility	  to	  
EAE	  in	  IL-­‐18-­‐/-­‐	  mice	  (Shi	  2000)	  suggesting	  a	  pathogenic	  role	  for	  NK	  cells	  in	  autoimmunity.	  
Supporting	   the	   studies	   noting	   an	   exacerbation	   of	   EAE	   in	   the	   absence	   of	   NK	   cells,	  
decreased	  numbers	  of	  NK	  cells	  have	  been	   recorded	   in	  MS	  patients	   (Munschauer	  1995)	  
and	   the	   observed	   reduction	   in	   relapse	   rate	   in	   pregnancy	   has	   been	   associated	  with	   an	  
increase	   in	   the	   CD56bright	   and	   decrease	   in	   CD56dim	  NK	   cell	   poplations	   (Airas	   2008).	   	   An	  
increase	   in	   NK2	   NK	   cells	   during	   remission	   (Takahashi	   2001)	   potentially	   negatively	  
regulating	  autoreactive	  T	  cells	  (Takahashi	  2004)	  and	  a	  decrease	  in	  the	  cytotoxic	  activity	  of	  
circulating	   NK	   cells	   during	   relapses	   have	   been	   described	   (Kastrukoff	   1998,	   Kastrukoff	  
2003).	   	  Also,	  an	  increase	  in	  NK	  cells	  number	  is	  seen	  through	  use	  of	   immunomodulatory	  
and	   immunosuppressant	   therapies	   such	   as	   daclizumab	   (Bielekova	   2006),	   and	   IFNβ	  
(Saraste	  2007).	   	  CNS	  infiltrating	  NK	  cells	  are	  also	  observed	  to	  produce	  factors	  favouring	  
neuroprotection	   such	   as	   brain-­‐derived	   neurotrophic	   growth	   factor	   and	   neurotropin-­‐3	  
(Hammarberg	   2000)	   during	   EAE,	   supporting	   their	   role	   in	   prevention	   of	   damage	   in	   the	  
CNS.	  	  	  
	  
8.3.2.8 CD8+	  T	  Cells	  
The	  role	  of	  CD8	  cells	   in	  MS	  has	  not	  until	  recently	  received	  as	  much	  attention	  as	  that	  of	  
CD4	   cells.	   This	   may	   be	   because	   EAE	   had	   been	   considered	   CD8-­‐independent	   and	   the	  
immunization	   protocol	   favours	   presentation	   through	   MHC	   class	   II	   antigens	   and	   thus,	  
activation	   of	   CD4	   cells.	   Unlike	   CD4	   cells	   which	   typically	   reside	   in	   the	   meningeal	   and	  
perivascular	  space,	  CD8	  T	  cells	  have	  been	  found	  to	  migrate	  to	  the	  brain	  parenchyma	  in	  





patients.	  Many	  of	  these	  are	  clonally	  expanded,	  which	  suggests	  an	  antigen-­‐driven	  process	  
(Babbe	   2000,	   Junker	   2007).	   	   There	   is	   an	   enrichment	   of	   CD8+	   T	   cells	   with	   an	  
effector/memory	  phenotype	   in	   the	  CNS	   and	  CSF	  of	  MS	  patients	   (Jilek	   2007)	   and	   these	  
show	   an	   increased	   adhesiveness	   and	   ability	   to	   cross	   an	   in	   vitro	   BBB	  model	   (Battistini	  
2003).	   	  CD8	  T	  cell	   responses	  to	  MBP	  and	  MOG	  were	  also	  shown	  to	  be	   increased	   in	  MS	  
patients	   as	   compared	   to	   controls	   (Van	   der	  Aa	   2003,	   Zang	   2004)	   further	   implicating	   an	  
important	  role	  for	  CD8	  T	  cells	  in	  MS	  pathology.	  
In	   contrast	   to	   CD4+	   T	   cells,	   CD8	   T	   cells	   recognize	   antigens	   presented	   by	   MHC	   class	   I	  
molecules.	  In	  the	  CNS,	  MHC	  class	  I	  antigens	  are	  more	  widely	  expressed	  than	  MHC	  class	  II	  
antigens,	   which	   is	   only	   seen	   on	   microglia.	   Most	   CNS	   resident	   cells,	   including	  
oligodendrocytes	  and	  neurons	  can	  express	  MHC	  class	   	  antigens,	  and	   they	  upregulate	   it	  
early	   in	   the	  MS	  disease	   course,	   before	   any	  demyelination	   (Hayashi	   1988,	  Gobin	  2001).	  	  
The	   cerebral	   endothelium	   presents	   antigens	   on	   MHC	   class	   I,	   allowing	   CD8	   T	   cells	   to	  
adhere	  and	  cross	  the	  BBB	  (Galea	  2007)	  and	  in	  addition,	  astrocytes,	  oligodendrocytes	  and	  
neurons	  express	  upregulated	  MHC	  class	  I	  antigens	  in	  acute	  MS	  lesions	  (Hoftberger	  2004).	  	  	  
Contributions	  have	  been	   found	   for	   the	  MHC	  class	   I	   region	   in	  MS	   (Haines	  1998,	   Sawcer	  
2005),	  although	  the	  strong	  influence	  through	  linkage	  disequilibrium	  of	  the	  neighbouring	  
HLA-­‐DRB1*15:01	  has	  been	   suggested	   to	   influence	   these	   results	   (Chao	  2008).	   	   The	  HLA	  
class	   I	   antigen	   HLA-­‐A3	   (A*03:01)	   has	   been	   shown	   to	   provide	   a	   genetic	   risk	   factor	   in	  
contrast	   to	  HLA-­‐A2	   (A*02:01)	  which	   reduces	   genetic	   risk	   (Fogdell-­‐Hahn	  2000,	   Brynedal	  
2007,	  Burfoot	  2008)	  underlining	  the	  importance	  of	  HLA	  class	  I	  antigens	  in	  autoimmunity	  
and	  therefore	  the	  likely	  involvement	  of	  CD8	  T	  cells	  in	  the	  disease	  process.	  	  HLA-­‐A*03:01	  





immunization	   with	   PLP45-­‐53	   with	   CD8	   T	   cells	   shown	   to	   mediate	   disease	   initiation.	  	  
However,	  on	  introduction	  of	  the	  transgenic	  HLA-­‐A*02:01	  allele,	  mice	  were	  protected,	  as	  
autoreactive	  T	  cells	  were	  deleted	  in	  the	  thymus	  (Friese	  2008).	  	  
The	  exact	  role	  that	  CD8	  T	  cells	  play	  in	  autoimmunity	  is	  a	  matter	  for	  debate.	  	  Evidence	  has	  
been	  compiled	  for	  both	  a	  protective	  and	  pathogenic	  role	  for	  these	  cells.	  	  Through	  studies	  
with	   CD8-­‐/-­‐	   mice,	   a	   reduction	   in	   demyelination	   and	   CNS	   inflammation	   during	   EAE	  
induction	  would	   support	   a	   pathogenic	   role	   for	   CD8s	   in	  MS	   (Abdul-­‐Majid	   2003).	   These	  
results	  are	  supported	  by	  some	  adoptive	  transfer	  experiments	  in	  mice.	  	  MOG35-­‐55	  reactive	  
CD8	  T	  cells	  generated	  in	  vivo	  or	  in	  vitro	  and	  MBP-­‐specific	  CD8	  T	  cells	  have	  been	  shown	  to	  
transfer	   EAE	   to	   recipient	   mice	   (Huseby	   2001a,	   Sun	   2001,	   Ford	   2005).	   	   This	   EAE	  more	  
closely	  resembled	  human	  MS	  than	  CD4	  transferred	  EAE,	  with	  lesions	  found	  in	  the	  higher	  
CNS	   rather	   than	   being	   limited	   to	   the	   spinal	   cord	   and	   the	   development	   of	   other	  
neurological	   symptoms	   not	   constrained	   to	   ascending	   paralysis	   and	   cellular	   infiltration	  
into	  the	  spinal	  cord.	  	  	  
CD8	   cells	   may	   not	   be	   directly	   involved	   in	   demyelination,	   but	   their	   role	   may	   be	   in	  
mediating	   an	   attack	   against	   the	   neurons.	   Axonal	   damage	   within	   lesions	   appears	   to	  
correlate	   best	   with	   the	   numbers	   of	   CD8+	   T	   cells	   (Bitsch	   2000,	   Kuhlmann	   2002)	   and	  
macrophages/microglia	  (Ferguson	  1997).	  	  In	  MHC	  class	  I	  antigen	  deficient	  mice	  there	  was	  
no	  axonal	  damage	  despite	  widespread	  demyelination	  (Rivera-­‐Quinones	  1998),	  compared	  
to	   MHC	   class	   II	   antigen	   knock-­‐out	   mice	   which	   developed	   both	   axonal	   damage	   and	  
demyelination.	   	   In	  the	  TMEV	  model	  of	  MS,	  axonal	   function	  could	  be	  preserved	  through	  






CD8	   T	   cells	   can	   however	   show	   direct	   action	   against	   oligodendrocytes.	   	   In	   two	  models	  
utilising	   a	   neo-­‐self	   antigen	   transgenic	   strategy,	   the	   specific	   expression	   of	   either	  
ovalbumin	   (OVA)	   or	   haemagglutinin	   (HA)	   in	   oligodendrocytes	   led	   to	   their	   lysis	   by	   CD8	  
cells	  and	  pathology	  resembling	  MS	  lesions	  upon	  introduction	  of	  the	  cognate	  MHC	  class	  I	  
antigen-­‐restricted	  T	  cell	  receptor	  or	  of	  pre-­‐activated	  cells	  (Na	  2008,	  Saxena	  2008).	  	  	  
Several	  studies	  have	  attempted	  to	  identify	  differences	  in	  frequency	  or	  activation	  of	  CD8	  T	  
cells	   between	   healthy	   controls	   and	   MS	   patients,	   although	   with	   limited	   success.	   	   The	  
frequency	   of	   myelin-­‐specific	   CD8	   T	   cells	   has	   found	   to	   be	   increased	   in	   blood	   of	   MS	  
patients	  compared	  to	  controls	  (Tsuchida	  1994,	  Crawford	  2004,	  Zang	  2004)	  and	  these	  cells	  
have	  been	  seen	  to	  be	  clonally	  expanded	  and	  carry	  effector	  or	  memory	  phenotypes	  in	  MS	  
patients	   rather	   than	   the	   naïve	   phenotype	   seen	   when	   extracted	   from	   healthy	   control	  
blood	  (Babbe	  2000,	  Crawford	  2004,	  Skulina	  2004,	  Zang	  2004).	  	  CD8	  cells	  extracted	  from	  
secondary	   progressive	   patient	   blood	   produced	  more	   lymphotoxin	   (Buckle	   2003)	  which	  
acts	   to	   induce	  apoptosis	  and	  can	  be	   toxic	   for	  oligodendrocytes	   in	  vitro	   (Selmaj	  1991b).	  	  
Other	  studies	  have	  reported	  no	  difference	  in	  frequency	  of	  myelin-­‐specific	  effector	  CD8	  T	  
cells	   as	  measured	  by	  proliferative	  potential	   (Huizinga	  2009)	  or	   IFNγ	   ELISPOT	   (Berthelot	  
2008).	  	  In	  response	  to	  IL-­‐23,	  IL-­‐17	  production	  by	  CD8+	  cells	  rivals	  that	  produced	  by	  CD4+	  
cells	  under	   the	   same	  conditions,	   is	  produced	  alongside	   IFNγ	   and	   IL-­‐10	   (Vanden	  Eijnden	  
2005)	  and	   in	   the	  CNS	  equal	  numbers	  of	  both	  CD4	  and	  CD8	  T	   cells	  have	  been	  detected	  
producing	  IL-­‐17	  (Tzartos	  2008).	   	  CD8	  T	  cells	  producing	  IL-­‐17	  have	  been	  called	  Tc17	  cells	  
and	  appear	  to	  differentiate	  in	  a	  mode	  similar	  to	  Th17	  cells	  (Huber	  2009).	  	  They	  have	  been	  
directly	  implicated	  in	  development	  of	  autoimmunity	  through	  an	  adoptive	  transfer	  model	  





to	   normal	   cytotoxic	   T	   lymphocytes	   (CTLs)	   (Tc1)	   as	   they	   produce	   less	   perforin	   and	  
granzyme	  B,	  which	  may	  explain	  the	  results	  seen.	  
A	   regulatory	  mode	  of	   action	   for	   CD8+	   T	   cells	   is	   a	   hypothesis	   that	   has	   received	   a	   lot	   of	  
support.	  	  Observations	  from	  EAE	  sighting	  an	  inverse	  correlation	  between	  disease	  severity	  
and	  proportion	  of	  CNS	  infiltrating	  CD8	  cells	  (Weiss	  2007)	  and	  CD8-­‐deficient	  mice	  showing	  
increased	   relapses	   despite	   an	   initial	   reduction	   in	   mortality	   (Jiang	   1992,	   Koh	   1992)	  
indicate	  a	  presence	  of	  a	  CD8	  regulatory	  T	  cell	  subset.	  	  Indeed,	  CD8	  T	  cells	  isolated	  from	  
mice	   that	  had	   recovered	   from	  EAE	  have	  also	  been	   shown	   to	  be	   capable	  of	   eliminating	  
MBP-­‐specific	  CD4	  T	  cells	  both	  in	  vitro	  and	  in	  vivo	  (Jiang	  2003)	  and	  this	  suppressive	  ability	  
of	   CD8	   T	   cells	   is	   seen	   to	   be	   impaired	   in	  MS	   patients	  with	   chronic,	   progressive	   disease	  
(Balashov	  1995).	  	  	  
Two	  populations	  of	   regulatory	  CD8	  subsets	  have	  been	  described,	   the	   first	   lacking	  CD28	  
expression	  with	  the	  other	  characterised	  by	  expression	  of	  CD122.	  	  The	  CD28-­‐	  subset	  have	  
been	  seen	  to	  exhibit	  a	  regulatory	  function	   in	  the	  MOG35-­‐55	  EAE	  model	  by	   inhibiting	  DCs	  
from	   upregulating	   co-­‐stimulatory	   molecules	   and	   forcing	   them	   into	   a	   tolerogenic	  
phenotype,	  unable	  to	  activate	  autoreactive	  CD4	  T	  cells	  (Najafian	  2003).	  	  The	  CD8+CD122+	  
subset	  act	  differently,	  secreting	  IL-­‐10	  and	  suppressing	  proliferation	  and	  IFNγ	  production	  
by	   CD8+	   T	   cells	   (Rifa'i	   2004,	   Endharti	   2005)	   such	   that	   in	   the	   MOG35-­‐55	   EAE	   model,	  
depletion	   of	   these	   cells	   increased	   the	   length	   of	   time	  mice	   persisted	   with	   high	   clinical	  
scores	  and	  reconstitution	  of	  the	  population	  by	  adoptive	  transfer	  of	  in	  vitro	  activated	  cells	  
significantly	  reduced	  EAE	  severity	  (Lee	  2008).	  	  Work	  in	  humans	  suggests	  that	  CD8+CXCR3+	  





action	   of	   copaxone	   has	   been	   attributed	   to	   the	   induction	   of	   regulatory	   CD8+	   cells	  
(Karandikar	  2002).	  	  	  
	  
	  
8.3.3 Innate	  Immune	  Signalling	  	  
8.3.3.1 TLRs	  
TLR	   activation	   offers	   an	   attractive	   hypothesis	   for	   the	   bridge	   between	  
innate/environmental	   and	   adaptive	   triggers	   leading	   to	   an	   autoimmune	   attack	   on	   the	  
CNS.	  	  TLRs	  are	  found	  throughout	  the	  CNS,	  on	  macrophages	  and	  microglia,	  mast	  cells	  and	  
dendritic	  cells.	  	  There	  are	  differences	  of	  expression	  patterns	  between	  mice	  and	  humans,	  
for	   example,	   human	   astrocytes	   are	   limited	   to	   TLR3	   expression	   only	   whereas	   mouse	  
astrocytes	  also	  transcribe	  TLR2,	  TLR4,	  TLR5	  and	  TL9	  mRNA	  (Bowman	  2003,	  Farina	  2005).	  	  
Microglia	  from	  both	  species	  however	  express	  all	  TLRs	  (Olson	  2004,	  Jack	  2005)	  illustrating	  
their	  central	  role	  in	  CNS	  surveillance.	  	  The	  requirement	  for	  adjuvants	  to	  initiate	  EAE	  has	  
implicated	  the	  TLRs	  in	  initiating	  the	  immune	  attack	  in	  animal	  models.	  	  Analysis	  of	  CSF	  and	  
brain	  lesions	  of	  MS	  patients	  and	  in	  EAE	  brains,	  have	  shown	  an	  increase	  in	  TLR	  expression	  
(Bsibsi	  2002,	  Hanisch	  2008)	  and	  through	  ligation	  with	  their	  cognate	  ligands,	  TLRs	  lead	  to	  
production	  of	  inflammatory	  cytokines	  which	  could	  drive	  T	  cell	  polarization.	  	  Specifically,	  
Th1	  polarizing	  cytokines	  have	  been	  shown	  to	  be	  secreted	  as	  a	  result	  of	  TLR3	  signalling,	  
leading	  to	  the	  upregulation	  of	  MHC	  class	  II	  molecules	  on	  microglia	  and	  differentiation	  of	  
T	   helper	   cells	   (Jack	   2007).	   	   However	   stimulation	   of	   the	   same	   TLR	   can	   also	   have	   anti-­‐
inflammatory	  effects,	  as	  PolyI:C	  induces	  the	  release	  of	  IFNβ	  and	  led	  to	  the	  suppression	  of	  





Specific	  TLR	  knockout	  mouse	  lines	  have	  been	  made	  and	  used	  to	  study	  their	  role	   in	  CNS	  
autoimmunity.	  	  TLR4-­‐/-­‐	  mice	  demonstrate	  more	  severe	  EAE	  (Marta	  2008)	  whereas	  TLR2-­‐/-­‐	  
(Prinz	  2006)	  and	  TLR6-­‐/-­‐	   (Marta	  2008)	  mice	   showed	  a	   similar	   clinical	   course	   to	  C57BL/6	  
mice.	   	   Contrasting	   roles	   have	   been	   shown	   for	   TLR9	   in	   EAE	   with	   groups	   showing	  
protection	   of	   knockout	   mice	   from	   EAE	   (Prinz	   2006)	   or	   increased	   susceptibility	   (Marta	  
2008).	  	  	  
Linking	  most	  TLRs	  is	  myeloid	  differentiation	  primary	  response	  gene	  88	  (MyD88),	  the	  main	  
adapter	  protein	  used	   in	  TLR	  signalling.	   	  MyD88	  knock-­‐out	  mice	  have	  been	  shown	  to	  be	  
resistant	  to	  both	  induced	  and	  passive	  EAE	  involving	  the	  adoptive	  transfer	  of	  autoreactive	  
T	  cells	  (Marta	  2008,	  Cohen	  2010b)	   illustrating	  the	  central	  role	  of	  TLRs	  in	  autoimmunity.	  	  
Tissue	  damage	  releases	  endogenous	  TLR	  ligands	  that	  have	  been	  shown	  to	  stimulate	  TLRs	  
on	   microglia	   to	   promote	   neurotoxic	   inflammatory	   mediators,	   more	   specifically	   heat	  
shock	  protein	  60	  (HSP60)	  release	  stimulates	  nitric	  oxide	  release	  through	  TLR4	  signalling	  
(Lehnardt	   2010).	   	   TLR	   stimulation	   on	   B	   cells	   however	   has	   been	   shown	   to	   promote	  
recovery	   from	   EAE	   through	   increased	   IL-­‐10	   production	   as	   mice	   with	   B	   cell-­‐restricted	  
deficiencies	  of	  MyD88,	  TLR2	  or	  TLR4	  develop	  chronic	  EAE	  with	  DC-­‐dependent	  production	  
of	  IL-­‐6	  blocked,	  but	  a	  deficiency	  of	  TLR9	  does	  not	  affect	  normal	  recovery	  (Lampropoulou	  
2008).	  	  	  
The	  major	  role	  of	  TLRs	  to	  detect	  microbial	  pathogens	  and	  their	  products	  provides	  a	  direct	  
link	   between	   TLRs	   and	   EAE	   as	   one	   of	   the	   major	   components	   of	   the	   immunization	  
protocol	  is	  Mycobacterium	  tuberculosis,	  a	  potent	  TLR4	  activating	  micro-­‐organism.	  	  Other	  
microbial	   products	   have	  been	   shown	   to	   be	   capable	   to	   inducing	   EAE	   along	  with	  myelin	  





lipopolysaccharide	   (LPS)	   (TLR4),	   albeit	   at	   delayed	   onset	   (Waldner	   2004)	   demonstrating	  
how	  micro-­‐organisms	   can	   prime	   T-­‐cell	   dependent	   inflammation	   through	   TLR-­‐mediated	  
activation	  of	  antigen	  presenting	  cells	  (APCs).	  	  Another	  microbial	  product,	  pertussis	  toxin	  
has	  even	  more	  severe	  impact	  on	  EAE	  as	  it	  not	  only	  promotes	  T	  helper	  cell	  differentiation	  
but	   also	   promotes	   T	   cell	   transendothelial	  migration	   across	   the	   BBB	   (Hou	   2003,	   Kügler	  
2007).	   	   Therefore	   stimulation	   of	   APCs	   by	   the	   innate	   immune	   system	   can	   overcome	  
peripheral	  tolerance	  and	  lead	  to	  autoimmunity,	  with	  TLRs	  being	  central	  to	  mediating	  this	  
fine	  balance.	  	  	  
	  
	  
8.4 TCR	  Transgenic	  Mice	  in	  Autoimmunity	  
8.4.1 Background	  
Animal	   models	   of	   diseases	   allow	   greater	   depth	   of	   investigation	   than	   simply	   human	  
studies	  and	  provide	  one	  other	   large	  advantage,	   that	   the	  genetics	  of	   the	  animal	   can	  be	  
manipulated	  and	  controlled	  to	  investigate	  specific	  aspects	  of	  a	  condition	  without	  having	  
to	  control	   for	   the	   large	  genetic	  diversity	  of	  a	  human	  population.	   	  The	  creation	  of	  T	  cell	  
receptor	   transgenic	   mice	   provides	   a	   cohort	   of	   T	   cells	   with	   defined	   restriction	   and	  
specificity	   that	   can	   be	   monitored	   phenotypically	   throughout	   the	   course	   of	   normal	  
development	  and	  in	  the	  context	  of	  a	  disease.	  	  It	  is	  usually	  hard	  to	  detect	  and	  follow	  the	  
fate	  of	  antigen	  specific	  cells	  through	  an	   immune	  response,	  as	  there	   is	   low	  frequency	  of	  
their	  precursors	  in	  the	  naïve	  animal.	  	  It	  has	  been	  estimated	  through	  limiting	  dilution	  and	  
TCR	  sequencing	  experiments	  to	  be	  between	  1	  in	  105	  or	  106	  T	  cells	  (Casrouge	  2000,	  Hou	  





generated	   ranges	  of	   1:200,000	   to	  1:2,000,000	   for	  CD4+	   T	   cells	   (Moon	  2007,	  Chu	  2009)	  
and	  1:20,000	  to	  1:1,300,000	  for	  CD8+	  T	  cells	  (Kotturi	  2008,	  Obar	  2008)	  in	  support	  of	  these	  
figures.	   	   TCR	   transgenic	  mice	   increase	   this	   frequency,	   such	   that,	  when	   examined	   on	   a	  
RAG-­‐null	   background	   to	  obviate	  endogenous	   rearrangements	   and	  dual-­‐TCR	  expression,	  
mice	   can	   be	   considered	   functionally	   monoclonal.	   	   This	   allows	   studies	   of	   T	   cell	  
development	  to	  be	  carried	  out	  at	  a	  clonotypic	   level,	  watching	  naïve	  precursors	  develop	  
into	  memory	  and	  effector	  cell	  populations.	  	  	  The	  location	  of	  T	  cell	  activation	  in	  response	  
to	   specific	   antigens	   can	   also	   be	   assessed	   and	   this	   may	   have	   very	   far-­‐reaching	  
consequences	  with	  regard	  to	  drug	  development	  and	  interventions	  in	  clinic.	  	  The	  choice	  of	  
MHC	   class	   restriction	   of	   the	   TCR	   in	   the	   mice	   allows	   investigation	   of	   the	   CD4	   or	   CD8	  
response	   to	   the	  antigen	  of	  choice	  and	  the	  extension	  of	   this	   selection	   is	   the	  creation	  of	  
humanized	  mice	  where	  human	  HLA	   class	   I	   or	   II	   heterodimer	   is	   introduced,	   so	   that	   the	  
immune	   response	   more	   closely	   resembles	   that	   which	   normally	   occurs	   in	   the	   human	  
setting.	   	   The	   TCR	   itself	   can	   also	   be	   derived	   directly	   from	   a	   human	   patient’s	   T	   cells,	  
thereby	  providing	  even	  more	  relevant	  immune	  responses	  in	  the	  context	  of	  development	  
and	  diseases.	  	  	  
	  
8.4.2 Initial	  Development	  
The	   first	  αβ	   TCR	   transgenic	  mice	  were	   reported	   in	  1988	   from	  the	   lab	  of	  von	  Boehmer.	  	  
They	  generated	  mice	  with	  a	  TCR	  that	  recognized	  the	  male	  HY	  antigen	  in	  the	  context	  of	  H-­‐
2Db.	  	  They	  investigated	  the	  development	  of	  thymic	  selection,	  illustrating	  the	  deletion	  of	  
self-­‐reactive	  T	  cells	   in	  the	  thymus	  (Kisielow	  1988a),	  that	  the	  interaction	  of	  the	  TCR	  with	  





stage	   (Teh	   1988)	   and	   the	   interaction	   with	   the	   MHC	   class	   I	   molecule	   is	   necessary	   to	  
generate	  antigen	  specific	  CD8	   lymphocytes	   (Kisielow	  1988b).	   	   Shortly	  after,	   the	  2C	  TCR	  
transgenic	  mouse	  was	  developed,	  with	  an	  anti-­‐Ld	  alloreactive	  αβ	  TCR	  (Sha	  1988),	  used	  to	  
investigate	  positive	  selection	  of	  the	  T	  cells	  by	  the	  cognate	  MHC	  molecule	  (Sha	  1988).	  	  
These	  first	   two	  mice	  were	  CD8	  specific	  and	   in	  the	  next	  year,	   two	  more	  studies	  showed	  
that	   the	   observations	   for	   CD8	   T	   cells	   were	   transferrable	   to	   CD4	   T	   cell	   selection	   (Berg	  
1989,	  Kaye	  1989).	  	  Both	  utilised	  TCRs	  specific	  for	  pigeon	  cytochrome	  c	  presented	  by	  I-­‐Ek	  
although	   they	   were	   generated	   from	   different	   T	   cell	   clones	   and	   on	   different	   mouse	  
backgrounds.	  	  Whilst	  these	  studies	  had	  investigated	  selection	  of	  CD4	  and	  CD8	  cells	  in	  the	  
thymus,	   the	   exact	   location	   at	   which	   tolerance	   was	   induced	   had	   not	   been	   deduced.	  	  
Pircher,	  Burki	  et	  al	  (1989)	  investigated	  this	  through	  the	  use	  of	  TCR	  transgenic	  mice	  with	  a	  
double	  specificity.	  	  Mice	  expressed	  a	  TCR	  specific	  for	  both	  lymphocytic	  choriomeningitis	  
virus	   (LCMV)	   –	   H-­‐2Db	   and	  minor-­‐lymphocyte	   stimulatory	   antigen	   (MIsa),	   subsequently	  
appreciated	   to	   be	   mouse	   mammary	   tumour	   virus	   (MMTV)	   and,	   depending	   on	   which	  
antigen	   was	   involved,	   differences	   were	   seen	   in	   the	   stage	   of	   T	   cell	   maturation	   and	  
location	   in	   the	   thymus	   as	   to	  when	   the	   TCR-­‐expressing	   cells	   could	   be	   tolerized	   (Pircher	  
1989).	  	  	  
Another	  early	  study	  looked	  at	  tolerance	  using	  a	  TCR	  specific	  for	  a	  circulating	  antigen	  and	  
investigated	  selection	  in	  a	  system	  with	  or	  without	  the	  target	  antigen	  (Zal	  1994).	  	  This	  was	  
used	  to	  show	  ‘piggy-­‐backing’	  of	  a	  self-­‐reactive	  TCR	  which	  would	  usually	  be	  deleted	  with	  






8.4.3 Neo-­‐self	  antigens	  
Mice	   transgenic	   for	   TCRs	   recognizing	   foreign	   antigens	   have	   been	   crossed	   with	   mice	  
transgenically	   expressing	   the	   foreign	   antigen	   as	   a	   neo-­‐self	   antigen,	   thereby	   allowing	  
detailed	   examination	   of	   tolerance	   to	   be	   carried	   out	   in	   settings	   that	   are	   not	   rooted	   in	  
physiological	   autoimmunity	   or	   infectious	   disease.	   	   The	   nature	   of	   local	   antigen	  
presentation	  was	  elucidated	  in	  TCR	  transgenic	  models	  also	  expressing	  the	  cognate	  LCMV	  
glycoprotein	   antigen	   in	   pancreatic	   islet	   cells	   (Ohashi	   1991).	   	   The	   requirement	   for	   co-­‐
stimulation	  in	  this	  interaction	  (Harlan	  1994)	  and	  the	  ability	  to	  break	  peripheral	  tolerance	  
in	   islets	   (von	   Herrath	   1995)	   were	   both	   observed.	   Another	   model,	   using	   injection	   of	  
ovalbumin	   specific	   T	   cells	   from	   the	   MHC	   class	   I-­‐restricted	   OVA	   specific	   (OT-­‐I)	   TCR	  
transgenic	   mouse	   into	   rat	   insulin	   promotor	   (RIP)-­‐mOVA	   mice	   expressing	   membrane	  
bound	  OVA	  in	  the	  pancreatic	  islet	  cells,	  demonstrated	  that	  cross-­‐presentation	  of	  antigen	  
in	  the	  draining	  lymph	  node	  was	  an	  important	  immunological	  mechanism	  (Kurts	  1996).	  	  	  
	  
Kb-­‐specific	  CD8	  TCR	  transgenic	  mice	  (Morahan	  1989),	  influenza	  haemagluttinin	  TCR	  (Scott	  
1994)	  and	  hen	  egg	   lysozyme	  CD4	  TCR	  transgenic	  models	  (Akkaraju	  1997)	  among	  others	  
show	   that	   factors	   including	   amount	   of	   the	   antigen	   (Ferber	   1994),	   genetic	   background	  
(Scott	  1994)	  and	  expression	  of	  neo-­‐self	   antigen	   in	   the	   thymus	   (Forster	  1995,	  McGargill	  
2002)	  play	  a	   role	   in	  mediation	  of	   tolerance.	   	  Mechanisms	  of	   tolerance	   in	   these	  models	  
have	  included	  down	  regulation	  of	  the	  TCR	  on	  self-­‐reactive	  T	  cells	  outside	  of	  the	  thymus	  
(Schonrich	   1991),	   and	   the	   generation	   of	   Treg	   cells,	   selected	   both	   by	   antigen	   affinity	  





Tregs	  generated	  in	  this	  way	  could	  also	  be	  shown	  to	  maintain	  their	  responsiveness	  in	  vivo	  
despite	  appearing	  anergic	  in	  vitro	  (Walker	  2003).	  	  
	  
8.4.4 Disease	  Specific	  TCRs	  
In	   contrast	   to	   TCR	   transgenic	   mice	   being	   used	   to	   understand	   general	   mechanisms	   of	  
immune	   development,	   the	   design	   of	   mice	   with	   autoimmune	   disease-­‐derived	   specific	  
TCRs	   has	   provided	   new	  models	   of	   disease	  with	   specific	   targets	   and	   an	   increase	   in	   the	  
antigen	   specific	   T	   cell	   population	   for	   further	   analysis.	   	   TCR	   transgenics	   for	   antigens	  
thought	   to	   be	   involved	   in	   three	  major	   autoimmune	   diseases,	  MS,	   type	   I	   diabetes	   and	  
rheumatoid	  arthritis,	  have	  been	  developed	  and	  will	  be	  looked	  at	  in	  turn.	  
	  
8.4.4.1 Rheumatoid	  Arthritis	  
Rheumatoid	   arthritis	   is	   an	   autoimmune	   condition	   affecting	   the	   joints,	   among	   other	  
organs	   and	   tissues.	   	   A	   much	   used	   mouse	   model	   for	   this	   disease	   is	   collagen-­‐induced	  
arthritis	  where,	  in	  the	  same	  manner	  as	  EAE,	  a	  target	  protein	  or	  peptide,	  in	  this	  case	  type	  
II	   collagen,	   is	   introduced	  with	  adjuvant	   to	   initiate	  an	  autoimmune	   reaction	   targeted	   to	  
the	   joints.	   	  Extending	  this	   idea,	   the	  first	  TCR	  transgenic	  was	  created	   in	  1992,	  with	  mice	  
expressing	  just	  the	  β	  chain	  from	  an	  I-­‐Aq-­‐restricted	  anti-­‐collagen	  type	  II	  T	  cell	  (Mori	  1992).	  	  	  
The	   introduction	   of	   the	   transgenic	   β	   chain	   and	   its	   subsequent	   association	   with	  
endogenous	  α	  chains,	  led	  to	  an	  enhanced	  immune	  response	  against	  type	  II	  collagen	  but	  
was	   not	   sufficient	   to	   make	   arthritis-­‐resistant	   SWR	   mice	   susceptible	   to	   arthritis	   (Mori	  
1992).	  	  Extending	  this	  idea,	  αβ	  TCR	  transgenic	  mice	  were	  created,	  still	  specific	  for	  type	  II	  





the	   thymus,	  and	  were	  not	  anergic.	  Arthritis	   could	  be	   induced	  with	   immunization	  of	  CII	  
and	   adjuvant,	   although	   no	   spontaneous	   disease	   development	   was	   observed.	   	   The	  
increased	  specificity	  of	   the	   immune	  response	  was	  notable	  as	  severe	  disease	  developed	  
twice	  as	  fast	  in	  the	  transgenic	  mice	  as	  in	  the	  non-­‐transgenic	  (Osman	  1998).	  	  	  
TCR	   transgenic	  mice	  have	  also	  been	  created	   for	  other	  antigens	  expressed	   in	   the	   joints.	  	  
Cartilage	  proteoglycan	  (PG)	  is	  another	  candidate	  target	  antigen	  in	  RA	  (Glant	  1980,	  Golds	  
1983,	   Goodstone	   1996)	   and	   immunization	   of	   BALB/c	   mice	   with	   human	   cartilage	   PG	  
(HuPG)	   induces	  a	  disease	  similar	   to	  RA	  (Glant	  1987)	  by	  cross-­‐reactivity	  of	   the	  T	  cells	   to	  
mouse	  proteoglycan.	  	  Mice	  expressing	  a	  TCR	  specific	  for	  HuPG	  were	  created	  (Berlo	  2006)	  
and	   termed	   5/4E8.	   	   Transfer	   of	   naive	   cells	   from	   these	  mice	   could	   transfer	   arthritis	   to	  
recipient	  animals,	  demonstrating	  their	  role	  in	  pathogenesis.	  	  	  
The	  major	   TCR	   transgenic	  mouse	  model	   used	   in	   the	   study	   of	   RA,	   however,	   is	   the	   KRN	  
model.	  	  KRN	  mice	  possess	  a	  TCR	  specific	  for	  bovine	  pancreas	  RNase	  in	  the	  context	  of	  I-­‐Ak	  
and	  when	  they	  were	  crossed	  with	  NOD	  mice,	   their	  offspring	  developed	  a	  spontaneous,	  
RA-­‐like	   joint	   disease	   (Kouskoff	   1996).	   	   Sera	   from	   these	   arthritic	   mice	   could	   transfer	  
disease	  and	  it	  was	  shown	  that	  it	  contained	  a	  major	  antigen	  from	  joints	  and	  other	  tissues,	  
glucose-­‐6-­‐phosphate	   isomerase,	   whose	   depletion	   from	   sera	   prevented	   disease	  
transmission	   (Matsumoto	   1999).	   	   The	   effector	   phase	   has	   been	   shown	   to	   require	  
neutrophils	   (Wipke	   2001,	  Monach	   2010),	   mast	   cells	   (Lee	   2002),	   complement	   C5a	   and	  
FcγRIII	   (Ji	   2002,	   Tsuboi	   2010).	   	   Since	   its	   discovery,	   this	   TCR	   transgenic	   model	   has	  
dominated	  mouse	  model	  based	  research	  into	  RA,	  either	  through	  its	  direct	  use	  or	  the	  use	  
of	  KRN	  T	  cells.	  	  Whilst	  a	  great	  deal	  is	  now	  known	  about	  this	  immune	  model,	  its	  success	  is	  





the	  more	  detailed	  questions	  we	  can	  use	  it	  to	  answer	  and	  so	  the	  more	  people	  will	  work	  on	  
it.	  However,	   the	  dominance	  of	   this	  model	  means	   that,	   for	  what	   is	  a	  poorly	  understood	  
and	   heterogeneous	   human	   disease,	   mechanistic	   studies	   may	   become	   somewhat	  
narrowed	  to	  a	  single	  mechanistic	  context.	  
	  
8.4.4.2 Type	  I	  Diabetes	  
Much	  research	   into	   type	   I	  diabetes	  has	  been	  carried	  out	  using	   the	  NOD	  strain	  of	  mice.	  	  
These	   were	   developed	   at	   Shiongi	   Research	   Laboratories	   in	   Aburhai,	   Japan	   and	   first	  
reported	  in	  1980	  (Makino	  1980).	  They	  spontaneously	  develop	  insulin	  dependent	  diabetes	  
resulting	  from	  T	  cell	  infiltration	  into	  the	  Islets	  of	  Langerhans	  and	  have	  been	  considered	  a	  
genetically,	   pathologically	   and	   immunologically	   faithful	   model	   of	   the	   human	   disease.	  	  
NOD	  mice	  have	  been	  used	  as	  the	  base	  strain	  for	  the	  TCR	  transgenic	  mouse	  lines	  created	  
to	  study	  diabetes	  with,	  each	  providing	  a	  mouse	  usually	  susceptible	  to	  diabetes	  but	  with	  a	  
T	  cell	  repertoire	  enhanced	  for	  one	  antigen	  specificity.	  	  	  
There	   are	   5	   ‘base-­‐strain’	   TCR	   transgenic	   mouse	   models	   used	   in	   diabetes	   research	   at	  
present,	  the	  first	  TCR	  transgenic	  to	  be	  developed	  from	  the	  NOD	  mouse	  was	  the	  BDC2.5	  
strain.	   	   This	   TCR	   has	   α	   and	   β	   chains	   derived	   from	   a	   NOD	   mouse	   recently	   found	   to	  
recognize	   chromogranin	   A,	   a	   pancreatic	   β	   cell	   antigen,	   presented	   by	   I-­‐Ag7	   (Katz	   1993,	  
Stadinski	   2010).	   	   In	   these	  mice,	   there	   are	   no	   signs	   of	   transgenic	   T	   cell	   deletion	   in	   the	  
thymus	   and	   because	   the	   NOD	   mice	   develop	   diabetes	   under	   normal	   circumstances,	  
increasing	  the	  proportion	  of	  T	  cells	  derived	  from	  a	  diabetogenic	  T	  cell	  clone,	  could	  only	  
accelerate	  disease	  progression	  (Haskins	  1990).	  	  When	  the	  mice	  were	  crossed	  onto	  a	  RAG-­‐





disease	   onset	   and	   progression	  was	   accelerated	   further	   (Luhder	   1998,	   Ji	   1999).	   	   These	  
mice	  have	  been	  used	  widely	   in	  diabetes	   research	  as	  a	  more	   susceptible	  mouse	  model,	  
increasing	  the	  speed	  with	  which	  experiments	  can	  be	  carried	  out	  and	  the	  reproducibility.	  	  	  
Utilising	  the	  same	  set	  of	  T	  cell	  clones,	  another	  TCR	  transgenic	  mouse	  has	  been	  created	  on	  
the	  NOD	  background	  (Pauza	  2004).	  	  The	  BDC6.9/NOD	  mice	  show	  increased	  susceptibility	  
and	  speed	  in	  developing	  diabetes	  relative	  to	  the	  BDC2.5/NOD	  mouse,	  but	  only	  when	  the	  
BDC6.9	   TCR	   is	   on	   the	  NOD	  background.	   	   The	   specific	   antigen	   is	   not	   present	   in	   BALB/c	  
mice	  and	  so	  by	  replacing	  the	  NOD	  antigen	  locus	  on	  chromosome	  6,	  with	  a	  segment	  from	  
a	   BALB/c	   mouse,	   they	   have	   been	   able	   to	   prevent	   diabetes	   onset	   (Pauza	   2004).	   	   The	  
discovery	   of	   this	   kind	   of	   genetic	   specificity	   of	   T	   cell	   clones	   hints	   at	   the	   sort	   of	   control	  
potentially	   present	   throughout	   the	   human	   population,	   where	   development	   of	  
autoimmunity	  is	  controlled	  by	  expression	  of	  endogenous	  polymorphic	  autoantigens.	  	  	  
The	  third	  TCR	  transgenic	  strain	  created	   is	   the	  NY4.1/NOD	  mouse	  (Schmidt	  1997).	   	  This,	  
like	   the	   BDC2.5/NOD	   strain,	   recognizes	   an	   islet	   antigen	   presented	   by	   I-­‐Ag7	   and	   shows	  
similar	  thymic	  selection	  but	  develops	  disease	  earlier	  and	  with	  an	  increased	  incidence	  in	  
transgenic	   males.	   	   Crossing	   the	   NY4.1/NOD	   mice	   onto	   a	   RAG	   deficient	   background	  
brought	  the	  onset	  of	  diabetes	  earlier	  as	  expected	  (Verdaguer	  1997)	  but	  incidence	  did	  not	  
reach	  100%,	  and	  plateaued	  at	  75%	  in	  females,	  and	  60%	  in	  males.	  	  The	  NY4.1/NOD	  mouse	  
strain	  was	  created	  from	  a	  CD4	  T	  cell	  clone	  and	  so	  provides	   information	  about	  the	  MHC	  
class	   II-­‐restricted	  component	  of	   the	   immune	   response.	   	  NY8.3/NOD	  mice	  were	  created	  
from	  a	   CD8	   T	   cell	   clone,	   and	   so	  work	  with	   them	   complements	   that	   seen	   in	   other	   CD8	  
models	   (Lieberman	  2003).	   	   The	  NY8.3/NOD	  mice	   showed	  similar	  disease	   incidence	  and	  





cell	  repertoire	  was	  constrained	  by	  crossing	  them	  with	  RAG2-­‐/-­‐	  mice.	  	  In	  this	  instance,	  the	  
cross	  showed	  a	  lower	  incidence	  of	  disease,	  roughly	  half	  of	  that	  seen	  by	  the	  NY4.1/RAG-­‐/-­‐	  
cross,	   suggesting	   a	   clear	   role	   for	   CD4	   T	   cells	   in	   diabetes	   development	   as	   endogenous	  
TCRs	  were	  present	  on	   the	  CD4+	  T	  cells	   in	  NY8.3/NOD	  mice	  but	  not	   in	   the	  RAG2-­‐/-­‐	   cross	  
(Lieberman	  2003).	  	  Therefore	  the	  comparison	  of	  two	  TCR	  transgenic	  mice	  allows	  a	  more	  
valuable	   conclusion	   to	   be	   drawn	   than	   seen	  by	   looking	   at	   one	  mouse	   strain	   alone,	   and	  
also	  highlights	  the	  importance	  of	  looking	  at	  T	  cell	  clones	  derived	  from	  both	  CD4	  and	  CD8	  
when	  designing	  TCR	  transgenic	  mice.	  	  	  
The	  final	  TCR	  transgenic	  mouse	  strain	  used	  in	  diabetes	  research	  is	  specific	  for	  GAD65286-­‐
300,	  a	  peptide	  from	  a	  candidate	  disease	  autoantigen	  usually	  expressed	   in	  only	  the	  brain	  
and	  islet	  cells	  (Tarbell	  2002).	  	  Despite	  this	  limited	  expression	  pattern,	  these	  mice	  showed	  
strong	  central	  tolerance	  as	  transgenic	  CD4+	  T	  cells	  were	  only	  selected	  if	  also	  possessing	  
an	   endogenous	   TCR	   α	   chain	   as	   well.	   	   These	   mice	   are	   different	   to	   the	   other	   TCR	  
transgenics	  derived	  from	  the	  NOD	  strain,	  as	  no	  development	  of	  diabetes	  was	  observed,	  
in	   line	  with	  some	  other	  data	   that	  suggested	  GAD65-­‐specific	  T	  cell	  were	  not	  pathogenic	  
(Tian	  1996).	  	  The	  anti-­‐p286	  TCR	  likely	  plays	  a	  protective	  role	  in	  diabetes,	  as	  when	  p286-­‐
specific	  T	  cells	  were	  co-­‐transferred	  with	  diabetogenic	  T	  cells	  into	  a	  NOD.SCID	  mouse,	  the	  
onset	  of	  diabetes	  was	  delayed	  (Tarbell	  2002).	  	  
These	   TCR	   transgenic	   mice	   have	   provided	   valuable	   information	   regarding	   the	  
pathogenesis	   of	   diabetes,	   but	   they	   represent	   a	   limited	   repertoire	   of	   TCRs	   and	   their	  
responses.	   	   Recently,	   a	   retrogenic	   approach	   has	   been	   used	   to	   develop	   multiple	   TCR	  
transgenic	  mice	  in	  a	  much	  more	  time-­‐efficient	  fashion	  (Burton	  2008).	  	  They	  use	  defined	  





vector	  into	  mice	  by	  retrovirus-­‐mediated	  stem	  cell	  transfer	  (Holst	  2006).	  	  In	  this	  study,	  17	  
TCR	   transgenic	  mice	  were	   tested,	   specific	   for	  known	  autoantigens	   (GAD65,	   insulinoma-­‐
associated	   protein	   2,	   IA2β/phogrin	   and	   insulin),	   unknown	   islet	   antigens	   (BDC6.9,	  
BDC10.1,	   NY4.1,	   1A4)	   and	   control	   antigens	   (generated	   from	   lab	   hybridomas)	   (Burton	  
2008).	   	  By	  developing	  multiple	  strains	  simultaneously,	  on	  defined	  genetic	  backgrounds,	  
they	  have	  been	  able	  to	  directly	  compare	  TCRs	  and	  their	  relative	  role	  in	  development	  of	  
diabetes.	  	  Using	  this	  system,	  they	  have	  attempted	  to	  classify	  TCRs	  based	  upon	  phenotype	  
in	  the	  context	  of	  disease;	  those	  failing	  to	  promote	  infiltration	  but	  able	  to	  aid	  later	  disease	  
progression,	  those	  mediating	  islet	  entry	  but	  not	  destruction,	  and	  those	  that	  mediate	  islet	  
destruction.	   	  These	   insights	  shed	   light	  on	  the	  role	  each	  TCR	  plays	  and	  more	  specifically	  
shows	  that	  autoreactivity	  does	  not	  imply	  pathogenicity.	  	  	  
	  
8.4.4.3 Multiple	  Sclerosis	  
EAE,	  the	  animal	  model	  for	  MS	  is	  induced	  by	  the	  introduction	  of	  CNS	  homogenate,	  protein	  
or	   peptides	   in	   the	   presence	   of	   a	   proinflammatory	   adjuvant.	   	   By	   extension,	   mice	  
expressing	   human	   or	   mouse-­‐derived	   transgenic	   TCRs	   specific	   for	   MBP,	   MOG	   or	   PLP	  
peptides	  have	  been	  used	   to	   study	   these	  populations	  of	   autoreactive	  T	   cells,	   and	   study	  
other	  factors	  influencing	  disease.	  
	  
8.4.4.3.1 MBP-­‐specific	  TCR	  Transgenic	  Mice	  
The	   first	   TCR	   transgenic	  mice	   in	   this	   field	   expressed	   a	   receptor	   specific	   for	  MBP	  Ac1-­‐11	  





and	  T	  cell	  selection,	  responded	  well	  to	  MBP	  and	  were	  initially	  used	  to	  study	  the	  role	  of	  
infectious	   agents	   in	   triggering	   autoimmune	   diseases	   (Goverman	   1993,	   Brabb	   1997).	  	  
These	  mice	  developed	  spontaneous	  EAE	  more	  frequently	  in	  the	  presence	  of	  pathogens	  as	  
observed	  by	  comparison	  of	  housing	  the	  mice	  under	  SPF	  (pathogen	  free)	  or	  conventional	  
conditions.	   	   In	   these	   cases,	   the	  male	  mice	  developed	   spontaneous	  disease	  more	  often	  
than	  the	  female	  mice,	  in	  contrast	  to	  the	  human	  condition.	  	  	  
The	   second	   TCR	   transgenic	  mice	   were	   developed	   to	   the	   same	  MBP	   epitope	   but	   were	  
derived	   from	   a	   different	   encephalitogenic	   T	   cell	   clone	   (Lafaille	   1994).	   	   In	   these	   mice,	  
removal	  of	  the	  non-­‐transgenic	  T	  cells	  (presumably	  encompassing	  the	  Treg	  repertoire)	  by	  
crossing	  with	  RAG-­‐/-­‐	  or	  TCR	  α-­‐/-­‐β-­‐/-­‐	  mice	  led	  to	  spontaneous	  EAE	  in	  all	  mice	  (Lafaille	  1994,	  
Olivares-­‐Villagomez	  1998)	  and	  was	   independent	  of	  microbial	   flora.	   	  This	  was	  argued	   to	  
implicate	   regulatory	   T	   cell	   activity,	   as	   the	   reintroduction	   of	   even	   a	   small	   number	   of	  
polyclonal,	  syngenic	  αβ	  T	  cells	  could	  prevent	  the	  spontaneous	  EAE	  (Olivares-­‐Villagomez	  
1998,	   Van	   de	   Keere	   1998).	   	   The	   level	   of	   spontaneous	   disease	   was	   also	   linked	   to	  
homozygous	   or	   heterozygous	   TCR	   expression,	   as	   homozygous	   mice	   showed	   a	   higher	  
frequency	   of	   spontaneous	   disease	   than	   heterozygous	   mice,	   attributed	   also	   to	   the	  
constrained	  TCR	  repertoire	  (Olivares-­‐Villagomez	  1998).	  	  Using	  these	  and	  the	  earlier	  MBP-­‐
specific	   TCR	   transgenic	   mice,	   the	   importance	   of	   localised	   in	   vivo	   tolerance	   was	  
highlighted.	   	   It	   was	   shown	   that	   many	   non-­‐transgenic	   T	   cells	   traffic	   to	   the	   CNS	   under	  
normal	   conditions	   which	   suggests	   that	   there	   is	   a	   steady	   state	   of	   T	   cells	   that	   traffic	  
through	   the	   CNS	   in	   a	   healthy	   animal	   and	   must	   be	   prevented	   from	   being	   activated,	  





Two	  further	  TCR	  transgenic	  mice	  were	  made	  with	  the	  same	  T	  cell	  specificity,	  but	  from	  a	  
new	  T-­‐cell	  clone	  (1934.4).	   	  Their	  methods	  of	  creation	  differed,	  with	  one	  using	  a	  human	  
CD2	  cassette	  to	  express	  the	  TCR	  genes	  (Tg4)	  (Liu	  1995),	  and	  the	  other	  using	  mouse	  TCR	  α	  
and	  β	   cassettes	   (Pearson	  1997).	   	   Tolerance	   induction	  was	   studied	  and	  no	   spontaneous	  
disease	  was	  observed.	  	  Using	  these	  mice,	  it	  was	  determined	  that	  clonal	  deletion	  could	  be	  
induced	  upon	  the	   i.p	   immunization	  of	  a	  peptide	  with	  a	  higher	  affinity	   for	   the	  TCR	  than	  
the	  unmodified	  peptide	  (Liu	  1995,	  Pearson	  1997),	  in	  the	  same	  way	  as	  had	  already	  been	  
seen	   in	   the	  DO11.10	  TCR	   transgenic	  mice	   (Murphy	  1990).	   	  Administration	  of	  a	  peptide	  
with	  an	  intermediate	  affinity	  was	  only	  able	  to	  induce	  appreciable	  clonal	  deletion	  in	  mice	  
expressing	  higher	  (than	  physiological)	  levels	  of	  TCR	  (Liu	  1995).	  	  	  
The	   first	   MBP-­‐specific	   TCR	   transgenic	   mice	   for	   a	   different	   epitope,	   MBP121-­‐150,	   were	  
designed	  and	  used	  to	  elucidate	  the	  role	  of	  the	  target	  protein	  in	  thymic	  selection.	  	  	  In	  mice	  
expressing	  MBP,	  these	  T	  cells	  were	  deleted,	  but	  in	  mice	  that	  were	  unable	  to	  express	  MBP	  
(shiverer)	  they	  were	  not	  (Harrington	  1998,	  Targoni	  1998).	  	  The	  clonal	  deletion	  appeared	  
proportional	   with	   age	   and	   therefore	   MBP	   accumulation,	   offering	   a	   window	   for	   the	  
initiation	   of	   autoimmune	   reactions	   before	   tolerance	   is	   complete	   (Huseby	   2001b).	   	   The	  
presence	  of	  MBP	  Ac1-­‐11	  TCR	  transgenic	  cells	  that	  are	  not	  deleted	  in	  earlier	  mice	  models	  
despite	  their	  ability	  to	  expressing	  MBP	  appears	  to	  be	  due	  to	  the	  low	  stability	  of	  the	  Ac1-­‐
11/I-­‐Au	  complex	  (Fairchild	  1993,	  Mason	  1995,	  Harrington	  1998).	  	  	  
	  
8.4.4.3.2 TCR	  Transgenic	  Mice	  for	  other	  Myelin	  Epitopes	  
Transgenic	  mice	   for	  other	  myelin	   antigens	  have	  also	  been	  made.	   	   TCR	   transgenic	  mice	  





PLP139-­‐151	   specific	  T	  cell	   clone	   (Waldner	  2000)	  as	  well	  as	   from	  a	  MOG35-­‐55	   specific	  T	  cell	  
clone	  (Bettelli	  2003).	   	  Both	  strains	  showed	  similar	  thymic	  selection	  to	  the	  Ac1-­‐11	  specific	  
mice,	   with	   TCR	   specific	   T	   cells	   neither	   anergic	   or	   deleted	   in	   the	   thymus.	   	   In	   the	   PLP	  
model,	  as	  the	  number	  of	  backcrosses	  was	  increased	  onto	  the	  susceptible	  SJL	  background,	  
the	   incidence	   of	   spontaneous	   EAE	   increased.	   	   Interestingly	   this	  was	   the	   case	   for	   TCRs	  
derived	   both	   from	   encephalitogenic	   and	   non-­‐encephalitogenic	   T	   cell	   clones	   (Waldner	  
2000).	   	   The	   MOG	   specific	   mice,	   called	   2D2,	   could	   be	   induced	   to	   develop	   EAE	   with	  
adjuvant/antigen	   and	   pertussis	   toxin	   but	   most	   interestingly,	   despite	   a	   small	   number	  
developing	  spontaneous	  EAE,	  there	  was	  a	  much	  higher	  incidence	  of	  optic	  neuritis	  (35%)	  
without	   EAE,	   and	   if	   the	   pertussis	   toxin	  was	   removed	   from	   the	   immunization	   protocol,	  
only	  optic	  neuritis	  was	  observed	  at	  the	  expense	  of	  EAE	  (Bettelli	  2003).	  	  This	  study	  raises	  
the	   possibility	   that	   TCR	   transgenics	   may	   offer	   potential	   for	   establishing	   causal	  
relationships	  between	  peptide	  specificity	  and	  lesion	  localisation.	  	  
The	   attempt	   to	  model	   relapsing-­‐remitting	  MS	   in	   a	   TCR	   transgenic	  mouse	   would	   draw	  
together	   both	   the	   specificity	   of	   the	   TCR	   transgenic	   and	   the	   complexity	   of	   repeated	  
immunological	  insults.	  	  The	  SJL/J	  mouse	  strain	  is	  prone	  to	  an	  EAE	  course	  with	  a	  relapsing-­‐
remitting	   disease	   course	   and	   using	   a	   MOG92-­‐106	   specific	   TCR,	   restricted	   to	   I-­‐As,	  
backcrossed	   onto	   the	   SJL/J	   strain	   leads	   to	   mice	   developing	   a	   spontaneous	   RR-­‐EAE	  
(Pollinger	  2009).	  	  The	  attacks	  alter	  between	  different	  CNS	  tissues	  and	  most	  interestingly,	  
there	   was	   no	   EAE	   seen	   in	   mice	   depleted	   of	   B	   cells	   or	   when	   crossed	   to	   MOG-­‐/-­‐	   mice.	  	  
Transgenic	   T	   cells	   expand	  MOG	   autoreactive	   B	   cells	   and	   they	   produce	   autoantibodies	  






8.4.4.3.3 Humanized	  TCR	  Transgenic	  Lines	  
The	  limitation	  of	  the	  models	  presented	  so	  far	  is	  the	  reliance	  on	  endogenous	  mouse	  MHC	  
mediated	  antigen	  presentation	  and	  the	  inability	  to	  map	  in	  vivo	  correlates	  of	  TCRs	  defined	  
from	   human	   patient’s	   clones.	   	   The	   logical	   extension	   of	   transgenic	  mouse	  models	   is	   to	  
include	  a	  human	  element	  on	  the	  other	  side	  of	  the	  T	  cell	  interaction	  so	  immune	  responses	  
will	   likely	  be	  more	   relevant	   to	   the	  human	  condition.	   	  Humanized	   transgenic	  mice	  were	  
made	   incorporating	   a	   human	   MBP84-­‐102	   specific	   TCR	   which	   would	   recognize	   peptide	  
presented	   by	   HLA-­‐DR15	   (Madsen	   1999).	   	   This	   system	   uses	   the	   conserved	   sequences	  
between	  the	  human	  and	  mouse	  MBP	  epitopes	  such	  that	  these	  T	  cells	  will	  react	  with	  the	  
same	  competence	  to	  both	  the	  mouse	  and	  human	  peptide.	  	  These	  mice	  were	  also	  bred	  to	  
express	   HLA	   class	   II	   DRA*01:01/DRB1*15:01	   under	   the	   control	   of	   the	   mouse	   I-­‐Eα	  
promoter	  and	  the	  human	  CD4	  molecule	  under	  the	  control	  of	  a	  mouse	  CD4	  enhancer.	  As	  
with	   earlier	   TCR	   transgenic	   models,	   a	   very	   low	   level	   of	   spontaneous	   disease	   was	  
observed	  (4%)	  but	  crossing	  onto	  RAG-­‐/-­‐	  increased	  this	  incidence	  to	  100%	  (Madsen	  1999).	  	  
The	   frequency	   of	   antigen-­‐specific	   T	   cells	   in	   this	  model	   however	   appeared	   to	   be	   lower	  
than	   in	   any	   other	   TCR	   transgenic	  model	   and	   fewer	   CD4	   cells	   reacted	   to	  MBP	   peptide.	  	  
The	   thymic	  architecture	  was	  also	  unaffected,	  a	   feature	  not	  usually	   seen	   in	  mice	  with	  a	  
high	   frequency	   of	   transgenic	   TCR	   specific	   cells	   that	   are	   positively	   selected	   (Goverman	  
1997,	  Pearson	  1997).	  	  Therefore	  it	  is	  likely	  that	  in	  these	  mice,	  the	  TCR	  repertoire	  diversity	  
is	  similar	  to	  normal.	  	  	  
Mice	   transgenic	   for	   the	   immunodominant	  MBP111-­‐129	   epitope	   in	  DRB1*0401	   individuals	  
were	   created	   from	   a	   T	   cell	   clone	   from	   a	   relapsing-­‐remitting	  MS	   patient.	   	   DR4	   is	  most	  





ethnic	   groups,	   most	   notably	   from	   the	   Mediterranean	   area	   (Marrosu	   1988).	   	   No	  
spontaneous	   disease	   was	   observed	   in	   these	   humanized	   TCR	   transgenic	   mice,	   but	  
adoptive	   transfer	   of	   TCR	   transgenic	   cells	   into	   DR4	   mice	   followed	   by	   pertussis	   toxin	  
administration,	   led	   to	   the	   development	   of	   normal	   EAE	   and	   dysphagia	   (Quandt	   2004).	  	  
Mouse	   MBP111-­‐129	   differs	   from	   the	   human	   MBP	   epitope	   by	   a	   conservative	   Arg	   to	   Lys	  
substitution	  in	  position	  122.	  	  Not	  all	  the	  T	  cell	  clones	  derived	  in	  the	  development	  of	  the	  
mice	   responded	   to	   mouse	   MBP	   but	   the	   clone	   selected	   (MS2-­‐3C8)	   showed	   equal	  
responsiveness	  and	  a	  clone	  not	  responding	  was	  used	  as	  a	  control	  (Quandt	  2004).	  	  	  	  	  
The	  role	  of	  B	  cells	  in	  a	  condition	  thought	  to	  be	  T	  cell	  mediated	  can	  be	  hard	  to	  elucidate	  
because	  of	   the	  adjuvants	   required	   for	   initiation	  already	  skewing	  T	  cell	   responses.	   	  Two	  
groups	  have	  crossed	  their	  TCR	  transgenic	  mouse	  strains	  with	  an	  IgHMOG	  strain,	  originally	  
created	  by	  replacing	  the	  germline	  JH	  locus	  with	  a	  rearranged	  immunoglobin	  heavy	  chain	  
gene	   derived	   from	   a	   pathogenic	   monoclonal	   antibody	   specific	   for	   MOG	   (Litzenburger	  
1998).	  	  Crossing	  the	  2D2	  TCR	  transgenic	  mice	  (Bettelli	  2003)	  led	  to	  EAE	  with	  optic	  neuritis	  
and	   spinal	   cord	   lesions.	   	   This	   is	   also	   seen	   in	   the	  MOG	   TCR	   mouse	   but	   the	   disease	   is	  
subclinical	   (Bettelli	   2006a,	   Krishnamoorthy	   2006)	   whilst	   crossing	   the	   TCR1640	   TCR	  
transgenic	  mice	  showed	  a	  similar	  presentation	  (Pollinger	  2009).	   	  Lesions	  were	  observed	  
in	   the	   optic	   nerve	   and	   spinal	   cord	   and	  were	   reminiscent	   of	   those	   seen	   in	   the	   human	  
condition	   and	   it	   may	   be	   that	   the	   B	   cells	   act	   to	   not	   only	   secrete	   autoantibodies	   but	  
concentrate	   the	   low	   levels	  of	  endogenous	  antigen	  and	  present	   it	   to	   the	  T	   cells.	   	   These	  
studies	  offer	  an	   interesting	   insight	   into	  the	  potential	   interplay	  between	  B	  and	  T	  cells	   in	  





As	  with	  the	  TCR	  transgenic	  models	  described	  for	  both	  rheumatoid	  arthritis	  and	  diabetes,	  
the	  same	  models	  have	  been	  utilized	  many	  times	  to	   interrogate	  different	  aspects	  of	  the	  
human	   condition.	   	   The	   2D2	   and	   Tg4	   transgenics	   have	   been	   the	  most	  widely	   used	   and	  
most	  of	  the	  work	  done	  is	  presented	  in	  an	  earlier	  section	  of	  this	  introduction.	  	  They	  have	  
not	  only	  been	  used	  to	  model	  disease	  dynamics	  themselves	  but	  their	  main	  use	  has	  been	  
as	   a	   source	   of	   TCR	   restricted	   T	   cell	   populations	   (O'Connor	   2008,	   Bauer	   2009,	   Zozulya	  
2009).	   	  These	  mice	  lines	  have	  been	  used	  as	  ‘mice	  prone	  for	  autoimmunity’	  and	  crossed	  
onto	   other	   knockout	   or	   knock-­‐in	   strains	   including	   TSP-­‐1null	   (Yang	   2009a),	   β1-­‐integrin-­‐/-­‐	  
(Bauer	  2009),	  and	  CD11dnR	  (Laouar	  2008)	  for	  the	  2D2	  mice	  and	  CTLA-­‐4-­‐/-­‐	  (Verhagen	  2009)	  
for	   the	   Tg4	   mice.	   	   The	   finding	   from	   these	   investigations	   have	   increased	   our	  
understanding	   of	   MS	   pathology	   but	   it	   is	   always	   worth	   remembering	   that	   with	   this	  
widespread	   use	   of	   a	   few	  models,	   all	   findings	   should	   be	   interpreted	   with	   the	   greatest	  
care.	  	  	  	  
	  
8.4.4.3.4 Line7	  
The	  Line7	  model	  of	  MS	  was	  one	  of	  several	  TCR	  transgenic	  lines	  generated	  in	  the	  Altmann	  
lab	  (in	  collaboration	  with	  Vijay	  Kuchroo)	  from	  the	  Ob1A12	  patient	  TCR.	  	  The	  Line8	  mouse	  
(Ellmerich	  2004)	  was	  created	  in	  the	  same	  series	  of	  microinjections	  as	  the	  Line7	  strain.	  All	  
of	   the	   TCR	   transgene-­‐positive	   founder	   strains	   were	   crossed	   such	   as	   to	   have	   a	   null	  
mutation	  for	  H2-­‐Aβ	  (Cosgrove	  1991),	  and	  introduction	  of	  human	  DR15:01	  by	  a	  full-­‐length	  
DRB1*15:01	   cosmid	   containing	   extensive	   5’	   and	   3’	   flanking	   sequences.	   	   The	   TCR	  
recognizes	  MBP85-­‐99	  derived	  from	  a	  human	  MS	  patient	  derived	  clone,	  Ob1A12.	  	  The	  TCR	  





(Kouskoff	  1995).	   	  The	  Line8	  mice	  had	  around	  44%	  of	  splenic	  CD4+	  T	  cells	  expressing	  the	  
TCR	   and	   so	   presented	   spontaneous	   disease	   in	   only	   a	   small	   percentage	   of	   mice	   but	  
showed	   a	   lack	   of	   regular	   movement	   as	   compared	   to	   wild	   type	   mice.	   	   There	   was	   no	  
obvious	   CNS	   pathology	   observed	   with	   this	   impairment	   but	   immunization	   with	   either	  
CFA/antigen	   or	   pertussis	   toxin	   alone	   was	   sufficient	   to	   initiate	   a	   mild	   disease.	   	   After	  
immunization	  with	  CFA/antigen	  and	  pertussis	  toxin	  all	  mice	  developed	  chronic	  paralysis	  
with	   no	   remission,	   as	   in	   regular	   EAE,	   and	   this	   disease	   development	   correlated	   with	   a	  
spread	   of	   reactivity	   of	   the	   T	   cells	   to	   other	   DR15	   restricted	  myelin	   antigens	   (Ellmerich	  
2004).	  	  	  
The	   Line7	   TCR	   transgenic	   strain	   however	   had	   a	   much	   higher	   percentage	   of	   TCR+	   CD4	  
(97%)	   and	  CD8	   (79%)	   T	   cells	   and	  developed	   a	  much	  higher	   proportion	  of	   spontaneous	  
disease	   (approx	   60%),	  which	   rose	   to	   100%	   if	   crossed	   onto	   a	   RAG-­‐/-­‐	   background.	   	  Mice	  
developed	   paralysis	   after	   approximately	   4	   or	   5	   months	   of	   age	   and	   inflammation	   was	  
associated	   with	   myelin	   loss	   in	   the	   cerebellum	   and	   spinal	   cord.	   	   Widespread	   axonal	  
degeneration	  was	  seen	  in	  mice	  with	  chronic,	  overt	  paralysis	  associated	  with	  dense	  areas	  
of	   lymphocytic	   infiltration	   (Ellmerich	   2005).	   	   In	   these	  mice	   there	  was	   also	   evidence	   of	  
epitope	  spread,	  with	  responses	  observed	  to	  DR15	  restricted	  epitopes	  MBP38-­‐59,	  MOG82-­‐96	  
and	  αB-­‐crystallin161-­‐175	  (Ellmerich	  2005)	  emphasising	  the	  relevance	  of	  this	  model	  and	  its	  
advantages	  over	   regular	  EAE	  as	  a	  more	   faithful	   representation	  of	   the	  human	  condition	  
and	  ability	  to	  study	  the	  development	  of	  CNS	  inflammation	  without	  the	  regular	  biases	  of	  







8.5 Aims	  of	  the	  Thesis	  
The	  main	  aim	  of	  this	  thesis	  is	  to	  clarify	  the	  relative	  roles	  of	  distinct	  immune	  cell	  subtypes,	  
namely	   Th1,	   Th17	   and	   Treg	   cells,	   in	   the	   pathogenesis	   of	   multiple	   sclerosis.	   	   A	   TCR	  
transgenic	  mouse	  model,	  named	  the	  Line7,	  will	  be	  used	  to	  further	  our	  understanding	  of	  
the	   initiation	   of	   autoimmunity.	   	   The	   Line7	   model	   has	   many	   advantages	   over	   other	  
commonly	   used	   mouse	   models	   in	   that	   disease	   develops	   spontaneously	   without	   the	  
requirement	   of	   immune	   adjuvants.	   	   These	   bring	   their	   own	   biases	   into	   the	  model,	   and	  
because	  the	  Line7	  mouse	  is	  humanized,	  all	  immune	  responses	  are	  directly	  relevant	  to	  the	  
human	   setting.	   	   This	   reduction	   in	   the	   distance	   between	   the	  mouse	  model	   and	   human	  
disease	   should	   allow	  more	  accurate	  prediction	  of	   a	  drug’s	   therapeutic	  potential	   saving	  
money	  and	  increasing	  the	  speed	  at	  which	  it	  may	  get	  into	  clinical	  use	  (Illes	  2004).	  	  	  
There	   is	   a	   lot	   of	   controversy	   about	   the	   importance	   of	   various	   candidate	   effector	   and	  
regulatory	  cell	  types	  in	  MS	  pathogenesis,	  and	  many	  immune	  cell	  types	  are	  implicated	  in	  
some	  way.	   	  The	  situation	  is	  clearly	  very	  complicated	  and	  this	   is	  further	  confused	  by	  the	  
lack	  of	  accessible	  tissue	  from	  human	  MS	  patients.	  	  It	  goes	  without	  saying	  that	  the	  CNS	  is	  
unobtainable	  and	  the	  nearest	  we	  can	  get	  is	  CSF	  samples,	  but	  these	  samples	  do	  not	  reflect	  
the	   site	   at	  which	   disease	   originates.	   	  Mouse	  models	   therefore	   allow	   target	   tissue	   and	  
encephalitogenic	   cells	   to	   be	   interrogated	   to	   determine	   the	   cause	   of	   disease.	   	   EAE	  
however	   is	   only	   partially	   useful	   in	   this	   aim.	   	   The	   adjuvants	   used	   promote	   Th17	  
polarization	  of	  T	  cells	  and	  so	  in	  my	  view	  it	  is	  not	  surprising	  that	  a	  large	  Th17	  response	  is	  
observed.	  	  Significant	  care	  should	  be	  taken	  when	  interpreting	  EAE	  conclusions	  regarding	  
mechanisms	   as	   it	   shows	   more	   similarities	   to	   an	   acute	   infection	   than	   a	   chronic	  





model	  is	  much	  more	  faithful	  to	  a	  chronic	  autoimmune	  disease	  and	  allows	  assessment	  of	  
disease	   throughout	   its	   initiation	   and	   progression.	   	   This	   should	   allow	   a	   more	   accurate	  
determination	   of	   the	   cells	   involved	   in	   the	   initial	   development	   of	   disease	   and	   its	  
subsequent	  progression.	  	  Through	  careful	  analysis	  of	  this	  model,	  my	  aim	  is	  to	  investigate,	  
in	  a	  spontaneous	  setting,	  the	  relative	  contributions	  of	  Th1	  and	  Th17	  cells	  to	  the	  initiation	  
of	  disease.	  	  
Without	  adjuvants	  dampening	  regulatory	  cell	  function,	  disease	  does	  not	  develop	  in	  other	  
TCR	   transgenic	   lines	  but	   it	   is	  apparent	   in	   the	  Line7	   strain.	   	  Not	  all	  of	   the	  mice	  develop	  
paralysis	  (60%)	  and	  so	  there	  must	  be	  a	  determining	  factor	  that	  triggers	  autoimmunity.	  	  In	  
the	  same	  way	  as	  identical	  twins	  show	  a	  low	  concordance	  of	  MS	  in	  the	  human	  condition,	  
the	  benefit	  of	  using	   these	  mice	   is	   that	   they	  are	  effectively	  all	   identical	   twins.	   	  This	   line	  
provides	  a	  unique	  opportunity	  to	  investigate	  early	  stages	  of	  disease	  which	  is	  impossible	  
in	  induced	  studies	  as	  the	  causes	  of	  disease	  development	  are	  the	  substances	  immunized.	  	  	  
The	  questions	  I	  will	  address	  in	  this	  thesis	  are:	  
• Is	  there	  evidence	  for	  differential	  roles	  of	  Th1	  and	  Th17	  cells	   in	  disease	   initiation	  
and	  progression?	  
• Does	   the	  Line7	  model	   support	  or	  oppose	   the	  view	   that	  Th17	  cells	  are	   the	  most	  
important	  T	  cell	  subset	  in	  the	  development	  of	  multiple	  sclerosis?	  
• Does	  disease	  in	  the	  L7	  mice	  progress	  due	  to	  aberrant	  regulation	  by	  Tregs	  or	  in	  the	  
face	  of	  competent	  regulatory	  function?	  







Overall,	   I	  aim	  to	  use	  the	  Line7	  to	  reappraise	  some	   immunological	   issues	  that	  may	  have	  
been	  unduly	   influenced	   in	   the	  EAE	  model	  by	  dependence	  on	  CFA	  and	  pertussis	   toxin.	   I	  
will	  contribute	  my	  view	  to	  the	  debate	  regarding	  Th1	  and	  Th17	  cells	  in	  MS,	  and	  the	  roles	  
of	  other	  effector	  cells.	  	  I	  will	  look	  at	  potential	  factors	  triggering	  autoimmunity	  and	  assess	  
the	   factors	   determining	   how	   a	   mouse	   is	   able	   to	   resist	   severe	   disease,	   putting	   great	  
emphasis	  on	  the	  role	  of	  regulatory	  T	  cells	  in	  limiting	  both	  the	  initiation	  of	  disease	  but	  also	  


















9 Materials	  and	  Methods	  
9.1 Non-­‐commercial	  reagents	  
1X	  Tris/Borate/EDTA	  (TBE)	  Buffer	  
10.8g	  Tris	  Base	  (Sigma	  Aldrich,	  Poole,	  UK)	  
5.5g	  Boric	  Acid	  (Sigma	  Aldrich,	  Poole,	  UK)	  	  
0.38g	  ethylenediaminetetraacetic	  acid	  (EDTA)	  (Sigma	  Aldrich,	  Poole,	  UK)	  
Up	  to	  1000ml	  deionised	  water.	  
2%	  Agarose	  gel	  
9g	  Molecular	  Grade	  Agarose	  (Sigma	  Aldrich,	  Poole,	  UK)	  
Up	  to	  450ml	  1X	  TBE	  Buffer	  
Enzyme	  Linked	  Immunosorbent	  Assay	  (ELISA)	  wash	  solution	  
0.05%	  Tween	  20/Phosphate	  buffered	  saline	  (PBS)	  pH7.4	  (Sigma	  Aldrich,	  Poole,	  UK)	  
ELISA	  blocking	  solution	  
1%	  Bovine	  serum	  albumin	  (BSA)/PBS	  (Sigma	  Aldrich,	  Poole,	  UK)	  
Complete	  Dulbecco’s	  Modified	  Eagle	  Medium	  (DMEM)	  
DMEM	  (Gibco,	  Invitrogen,	  Paisley,	  UK)	  
10%	  Foetal	  Calf	  Serum	  (Biosera,	  Ringmer,	  UK)	  
1%	  Penicillin/streptomycin	  (Invitrogen,	  Paisley,	  UK)	  	  







0.1%	  Triton/PBS	  (Sigma	  Aldrich,	  Poole,	  UK)	  
Tissue	  lysis	  buffer	  
100mM	  NaCl	  (Sigma	  Aldrich,	  Poole,	  UK)	  
10mM	  Tris-­‐Cl,	  pH	  8	  (Sigma	  Aldrich,	  Poole,	  UK)	  
25mM	  EDTA,	  pH	  8	  (BDH,	  VWR,	  Letterworth,	  UK)	  
0.5%	  Sodium	  dodecyl	  sulphate	  (SDS)	  (BDH,	  VWR,	  Letterworth,	  UK)	  
FACS	  buffer	  	  
3%	  FCS/PBS	  (Biosera,	  Ringmer,	  UK)	  
10mM	  Sodium	  Citrate	  buffer	  
100mM	  Citric	  Acid	  (Sigma	  Aldrich,	  Poole,	  UK)	  
100mM	  Sodium	  Citrate	  (Sigma	  Aldrich,	  Poole,	  UK)	  
Up	  to	  1000ml	  deionised	  water	  
	  
	  
9.2 Animals	  used	  in	  this	  study	  
Mice	   were	   housed	   in	   the	   Central	   Biomedical	   Services	   centre	   at	   the	   Hammersmith	  
Hospital	   London,	   a	  barrier	  maintained	  mouse	   facility.	   	  Mice	  were	   kept	   initially	   in	  open	  
cages	   but	   subsequently	   moved	   into	   individually	   ventilated	   cages	   (IVCs)	   as	   the	   animal	  
facility	  was	  refurbished.	  	  The	  mouse	  pathogen	  status	  was	  regularly	  monitored	  every	  3-­‐4	  





Helicobacter	   hepaticus,	   Helicobacter	   rodentium	   and	   Tritrichomonas	   sp	   in	   the	   original	  
open	  caged	  facility.	  	  Complete	  diet	  was	  administered	  to	  all	  strains.	  	  All	  studies	  involving	  
mice	   underwent	   ethical	   review	   and	   were	   carried	   out	   in	   accordance	   with	   the	   Animals	  
(Scientific	  Procedures)	  Act	  1986.	  
	  
9.2.1 Line7	  
Line7	  mice	  were	  previously	  generated	  in	  the	  laboratory	  by	  Stephan	  Ellmerich	  prior	  to	  use	  
in	   this	   study.	   	   Their	   derivation	   is	   described	  elsewhere	   (Ellmerich	  2004,	   Ellmerich	  2005)	  
but	   in	   brief,	   (C57BL/6	   x	   CBA)F2	   oocytes	   were	   microinjected	   with	   cosmids	   containing	  
linearised	   HLA-­‐DRA1*01:01	   (cosmid	   4.2)	   (Altmann	   1993,	   Altmann	   1995)	   and	   HLA-­‐
DRB1*15:01	  alongside	  5’	  and	  3’	  flanking	  regulatory	  sequences	  (clone	  11)	  (Lock	  1988)	  and	  
one	   founder	   (24)	   from	   this	   generation	   was	   mated	   for	   more	   than	   6	   generations	   with	  
C57BL/6	  Aβ⁰	  mice	  (Cosgrove	  1991)	  to	  yield	  DR15	  Aβ⁰	  mice.	  	  	  Segments	  from	  rearranged	  
Vα3.1Jα40	  and	  Vβ2.1Jβ2.1,	  derived	  from	  the	  Ob1A12	  T	  cell	  clone	  (Ausubel	  1997),	  were	  
amplified	   by	   PCR	   and	   subcloned	   into	   genomic	   TCR	   expression	   cassettes,	   pTαCass	   and	  
pTβCass	   (Kouskoff	   1995,	   van	   Noort	   1995).	   	   These	   cassettes,	   containing	   mouse	   TCR	  
specific	   regulatory	   elements,	   were	   micro-­‐injected	   into	   (C57BL/6	   x	   CBA)F2	   fertilised	  
oocytes	  to	  generate	  a	  number	  of	  TCR-­‐positive	  founders.	  	  One	  of	  these,	  termed	  Line7,	  was	  
subsequently	  mated	  with	  C57BL/6	  DR15	  Aβ⁰	  mice	  for	  5	  generations	  to	  produce	  the	  Line7	  
mice	  on	  a	  C57BL/6	  background	  as	  used	  in	  this	  study.	  
At	  each	  stage	  in	  their	  derivation,	  throughout	  the	  life	  of	  the	  colony	  and	  through	  this	  study,	  
genotype	  was	  confirmed	  by	  PCR	  of	  DNA	  extracted	  from	  a	  tail	  biopsy	  using	  primers	  pairs	  





protocol.	  	  Mice	  were	  used	  in	  this	  study	  across	  the	  range	  of	  age,	  according	  to	  their	  clinical	  
score.	  	  	  
	  
9.2.2 Foxp3DTR	  
Foxp3DTR	  mice	  were	  obtained	  from	  Alexander	  Rudensky,	  University	  of	  Washington.	  	  They	  
are	   C57BL/6	   mice	   that	   contain	   the	   human	   diphtheria	   toxin	   receptor	   fused	   to	   green	  
fluorescent	   protein	   DNA,	   equipped	   with	   an	   internal	   ribosomal	   entry	   site	   into	   the	   3’	  
untranslated	  region	  of	  the	  Foxp3	  locus.	  	  This	  allows	  selective	  depletion	  of	  Foxp3+	  T	  cells	  
through	   the	   addition	   of	   diphtheria	   toxin	   (Kim	  2007).	   	  Mice	  were	   genotyped	  by	   PCR	  of	  
DNA	  extracted	  from	  a	  tail	  biospsy	  using	  primer	  pairs	  to	  detect	  the	  presence	  or	  absence	  of	  
the	   introduced	  DTR-­‐GFP	  DNA	  within	  the	  Foxp3	  locus	  (Table	  3).	   	  Mice	  used	  in	  this	  study	  
were	  6-­‐8	  weeks	  of	  age.	  
	  
9.2.3 L7Fox	  
L7Fox	  mice	  were	  created	  by	  the	  mating	  of	  Line7	  male	  mice	  with	  Foxp3DTR	  female	  mice.	  	  
All	   offspring	  were	   genotyped	   following	   the	   same	   protocol	   as	   Line7	   and	   Foxp3DTR	  mice	  
(Table	  3)	  and	  subsequent	  mating	  pairs	  set	  up	  according	  to	  genotyping	  results.	  	  The	  mice	  
were	   bred	   through	   3	   generations	   before	   use	   to	   ensure	   the	   correct	   transgenic	  
combination	  and	  genotype	  confirmed	  before	  any	  experimental	  procedures	   carried	  out.	  	  
Mice	  used	  in	  this	  study	  were	  6-­‐8	  weeks	  of	  age.	  	  
	  
9.2.4 C57BL/6	  
C57BL/6	  mice	  were	  obtained	   from	   (Harlan,	  Bicester,	  UK	  or	  Charles	  River,	  Margate,	  UK)	  





9.3 Assessment	  of	  disease	  in	  L7	  
Line7	  mice	  were	   scored	   according	   to	   guidelines	   detailed	   in	   Professor	   Altmann’s	   Home	  
Office	  Project	   Licence.	   	  Mice	  were	  checked	  weekly	   from	  birth	  and	   then	  scored	  at	   least	  
twice	   weekly	   from	   first	   signs	   of	   paralysis.	   	   Upon	   reaching	   score	   3,	   mice	   were	   initially	  
weighed	  and	  then	  scored	  and	  weighed	  every	  other	  day	  and	  upon	  reaching	  score	  4,	  mice	  
were	  weighed	  and	  scored	  twice	  daily.	  	  	  Weights	  were	  recorded	  to	  ensure	  mice	  were	  still	  
able	  to	  eat,	  despite	  physical	  impairment.	  	  The	  following	  disease	  landmarks	  were	  used	  to	  
assign	  scores:	  
0	  -­‐	  normal	  
1	  -­‐	  limp	  tail	  
2	  -­‐	  impaired	  righting	  reflex	  or	  waddling	  gait	  
3	  -­‐	  partial	  hind	  limb	  paralysis	  
4	  -­‐	  total	  hind	  limb	  paralysis	  
5	  -­‐	  total	  limb	  paralysis	  
6	  -­‐	  moribund	  
	  
	  
9.4 Nucleic	  Acid	  Protocols	  	  
9.4.1 gDNA	  extraction	  
To	  extract	  genomic	  DNA	  (gDNA)	  for	  analysis	  of	  mouse	  genotype,	  a	  small	  piece	  of	  mouse	  
tail	   was	   removed	   and	   digested	   in	   Tissue	   lysis	   buffer	   with	   proteinase	   K	   (0.25mg/ml)	  





separation	   of	   the	   DNA	   by	   centrifugation	   at	   12000g	   for	   15min.	   	   DNA	  was	   precipitated	  
upon	  addition	  of	  the	  supernatant	  to	  600μl	  isopropanol	  and	  gentle	  agitation	  followed	  by	  
centrifugation	  at	  9000g	  for	  10min.	  	  Extracted	  DNA	  was	  washed	  with	  70%	  ethanol	  and	  the	  
pellet	  air-­‐dried	  to	  remove	  any	  residual	  ethanol	  before	  being	  resuspended	  in	  RNase	  free	  
molecular	  grade	  water	  and	  quantified	  by	  picodrop	  analysis.	  
	  
9.4.2 RNA	  extraction	  	  
RNA	  was	  extracted	  from	  mouse	  tissue	  using	  the	  Trizol	  Plus	  RNA	  Extraction	  kit	  supplied	  by	  
Invitrogen	  (Paisley,	  UK)	  and	  which	  is	  based	  on	  the	  acid	  phenol	  method.	  	  In	  brief,	  mouse	  
tissue	   was	   thoroughly	   homogenised	   in	   1ml	   Trizol,	   0.2ml	   chloroform	   added	   and	   the	  
mixture	  vigorously	  mixed.	  	  After	  a	  brief	  incubation,	  the	  sample	  was	  spun	  at	  12000g	  for	  15	  
min	  at	  4⁰C	  and	  the	  top,	  clear	  aqueous	  layer	  aspirated.	  	  An	  equal	  volume	  of	  70%	  ethanol	  
was	   added,	   vortexed	   to	  mix,	   and	   the	   solution	   run	   through	   the	   supplied	   PureLink	   spin	  
columns.	   	   Subsequent	   washing	   steps	   followed	   using	   the	  wash	   buffers	   supplied	   before	  
elution	  of	  the	  RNA	  into	  50μl	  RNase	  free	  H2O.	  	  The	  RNA	  concentration	  was	  determined	  by	  











9.5 Primer	  design	  	  
Primers	  for	  real-­‐time	  PCR	  analysis	  were	  designed	  using	  Primer3	  software	  (Rozen	  2000).	  	  
Reference	   sequences	   (Table	   5)	   were	   used	   and	   primer	   pairs	   with	   hydrolysis	   probes	  
selected	  based	  on	  the	  following	  criteria:	  	  
• 20-­‐27bp	  in	  length	  
• 30-­‐70%	  GC	  content	  
• Primer	  melting	  temperature	  60⁰C	  ±3⁰C	  
• Hydrolysis	  probe	  melting	  temperature	  70⁰C	  ±3⁰C	  
• Hydrolysis	  probe	  dual	  fluorescence	  label	  (5’-­‐FAM	  3’-­‐TAMRA)	  
Primer	  and	  probe	  secondary	  structure	  was	  analysed	  using	  NetPrimer	  software	  (Premier	  
Biosoft	   International)	   to	   ensure	   minimal	   primer	   dimers	   and	   hairpin	   loops.	   	   All	   oligo	  
peptides	   were	   ordered	   from	   SigmaGenosys	   and	   were	   resuspended	   in	   RNase	   free	  
molecular	  grade	  water.	  
	  
	  
9.6 Polymerase	  Chain	  Reaction	  	  	  
Polymerase	  Chain	  Reaction	  (PCR)	  was	  used	  to	  both	  establish	  the	  genotype	  of	  mice	  and	  to	  
test	  primer	  pairs	  which	  would	  be	  used	  for	  real-­‐time	  PCR.	  	  General	  reaction	  mixtures	  are	  








Reaction	  mix	  for	  genotyping:	  
Reagent	   Final	  Concentration	   Volume	  per	  reaction	  
NH4	  Buffer	  (10X)	   1X	   2.5μl	  
MgCl2	  (15mM)	   3mM	   5μl	  
dNTPs	  (1mM	  each)	   0.2mM	  each	   5μl	  
Forward	  Primer	  (10μM)	   0.5μM	   1.25μl	  
Reverse	  Primer	  (10μM)	   0.5μM	   1.25μl	  
BioTaq	  DNA	  polymerase	  (5u/μl)	   1unit	   0.2μl	  
gDNA	  (40ng/μl)	   100ng	   2.5μl	  
H2O	   -­‐	   7.3μl	  
Total	   -­‐	   25μl	  
Table	  1.	  	  Genotyping	  PCR	  Mix.	  
Reaction	  mix	  for	  primer	  testing	  and	  general	  PCR:	  
Reagent	   Final	  Concentration	  	   Volume	  per	  reaction	  
NH4	  Buffer	  (10X)	   1X	   2μl	  
MgCl2	  (50mM)	   5mM	   2μl	  
dNTPs	  (1mM	  each)	   0.2mM	  each	   4μl	  
Forward	  Primer	  (10μM)	   0.5μM	   1μl	  
Reverse	  Primer	  (10μM)	   0.5μM	   1μl	  
BioTaq	  DNA	  polymerase	  (5u/μl)	   1unit	   0.2μl	  
cDNA	  (50ng/μl)	   50ng	   1μl	  
H2O	   -­‐	   8.8μl	  
Total	   -­‐	   20μl	  



















Cycles	   Product	  
Length	  
DRα	   Sense	   CTCCAAGCCCTCTCCCAGAG	  	   94⁰C/60	   55⁰C/60	   72⁰C/60	   32	   150	  
Antisense	   ATGTGCCTTACAGAGGCCCC	  
DRβ	   Sense	   TTCAATGGGACGGAGCGGGTG	   94⁰C/60	   55⁰C/60	   72⁰C/60	   32	   200	  
Antisense	   CTGCACTGTGAAGCTCTC	  
TCRα	   Sense	   ATTCAGGTAGAGGCCTTGTCCA	   94⁰C/45	   55⁰C/30	   72⁰C/120	   30	   200	  
Antisense	   GAGGTAGTATCCGTAGCACAG	  
TCRβ	   Sense	   GATGGCAACTTCCAATGAGGGCT	   94⁰C/45	   60⁰C/30	   72⁰C/120	   30	   200	  
Antisense	   CGCCCCGCTAGTTAGATCTC	  
MHC	  WT	   Sense	   TCCGCAGGGCATTTCGTGTA	   94⁰C/45	   60⁰C/45	   72⁰C/60	   30	   200	  
Antisense	   AGGGAGGTGTGGGTCTCCGG	  
MHC	  
KO3	  
Sense	   TCCGCAGGGCATTTCGTGTA	   94⁰C/45	   60⁰C/45	   72⁰C/60	   30	   500	  
Antisense	   GAGGATCTCGTCGTGACCCA	  
Foxp3	  
WT	  
Sense	   TGGACCGTAGATGAATTTGAGTT	   94⁰C/40	   53⁰C/40	   72⁰C/30	   35	   550	  
Antisense	   CCAGATGTTGTGGGTGAGTG	  
Foxp3	  
DTR	  
Sense	   GGGACCATGAAGCTGCTCCG	   94⁰C/15	   59⁰C/15	   72⁰C/45	   35	   600	  
Antisense	   TCAGTGGGAATTAAGTCATGCC	  









9.6.2 Testing	  primer	  pairs	  and	  general	  PCR:	  
50⁰C	   for	   2min	   then	   95⁰C	   10min	   followed	   by	   40	   cycles	   of	   95⁰C	   30s,	   varied	   annealing	  
temperature	   30s,	   72⁰C	   30s.	   	   The	   annealing	   temperature	  was	   run	   as	   a	   gradient	   to	   test	  
primers	  but	  varied	  according	  to	  the	  specific	  primer	  pairs.	  	  For	  all	  primer	  pairs	  in	  the	  real-­‐
time	  PCR	  analysis,	  the	  annealing	  temperature	  was	  60⁰C.	  	  
	  
	  
9.7 Reverse	  transcription	  	  
Reverse	   transcription	   of	   extracted	   RNA	   was	   carried	   out	   using	   the	   Quantitect	   Reverse	  
Transcription	  kit	  from	  Qiagen	  (Crawley,	  UK).	  	  For	  1μg	  RNA,	  2μl	  gDNA	  wipeout	  buffer	  was	  
added	  to	  12μl	  of	  H2O	  containing	  1μg	  RNA	  and	  incubated	  at	  42⁰C	  for	  2min.	  	  Then	  1μl	  RT	  
primer	  mix,	   1μl	   RT	   enzyme	   and	   4μl	   RT	   buffer	   were	   added	   and	   incubated	   at	   42⁰C	   for	  












9.8 Real-­‐time	  PCR	  
Real-­‐time	  PCR	  was	  used	  to	  assess	  relative	  expression	  of	  target	  genes.	  	  Reaction	  mixture	  
was	  as	  in	  Table	  4,	  primer	  details	  are	  in	  Table	  5.	  
	  
	  
Reagent	   Final	  Concentration	  	   Volume	  per	  reaction	  
TaqMan	   Gene	   Expression	   Mastermix	  
(2X)	  
1X	   10μl	  
Forward	  Primer	  (10μM)	   0.5μM	   1μl	  
Reverse	  Primer	  (10μM)	   0.5μM	   1μl	  
Hydrolysis	  Probe	  (1μM)	   0.1μM	   2μl	  
cDNA	  (50ng/μl)	   12.5ng	   0.25μl	  
H2O	   -­‐	   5.75μl	  
Total	   -­‐	   20μl	  
Table	  4.	  	  Real-­‐time	  PCR	  Mix.	  
	  
Samples	  were	  run	  on	  a	  Stratagene	  Mx3000p	  machine	  following	  these	  cycling	  conditions:	  	  









Gene	   Forward	  Primer	   Reverse	  Primer	  
Probe	  	  
(all	  5’	  FAM	  –	  TAMRA	  3’)	  
Product	  
Size	   Ref	  Seq	  
Innate	  Immune	  Markers	   	   	   	   	  	  
TLR2	   CAGACAAAGCGTCAAATCTCAG	  	   CGTTTGCTGAAGAGGACTGTTAT	  	   TTTGGCTCTTCTGGATCTTGGTGGC	  	   87	   NM_011905.3	  
TLR3	   CCTCCAAGAACTGCTCTTAGCAA	  	   GGAGAACTCTTTAAGTGGATTTGA	  	   TCCTTGCGTTGCGAAGTGAAGAACT	  	   124	   NM_126166.4	  
TLR4	   AATCCCTGCATAGAGGTAGTTCCTA	   AAGCTCAGATCTATGTTCTTGGTTG	   CCAATGCATGGATCAGAAACTCAGCA	   110	   NM_021297.2	  
TLR9	   AGTGTCACTTCCTCAATTCTCTGA	   ATGTTGGGAGATGGAGGATTC	   ATCATTCTCTGCCGCCCAGTTTGTC	   104	   NM_031178.2	  
Transcription	  Factors	   	   	   	   	  	  
T-­‐bet	   ACTTTGAGTCCATGTACGCATCT	   AGGATACTGGTTGGATAGAAGAGGT	   CACCTGGACCCAACTGTCAACTGCTT	   113	   NM_019507.1	  
GATA3	   TACCACCTATCCGCCCTATGT	   ACACACTCCCTGCCTTCTGT	   ACAGCTCTGGACTCTTCCCACCCAG	   138	   NM_008091.3	  
RORγt	   GTCTGCAAGTCCTTCCGAGAG	   ATCTCCCACATTGACTTCTG	   CTGCGACTGGAGGACCTTCTACGGC	   119	   NM_011281.2	  
Foxp3	   ATAGTTCCTTCCCAGAGTTCTTCC	   ATGGTAGATTTCATTGAGTGTCCTC	   CACCTATGCCACCCTTATCCGATGG	   143	   NM_054039.1	  
Cell	  Lineage	  Factors	   	   	   	   	  	  
AHR	   CACATCCGCATGATTAAGACTG	   GATGTAATCTGGTCTTCCATTTCTG	  	   AAACACAGTCGCTGGAGGTGGGTC	   129	   NM_013464.4	  
Cytokines	   	   	   	   	  	  
IL-­‐1β	   ATCAACCAACAAGTGATATTCTCCA	   CGTCTTTCATTACACAGGACAGGT	   ACAAGGAGAACCAAGCAACGACAAA	   121	   NM_008361.2	  
IL-­‐6	   GTTCCTCTCTGCAAGAGACTTCC	  	   GTATCCTCTGTGAAGTCTCCTCTCC	  	   CTTGGGACTGATGCTGGTGACAACC	  	   111	   NM_031168.1	  
IL-­‐10	   TTAATGCAGGACTTTAAGGGTTACTT	   ATTCAAATGCTCCTTGATTTCTG	   CCAAGCCTTATCGGAAATGATCCAGTT	   123	   NM_010548.1	  
IL-­‐17a	   CTGTGTCTCTGATGCTGTTGCT	   AAGGGAGTTAAAGACTTTGAGGTTG	   AGCTCAGCGTGTCCAAACACTGAGG	   149	   NM_010552.3	  
p19	   ATGAATCTACTAAGAGAAGAAGAGG
ATG	  	  
CTGTTGTCCTTGAGTCCTTGTG	  	   CCGTATCCAGTGTGAAGATGGTTGTGA	   102	   NM_031252.2	  
p35	   AGAGAGACTTCTTCCACAACAAGAG	   TCTTCAAGTCCTCATAGATGCTACC	   CGTCTTTGATGATGACCCTGTGCCT	   100	   NM_008351.1	  
IFNγ	   TCATTGAATCACACCTGATTACTACC	   TTGACCTCAAACTTGGCAATAC	   CTTCTTCAGCAACAGCAAGGCGAA	   88	   NM_008337.3	  
iNOS	   CTCAGCCCAACAATACAAGATG	   GGGATTCTGGAACATTCTGTG	   TAAGAGTCACCAAAATGGCTCCCCG	   90	   NM_010927.3	  
TGFβ	   ATGTTCTTCAATACGTCAGACATTC	   TTGCTATATTTCTGGTAGAGTTCCA	   TGCAGAGCTGCGCTTGCAGAGATTAA	   131	   NM_011577.1	  
TNFα	   CTCACACTCAGATCATCTTCTCAAA	   CTCCACTTGGTGGTTTGCTA	   ACAAGCCTGTAGCCCACGTCGTAGC	   75	   NM_013693.2	  
Housekeeping	  Genes	   	   	   	   	  	  
GAPDH	   GAGAAACCTGCCAAGTATGATGAC	  	   AGACAACCTGGTCCTCAGTGTAG	  	   TCAAGAAGGTGGTGAAGCAGGCATC	  	   100	   NM_008084.2	  
Hprt1	   AACCAGGTTATGACCTAGATTTGTTT	  	   CAAGTCTTTCAGTCCTGTCCATAAT	  	   CCTAATCATTATGCCGAGGATTTGGAA	   108	   NM_013556.2	  
Tbp	   CAGTGCCCAGCATCACTATTT	  	   GCATCCTCTGAATATCTCCTTAGAA	  	   CATGGTGTGTGAAGATAACCCAGAACA	  	   83	   NM_013684.3	  
B2m	   CTACTGGGATCGAGACATGTGAT	  	   TGTGTACATTGCTATTTCTTTCTGC	  	   TGCTCTGAAGATTCATTTGAACCTGCT	  	   130	   NM_009735.3	  
Rpl-­‐13a	   CCTACCAGAAAGTTTGCTTACCTG	  	   GATCTGCTTCTTCTTCCGATAGTG	  	   TGACAGCCACTCTGGAGGAGAAACG	  	   132	   NM_009438.4	  
YWHAZ	   AACTTAACATTGTGGACATCGGATA	  	   TGGATGACAAATGGTCTACTGTGTA	  	   TGAAGCAGAAGCAGGAGAAGGAGGG	  	   131	   NM_011740.2	  
TfrC	   AATGGTAACTTAGACCCAGTGGAG	  	   ATTAGCATGGACCAGTTTACCAGA	  	   TCCCGAGGGTTATGTGGCATTCAGT	  	   90	   NM_011638.3	  
Sdha	   CTGGTGTGGATGTCACTAAGGAG	  	   CACCTGTCCCTTGTAGTTAGTGG	  	   CACTGTGCATTACAACATGGGTGGG	  	   92	   NM_023281.1	  






9.9 Real-­‐time	  analysis	  
Analysis	  of	  real-­‐time	  PCR	  results	  was	  carried	  out	  using	  REST	  software	  (M.	  Pfaffl	  (Technical	  
University	  Munich))	  which	  derives	  relative	  expression	  values	  based	  upon	  Ct	  values	  from	  a	  
comparison	   of	   housekeeping	   and	   target	   genes	   and	   their	   respective	   efficiencies	   of	  
amplification.	  
	  
9.10 Infiltrating	  cell	  analysis	  
9.10.1 Infiltrating	  cell	  extraction	  
To	  extract	   infiltrating	  cells	   from	  the	  CNS,	  mice	  were	   first	  perfused	  with	  PBS	   to	   remove	  
blood	   and	   avoid	   any	   contamination	   with	   peripheral	   blood	   cells.	   During	   terminal	  
anaesthesia,	   the	   sternum	   of	   the	   mouse	   was	   opened	   and	   ribcage	   lifted	   to	   expose	   the	  
heart,	  a	  25g	  needle	  inserted	  into	  the	  left	  ventricle	  and	  PBS	  slowly	  injected	  in.	  	  The	  right	  
atrium	  was	  cut	  to	  release	  blood	  and	  the	  flow	  of	  PBS	  continued	  until	  no	  blood	  could	  be	  
seen	   leaving	   the	   heart	   and	   the	   liver	   had	   lost	   its	   colour.	   	   After	   perfusion,	   the	   CNS	  was	  
dissected	  out	  and	  chopped	  up	  in	  1ml	  complete	  DMEM	  media	  containing	  25μl	  collagenase	  
(100mg/ml	  stock)	  and	  10μl	  DNase	  I	  (100mg/ml	  stock)	  (Sigma	  Aldrich,	  Poole,	  UK),	  further	  
disrupted	  by	  movement	  through	  a	  1ml	  syringe	  and	  the	  homogenate	  incubated	  for	  2h	  at	  
37⁰C.	   	   The	   homogenate	   was	   then	   passed	   through	   a	   70μm	   cell	   strainer	   (BD	   Falcon)	  
washed	  with	  complete	  DMEM	  to	  remove	  residual	  enzymes.	  	  The	  pellet	  was	  resuspended	  
in	   4ml	   30%	   Percoll	   (Sigma	   Aldrich,	   Poole,	   UK)	   made	   up	   with	   complete	   DMEM	   and	  
overlayed	   on	   4ml	   70%	   percoll	   solution	   made	   up	   with	   PBS	   and	   3ml	   HBSS	   (Gibco,	  





with	   no	   brake	   and	   reduced	   acceleration.	   	   The	   floating	   material	   between	   the	   top	   two	  
layers	  was	  removed	  and	  discarded	  and	  the	  desired	  cells	  extracted	  from	  the	  interface	  of	  
the	  30	  and	  70%	  solutions,	  washed	  with	  complete	  DMEM	  and	  counted	  before	  further	  use.	  
	  
9.10.2 ICCS	  staining	  
Intracellular	   cytokine	   staining	   was	   carried	   out	   on	   stimulated	   cells	   using	   the	   BD	  
cytofix/cytoperm	  solution	  kit	  (BD	  Biosciences,	  Oxford,	  UK).	  	  Up	  to	  1	  x	  106	  cells	  extracted	  
from	  the	  spleen	  or	  CNS	  were	  stimulated	  with	  PMA	  (50ng/ml)	  (Sigma	  Aldrich,	  Poole,	  UK)	  
and	  ionomycin	  (1μg/ml)	  (Sigma	  Aldrich,	  Poole,	  UK)	  for	  4h	  in	  the	  presence	  of	  Brefeldin	  A	  
(Sigma	  Aldrich,	   Poole,	  UK)	   at	   50μg/ml	   in	   complete	  DMEM	  media	   in	   a	   96well	   v-­‐bottom	  
plate.	  	  At	  the	  end	  of	  culture,	  cells	  were	  centrifuged	  at	  600g	  (g	  equivalent)	  for	  5min	  and	  
washed	  three	  times	  with	  cold	  PBS.	  	  Cells	  were	  incubated	  for	  10min	  at	  4⁰C	  with	  100μl	  Fc	  
Block	   (eBioscience,	   Hatfield,	   UK)	   (1/1000)	   in	   FACS	   buffer	   before	   being	   incubated	   with	  
surface	  staining	  antibodies	  (Table	  7)	  100μl	  (1/200)	  in	  FACS	  buffer	  for	  20min	  at	  4⁰C	  in	  the	  
dark.	  	  Stained	  cells	  were	  washed	  once	  with	  cold	  PBS	  and	  then	  resuspended	  thoroughly	  in	  
200μl	  BD	  cytofix/cytoperm	  solution	  and	  incubated	  for	  30min	  at	  4⁰C	  in	  the	  dark.	   	  At	  the	  
end	   of	   the	   incubation,	   cells	   were	   washed	   with	   200μl	   BD	   permeabilisation	   buffer	   and	  
incubated	  with	  intracellular	  antibodies	  (see	  Table	  7)	  100μl	  (1/100)	  in	  BD	  permeabilisation	  
buffer	  for	  30min	  at	  4⁰C	  in	  the	  dark.	  	  Two	  subsequent	  washes	  with	  BD	  perm	  buffer	  follow	  







9.11 Flow	  cytometry	  analysis	  
Flow	   cytometric	   analysis	   of	   samples	   was	   carried	   out	   using	   a	   BD	   FACS	   Aria	   II	   running	  
FACSDiva	  software.	  	  Further	  analysis	  was	  carried	  out	  using	  FlowJo	  software	  (Tree	  Star	  Inc,	  
Ashland,	  USA).	  
	  
9.11.1 FACS	  phenotyping	  
Some	  genotyping	  analysis	  was	  carried	  out	  by	  flow	  cytometric	  investigation	  of	  peripheral	  
blood	  rather	  than	  PCR	  based	  assays	  on	  genomic	  DNA.	  	  Staining	  was	  carried	  out	  on	  1	  x	  106	  
cells	   in	  which	   the	  red	  blood	  cells	  had	  been	   lysed,	  washed	  twice	  with	  PBS/10%	  FCS	  and	  
then	  incubated	  with	  the	  relevant	  antibodies	  (see	  Table	  6)	  for	  30min	  at	  4⁰C,	  washed	  twice	  
more	  and	  then	  resuspended	  in	  4%	  PFA	  before	  reading.	  	  	  
	  
9.11.2 Antibody	  list	  genotyping	  and	  intracellular	  cytokine	  staining	  (ICCS)	  
	  
Antibody	   Company	   Fluoro-­‐
chrome	  
Reactivity	   Clone	   Dilution	  	  
B220	   BD	  Biosciences	   FITC	   Mouse	   RA3-­‐6B2	   1/50	  
B220	   BD	  Biosciences	   PE	   Mouse	   RA3-­‐6B2	   1/50	  
I-­‐A/I-­‐E	   BD	  Biosciences	   PE	   Mouse	   M5/114.15.2	   1/100	  
Pan-­‐DRDQDP	   BD	  Biosciences	   FITC	   Human	   TU39	   1/50	  
Vβ2	   Serotec	   PE	   Human	   MPB2D5	   1/20	  
CD31	   eBioscience	   PE	   Mouse	   390	   1/50	  






Antibody	   Company	   Fluorochrome	   Reactivity	   Clone	  
CD4	   BD	  Biosciences	   V500	   Mouse	   RM4-­‐5	  
CD8a	   BD	  Biosciences	   V450	   Mouse	   53-­‐6.7	  
IL-­‐10	   BD	  Biosciences	   PE	   Mouse	   JES5-­‐16E3	  
IL-­‐17a	   BD	  Biosciences	   Alexa647	   Mouse	   TC11-­‐18H10	  
Foxp3	   BD	  Biosciences	   Alexa488	   Mouse	   MF23	  
NK1.1	   BD	  Biosciences	   PE-­‐Cy7	   Mouse	   PK136	  
IFNγ	   BD	  Biosciences	   Alexa700	   Mouse	   XMG1.2	  
Table	   7.	   	   Antibodies	   used	   for	   surface	  marker	   and	   intracellular	   cytokine	   flow	   cytometry	  
analysis.	  
	  
Antibody	   Company	   Fluorochrome	   Reactivity	   Clone	  
CD3e	   BD	  Biosciences	   V500	   Mouse	   500A2	  
NKp46	   eBioscience	   eFluor450	   Mouse	   29A1.4	  
CD49b	   eBioscience	   FITC	   Mouse	   DX5	  
CD8a	   BD	  Biosciences	   V450	   Mouse	   53-­‐6.7	  








9.12.1 Tissue	  preparation	  for	  histology	  
For	  histological	  analysis	  of	  tissue,	  mice	  were	  first	   fix/perfused	  with	  PBS	  followed	  by	  4%	  
PFA	  and	  the	  entire	  CNS	  (brain	  and	  length	  of	  spinal	  cord)	  tissue	  dissected	  out.	  	  The	  tissue	  
was	   submerged	   in	  4%	  PFA	   for	  4h	  and	   then	   submerged	   in	  30%	  sucrose	  at	  4⁰C	  until	   the	  
tissue	  sank	   in	   the	  solution.	   	  At	   this	  point,	   the	   tissue	  was	  dried	  and	  cut	   to	   separate	   the	  
cortex,	  cerebellum	  and	  spinal	  cord.	   	  Each	  was	  mounted	   in	  OCT	  (VWR,	  Letterworth,	  UK)	  
individually	  and	  snap	  frozen	  in	  cooled	  isopentane	  on	  dry	  ice	  and	  stored	  at	  -­‐20⁰C.	  	  10μm	  
sections	  of	  tissue	  were	  cut	  from	  these	  blocks	  on	  a	  Leica	  cm1850	  cryostat	  and	  mounted	  
onto	  clear	  microscope	  slides	  (VWR,	  Letterworth,	  UK)	  for	  further	  staining	  analysis.	  
	  
9.12.2 Haematoxylin	  and	  Eosin	  staining	  
Haemtoxylin	  and	  Eosin	  (H&E)	  staining	  was	  carried	  out	  using	  the	  following	  protocol.	  	  The	  
sections	  were	  thawed	  and	  allowed	  to	  air	  dry	  for	  10min	  before	  being	  rehydrated	   in	  PBS	  
for	  5min	  and	  incubated	  in	  1%	  Mayer’s	  Haemalum	  (BDH,	  VWR,	  Letterworth,	  UK)	  for	  30s.	  	  
The	   haemalum	   was	   differentiated	   in	   3%	   acid	   alcohol	   solution	   for	   10s	   and	   washed	   in	  
running	   tap	   water	   for	   30s.	   	   Haemalum	   staining	   was	   checked	   microscopically	   and	   if	  
necessary,	  the	  steps	  repeated.	  	  Sections	  were	  then	  incubated	  in	  (1%)	  eosin	  (BDH,	  VWR,	  
Letterworth,	   UK)	   for	   5min,	   washed	   briefly	   with	   running	   tap	   water	   and	   dehydrated	   by	  
taking	  the	  slides	  through	  sequential	  solutions	  of	  70%	  ethanol,	  100%	  ethanol,	  and	  xylene	  
(1	  min	  in	  each	  solution).	   	  Slides	  were	  left	  for	  5min	  to	  clear	  in	  xylene	  and	  mounted	  with	  





9.12.3 Fluorescence	  staining	  
For	  fluorescence	  staining,	  slides	  were	  thawed	  and	  allowed	  to	  air	  dry	  for	  10min	  and	  the	  
sections	  drawn	  around	  using	  a	  PAP-­‐pen	  (VWR,	  Letterworth,	  UK)	  to	  allow	  smaller	  volumes	  
of	  washing	  buffers	  and	  antibody	  solutions	  to	  be	  used	  and	  rehydrated	  with	  PBS.	  	  For	  some	  
antibodies	   antigen	   retrieval	   was	   required	   and	   two	   different	   protocols	   were	   followed.	  	  
The	  first	  was	  incubation	  of	  sections	  with	  methanol	  +	  3%	  H2O2	  for	  5min	  followed	  by	  three	  
washes	  with	  PBS-­‐T	  and	  the	  second	  had	  the	  additional	  step	  of	  immersing	  the	  sections	  in	  
citrate	  buffer,	  bringing	  the	  solution	  to	  the	  boil	  and	  simmering	  for	  3min	  before	  allowing	  to	  
cool	  for	  10min	  and	  subsequent	  washing	  with	  PBS-­‐T.	  	  	  
After	  optional	  antigen	  retrieval,	  sections	  were	  incubated	  with	  relevant	  primary	  antibody	  
mixes	  (see	  Table	  9)	  in	  PBS-­‐T	  containing	  3%	  Normal	  Goat	  Serum	  (Sigma	  Aldrich,	  Poole,	  UK)	  
overnight	  at	  room	  temperature.	   	  The	  following	  morning,	  sections	  were	  washed	  3	  times	  
with	  PBS-­‐T	  and	  incubated	  with	  secondary	  antibodies	  (see	  Table	  10)	  (1/500)	  in	  PBS-­‐T	  for	  
2h	   at	   room	   temperature.	   	   Sections	   were	   then	   washed	   again	   3	   times	   with	   PBS-­‐T	   and	  
incubated	  with	   DAPI	   (Sigma	   Aldrich,	   Poole,	   UK)	   (1/5000)	   in	   PBS-­‐T	   for	   5min,	   washed	   3	  
further	   times	   and	   mounted	   with	   fluorescence	   mounting	   medium	   (Vectorlabs,	  
Peterborough,	  UK).	  	  The	  coverslips	  were	  sealed	  with	  nail	  varnish	  to	  prevent	  the	  sections	  










Antibody	   Company	   Host	  species	   Reactivity	   Clone	  
CD4	   Serotec	   Monoclonal	  Rat	   Mouse	   RM4-­‐5	  





NK1.1	   eBioscience	   Monoclonal	  
Mouse	  
Mouse	   PK136	  
Table	  9.	  	  Primary	  antibodies	  used	  in	  immunofluroescence.	  
	  
Fluorochrome	   Company	   Host	  Species	   Reactivity	  
Alexa488	   Invitrogen	   Goat	   Rabbit	  
Alexa568	   Invitrogen	   Goat	   Rat	  
Alexa546	   Invitrogen	   Goat	   Mouse	  
Alexa546	   Invitrogen	   Goat	   Rabbit	  
Table	  10.	  	  Secondary	  antibodies	  used	  for	  immunofluorescence.	  
	  
9.12.4 Photomicroscopy	  
H&E	   images	   were	   captured	   using	   Oasis	   scanning	   software	   (Microimaging	   Applications	  
Group,	  Buckinghamshire,	  UK)	  which	  was	  connected	  to	  a	  Prior	  motorised	  stage	  attached	  
to	   a	  Nikon	   Eclipse	   50i	  microscope.	   	   Fluorescence	   images	  were	   captured	   using	   a	  Nikon	  
e1000	  microscope	  with	  motorised	  stage	  (Prior	  scientific,	  Cambridge,	  UK),	  digital	  camera	  







9.13 Treg	  Suppression	  Assay	  
Single	  cell	  suspensions	  of	  lymphocytes	  extracted	  from	  either	  the	  spleen	  or	  CNS	  of	  3	  mice	  
were	  pooled	  together	  and	  sorted	  on	  a	  BD	  FACS	  Aria	   II	  on	  the	  basis	  of	  their	  GFP	  status.	  	  
GFP+	  Tregs	  and	  GFP-­‐	  effector	  T	  cells	  (Teff)	  were	  separated	  from	  each	  suspension	  and	  co-­‐
cultured	   in	   combinations	   as	   per	   the	   design	   of	   the	   experiment	   for	   3	   days	   with	   30,000	  
effector	  cells	  per	  well.	   	  Tregs	  were	  added	   if	  necessary	  at	  a	   ratio	  of	  1:1	  Treg:Teff.	   	  Treg	  
suppression	  was	  measured	  by	  thymidine	  incorporation	  by	  proliferating	  cells	  and	  cytokine	  
release	  into	  the	  growth	  medium.	  	  	  
	  
9.14 Proliferation	  assay	  
3H	   thymidine	   incorporation	   was	   used	   as	   a	   measure	   of	   cell	   proliferation	   to	   different	  
stimuli	   and	   from	   different	   experimental	   contexts.	   	   Cells	   were	   cultured	   in	   complete	  
DMEM	   with	   various	   concentrations	   of	   stimulant	   for	   3-­‐5	   days	   at	   37⁰C	   with	   5%	   CO2.	  	  
Supernatants	   from	  the	  cell	   culture	  were	  aspirated	   for	   cytokine	  analysis	  and	  media	  was	  
replaced	  alongside	  1µCi	  of	  thymidine	  per	  well.	  	  After	  8-­‐16h	  further	  incubation	  the	  culture	  
was	  frozen	  at	  -­‐20⁰C	  to	  prevent	  the	  cells	  proliferating	  any	  further	  and	  to	  allow	  storage	  of	  
the	  plate	  until	  reading.	  	  Plates	  were	  harvested	  using	  a	  plate	  harvester	  (Tomtec,	  Hamden,	  
USA)	   and	   read	   using	   a	  Wallac	  Microbeta	   Trilux	   system	   (Perkin	   Elmer,	   Cambridge,	   UK).	  	  







9.15 ELISA	  	  
Cytokine	   release	   from	   cultured	   cells	   was	   assessed	   using	   an	   ELISA.	   	   ELISA	   kits	   were	  
ordered	  from	  Mabtech,	  Sweden	  and	  optimised	  in	  the	  lab.	  	  Detection	  limits	  advertised	  by	  
the	  manufacturer	  were	  confirmed	  by	  limiting	  dilution	  of	  known	  standards	  before	  each	  kit	  
was	  used	  to	  quantify	  cytokine	  release.	  	  Detection	  antibody	  was	  coated	  onto	  ELISA	  plates	  
at	   the	   relevant	  concentration	   (see	  Table	  11)	  overnight	  at	  4oC	  or	   for	  2h	  at	  37⁰C.	   	  Plates	  
were	  washed	  with	  PBS	  before	  being	  blocked	  with	  1%BSA	  in	  PBS	  for	  a	  minimum	  of	  1	  hour	  
at	   room	   temperature.	   	   Plates	  were	  washed	  with	   0.05%Tween	   in	   PBS	   (washing	   buffer)	  
before	  supernatants	  and	  standards	  were	  diluted	  to	  useable	  concentrations	  and	  allowed	  
to	  incubate	  in	  the	  plates	  overnight	  at	  4⁰C.	  	  Plates	  were	  washed	  again	  with	  washing	  buffer	  
in	   PBS	   before	   the	   detection	   antibody	   was	   added	   in	   1%BSA/PBS	   at	   the	   relevant	  
concentration	   (see	   Table	   11)	   and	   incubated	   for	   1	   hour	   at	   room	   temperature.	  	  
Streptavidin	  at	  1/1000	  dilution	  was	  added	  after	  further	  washes	  with	  washing	  buffer	  and	  
incubated	  at	   room	  temperature	   for	  half	  an	  hour.	   	  One	   final	  washing	  step	   followed	  and	  
the	   substrate	   for	   the	  horseradish	  peroxidase	   (HRP)	  was	   introduced	   to	   the	  plate.	   	  After	  
between	   10min	   and	   1	   hour,	   1M	   H2SO4	   was	   added	   to	   stop	   the	   reaction	   and	   the	  
absorbance	  of	  each	  well	  read	  on	  a	  μQuant	  ELISA	  reader	  (Biotek	  Instruments	  Inc,	  Potton,	  
UK)	  using	  KCJunior	  software.	  	  The	  data	  for	  each	  well	  was	  compared	  to	  the	  standard	  curve	  
to	  obtain	  a	  concentration	  of	  cytokine	  and	  multiplied	  by	  any	  dilution	  factor	  to	  achieve	  the	  


















Human	   TNFα	   NaHCO3	   pH	  
8.3	  
1/500	   1/1000	   29pg/ml	  
Mouse	   IFNγ	   NaHCO3	   pH	  
8.3	  
1/1000	   1/2000	   3.16pg/ml	  
Mouse	   IL-­‐10	   NaHCO3	   pH	  
8.3	  
1/250	   1/2500	   20pg/ml	  
Mouse	   IL-­‐17a	   PBS	  pH	  7.4	   1/500	   1/1000	   5pg/ml	  















9.16 TLR	  agonist	  immunization	  
TLR	  agonists	  from	  TLR2	  agonist	  kit	  (Invivogen,	  Nottingham,	  UK)	  were	  resuspended	  using	  
molecular	   grade	   H2O	   and	   diluted	   to	   the	   desired	   concentration	   in	   PBS	   (see	   Table	   12).	  	  
100μl	  of	  the	  solution	  was	  injected	  i.p.	  into	  the	  mice	  twice	  weekly	  for	  three	  weeks.	  
First	  run:	  
Agonist	   Concentration	  	   Total	   per	  
injection	  
LPS	   10μg/ml	   1μg	  
LM-­‐MS	   1μg/ml	   0.1μg	  
LTA	   10μg/ml	   1μg	  
Second	  Run:	  
LTA	   50μg/ml	   5μg	  
Table	  12.	  	  TLR	  agonist	  immunization	  concentrations.	  
	  
9.17 Whole	  Blood	  Assay	  
9.17.1 Methodology	  
To	  assess	  reactivity	  of	  patients	  and	  controls	  to	  TLR	  ligands,	  plates	  were	  set	  up	  containing	  
50μl	   selections	  of	  TLR	   ligands	   in	  RPMI	   (Gibco,	   Invitrogen,	  Paisley,	  UK)	  +	  10%	  FCS,	   from	  
various	  Invivogen	  TLR	  and	  NBOD	  agonist	  kits,	  and	  stored	  at	  -­‐20⁰C	  until	  use	  (See	  Table	  14).	  	  
Whole	  blood	  from	  patients	  and	  controls	  was	  extracted	  into	  BD	  Vacutainer©	  plus	  plastic	  





10%	  FCS	  before	  use.	  	  The	  stimulant	  plates	  were	  thawed	  prior	  to	  use	  and	  50μl	  aliquots	  of	  
diluted	   whole	   blood	  were	   added	   to	   the	   50μl	   of	   stimulant	  mix	   to	   provide	   a	   1/10	   final	  
dilution	   of	   the	  whole	   blood,	   and	   the	   plates	   incubated	   at	   37⁰C	   5%	   CO2	   for	   24h.	   	   After	  
incubation,	   the	   plates	   were	   centrifuged	   at	   300g	   for	   10min	   and	   the	   supernatants	  
aspirated	  for	  secreted	  cytokine	  analysis	  by	  ELISA.	  
	  
9.17.2 Ethical	  Consideration	  and	  Demographics	  of	  MS	  and	  Control	  Patient	  Recruitment	  
Informed	  consent	  was	  received	  from	  all	  persons	  donating	  blood	  for	  use	  in	  this	  study.	  	  MS	  
patients	  used	  in	  this	  study	  presented	  to	  MS	  clinics	  hosted	  by	  Dr	  Richard	  Nicholas	  and	  Dr	  
Omar	  Malik	  at	  the	  Charing	  Cross	  Hospital,	  London	  where	  details	  of	  potential	  uses	  of	  their	  
blood	  was	  described	  and	  consent	  taken	  for	  this	  purpose.	  	  Healthy	  controls	  were	  recruited	  
to	   age	   and	   sex-­‐match	   the	  MS	  patients	   and	   consent	  was	   taken	   in	   the	   same	  way	   to	  MS	  
patients.	  	  The	  demographics	  of	  both	  populations	  are	  shown	  below.	  	  	  
	   MS	  Patients	   Healthy	  Controls	  
Number	   10	   8	  
Average	  Age	   40.5	   43.4	  
Standard	  Deviation	   12.3	   11.7	  
Gender	  Contribution	   All	  female	   All	  female	  
Clinical	  Presentation	   All	  RR-­‐MS	   n/a	  









TLR	  Agonist	   Agonist	  for	   Concentration	  
γ-­‐D-­‐glutamyl-­‐meso-­‐diaminopimelic	  acid	  	  (iE-­‐DAP)	   NBOD1	   1μg/ml	  
Salmonella	  typhimurium	  Flagellin	   TLR5	   1μg/ml	  
Fibroblast	  Stimulating	  Ligand-­‐1	  (FSL1)	   TLR6/2	   10ng/ml	  
Heat	  Killed	  Listeria	  monocytogenes	  (HKLM)	   TLR2	   108	  cells	  
Imiquimod	   TLR7	   1μg/ml	  
Lipomannan	  from	  Mycobaterium	  smegmatis	  (LM-­‐MS)	   TLR2	   10ng/ml	  
Lipopolysaccharide	   from	   Esherichia	   coli	   K12	   (LPS	   E.coli	  
K12)	  
TLR4	   100ng/ml	  
Porphyromopnas	  gingivalis	  Lipopolysaccharide	  (LPS)	   TLR2	   1μg/ml	  
Staphylococcus	  aureus	  Lipoteichoic	  acid	  (LTA)	   TLR2	   100ng/ml	  
Muramyl	  Dipeptide	  (MDP)	   NBOD2	   10μg/ml	  
Synthetic	  Lipopeptide	  Pam3Cys-­‐Ser-­‐(Lys)4	  	  (Pam3CSK4)	   TLR1/2	   1μg/ml	  
Insoluble	  Peptidoglycan	  from	  E.	  coli	  K12	  (PGN-­‐ECndi)	   NBOD1/2	   1μg/ml	  
Peptidoglycan	  from	  S.	  aureus	  (PGN)	   TLR2	   1μg/ml	  
Phytohaemagglutinin	  	  (PHA)	   	   20μg/ml	  
Polyinosinic:polycytidylic	  acid	  	  (PolyI:C)	   TLR3	   1μg/ml	  
20-­‐mer	   GU-­‐rich	   Single-­‐Stranded	   RNA	   Oligonucleotide	  
(ssRNA40)	  
TLR8	   1μg/ml	  







9.18 Treg	  depletion	  and	  other	  antibody	  depletions	  
For	  Treg	  depletion	  in	  the	  Foxp3DTR	  mice	  or	  L7Fox	  cross,	  100μl	  diphtheria	  toxin	  (50μg/kg)	  
(Sigma	   Aldrich,	   Poole,	   UK)	   was	   injected	   at	   12.5μg/ml	   in	   PBS	   i.p.	   per	   dose.	   	   For	   CD8	  
depletion,	  100μl	  YTS169	  antibody	  (Cobbold	  1990)	  at	  1mg/ml	  in	  PBS	  was	  injected	  i.p	  per	  
dose.	  	  For	  NK1.1	  depletion,	  200μl	  anti-­‐NK1.1	  (eBioscience,	  Hatfield,	  UK)	  at	  1mg/ml	  in	  PBS	  
was	  injected	  i.p	  per	  dose.	  
	  
	  
9.19 Statistical	  Analysis	  
9.19.1 Real-­‐time	  PCR	  
Statistical	   analysis	   of	   real-­‐time	   PCR	   data	   was	   done	   by	   using	   randomisation	   tests	   with	  
pairwise	  reallocation.	   	  This	  analysis	   is	   in	  built	   in	  the	  REST	  software	  (M.	  Pfaffl	   (Technical	  
University	  Munich))	  used	  to	  generate	  relative	  expression	  values	  and	  is	  displayed	  through	  
the	  use	  of	  a	  p	  value	  for	  which	  significance	  is	  measured	  as	  being	  p<0.05.	  	  Randomisation	  
tests	  do	  not	  assume	  a	  normal	  distribution	  in	  the	  data,	  rather	  that	  the	  allocation	  of	  results	  
into	  different	  groups	  is	  random.	  	  They	  then	  determine	  how	  likely	  the	  difference	  observed	  
between	   the	   two	   groups	   could	   be	   explained	   by	   this	   allocation	   through	   the	   analysis	   of	  
over	  5000	  iterations	  of	  other	  random	  pairs	  of	  data.	  	  Significant	  results	  are	  shown	  in	  two	  
ways;	  *	   illustrates	  significance	  with	  regard	  to	  the	  baseline	  expression	  (C57BL/6	  mouse),	  






9.19.2 FACS	  and	  ELISA	  Analysis	  
Statistical	   analysis	   was	   carried	   out	   on	   means	   generated	   from	   the	   analysis	   of	   multiple	  
mice	  within	  specific	  experimental	  groups,	  determined	  by	  the	  design	  of	  the	  investigation.	  	  
The	   means	   are	   assumed	   to	   come	   from	   normally	   distributed	   populations	   and	   so	  
comparison	   of	   the	   means	   was	   done	   using	   a	   two-­‐tailed	   Student’s	   T	   test	   with	   Welch’s	  
correction.	   	   This	   allows	   comparison	   of	   means	   without	   assurance	   of	   equal	   variance,	  
necessary	  as	  many	  means	  were	  calculated	  from	  limited	  sample	  sizes.	   	  A	  two-­‐tailed	  test	  
was	  used	  in	  favour	  of	  a	  one-­‐tailed	  as	  the	  null	  hypothesis	  was	  that	  there	  was	  no	  significant	  
difference	   between	   the	   two	   groups	   without	   a	   consideration	   of	   which	   direction	   the	  
difference	   may	   be.	   	   Significant	   differences	   are	   highlighted	   on	   each	   graph	   with	   the	  
corresponding	  significance	  level;	  *	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001.	  	  ANOVA	  analysis	  was	  
not	  used	  as	   interest	  was	   in	  differences	  between	  distinct	  disease	   landmarks	  rather	   than	  
investigating	   whether	   the	   disease	   landmarks	   together	   would	   explain	   the	   variance	  














10 Characterisation	  of	  the	  Line7	  model	  
10.1 Introduction	  
In	   recent	   years,	   a	   great	   deal	   of	   attention	   has	   focused	   on	   the	   role	   of	   Th17	   cells	   in	   the	  
development	  of	  autoimmunity.	  	  From	  the	  initial	  studies	  showing	  the	  importance	  of	  IL-­‐23	  
(Cua	  2003)	  and	  IL-­‐17	  in	  EAE	  (Langrish	  2005,	  Komiyama	  2006)	  those	  that	  showed	  IFNγ	  to	  
be	   dispensible	   for	   EAE	   (Ferber	   1996),	   and	   the	   subsequent	   confirmation	   findings	   that	  
Th17	  cells	  could	  transfer	  EAE	  (Langrish	  2005).	  There	  may	  have	  been	  a	  resulting	  tendency	  
in	   the	   field	   to	  attribute	  a	  central	   role	  of	  Th17	  cells	  as	  necessary	  and	  sufficient	   for	  EAE,	  
and	   by	   extrapolation,	  MS	   (Cua	   2003,	   Hofstetter	   2005,	   Komiyama	   2006,	   Reboldi	   2009).	  	  	  
However,	   in	   this	   same	   period,	  many	   conflicting	   and	   results	   have	   been	   generated	   that	  
make	  such	  a	  view	  contentious.	  Examples	  of	  observation	  that	  do	  not	  readily	  fit	  a	  simple	  
Th17	  model	  are	  the	  requirement	  of	  T-­‐bet	  for	  encephalitogenicity	  of	  both	  Th1	  and	  Th17	  
cells	   (Yang	   2009b),	   that	   the	  majority	   of	   CNS	   infiltrating	   CD4	   cells	   are	   exTh17	   Th1	   cells	  
(Hirota	  2011)	  and	  the	  identification	  of	  T-­‐bet+RORγt+	  cells	  (Abromson-­‐Leeman	  2009).	   	  As	  
the	  original	  idea	  of	  Th1	  and	  Th2	  cells	  survived	  for	  around	  20	  years	  before	  it	  was	  shown	  to	  
be	   inadequate,	  other	   ideas	  should	  be	  entertained	  despite	   the	  vast	   support	   for	  one	  cell	  
type	  over	  another.	  	  	  
Animal	  models	   are	   utilized	   in	  MS	   research	   because	   they	   provide	  what	   is	   lacking	   from	  
human	   studies,	   namely	   direct	   investigation	   of	   diseased	   organs	   at	   differential	   disease	  
states.	  	  Human	  studies	  rely	  mainly	  on	  post-­‐mortem	  brain	  tissue	  and	  blood	  samples	  taken	  
from	   patients,	   with	   some	   work	   done	   with	   CSF	   samples,	   although	   even	   these	   are	   not	  





The	  largest	  difficulty	  faced	  when	  using	  animal	  models	  is	  understanding	  which	  aspects	  can	  
be	  directly	  transferred	  to	  interpretation	  of	  the	  human	  condition	  (Sriram	  2005,	  Steinman	  
2006)	  and	  which	  are	  just	  artefacts	  of	  either	  the	  animal	  physiology	  or	  the	  model	  itself.	  EAE	  
in	  this	  way	  provides	  many	  difficulties	  in	  drawing	  conclusions	  with	  regard	  to	  human	  MS:	  
not	  only	  is	  it	  a	  very	  severe,	  experimentally-­‐induced	  condition	  but	  it	  is	  carried	  out	  in	  such	  
a	   wide	   range	   of	   different	   genetic	   backgrounds	   and	   with	   a	   wide	   range	   of	   neurological	  
antigens	   that	   results	   from	  one	   study	   are	   not	   always	   directly	   comparable	  with	   another	  
(Lassmann	  2007).	  	  That	  being	  said,	  some	  EAE	  models	  have	  proved	  to	  be	  more	  successful	  
and	  more	  widely	  used	  than	  others,	  dominating	  the	  published	  research,	  and	  leading	  some	  
observers	  to	  look	  no	  further	  when	  considering	  the	  human	  condition.	  	  	  
A	   resulting	   tendency	   to	   allow	   findings	   from	   a	   very	   narrow	   part	   of	   the	   disease	   model	  
spectrum	   to	   dominate	   the	   literature	   may	   be	   to	   the	   detriment	   of	   achieving	   a	   strong	  
understanding	   of	   the	   human	   disease	   which	   is	   far	   more	   complicated	   than	   the	   animal	  
model.	  	  Inducing	  disease	  in	  an	  EAE	  model	  necessarily	  requires	  the	  introduction	  of	  a	  large	  
number	  of	  biases	   into	   the	   immune	  system.	   	  The	   impact	   that	  each	  aspect	  of	   the	  model	  
required	  for	  EAE	  induction,	  such	  as	  the	  nature	  and	  effects	  of	  the	  CFA,	  pertussis	  toxin	  and	  
antigen	   used	   (Veldhoen	   2006a,	   Veldhoen	   2006b,	   Li	   2007)	   has	   on	   the	   final	   outcome	   is	  
often	   ignored	   in	   the	   interpretation	   of	   the	   generated	   results	   and	   therefore	   should	   be	  
properly	   controlled	  when	  delineating	   a	  mechanism	  of	   action	   in	   the	  human	   context.	   	   A	  
specific	  example	  is	  the	  promotion	  of	  Th17	  cells	  through	  the	  use	  of	  pertussis	  toxin	  (Chen	  
2007)	  and	  CFA	  (Tigno-­‐Aranjuez	  2009).	  
Therefore	   there	   is	   a	   need	   to	   investigate	   spontaneous	  mouse	   disease	  models,	   without	  





other	   injections,	   to	   facilitate	   interpretation	  of	   the	  generated	   results.	   	   The	  Line7	  mouse	  
model	  was	   designed	  with	   these	   intentions,	   to	   generate	   a	  more	   relevant	  model	   to	   the	  
human	   condition,	   and	   to	   provide	   data	   to	   contribute	   to	   the	   immunological	   debate	  
(Ellmerich	   2005).	   	   The	   model	   benefits	   from	   the	   ability	   to	   select	   mice	   from	   different	  
disease	   scores,	   representing	   the	   distinct	   stages	   of	   disease	   progression.	   	   By	   separating	  
mice	  according	  to	  disease	  landmarks,	  it	  should	  be	  possible	  to	  understand	  which	  cells	  are	  
important	   at	   which	   stages	   and	   whether	   one	   cell	   type	   is	   proximal	   to	   another	   in	   the	  
initiation	  of	  disease.	  	  	  
The	   first	   priority	   with	   such	   a	   model	   is	   to	   fully	   characterize	   the	   immunological	  
developments	  throughout	  disease	  progression,	  rather	  than	  just	  a	  simple	  pre-­‐disease	  and	  
peak	   disease	   comparison	   allowed	   by	   most	   EAE	   models	   because	   of	   the	   rate	   of	  
progression.	  	  
A	  combination	  of	  techniques	  are	  required	  to	  build	  up	  a	  full	  picture	  of	  the	  developments	  
at	  each	  stage	  in	  disease	  progression,	  and	  whilst	  not	  directly	  concluding	  the	  mechanism	  of	  
action,	  the	  importance	  of	  cell	  types	  can	  be	  inferred	  from	  the	  findings.	  	  A	  combination	  of	  
real-­‐time	   PCR,	   immunofluorescence	   staining,	   and	   flow-­‐cytometric	   analysis	   were	  
employed	  on	  mice	  at	  different	   stages	  of	  disease.	  The	  aim	  has	  been	   thus	   to	  generate	  a	  
dataset	   illustrating	   the	   progressive	   activation	   of	   immune	   cells	   through	   the	   disease	  
process,	  encompassing	  direct	  observation	  of	   infiltrating	  cells	  and	  direct	   interrogation	  of	  
the	  polarization	  of	   the	   cellular	   infiltrate	   respectively.	   	   Real-­‐time	  PCR	   is	   a	   very	   sensitive	  
method	  for	  detecting	  changes	   in	  the	  transcription	  of	  genes,	   indicative	  of	  activation	  and	  
inferred	  to	   lead	  to	  correlate	  with	  protein	   levels.	   	   In	   this	  context,	  whole	   tissue	  could	  be	  





factors.	  	  Whilst	  results	  cannot	  be	  attributed	  to	  specific	  cells,	  it	  can	  implicate	  increases	  in	  
activation	  of	  one	  cell	  type	  at	  the	  expense	  of	  another	  and	  also	  the	  activated	  environment	  
of	  the	  diseased	  tissue.	  	  	  
Direct	   observation	   of	   infiltrating	   cells	   is	   the	   clearest	   way	   to	   show	   the	   presence	   of	  
immune	  cells	  at	  the	  site	  of	  damage.	  	  Analysis	  by	  immunofluorescence	  and	  flow	  cytometry	  
provides	  an	  important	  checkpoint	  to	  implicate	  cells	  in	  the	  pathogenesis	  of	  disease.	  	  Both	  
can	  highlight	  the	  importance	  or	  unimportance	  of	  infiltrating	  cell	  populations	  based	  upon	  
their	   localization	   in	   the	   inflamed	  tissue	  and	  detected	  cytokine	  production.	   	  This	  can	  be	  
attributed	   to	   individual	   cells	   rather	   than	   gross	   measurement	   of	   the	   whole	   tissue	   to	  
implicate	  the	  determinant	  factors	  in	  disease	  progression.	  	  In	  this	  way	  a	  full	  picture	  of	  the	  
model	   can	   be	   drawn,	   illuminating	   the	   important	   questions	   to	   ask	   rather	   than	  














10.2.1 Development	  of	  Paralysis	  
The	  Line7	  transgenic	  model	  exhibit	  spontaneous	  ascending	  paralysis	  that	  passes	  through	  
distinct	   symptomatic	   landmarks	   that	   allow	   assessment	   of	   severity	   and	   comparison	  
between	  mice	  in	  which	  disease	  has	  progressed	  to	  different	  extents.	  	  In	  order	  to	  gain	  an	  
understanding	   of	   the	   progression	   of	   disease,	  mice	  were	   scored	   daily	   according	   to	   the	  
guidelines	  in	  the	  Materials	  and	  Methods	  section	  and	  in	  accordance	  with	  requirements	  of	  
Professor	   Altmann’s	   Home	   Office	   Project	   Licence	   under	   the	   Animals	   (Scientific	  
Procedures)	   Act	   1986.	   	   Disease	   scores	   were	   collated	   for	   each	   mouse	   and	   transposed	  
relative	  to	  the	  date	  of	  birth	  of	  each	  mouse.	  	  An	  average	  for	  each	  day	  was	  calculated	  and	  
plotted	  as	  a	  point	  on	  a	  scatter	  plot	  to	  illustrate	  the	  progression	  of	  disease	  over	  time.	  	  Not	  
all	  mice	  were	  retained	  in	  the	  cohort	  through	  to	  one	  year	  of	  age	  through	  requirements	  for	  
experiments	  and	  so	  they	  were	  removed	  from	  the	  averaging	  process	  at	  that	  time.	  	  Their	  
scores	  however	  were	  used	  to	  contribute	  to	  the	  average	  for	  the	  period	  of	  time	  they	  were	  
alive.	  	  Mice	  not	  developing	  signs	  of	  disease	  were	  not	  included	  in	  the	  calculation	  so	  that	  
the	  progression	   is	   relevant	   to	   the	   ‘average’	  mouse	  developing	  signs	  of	  disease	  and	  not	  
the	   whole	   colony	   as	   this	   would	   generate	   an	   unrealistic	   profile	   for	   the	   mice	   that	   did	  
develop	  signs	  of	  disease.	  	  	  
	  
The	  progression	  of	  paralysis	  scores	  of	   the	  affected	  mice	   is	  shown	   in	  Figure	  1.	   	   It	  shows	  
that	   first	   signs	   of	   disease	   are	   observed	   in	   mice	   at	   approximately	   3	   months	   of	   age,	  
although	  other	  mice	   in	   the	  colony	  continue	   to	  present	   first	   signs	  of	  disease	   through	  to	  





faster	  rate	  than	  male	  mice	  although	  this	   is	  not	  a	  significant	  difference.	   	  After	  the	   initial	  
signs,	  disease	  progresses	  at	  variable	  rates	  in	  individual	  mice,	  which	  results	  in	  the	  average	  
disease	  score	  to	  follow	  a	  gradual	  progression	  (Figure	  1B).	  	  	  The	  progression	  of	  disease	  in	  
the	  affected	  miceis	  not	  associated	  with	  any	  weight	  loss	  (data	  not	  shown).	  	  Around	  40%	  of	  
mice	  do	  not	  develop	  signs	  of	  disease	  at	  all	  and	  these	  remain	  unaffected	  through	  to	  a	  year	  
of	  age	  (Ellmerich	  2005).	  These	  mice	  are	  termed	  score	  0	  (old)	  or	  0o	  to	  distinguish	  these	  
mice	   from	   the	  pre-­‐disease	   young	   score	   0	  mice	  which	   are	   termed	  0y	   (0	   young).	   	   It	   has	  
been	   noted	   in	   other	   spontaneous	   models	   that	   disease	   is	   profoundly	   affected	   by	   the	  
microbiological	   status	   of	   the	   animal	   facility	   (Goverman	   1999).	   	   For	   only	   the	   disease	  
progression,	  Line7	   tissue	  cryosection	  analysis	  and	   real-­‐time	  PCR	   transcriptional	  analysis	  
experiments,	  mice	  were	  housed	  in	  the	  H1	  facility	  at	  the	  MRC	  Clinical	  Sciences	  Centre	  and	  
the	   following	   infections	  were	   commonly	  detected	  on	   screening;	  Helicobacter	  hepaticus	  
bacteria,	  Helicobacter	   rodentium	  bacteria	  and	  Tritrichomonas	  sp	  parasite.	   	  For	  all	  other	  
experiments,	   mice	   were	   housed	   in	   the	   H2	   facility	   in	   the	   Burlington	   Danes	   Building,	  













A	  –	  Variable	  presentation	  of	  first	  signs	  of	  disease	  occurs	  throughout	  the	  first	  year	  of	  life.	  	  
The	   day	   when	   first	   signs	   of	   disease	   were	   observed	   was	   recorded	   and	   displayed	   as	   a	  
cumulative	   percentage	   of	   all	   mice	   presenting	   disease	   signs.	   	   B	   –	   Scores	   from	   all	   mice	  
presenting	   signs	   of	   disease	   averaged	   to	   generate	   ‘standard’	   progression	   of	   disease	   as	  
measured	   by	   increasing	   physical	   symptoms.	   	   For	   A	   and	   B,	   mice	   housed	   in	   H1	   mouse	  
facility.	  n=137	  total.	  	  	  C	  –	  Counts	  of	  infiltrating	  cells	  as	  extracted	  using	  density	  gradients.	  	  
Scores	   at	   time	   of	   extraction	   averaged	   and	   shown	   with	   SEM.	   	   Mice	   at	   various	   disease	  
scores	   are	   compared	   to	   young,	   pre-­‐diseased	  mice	   (0y)	   and	   old,	   unaffected	  mice	  which	  
have	   resisted	   signs	   of	   disease	   past	   8	   months	   of	   age	   (oo).	   	   Mice	   housed	   in	   H2	   mouse	  
facility.	  	  n=26	  total.	  
	  
Any	  mouse	  not	  presenting	  signs	  of	  disease	  by	  the	  age	  of	  8	  months	  will	  only	  present	  signs	  
on	   very	   rare	   occasions	   and	   so	   these	   are	   treated	   as	   non-­‐affected	   mice	   in	   further	  
experiments.	   	   Interestingly,	   these	   unaffected	   mice	   are	   all	   male	   and	   all	   female	   mice	  
develop	  paralysis,	  albeit	  at	  differing	  severities.	  	  	  
The	  progression	  pattern	  of	  male	  and	  female	  mice	  is	  also	  slightly	  different,	  with	  male	  mice	  
typically	   presenting	   earlier	   than	   female	   mice.	   	   First	   signs	   of	   disease	   are	   observed	   at	  
younger	   ages	   on	   average	   in	  male	  mice	   although	   the	   further	   progression	   of	   disease	   is	  
slower	   in	   males	   than	   females	   (Figure	   1A).	   This	   illustrates	   a	   sex-­‐dependent	   difference	  






10.2.2 Visualization	  of	  Cellular	  Infiltration	  
Progression	   of	   signs	   of	   disease	   in	   the	   Line7,	   as	  with	   EAE,	   is	   associated	  with	   increasing	  
cellular	   infiltration	   into	   the	   spinal	   cord.	   	   By	   developing	   a	   technique	   for	   extraction	   of	  
lymphocytes	   from	   the	   CNS,	   it	   became	   possible	   to	   investigate	   the	   infiltrating	   cell	  
populations	  at	  each	  stage	  of	  disease	  and	  determine	  whether	  a	  development	  of	  signs	  of	  
disease	  could	  be	  attributed	  to	  one	  or	  many	  cell	  types.	   	  The	  protocol	   is	  described	  in	  the	  
materials	  and	  methods	  section	  but	  in	  brief	  involved	  an	  enzymatic	  digestion	  followed	  by	  
density	  gradient.	  	  The	  technique	  proved	  sufficiently	  successful	  as	  to	  allow	  investigation	  of	  
mice	  individually,	  rather	  than	  requiring	  pooled	  cell	  populations,	  and	  means	  that	  averages	  
could	   be	   calculated	   for	  mice	   at	   different	   disease	   severities	   from	  multiple	   experiments	  
reducing	   the	  error	   introduced	  by	   recording	  whole	   samples	   from	  each	  disease	   score	  on	  
only	  one	  day.	  	  	  
Infiltrating	   cells	   extracted	   from	  CNS	  of	   animals	  at	   various	  disease	   scores	  were	   counted	  
using	  a	  haemocytometer	  to	  determine	  the	  size	  of	  the	  infiltrating	  population	  (Figure	  1B)	  
before	  being	  further	  stimulated	  and	  incubated	  with	  fluorescently	  conjugated	  antibodies.	  	  
The	   infiltration	  was	  found	  to	  correlate	  with	  the	  severity	  of	  signs	  of	  disease,	  such	  that	  a	  
larger	  infiltrating	  population	  was	  associated	  with	  more	  severe	  signs	  and	  the	  relationship	  
appears	   to	   be	   increasing	   in	   an	   approximate	   exponential	   manner	   as	   disease	   develops	  
(Figure	  1B).	   	  Despite	  not	  presenting	  signs	  of	  disease,	  there	  are	  detectable	  levels	  of	  cells	  
infiltrating	   the	   CNS	   of	   both	   young	   mice	   (less	   than	   2	   months)	   and	   old	   mice	   (over	   8	  












Figure	  2.	  	  Progression	  of	  disease	  associated	  with	  increased	  cellular	  infiltration	  ascending	  
the	  spinal	  cord.	  	  	  
10μm	  fix/perfused	   tissue	  sections	   from	  mice	  at	  distinct	  disease	   landmarks	  were	  stained	  
with	  DAPI	  to	  indicate	  nuclei.	  	  Images	  are	  tiled,	  inverted	  views	  of	  10X	  fields	  of	  view.	  	  Tiling	  
was	   done	   using	   ImagePro	   7	   software	   and	   images	   inverted	   using	   Adobe	   Photoshop	  
software.	  	  	  Representative	  images	  of	  at	  least	  3	  mice	  from	  each	  disease	  score.	  
	  
	  
Staining	  of	  cryosections	  with	  DAPI	  to	  visualize	  DNA,	  was	  carried	  out	  to	  show	  the	  location	  
and	  timing	  of	  cellular	  infiltration	  in	  the	  model.	  This	  simple	  observation	  does	  not	  provide	  
any	  information	  with	  regard	  to	  cell	  phenotype	  but	  allows	  aggregations	  of	  cells	  to	  be	  seen	  
and	  provides	  a	  supporting	  observation	  to	  the	  cell	  counts	  derived	  from	  the	  cell	  extraction	  
protocol.	   	   The	   image	   was	   reduced	   to	   black	   and	   white	   to	   improve	   the	   visualisation	   of	  
individual	  cells.	  	  Multiple	  10X	  single	  frame	  of	  views	  were	  tiled	  together	  to	  generate	  views	  
of	  whole	   tissue	   sections	  using	   ImagePro	   software	   (Media	  Cybernetics).	   	   The	  density	   of	  
cellular	   infiltration	   rendered	   a	   quantitative	  measure	   impossible	   as	   cells	   could	   be	   seen	  
overlapping	  with	  each	  other	  and	  would	  not	  be	  individually	  distinguishable,	  necessary	  for	  
counting.	   	   	   Consideration	   of	   these	   images	   showed	   infiltration	   typically	   in	   the	   lumbar	  
regions	  and	  ascending	  to	  the	  thoracic	  and	  cervical	  regions	  when	  the	  severity	  of	  disease	  
increases	   (Figure	  2).	   	  Control	   tissue	  also	  stained	  showed	   little	  cellular	   infiltration	  above	  
the	   normal	   density	   of	   neuronal	   cells	   present.	   	   Infiltrating	   cells	   could	   be	   seen	   to	  





and	  ventral	  fissures	  as	  well	  as	  direct	  localised	  infiltration	  directly	  into	  the	  tissue	  with	  no	  
obvious	  pattern	  of	  location	  (Figure	  3).	  	  	  
	  
These	   same	   cryosections	  were	   also	   stained	  with	   antibodies	   directed	   towards	   CD4	   and	  
CD8	  (Figure	  3A,	  B,	  C,	  D,	  F),	  and	  NK1.1	  (E).	  	  Primary	  antibodies	  directed	  against	  cell	  surface	  
markers	   (and	   raised	   in	   different	   species	   if	   used	   in	   conjunction	   with	   another	   primary	  
antibody)	   were	   initially	   incubated	   with	   the	   sections	   to	   adhere	   to	   specific	   cell	   surface	  
markers	   before	   sections	   were	   washed	   to	   remove	   unbound	   antibody	   from	   the	   slide.	  	  
Fluorescently	  conjugated	  secondary	  antibodies,	  directed	  against	  the	  primary	  antibodies,	  
were	   then	  used	   to	   visualise	   the	   location	  of	   the	  primary	   antibodies	   as	   they	  amplify	   the	  
signal	  making	  it	  easier	  to	  detect	  under	  the	  microscope.	  	  This	  staining	  was	  carried	  out	  to	  
determine	  the	  composition	  of	  the	  cellular	  infiltrate	  and	  identify	  any	  different	  infiltration	  
patterns	   for	   each	   cell	   type.	   	   Non-­‐overlapping	   fluorescent	  molecules	  were	   used	   on	   the	  
secondary	   antibodies	   in	   each	   analysis	   so	   that	   the	   different	   cellular	   makers	   could	   be	  
distinguished	   by	   the	   wavelength	   of	   light	   required	   to	   excite	   and	   the	   subsequent	  
wavelength	  of	  the	  emitted	  light	  observed.	  	  A	  typical	  example	  if	  two	  antibodies	  were	  to	  be	  
used	  would	  be	  peak	  excitations	  at	  495nm	  and	  590nm	  with	  peak	  emissions	  at	  519nm	  and	  
617nm	  respectively	  (Alexa488	  and	  Alexa594	  dyes).	  	  Therefore	  one	  marker	  would	  appear	  
green	  whilst	   the	   other	   red.	   	  Minimal	   fluorescence	   contamination	  would	   also	   be	   seen,	  
resulting	   from	   the	   overlap	   of	   the	   emission	   spectrum	   of	   one	   dye	   with	   the	   excitation	  
wavelength	  of	  the	  other.	  	  All	  three	  cell	  types;	  CD4,	  CD8	  and	  NK,	  could	  be	  identified	  in	  the	  
infiltrating	  population.	  The	   initial	  description	  of	   this	  model	  by	  Ellmerich	  and	  colleagues	  





particular	  line	  (but	  not	  other	  founders	  from	  the	  same	  pronuclear	  microinjections),	  selects	  
into	  both	  the	  CD4	  and	  CD8	  SP	  populations.	  	  Representative	  images	  are	  shown	  in	  Figure	  3	  
showing	  all	   these	  cell	   types	   infiltrating.	   	  Most	  notably	  cells	  were	  seen	   in	   large	  numbers	  
throughout	   the	  meningeal	   tissue	   of	   the	   spinal	   cord	   and	   infiltration	   could	   be	   observed	  
occurring	   through	   the	   dorsal	   fissure	   (Figure	   3A).	   	   Similar	   patterns	   of	   infiltration	   were	  
observed	   through	   the	   ventral	   fissure	   of	   the	   spinal	   cord	   (Figure	   3F)	   and	   comparative	  
sections	  taken	  from	  control	  C57BL/6	  mice	  showed	  no	  meningeal	  aggregation	  of	  cells	  or	  
infiltration	  through	  either	  the	  dorsal	  or	  ventral	  fissures	  (Figure	  3B,C).	  	  Despite	  this	  large	  
abundance	  of	  infiltrating	  cells,	  no	  specific	  pattern	  of	  infiltration	  could	  be	  attributable	  for	  
each	  cell	  type.	  	  There	  were	  seemingly	  equal	  distributions	  among	  all	  infiltrating	  locations	  
and	  no	  temporal	   infiltration	  of	  one	  cell	   type	  before	  the	  others	   (Figure	  3).	   	   	   Infiltrations	  
containing	  both	  CD4	  and	  CD8	  cells	  could	  be	  seen	  occurring	  in	  the	  tissue	  away	  from	  the	  
fissures	   in	   specific	   locations	   (Figure	   3A,	   D)	   and	   also	   in	   a	   more	   widespread	   diffusion	  
(Figure	   3E).	   	   Overall,	   these	   date	   provide	   an	   illustration	   of	   the	   cellular	   infiltration	   and	  
confirmation	   that	   CD4,	   CD8	   and	   NK	   cells	   are	   present,	   co-­‐localised	   in	   infiltration	  
populations.	  	  These	  pictures	  provide	  circumstantial	  evidence	  for	  a	  role	  in	  mediating	  CNS	  
damage	   but	   not	   direct	   evidence.	   	   No	   conclusion	   could	   be	   drawn	   with	   regard	   to	  
importance	  in	  controlling	  infiltration	  or	  mediation	  of	  neuronal	  damage	  at	  this	  stage	  and	  












Figure	  3.	  Cellular	  infiltration	  into	  the	  spinal	  cord	  of	  Line7	  mice.	  	  	  
L7	   and	  mice	   from	  distinct	   disease	   landmarks	  were	   fix/perfused	  and	  10µm	  sections	   cut.	  	  
Representative	  10X	  pictures	  are	  shown	  from	  indicated	  locations	  in	  the	  lumbar	  spinal	  cord.	  	  
A	  –	  Entry	  of	  cells	   into	  the	  dorsal	   fissure	  from	  the	  meningeal	  space	  and	  emanating	  from	  
vascular	   structures	   inside	   the	  white	  matter.	   	   Score	  4	   Line7,	  CD4	   (red)	  CD8	   (green)	  DAPI	  
(blue).	   	   B	   –	   View	   of	   dorsal	   fissure	   in	   C57BL/6	   mouse	   showing	   no	   infiltration	   and	  
accumulation	  of	  cells,	  staining	  as	  (A).	  	  C	  –	  View	  of	  ventral	  fissure	  in	  C57BL/6	  showing	  no	  
infiltration	  and	  accumulation	  of	  cells,	  staining	  as	  (A).	  	  D	  –	  CD4	  and	  CD8	  cells	  accumulating	  
in	  meningeal	  tissue	  and	  isolated	  infiltration	  events	  in	  a	  score	  4	  Line7,	  staining	  as	  (A).	  	  E	  –	  
NK	  cells	  accumulating	  throughout	  meningeal	  tissue	  in	  a	  score	  4	  Line7	  mouse,	  NK1.1	  (red)	  
DAPI	   (blue).	   	   F	   –	   Large	   numbers	   of	   infiltrating	   cells	   surrounding	   vascular	   tissue	   in	   the	  
ventral	  fissure	  of	  a	  score	  3	  Line7,	  CD4	  (red)	  CD8	  (green)	  DAPI	  (blue).	  
	  
	  
10.2.3 Analysis	  of	  Infiltrating	  Cell	  Populations	  
The	  protocol	  for	  extraction	  and	  isolation	  of	  CNS-­‐infiltrating	  cells	  was	  developed	  such	  that	  
cells	  could	  be	  investigated	  from	  individual	  mice	  without	  the	  need	  to	  pool	  samples.	  	  Using	  
this	  method	   it	  was	   possible	   to	   take	  mice	   from	   each	   disease	   score	   and	   investigate	   the	  





were	  taken	  at	  each	  disease	  score	  to	  control	   for	  any	  gender	  bias.	   	  After	  extraction,	  cells	  
were	   stimulated	  using	   the	  non-­‐specific	   stimulant	  of	  PMA	  and	   ionomycin.	   	   PMA	  acts	   to	  
activate	  PKC	  pathways	  whilst	  ionomycin	  increases	  the	  intracellular	  calcium	  levels,	  acting	  
together	  to	  stimulate	  the	  release	  of	  cytokines.	  	  It	  is	  assumed	  that	  the	  cytokines	  released	  
in	   response	   to	   this	   stimulation	   are	   indicative	   of	   those	   primed	   released	   in	   the	   in	   vivo	  
environment,	   as	   the	   stimulation	   does	   not	   affect	   the	   polarisation	   of	   the	   cells.	   	   The	  
stimulation	  was	  carried	  out	   in	  the	  presence	  of	  Brefeldin	  A,	  a	  protein	  transport	   inhibitor	  
that	   prevents	   the	  movement	   of	   proteins	   from	   the	   endoplasmic	   reticulum	   to	   the	   golgi	  
apparatus,	   and	   therefore	   keeps	   cytokines	   destined	   for	   release	   sequestered	  within	   the	  
cells	   producing	   them.	   	   After	   surface	   staining	   and	   cell	   fixation,	   it	   is	   then	   possible	   to	  
permeablise	  cells	  and	  stain	  for	  the	  intracellular	  cytokines	  to	  determine	  the	  polarisation	  of	  
the	   cell	   population	   extracted.	   	   Two-­‐tailed	   t	   tests	   with	  Welch’s	   correction	   for	   unequal	  
variance	  were	  used	  to	  analyse	  differences	  in	  means	  of	  cell	  proportions	  resulting	  from	  this	  
experiment.	  
Surface	  staining	  of	  cells	  shows	  that	  the	  largest	  population	  of	  infiltrating	  lymphocytes	  are	  
in	   fact	  NK	  cells,	  as	  defined	  here	  by	  being	  cells	   in	   the	   lymphocyte	  gate	   that	  are	  NK1.1+.	  	  
Unfortunately	   due	   to	   the	   number	   of	   antibodies	   used	   in	   this	   analysis	   and	   the	   limited	  
range	   of	   fluorescent	   molecules	   available,	   it	   was	   not	   possible	   to	   further	   confirm	   this	  
population	  with	  other	  markers	  such	  as	  NKp46.	  	  They	  consistently	  make	  up	  around	  50%	  of	  
the	   infiltrating	   lymphocyte	   population	   but	   do	   not	   significantly	   change	   in	   proportion	   as	  
disease	   progresses	   although	   there	   is	   a	   higher	   proportion	   observed	   in	   mice	   resisting	  







Figure	   4.	   	   Phenotypic	   analysis	   of	   infiltrating	   lymphocyte	   population	   across	   spectrum	   of	  
disease	  in	  Line7	  mice.	  	  	  
Cells	  were	  extracted	  from	  perfused	  L7	  CNS	  tissue	  by	  enzymatic	  digestion	  and	  separation	  
on	   a	   percoll	   density	   gradient.	   	   Cells	   were	   incubated	   with	   antibodies	   for	   cell	   surface	  
markers	   CD4,	   CD8	  and	  NK1.1	  and	   read	  on	  a	  BD	   FACS	  Aria	   II,	   gated	  on	   the	   lymphocyte	  
population	   and	   percentage	   distributions	   calculated	   for	   each	  mouse.	   	   Data	   presented	   is	  
average	   of	   mice	   at	   that	   disease	   score	   with	   SEM	   (n=18	   total).	   	   *	   shows	   statistical	  
significance	   between	   cell	   populations	   of	   different	   disease	   scores	   (p<0.05)	   (two-­‐tailed	   T	  
test).	  
There	   is	   a	   smaller	   (5-­‐10%)	  but	   consistent	  population	  of	   infiltrating	  CD8+	   cells	   across	  all	  
disease	   scores,	   but	   it	   is	   the	   CD4+	   population	   that	   correlates	   with	   initiation	   of	   disease	  





increases	  as	  a	  proportion	  of	  infiltrating	  lymphocytes.	  	  At	  the	  peak	  of	  disease	  an	  increased	  
infiltration	   of	   NK	   cells	   lowers	   the	   proportion	   of	   the	   infiltrate	   that	   are	   CD4+,	   although	  
neither	  of	  these	  changes	  show	  significance	  upon	  statistical	  analysis.	  	  The	  mice	  remaining	  
unaffected	   show	  a	   similar	   infiltration	  pattern	   to	   the	  pre-­‐diseased	  mice	   in	   all	   cell	   types	  
(Figure	  4).	  
In	  addition	  to	  surface	  staining,	  the	  non-­‐specific	  stimulation,	  in	  the	  presence	  of	  Brefeldin	  
A	  allowed	   intracellular	   staining	   to	  be	  conducted	   for	   IFNγ	  and	   IL-­‐17,	   to	   interrogate	  cells	  
within	   the	   lymphocyte	   gate	   as	   to	   which	   cytokines	   they	   were	   producing.	   	   Much	  
controversy	   is	   directed	   at	   the	   composition	   of	   the	   cellular	   infiltrate	   of	   autoimmune	  
conditions	  with	  the	  relative	  contribution	  of	  Th1	  and	  Th17	  cells	  unclear.	  	  Interestingly,	  the	  
proportion	   of	   the	   infiltrate	   that	   are	   IFNγ+	   mirrors	   the	   pattern	   of	   CD4+	   cells,	   with	   the	  
proportion	  of	   infiltrating	  cells	   increasing	  with	  disease	  score	  at	  early	  stages,	  through	  the	  
initiation	  of	  disease	  signs,	  but	  falling	  off	  to	  early	  levels	  at	  peak	  of	  disease	  (Figure	  5A).	  	  A	  
significant	   increase	   in	   IFNγ+	   cells	   is	   seen	   at	   early	   disease	   scores	   relative	   to	   pre-­‐disease	  
(Figure	  5A).	   	   In	   contrast,	   the	   IL-­‐17+	   cells	   appear	   in	   their	   highest	  proportion	  only	   at	   the	  
peak	   of	   disease.	   	   Through	   disease	   initiation	   and	   early	   progression	   they	   are	   present	   in	  
lower	  proportions	  than	  IFNγ+	  cells	  and	  in	  fact	  are	  first	  consistently	  detectable	  in	  mice	  at	  
score	   2,	  when	  disease	  has	   already	  been	   initiated	   and	  other	   T	   cells	   have	   infiltrated	   the	  
CNS	   (Figure	   5A).	   	   Analysis	   of	   mice	   that	   resisted	   autoimmunity	   showed	   populations	   of	  
both	  IFNγ+	  and	  IL-­‐17+	  single	  positive	  cells	  infiltrating	  the	  CNS	  to	  a	  greater	  level	  than	  pre-­‐
disease	  mice,	  although	  the	  total	  infiltrating	  population	  in	  both	  groups	  is	  very	  small	  and	  so	  







Figure	  5.	  	  IFNγ	  precedes	  IL-­‐17	  production	  in	  disease	  initiation.	  	  	  
CNS	  infiltrating	  cells	  were	  extracted	  from	  perfused	  L7	  CNS	  tissue	  by	  enzymatic	  digestion	  
and	  separation	  on	  a	  percoll	  density	  gradient.	  	  Intracellular	  and	  surface	  antibody	  staining	  
was	  carried	  out	  on	  extracted	  cells	  from	  the	  CNS	  after	  stimulation	  with	  PMA/ionomycin	  for	  
4h	  with	  BFA	  and	  read	  using	  a	  BD	  FACS	  Aria	  II.	   	  Data	  presented	  is	  average	  of	  all	  mice	  at	  





lymphocyte	   (A),	   CD4	   (B),	   CD8	   (C),	   NK	   (D)	   cell	   population	   at	   each	   disease	   severity.	  	  
Lymphocytes	   were	   gated	   initially	   according	   to	   cell	   surface	   markers	   and	   positive	   cells	  
interrogated	  to	  determine	  the	  size	  of	  cytokine	  positive	  populations.	   	  Proportion	  of	   IFNγ+	  
cells	  also	  positive	  for	   IL-­‐17	  shown	  at	  each	  disease	  score	  (E).	   	  Asterisks	  denote	  statistical	  
significance	   between	   cell	   populations	   of	   indicated	   disease	   scores;	   	   *	   p<0.05,	   **	   p<0.01	  
(two-­‐tailed	  T	  test).	  
	  
	  
In	  addition	  to	  analysis	  of	  each	  surface	  or	  cytokine	  marker	  alone,	  the	  cytokine	  production	  
within	   each	   lymphocyte	   population	  was	   also	   investigated.	   	   This	   was	   achieved	   through	  
gating	  on	  each	  surface	  marker	  using	  FlowJo	  software,	   to	  show	  only	   those	  cells	  positive	  
for	   each	   cell	   surface	  marker	   and	   then	   the	   subsequent	   analysis	   of	   cytokine	   production	  
within	   these	  populations.	   	  The	  patterns	  of	  cytokine	  production	   in	   the	   total	   lymphocyte	  
gate	  are	   recapitulated	  by	  analysis	  within	  gates	  of	   individual	   surface	  markers;	  CD4,	  CD8	  
and	  NK1.1.	   	  All	  three	  show	  an	  increase	  in	  IFNγ+	  cells	  as	  disease	  initiates	  and	  IL-­‐17+	  cells	  
appearing	   around	   the	  peak	  of	   disease	   (Figure	   5B,C,D).	   	   The	  peak	  of	   IFNγ	   production	   is	  
however	  not	  significantly	  different	  to	  any	  other	  disease	  score	  in	  either	  of	  the	  CD4	  or	  CD8	  
populations,	   and	   only	   within	   the	   NK	   population	   is	   a	   significantly	   higher	   proportion	   of	  
IFNγ+	   cells	   seen	   at	   early	   disease	   (score	   1)	   compared	   to	   pre-­‐disease	   (score	   0y).	   	   The	  
patterns	   of	   IFNγ+	   cells	   resemble	   that	   seen	   in	   the	   total	   lymphocyte	   population	  with	   an	  
increase	  in	  proportion	  as	  disease	  develops	  before	  reducing	  in	  proportion	  at	  peak	  disease.	  
This	  would	  suggest	  that	  no	  one	  cell	  type	  forms	  the	  dominant	  contributor	  to	  IFNγ	  release	  





There	  is	  no	  significantly	  increased	  IL-­‐17	  release	  at	  any	  disease	  score	  relative	  to	  another.	  
In	  both	  CD8	  and	  NK	  cell	   populations,	   the	  highest	  proportion	  of	   IL-­‐17+	   cells	   are	   seen	  at	  
peak	   disease	   but	   there	   is	   a	   large	   degree	   of	   variation	   between	   mice,	   with	   only	   one	  
showing	   a	   substantial	   population,	   meaning	   that	   this	   does	   not	   achieve	   statistical	  
significance	  as	  compared	  to	  pre-­‐diseased	  mice.	  	  In	  these	  two	  cell	  types	  the	  proportion	  at	  
peak	   disease	   is	   similar	   to	   that	   seen	   in	   mice	   that	   fail	   to	   develop	   signs	   of	   disease,	  
suggesting	  a	  potentially	  protective	  role	   for	   these	  cells.	   	   It	   is	  only	   in	   the	  CD4	  population	  
that	   a	   correlation	   with	   disease	   severity	   is	   observed.	   	   As	   with	   the	   total	   lymphocyte	  
population,	  no	   IL-­‐17+	   cells	   can	  be	  observed	  until	   disease	   is	   established	   (score	  2)	  whilst	  
the	  peak	  is	  reached	  at	  highest	  disease	  scores.	  	  The	  population	  of	  CD4+IL-­‐17+	  cells	  in	  mice	  
not	  developing	  signs	  of	  disease	   is	  similar	   to	  that	  of	  CD4+IFNγ+	  cells,	  although	   in	  neither	  
case	  significantly	  lower	  than	  peak	  disease	  levels.	  	  	  
The	   increase	   in	   IL-­‐17+	   cells	   at	   peak	   disease	   appears	   to	   be	   associated	   with	   IFNγ	   co-­‐
production.	  	  Through	  analysis	  of	  double	  positive	  cells	  (IL-­‐17+	  cells	  within	  the	  IFNγ+	  gate),	  
the	  proportion	   can	  be	   seen	   to	  peak	  at	  high	  disease	  having	  been	  a	   significantly	   smaller	  
population	  at	  earlier	  stages	  of	  disease	  (Figure	  5E).	  	  This	  would	  suggest	  that	  a	  proportion	  
of	  the	  IL-­‐17	  production	  identified	  in	  this	  model	  comes	  from	  cells	  already	  producing	  IFNγ	  
and	  it	  may	  be	  that	  the	  remaining	  IL-­‐17	  comes	  from	  cells	  that	  no	  longer	  produce	  IFNγ	  but	  
it	  is	  impossible	  to	  tell	  in	  this	  analysis	  (Hirota	  2011).	  
Analysis	  of	  peripheral	  lymphocyte	  activation	  and	  cellular	  proportion	  (in	  the	  same	  manner	  
as	   CNS	   infiltrating	   cells)	   by	   analysis	   of	   splenocytes	   is	   important	   to	   determine	  whether	  
these	  changes	  in	  cellular	  dynamics	  and	  activation	  is	  a	  result	  of	  organ-­‐specific	  or	  systemic	  





of	  cellular	  composition,	  apart	   from	  a	  slight	   increase	   in	  proportion	  of	  CD4+	  cells	  at	  peak	  
disease	  (Figure	  6A).	  	  In	  the	  spleen,	  CD4	  cells	  make	  up	  the	  highest	  proportion	  of	  cells	  at	  all	  
disease	  states,	  with	  lower	  levels	  of	  NK	  cells	  than	  seen	  in	  the	  CNS	  infiltrate.	   	  There	  is	  no	  
change	   in	   the	  proportion	  of	   CD8	  or	  NK	   cells	   between	  disease	   scores	   and	   although	   the	  
increase	  in	  proportion	  of	  CD4+	  cells	  is	  seen	  at	  peak	  disease,	  it	  is	  not	  statistically	  significant	  
to	  pre-­‐disease	  or	   indeed,	  those	  mice	  which	  resist	  development	  of	  paralysis	   (Figure	  6A).	  	  
There	   is	   no	   change	   in	   peripheral	   IL-­‐17	   production	   throughout	   disease	   progression	   or	  
increase	   in	   IFNγ	   release	   correlating	   with	   disease	   progression	   in	   contrast	   to	   the	  
observations	  from	  the	  CNS	  (Figure	  6B).	  
	  
Further	   analysis	   of	   cytokine	   production	   from	  within	   the	   CD4,	   CD8	   and	  NK	   lymphocyte	  
divisions	   all	   show	   a	   consistently	   higher	   proportion	   of	   IFNγ+	   cells	   than	   IL-­‐17+	   (Figure	  
6C,D,E).	   	   No	   variation	   is	   seen	   within	   the	   IL-­‐17+	   population	   of	   each	   group	   as	   disease	  
progresses.	   	   The	   proportion	   of	   NK	   cells	   IFNγ+	   does	   not	   show	   any	   significant	   variation	  
despite	  a	  trend	  towards	  decreasing	  as	  disease	  develops.	  	  A	  slightly	  higher	  proportion	  of	  
IFNγ+	  cells	  within	  the	  CD4	  gate	  of	  affected	  mice	  is	  not	  statistically	  significant	  compared	  to	  
mice	   without	   signs	   of	   disease.	   	   The	   only	   statistically	   significant	   difference	   is	   a	   lower	  
proportion	  of	  CD4+IFNγ+	  cells	  in	  mice	  resisting	  disease	  than	  those	  before	  signs	  of	  disease	  
could	  develop.	  	  In	  the	  early	  stages	  of	  disease	  (score	  1	  and	  2),	  a	  trend	  towards	  an	  increase	  
in	  the	  proportion	  of	  CD8	  cells	  producing	  IFNγ	  could	  be	  observed	  compared	  to	  pre-­‐disease	  
mice,	  but	  this	  had	  reduced	  by	  peak	  disease	  although	  remaining	  higher	  than	  pre-­‐disease.	  	  





disease	   than	   those	  before,	   suggesting	   that	   such	  an	   increase	  may	   just	  be	   in	   the	  normal	  
development	  of	  the	  mouse	  and	  not	  important	  to	  this	  disease.	  	  	  
	  
	  
Figure	  6.	  	  No	  variation	  in	  peripheral	  cellular	  composition	  across	  disease	  progression.	  	  	  
Lymphocytes	  were	  extracted	  from	  the	  spleen	  of	  L7	  mice	  across	  all	  stages	  of	  disease	  and	  
were	  stimulated	  with	  PMA/ionomycin	  for	  4h	  with	  BFA.	  	  Spleen	  derived	  lymphocytes	  were	  





Aria	  II.	  	  A	  –	  Surface	  staining	  of	  total	  lymphocyte	  populations.	  	  IFNγ	  and	  IL-­‐17	  positive	  cells	  
as	  measured	   from	   total	   lymphocyte	   (B),	   CD4	   (C),	   CD8	   (D),	   and	  NK	   (E)	   cell	   populations.	  	  
Lymphocytes	   were	   gated	   initially	   according	   to	   cell	   surface	   markers	   and	   positive	   cells	  
interrogated	   to	   determine	   the	   size	   of	   cytokine	   positive	   populations.	   	   Asterisks	   denote	  
statistical	  significance	  between	  cell	  populations	  of	  indicated	  disease	  scores;	  	  *	  p<0.05,	  **	  
p<0.01	  (two-­‐tailed	  T	  test).	  
	  
	  
10.2.4 Transcriptional	  Profile	  
In	  addition	  to	  the	  phenotypic	  analysis	  of	  the	  cellular	  infiltrates,	  the	  transcriptional	  profile	  
of	   CNS	   and	  peripheral	   tissue	  was	   assessed	   across	   the	  duration	  of	   disease	   signs.	   	  Gene	  
expression	   from	   6	   mice	   (3	   male	   and	   3	   female)	   were	   measured	   for	   target	   genes	   run	  
alongside	   2	   housekeeping	   genes	   to	   act	   as	   reference	   marks.	   	   Ct	   values	   derived	   for	   all	  
samples	  run	  were	  compared	  to	  other	  groups	  by	  using	  REST	  software	  to	  generate	  results	  
in	   the	   form	  of	   relative	  expression.	   	  REST	  analysis	  also	   incorporates	   randomisation	   tests	  
and	   a	   pairwise	   reallocation	   to	   determine	   statistical	   significance	   between	   relative	  
expression	  values.	  	  Measurement	  of	  the	  level	  of	  transcription	  is	  an	  indication	  of	  the	  first	  
stage	   in	   the	   process	   of	   activating	   a	   gene.	   	   mRNA	   is	   transcribed	   from	   DNA	   sequence	  
before	  being	   translated	   to	  produce	   the	   final	  protein	   released	   into	   the	  cell.	   	  Comparing	  
the	   expression	   of	   genes	   can	   allow	   the	   determination	   of	   whether	   a	   gene	   plays	   an	  
important	   role	   in	  a	  process	   through	  comparison	  of	   its	  expression	  to	  a	  baseline.	   	   In	   this	  
instance	   the	   baseline	   was	   created	   by	   measuring	   transcription	   levels	   in	   C57BL/6	   mice	  





Real-­‐time	  PCR	  was	  used	   to	  measure	   the	   relative	  expression	  of	   transcription	   factor	   and	  
cytokine	  genes	  derived	  from	  both	  the	  inflamed	  CNS	  and	  spleen	  tissue.	  	  Whole	  tissue	  was	  
dissected	  out	  of	  mice	  and	  immediately	  homogenized	  in	  Trizol	  to	  preserve	  RNA	  integrity.	  	  
RNA	  was	  extracted	  from	  tissue	  and	  suspended	  in	  RNase	  free	  water	  to	  allow	  ease	  of	  use	  in	  
PCR	  reactions.	  	  Details	  of	  the	  primer	  and	  probe	  pairs	  used	  are	  in	  Table	  5	  in	  the	  materials	  
and	   methods	   section.	   	   Primers	   and	   probe	   pairs	   were	   designed	   to	   match	   sequence	  
spanning	  exon-­‐exon	  boundaries	  of	  mRNA	  meaning	  that	  they	  would	  not	  anneal	  to	  gDNA	  
sequence	   but	   only	   transcribed	   and	   spliced	  mRNA	   sequence.	   	   As	   an	   additional	   control,	  
housekeeping	   gene	   transcription	   was	   measured	   in	   representative	   samples	   from	   all	  
disease	   scores.	   	  The	   two	  most	   consistently	  non-­‐varying	  housekeeping	  genes	  were	   then	  








Figure	   7.	   	   Relative	   expression	   profile	   of	   Line7	   mice	   across	   disease	   progression	   as	  





mRNA	   was	   extracted	   from	   spleen	   and	   spinal	   cord	   tissue	   of	   L7	   mice	   taken	   at	   distinct	  
disease	  landmarks.	  	  Following	  reverse	  transcription	  of	  mRNA	  to	  cDNA,	  real-­‐time	  PCR	  was	  
used	   to	   quantify	   relative	   expression	   of	   selected	   gene	   transcripts	   using	   individually	  
designed	   hydrolysis	   probe	   based	   assays.	   	   Expression	   of	   the	  major	   transcription	   factors	  
helper	   T	   cell	   subsets	   in	   the	   spleen	   (A)	   and	   spinal	   cord	   (B)	   shown	   with	   *	   to	   show	  
significance	   compared	   to	   control	   (p<0.05)	   and	   **	   to	   show	   significance	   between	   scores	  
(p<0.05	  (randomisation	  analysis).	  	  Summarised	  in	  C	  and	  D.	  	  n=33	  total,	  6	  mice	  per	  disease	  
score	  (3	  male	  and	  3	  female)	  and	  3	  C57BL/6	  controls	  (all	  female).	  
	  
In	  the	  spleen,	  representative	  of	  the	  periphery,	  there	  is	  relatively	  consistent	  expression	  of	  
all	   T	   helper	   cell	   transcription	   factors	   similar	   to	   those	   seen	   in	   unaffected	  C57BL/6	  mice	  
(Figure	  7A,C).	  	  T-­‐bet	  is	  expressed	  at	  similar	  levels	  throughout	  disease	  progression	  and	  is	  
comparable	  to	  the	  baseline	  expression	  observed	  in	  a	  C57BL/6	  mouse.	  	  RORγt	  mimics	  this	  
pattern	  although	  does	  show	  significantly	  increased	  expression	  at	  peak	  disease	  relative	  to	  
a	  C57BL/6	  mouse	  but	  not	   to	  any	  other	   Line7	  disease	   severity.	  GATA3	   is	  highest	  during	  
early	  disease	  and	  significantly	  higher	  than	  both	  baseline	  expression	  and	  expression	  seen	  
at	  all	  other	  scores	  except	  peak	  disease.	  	  Whilst	  GATA3	  expression	  is	  significantly	  lower	  in	  
mice	   that	   resist	   disease	   than	   those	   in	   the	   early	   stages,	   the	   older	   mice	   do	   show	  
significantly	   higher	   GATA3	   expression	   than	   the	   baseline	   C57BL/6	   mouse.	   	   Foxp3	  
expression	  fluctuates	  around	  the	  levels	  observed	  in	  a	  C57BL/6	  mouse	  but	  never	  reaches	  
statistical	  significance.	  	  When	  expression	  between	  disease	  scores	  is	  compared	  however,	  
score	  2	  mice	  are	   seen	   to	  have	   lower	  expression	   than	  both	  score	  1,	  3	  and	  pre-­‐diseased	  






Figure	  8.	  Relative	  expression	  profile	  of	  Line7	  mice	  across	  disease	  progression	  as	  compared	  
to	  C57BL/6	  controls.	  	  	  
mRNA	   was	   extracted	   from	   spleen	   and	   spinal	   cord	   tissue	   of	   L7	   mice	   taken	   at	   distinct	  





used	   to	   quantify	   relative	   expression	   of	   selected	   gene	   transcripts	   using	   individually	  
designed	  hydrolysis	   probe	  based	  assays.	   	   Expression	  of	   representative	   cytokines	   for	   the	  
differentiation	  and	  expansion	  of	  major	  helper	  T	  cell	  subsets	   in	  the	  spleen	  (A)	  and	  spinal	  
cord	  (B)	  shown	  with	  *	  to	  show	  significance	  compared	  to	  control	  (p<0.05)	  and	  **	  to	  show	  
significance	  between	  scores	  (p<0.05)	  (randomisation	  analysis).	  	  Summarised	  in	  Figure	  7	  C	  
and	  D.	  	  n=33	  total,	  6	  mice	  per	  disease	  score	  (3	  male	  and	  3	  female)	  and	  3	  C57BL/6	  controls	  
(all	  female).	  
	  
Similar	   patterns	   are	   not	   seen	   in	   the	   spinal	   cord.	   	   GATA3	   expression	   steadily	   increases	  
from	  a	   level	   comparable	   to	   that	   seen	  at	  baseline	   to	  a	   significantly	  higher	  expression	   in	  
moderately	   affected	   mice	   at	   score	   2.	   	   Mice	   that	   resist	   paralysis	   however,	   have	   the	  
highest	  spinal	  cord	  GATA3	  expression,	  with	  significantly	  higher	  expression	  compared	  to	  
both	   baseline	   and	   pre-­‐disease	   mice.	   	   RORγt	   expression	   is	   noticeably	   dampened,	   only	  
comparable	  levels	  to	  BL/6	  mice	  at	  high	  disease	  (scores	  2	  and	  3)	  and	  in	  mice	  resisting	  signs	  
of	   disease	   despite	   the	   large	   cellular	   infiltration	   compared	   to	   the	   C57BL/6	   mice.	   	   By	  
contrast,	  T-­‐bet	   is	  upregulated	   in	   the	  CNS	   in	  disease,	  with	  a	   significant	   increase	  evident	  
from	  mice	  of	  score	  2	  (Figure	  7B,D).	  	  Foxp3	  expression	  is	  significantly	  higher	  than	  in	  mice	  
at	   baseline	   and	   shows	   significantly	   higher	   transcription	   at	   peak	   disease	  with	   regard	   to	  
that	  seen	  at	  all	  other	  disease	  scores.	  
	  
In	  addition	  to	  analysis	  of	  transcription	  factors,	  further	  analysis	  of	  cytokine	  expression	  was	  
carried	  out	  to	  confirm	  the	  ex	  vivo	   flow	  cytometry	  data	   (Figure	  8).	   	   In	   the	  periphery,	  no	  





IFNγ	  expression	   remained	  at	   the	   level	  of	  C57BL/6	  mice	   throughout	  disease	  progression	  
but	  was	  observed	  expressed	  at	  higher	  levels	  in	  mice	  that	  did	  not	  develop	  signs	  of	  disease.	  	  
Peripheral	   Line7	   pre	   and	   peak-­‐disease	   expression	   of	   IL-­‐17	  was	   higher	   than	   in	   C57BL/6	  
controls	   although	   it	   was	   significantly	   lower	   at	   mid-­‐disease	   than	   at	   any	   other	   disease	  
severity.	   	   The	   expression	   of	   cytokines	   that	   have	   a	   role	   in	   either	   Th1,	   Th17	   or	   Treg	  
polarization	   were	   also	   investigated.	   	   IL-­‐6	   and	   IL-­‐23p19	   are	   important	   cytokines	   to	  
differentiate	  and	  maintain	   the	  Th17	  phenotype	  whilst	   IL-­‐12p35	   is	   important	   to	   the	  Th1	  
phenotype.	   	   TGFβ	   and	   IL-­‐10	   are	   in	   general	   anti-­‐inflammatory	   cytokines	   and	   aid	   in	   the	  
differentiation	   and	   mechanism	   of	   action	   of	   Tregs	   respectively.	   	   IL-­‐6	   did	   not	   vary	  
throughout	   disease	   and	   was	   transcribed	   at	   comparable	   levels	   to	   baseline.	   	   IL-­‐23p19	  
expression	  did	  not	  correlate	  with	  disease	  symptoms,	  and	  only	  showed	  a	  significant	  dip	  in	  
expression,	  centered	  on	  mid-­‐disease	  when	  it	  was	  expressed	  at	  lower	  than	  baseline	  levels.	  	  
IL-­‐12p35	   expression	   was	   consistently	   significantly	   higher	   than	   baseline	   although	   there	  
was	   no	   variation	   between	   disease	   severities.	   	   Expression	   of	   TGFβ	   fluctuated	   around	  
baseline	  levels.	  	  Differences	  were	  observed	  between	  consecutive	  disease	  severities	  such	  
that	  expression	  was	  significantly	  different	  between	  mice	  scoring	  0	  and	  1,	  1	  and	  2,	  and	  2	  
and	   3,	   representative	   of	   an	   inconsistent	   expression	   profile.	   IL-­‐10	   expression	   showed	  
peaks	   at	   mid-­‐disease	   and	   in	   unaffected	  mice,	   which	   were	   significantly	   higher	   than	   all	  
other	  scores	  and	  baseline	  C57BL/6	  expression.	  	  Therefore,	  expression	  of	  cytokines	  in	  the	  
periphery	  did	  not	  show	  a	  clear	  pattern	  that	  reflected	  disease	  progression.	  	  However,	  as	  
with	   the	   flow	   cytometric	   analysis	   on	   splenocytes,	   this	   result	   is	   not	   surprising	   as	   the	  
inflammation	  in	  CNS	  restricted	  and	  rather	  shows	  that	  the	  inflammation	  is	  limited	  to	  the	  





Investigation	  of	  transcription	  in	  the	  spinal	  cord	  would	  provide	  more	  informative	  data	  and	  
due	   to	   the	   rapidity	   of	   sample	   collection,	   allows	   a	   direct	   look	   at	   the	   inflamed	   tissue	  
without	  any	  potential	  manipulation	  of	  phenotype	  by	   in	  vitro	  conditioning.	   	  Higher	   than	  
baseline	  expression	  is	  to	  be	  expected	  in	  this	  tissue	  due	  to	  the	  larger	  cellular	  infiltrate	  in	  
affected	  mice.	   	  There	  would	  also	  be	  expected	  to	  be	  increases	   in	  transcription	  similar	  to	  
the	   increases	   in	   infiltration	   if	   cells	   are	   either	  migrating	   in	   already	  polarized	  or	   become	  
polarized	  once	  they	  reach	  the	  site	  of	  inflammation.	  	  	  	  	  
In	   the	   spinal	   cord,	   IFNγ	  was	  expressed	  consistently	  higher	   than	  baseline	  and	   showed	  a	  
peak	   of	   expression	   relative	   to	   other	   disease	   scores	   in	   a	   similar	   pattern	   to	   the	   flow	  
cytometry	  data.	   	  Significantly	  lower	  expression	  was	  seen	  in	  mice	  of	  pre	  or	  early-­‐disease	  
and	   also	   in	   mice	   that	   resisted	   signs	   of	   disease,	   but	   in	   all	   cases,	   expression	   was	  
significantly	  elevated	  above	  baseline	  levels,	  likely	  representative	  of	  the	  cellular	  infiltrate	  
in	  all	  mice.	  	  In	  a	  similar	  way,	  IL-­‐17	  transcription	  mirrored	  that	  seen	  from	  the	  FACS	  analysis	  
as	  the	  only	  peak	  in	  transcription	  was	  observed	  at	  the	  highest	  disease	  severity.	  	  However,	  
even	  at	   this	  peak,	   expression	   levels	  were	  not	   significantly	  different	   to	  baseline	  despite	  
the	  large	  cellular	  infiltrate.	  	  These	  data	  confirm	  the	  findings	  from	  the	  cell	  extraction	  and	  
acts	  to	  endorse	  the	  reliability	  of	  the	  in	  vitro	  stimulation.	  	  	  	  	  
As	   with	   the	   spleen	   analysis,	   expression	   of	   cytokines	   important	   in	   polarizing	   and	  
maintenance	   of	   T	   helper	   subsets	   was	   investigated.	   	   IL-­‐6,	   important	   in	   polarizing	   Th17	  
cells	  was	  only	  observed	  at	  levels	  above	  baseline	  in	  mid	  and	  high	  disease	  mice.	  	  In	  this	  way	  
it	   could	   be	   seen	   to	   precede	   the	   IL-­‐17	   expression	   and	   would	   be	   indicative	   of	   the	  
development	   of	   a	   polarizing	   environment.	   	   Significantly	   increased	   expression	   with	  





IL-­‐23p19,	   thought	   to	   be	   required	   to	   maintain	   the	   Th17	   phenotype,	   was	   increased	   at	  
these	   times.	   	   Expression	   returned	   to	   baseline	   during	  mid	  disease	  but	   significantly	   rose	  
again	   at	   peak	   disease	   signs.	   	   Both	   cytokines	  were	   expressed	   at	   baseline	   levels	   in	  mice	  
resisting	  disease.	  	  IL-­‐12p35	  showed	  a	  trend	  towards	  increased	  expression	  with	  increased	  
disease	   severity	   but	  was	   only	   observed	   at	   greater	   than	   baseline	   levels	   at	  mid	   disease.	  	  
There	  was	  however	  significantly	  higher	  transcription	  in	  the	  spinal	  cord	  of	  mice	  resisting	  
signs	  of	  disease	   than	   those	  prior	   to	  development	  of	   signs,	  although	   the	   increase	   is	  not	  
particularly	  large.	  	  	  
The	  patterns	  of	   IL-­‐10	  and	  TGFβ	   expression	  were	  very	   similar.	   	   Expression	  of	  both	   IL-­‐10	  
and	  TGFβ	  peaked	  at	  score	  2	  and	  both	  were	  expressed	  significantly	  higher	  than	  baseline	  
and	   early	   stages	   of	   disease	   in	   the	   spinal	   cord	   at	   the	   largest	   disease	   scores	   (2	   and	   3).	  	  
Baseline	   levels	   of	   expression	   were	   observed	   in	   pre	   and	   early	   disease	   mice	   and	   high	  
transcription	   was	   observed	   in	   both	   in	   mice	   resisting	   signs	   of	   disease	   although	   it	   only	  
showed	   statistical	   significance	   for	   TGFβ.	   	   This	   high	   transcription	   of	   anti-­‐inflammatory	  
cytokines	   is	   presumably	   a	   response	   in	   the	   inflamed	   tissue	   to	   try	   and	   limit	   further	  
inflammation.	   	   Overall,	   the	   cytokine	   profile	   in	   the	   mice	   resisting	   signs	   of	   disease	  
appeared	  to	  indicate	  a	  controlled	  level	  of	  sub-­‐clinical	  disease.	  
Transcriptional	  profile	  data	  is	  summarized	  in	  Figure	  7C	  and	  D.	  	  These	  show	  the	  expression	  
changes	  as	   lines	  against	  disease	  severity,	  such	  that	  a	  positive	  gradient	   is	  representative	  
of	  an	   increase	   in	  expression	  as	  disease	  develops	  whilst	  a	  flat	   line	  represents	  no	  change	  
with	  disease.	  	  Only	  the	  most	  important	  genes	  involved	  in	  Th1	  and	  Th17	  polarization	  have	  
been	   included	   to	   help	   highlight	   the	   differences.	   	   From	   these	   it	   shows	   that	   there	   is	  





lines	  remain	  close	  to	  horizontal	  from	  pre-­‐disease	  to	  peak	  disease.	  	   In	  the	  CNS	  however,	  
Th17	   genes	   (IL-­‐17,	   RORγt	   and	   IL-­‐6)	   do	   not	   begin	   to	   increase	   until	   after	   disease	   is	  
established.	   	   RORγt	   expression	   never	   reaches	   comparable	   C57BL/6	   levels	   whilst	   IL-­‐6	  
increases	  after	  score	  1	  and	   IL-­‐17	   is	  only	  observed	   increasing	  after	  score	  2.	   	   In	  contrast,	  
both	  T-­‐bet	  and	  IFNγ	  peak	  at	  score	  2	  similar	  to	  the	  FACS	  data	  on	  infiltrating	  cells	  and	  show	  
higher	  relative	  expression	  than	  their	  respective	  Th17	  genes.	  	  	  
	  
10.2.5 Treg	  Infiltration	  
A	   previous	   observation	   made	   in	   the	   lab	   was	   a	   paradoxically	   high	   proportion	   of	  
CD4+CD25+	   cells,	   presumed	   to	   be	   Tregs,	   extracted	   from	   the	   CNS	   of	   affected	   mice;	   (a	  
previous	  project	  student	  in	  the	  lab	  had	  indicated	  that	  around	  a	  third	  of	  the	  lymphocyte	  
infiltrate	   may	   comprise	   Tregs;	   (Felicity	   Holt,	   MSc	   Thesis,	   Imperial	   College).	   	   The	  
observation	   of	   a	   strong	   Treg	   component	   was	   confirmed	   though	   analysis	   of	   Foxp3	  
transcription,	  as	  measured	  by	  real-­‐time	  PCR,	  correlating	  directly	  with	  disease	  progression	  
(Figure	  9A).	  	  Increased	  transcription	  was	  observed	  above	  levels	  seen	  in	  C57BL/6	  mice	  and	  
this	  increased	  as	  the	  mice	  became	  more	  affected,	  reaching	  a	  peak	  transcription	  at	  peak	  
disease,	  and	  also	  being	  at	  lower	  levels	  in	  those	  mice	  never	  affected	  (Figure	  7B).	  
By	  crossing	  the	  Line7	  line	  with	  the	  Foxp3DTR	  line,	  first	  described	  by	  the	  Rudensky	  lab	  (Kim	  
2007)	  to	  generate	  a	  new	  line,	  termed	  L7Fox,	  it	  was	  possible	  to	  directly	  show	  Treg	  cells	  in	  
the	   CNS.	   	   Tregs	  were	   observed	   as	  GFP+	   cells	   seen	   both	   in	   the	   lymphocyte	   gate	   of	   the	  
cellular	   infiltrate,	   by	   flow	   cytometry	   (Figure	   1B)	   and	   by	   immunofluorescence	   on	  






Figure	  9.	  	  Infiltration	  of	  Tregs	  into	  CNS	  correlating	  with	  increased	  disease	  severity.	  	  
	  A	  –	  Real-­‐time	  PCR	  assessment	  of	  Foxp3	  mRNA	  transcript	  expression	  in	  spinal	  cord	  of	  mice	  
at	   different	   stages	   of	   disease.	   	   mRNA	   was	   extracted	   from	   spinal	   cord	   tissue,	   reverse	  
transcribed	   to	   cDNA	   before	   real-­‐time	   PCR	   analysis	   with	   an	   individually	   designed	  
hydrolysis	  probe	  assay.	  	  Shown	  with	  *	  to	  show	  significance	  compared	  to	  control	  (p<0.05)	  
and	   **	   to	   show	   significance	   between	   scores	   (p<0.05)	   (randomisation	   analysis).	   n=27	  





B	   –	   Representative	   image	   of	   GFP+	   cells	   extracted	   from	   CNS	   of	   score	   3	   L7Fox	   mouse.	  	  
Lymphocytes	   were	   extracted	   from	   CNS	   of	   L7	   mice	   following	   perfusion,	   enzymatic	  
digestion	  and	  separation	  on	  percoll	  density	  gradients.	   	   	   	  Percentage	  of	  total	   lymphocyte	  
population	  is	  shown.	  	  No	  PE	  antibody	  was	  used	  to	  stain	  cells	  but	  the	  PE	  axis	  was	  used	  to	  
eliminate	  autofluorescent	  cells.	  
	  
A	   typical	   flow	   cytometry	   plot	   is	   shown	   illustrating	   the	   GFP+	   cell	   population	  within	   the	  
cellular	   infiltrate.	   	   Using	   this	   approach,	   the	   percentage	   of	   Tregs	   is	   reduced	   from	   the	  
original	   estimates	   of	   around	   30%	   to	   around	   10%,	   but	   this	   can	   be	   explained	   by	   using	  
Foxp3	  as	  a	  marker	  rather	  than	  CD25	  and	  the	  elimination	  of	  activated	  cells	  from	  the	  Treg	  
gate.	   	   The	   Tregs	   cells	   show	   an	   infiltration	   pattern	   similar	   to	   other	   infiltrating	   cell	  
populations,	  infiltrating	  initially	  through	  the	  lower	  regions	  of	  the	  spinal	  cord	  and	  entering	  
via	  the	  dorsal	  and	  ventral	  fissures	  (Figure	  10A,	  B,	  C).	  	  They	  show	  some	  aggregation	  in	  the	  
meningeal	  tissue	  and	  in	  the	  regions	  where	  other	  cells	  are	  infiltrating.	  	  Such	  a	  pattern	  of	  
infiltration	  was	  not	  observed	  in	  an	  unaffected	  L7Fox	  littermate	  illustrating	  that	  the	  Tregs	  
do	  migrate	  to	  the	  site	  of	  inflammation	  and	  are	  not	  purely	  resident	  there	  (Figure	  10C).	  	  In	  
addition,	   Tregs	   are	   also	   found	   throughout	   the	   spinal	   cord	   in	   areas	   with	   large	   cellular	  
infiltrates	  (Figure	  10E,	  F,	  G),	  evenly	  dispersed	  throughout	  the	  tissue.	   	  They	  can	  be	  seen	  
occupying	   the	   same	   locations	   as	  NK	   (Figure	   10B)	   and	   CD8	   (Figure	   10D,	   F)	   effector	   cell	  
populations	   during	   infiltration,	   illustrating	   the	   potential	   that	   they	   may	   act	   directly	   to	  
inhibit	   inflammation.	   	   As	   with	   the	   earlier	   immunofluorescence,	   this	   confirms	   a	   Treg	  
presence	   in	   the	   CNS	   and	   supports	   previous	   observations	   but	   requires	   further	  












L7Fox	   mice	   from	   distinct	   disease	   landmarks	   were	   fix/perfused	   and	   10µm	   sections	   cut.	  	  
Representative	  10X	  pictures	  are	  shown	  from	  indicated	  locations	  in	  the	  lumbar	  spinal	  cord.	  	  
A	   –	   Treg	  accumulation	  and	   infiltration	   from	  meningeal	   tissue	   in	   the	   dorsal	   fissure,	   10X	  
view	   of	   score	   4	   L7Fox,	   GFP	   (green)	   DAPI	   (blue).	   	   B	   –	   Tregs	   found	   at	   same	   location	   as	  
infiltrating	  NK	  cells	  in	  the	  dorsal	  fissure,	  at	  10X	  magnification,	  of	  a	  score	  4	  L7Fox	  mouse,	  
NK1.1	  (red)	  GFP	  (green)	  DAPI	  (blue).	  	  C	  –	  10X	  view	  of	  dorsal	  fissure	  from	  unaffected	  L7Fox	  
littermate	  showing	  no	  accumulation	  of	  Tregs	  in	  mice	  with	  no	  presentation	  of	  symptoms,	  
CD8	   (red)	   GFP	   (green)	   DAPI	   (blue).	   	   D	   –	   Large	   population	   of	   Tregs	   co-­‐localising	   with	  
infiltrating	   CD8	   T	   cells,	   at	   20X	  magnification	   in	   a	   score	   4	   L7Fox	  mouse,	   CD8	   (red)	   GFP	  
(green)	  DAPI	   (blue).	   	   E	  –	   Infiltrating	  CD4+	  Tregs	  alongside	  GFP-­‐CD4+	  T	   cells	   in	   the	  white	  
matter,	   at	   20X	   magnification,	   in	   a	   score	   4	   L7Fox	   mouse,	   CD4	   (red)	   GFP	   (green)	   DAPI	  
(blue).	   	   F	   –	   Tregs	   throughout	   the	   white	   matter	   surrounding	   large	   aggregation	   of	  
infiltrating	  effector	  cells,	  at	  10X	  magnification,	   in	  a	  score	  4	  L7Fox	  mouse,	  CD8	  (red)	  GFP	  
(green)	   DAPI	   (blue).	   	   G	   –	   Large	   distribution	   of	   Tregs	   throughout	   white	   matter,	   not	  
constrained	   to	   the	   meningeal	   tissue,	   at	   10X	   magnification,	   in	   a	   score	   4	   L7Fox	   mouse,	  










The	   basic	   immunological	   characterization	   of	   a	   model	   is	   crucial	   in	   order	   to	   lay	   the	  
foundations	  for	  further	  experiments,	  especially	  in	  a	  spontaneous	  model.	  	  Appreciation	  of	  
how	  disease	   develops	  without	   any	   interference	   from	  outside	   factors	   enables	   unbiased	  
interpretations	  to	  be	  drawn	  and	  highlights	  the	   large	  effects	  that	   immune	  adjuvants	  can	  
have	   on	   our	   understanding	   of	   autoimmunity.	   	   While	   a	   number	   of	   other	   labs	   have	  
published	   spontaneous,	   TCR	   transgenic	   models	   of	   EAE-­‐like	   disease	   (Goverman	   1993,	  
Lafaille	  1994,	  Waldner	  2000),	  the	  model	  used	  here	  is	  the	  only	  one	  in	  which	  there	  is	  a	  high	  
level	   of	   spontaneous	   disease	   in	   a	   model	   driven	   by	   a	   TCR	   derived	   from	   a	   human	   MS	  
patient.	  
Evidence	  for	  a	  role	  for	  cells	  in	  the	  development	  of	  disease	  is	  provided	  by	  the	  correlation	  
of	  disease	  severity	  with	  cellular	  infiltration.	  	  This	  simple	  count	  supports	  a	  direct	  role	  for	  
infiltrating	   cells	   in	   mediating	   neuroinflammation,	   a	   process	   that	   can	   be	   prevented	   by	  
limitation	   of	   cellular	   infiltration,	   as	   observed	   in	   mice	   resisting	   disease	   development.	  	  
Cytokine	   positive	   cells	   could	   be	   extracted	   from	   the	   CNS	   of	   non-­‐diseased	   old	   mice	  
illustrating	  that	   in	  situ	  activation	  was	  occurring	  but	  the	   lack	  of	  substantial	  cell	  numbers	  
likely	  prevented	  development	  of	  autoimmunity.	  	  	  
MS	  is	  thought	  to	  be	  a	  CD4-­‐mediated	  disease	  by	  extrapolation	  from	  work	  in	  EAE	  (Ben-­‐Nun	  
1981,	   Pettinelli	   1981),	   and	   analysis	   of	   the	   cellular	   dynamics	   in	   the	   Line7	  mouse	  would	  
support	   this	   conclusion.	   	   Infiltration	   of	   CD4+	   cells	   correlated	   with	   disease	   initiation	  
suggesting	  they	  were	  directly	  involved	  in	  the	  process,	  and	  this	  would	  not	  be	  surprising	  as	  
the	  model	  utilizes	  an	  HLA	  class	   II	   restricted	  TCR	  and	  and	  also	   carries	   the	   cognate	  HLA-­‐





proportion	  of	  the	  cellular	   infiltrate	  that	  was	  NK1.1+.	   	  These	  are	  assumed	  to	  be	  NK	  cells,	  
although	  the	  contribution	  of	  NKT	  cells	  to	  this	  population	  was	  not	  addressed	  in	  this	  study.	  	  
A	  major	  role	  of	  NKT	  cells	  is	  the	  production	  of	  a	  wide	  range	  of	  cytokines	  and	  so	  it	  could	  be	  
cytokine	   production	   is	   derived	   from	   NKT	   rather	   than	   NK	   cells	   and	   this	   would	   require	  
further	  investigation.	  	  	  
NK	  cells	  have	  been	   found	   in	  demyelinating	  MS	   lesions	   (Traugott	  1985)	  but	   the	  scale	  of	  
the	   infiltration	  was	  unexpected.	   	   The	   role	   these	  cells	  play	   in	   the	  disease	  dynamics	  was	  
not	   investigated	   at	   this	   point	   but	   the	   case	   could	   be	  made	   that	   their	   infiltration	   is	   not	  
directly	   linked	   to	  disease	  progression	   as	  no	   change	   in	   their	   proportion	  of	   the	   infiltrate	  
was	  observed.	   	  The	  activation	  state	  of	  the	  NK1.1+	  cells	   infiltrating,	  as	  measured	  by	  IFNγ	  
production,	   however	   correlates	   with	   disease	   initiation	   and	   progression.	   	   It	   has	   been	  
shown	  that	  the	  secretion	  of	  IFNγ	  from	  NK	  or	  NKT	  cells	  can	  play	  a	  role	  in	  driving	  Th1	  cell	  
polarization	  (Martin-­‐Fontecha	  2004,	  Morandi	  2006)	  or	  exacerbate	  existing	  inflammation	  
(Wilson	  2003,	  Kent	  2005),	  which	  in	  this	  model	  may	  act	  to	  amplify	  the	  activity	  of	  Th1	  cells	  
in	  the	  early	  stage	  of	  disease.	  	  Despite	  the	  proportion	  of	  the	  infiltrate	  not	  increasing,	  the	  
number	  of	  NK	  cells	   infiltrating	  does	   increase	  as	  disease	  progresses.	   	  NK	  cells	  have	  been	  
shown	   to	   possess	   cytotoxic	   activity	   directed	   at	   neurons	   (Backstrom	   2003)	  
oligodendrocytes,	  astrocytes	  and	  microglial	  cells	  (Antel	  1998,	  Morse	  2001,	  Saikali	  2007)	  
so	   it	   could	   be	   that	   they	   are	   directly	   responsible	   for	   immune	   damage	   although	   their	  
migration	  pattern	  does	  not	  highlight	  a	  leading	  role.	  	  	  
In	  contrast,	  CNS	  infiltrating	  NK	  cells	  have	  been	  seen	  to	  produce	  neuroprotective	  factors	  





during	   EAE.	   	   The	   infiltration,	   albeit	   at	   a	   consistent	   rate	   could	   be	   a	   reaction	   to	   the	  
inflammation	  and	  NK	  cells	  are	  acting	  to	  protect	  the	  CNS	  from	  immune-­‐mediated	  damage.	  	  	  
The	   infiltration	   is	   very	   high	   despite,	   and	   despite	   not	   correlating	  with	   disease	   severity;	  
NK1.1+	  cells	  still	  make	  up	  the	  largest	  infiltrating	  lymphocyte	  population.	  	  Both	  protective	  
and	  pathogenic	   roles	  have	  been	  suggested	   for	  NK	  cells	  although	   it	   is	   impossible	  at	   this	  
stage	  to	  delineate	  which	  is	  the	  most	  important	  in	  this	  context.	  	  NK	  cells	  in	  the	  CNS	  have	  
been	  shown	  to	  control	  the	  magnitude	  of	  local	  inflammatory	  and	  autoimmune	  responses	  
against	   myelin	   (Hao	   2010)	   and	   so	   it	   is	   likely	   their	   role	   in	   Line7	   mice	   encompasses	   a	  
balance	   between	   both	   this	   protective	   role	   and	   an	   indirect	   pathogenic	   role,	   mediated	  
through	  release	  of	  pro-­‐inflammatory	  cytokines.	  	  	  
Analysis	  of	  the	  dynamics	  of	  cytokine	  positive	  cells	  was	  the	  most	  informative	  result	  from	  
this	  model.	   	  The	  discovery	   that,	  without	   the	  use	  of	  any	   immune	  adjuvants	  or	  polarized	  
cell	   populations,	   IL-­‐17+	   cells	   were	   only	   observed	   at	   peak	   disease	   and	   not	   seen	   in	   any	  
number	  at	  scores	  before	  that,	  suggested	  that	  they	  were	  not	  involved	  in	  the	  initiation	  of	  
autoimmunity.	   	  This	  is	   in	  stark	  contrast	  to	  other	  studies	  which	  have	  concluded	  that	  it	   is	  
Th17	   cells	   which	   initiate	   autoimmunity	   (Hofstetter	   2005,	   Langrish	   2005,	   Komiyama	  
2006).	   	  Whilst	  a	  disregard	   for	   the	   importance	  of	  Th17	  cells	   in	  Line7	  disease	  as	  a	  whole	  
would	  be	  naïve,	  this	  evidence	  would	  support	  the	  conclusion	  that	  any	  Th17	  cells	  were	  only	  
involved	  in	  the	  progression	  of	  a	  previously	  initiated	  autoimmune	  attack.	  	  The	  observation	  
of	   IL-­‐17	   derived	   from	   IFNγ+	   cells	   at	   high	   disease	   also	   adds	   a	   twist	   on	   interpretation	   of	  
results	  as	  it	  would	  support	  a	  potential	  change	  in	  cytokine	  profile	  from	  the	  same	  cells.	  In	  
other	  studies,	  T-­‐bet+RORγt+	  cells	  have	  been	  identified	  (Abromson-­‐Leeman	  2009)	  and	  it	  is	  





plasticity	   of	   T	   helper	   cells	   switching	   from	   a	   Th1	   to	   Th17	   phenotype,	   a	   dynamic	   not	  
recognised	  as	  being	  possible	  from	  work	  in	  other	  studies	  (Shi	  2008,	  Wei	  2009).	  
IFNγ+	   cells	   on	   the	   contrary	   were	   readily	   identified	   in	   early	   diseased	   mice	   whilst	   not	  
evident	   before,	   a	   pattern	   indicative	   of	   direct	   involvement.	   	   The	   peak	   infiltration,	   as	  
measured	  by	  proportion	  of	  the	   infiltrate,	   is	  at	  score	  2	  (mid-­‐disease)	  and	  the	  proportion	  
tails	  off	  at	  peak	  disease.	  	  Cellular	  infiltration	  however	  continues	  to	  increase	  and	  so	  whilst	  
a	  decrease	   in	  their	  proportion	  suggests	  a	   lack	  of	   involvement,	  the	  absolute	  numbers	  of	  
IFNγ+	  infiltrating	  cells	  actually	  continued	  to	  increase.	  	  Not	  all	  of	  the	  IFNγ	  was	  derived	  from	  
Th1	   cells	   though.	   	   Cytokine	   positive	   cells	   were	   observed	  within	   CD4,	   CD8	   and	   NK	   cell	  
populations	  as	  disease	  progressed	  supporting	  a	  level	  of	  redundancy	  in	  the	  production	  of	  
pro-­‐inflammatory	   cytokines.	   	   However,	   it	   is	   not	   clear	   whether	   each	   mediates	  
neuroinflamation,	  or	  whether	  the	  production	  of	  IFNγ	  by	  NK	  cells	  for	  example,	  may	  act	  to	  
aid	  in	  the	  polarisation	  of	  Th1	  cells	  in	  the	  CNS	  as	  seen	  by	  other	  studies	  (Martin-­‐Fontecha	  
2004,	  Morandi	  2006).	  
Transcriptional	   analysis	   has	   a	   very	   important	   role	   to	   play	   in	   qualifying	   flow	   cytometry	  
data	  as	  it	  is	  a	  direct	  measure	  of	  gene	  activation	  within	  the	  inflamed	  tissue.	  	  Observation	  
of	  spinal	  cord	  transcripts	  across	  disease	  mirrored	  the	  pattern	  seen	  from	  the	  FACS	  data,	  
showing	   IL-­‐17	   transcription	   appearing	   only	   once	   disease	   had	   already	   initiated	   and	  
peaking	  at	  high	  disease.	  	  T-­‐bet	  and	  IFNγ	  transcription	  was	  detectable	  and	  peaked	  earlier,	  
adding	  further	  support	  to	  their	   importance	  in	  the	  early	  stages	  of	  disease.	   	  Studies	  have	  
suggested	   T-­‐bet	   defines	   the	   encephalitogenicity	   of	   T	   cells,	   and	   these	   findings	   would	  
support	   that	   conclusion	   (Gocke	   2007,	   Yang	   2009b).	   	   The	   highest	   CNS	   transcription	   of	  





support	  for	  the	  importance	  of	  Th1	  or	  Th17	  cells	  in	  mediation	  of	  disease.	  	  In	  these	  mice,	  a	  
Th2	  response	  would	  act	  to	  limit	  the	  Th1	  or	  Th17	  activation,	  suggesting	  potentially	  that	  a	  
localised	   anti-­‐inflammatory	   boost	   may	   act	   to	   limit	   CNS	   autoimmunity.	   	   However,	  
previous	  studies	  have	  shown	  MBP-­‐specific	  Th2	  cells	  to	  be	  capable	  of	  causing	  EAE	  (Lafaille	  
1997),	  and	  so	  any	  steps	  in	  that	  direction	  should	  be	  taken	  with	  care.	  
Very	  noticeable	  was	  the	  lack	  transcription	  of	  any	  Th17	  polarizing	  cytokines	  and	  RORγt	  in	  
the	   spinal	   cord	  until	  disease	  had	  established.	  Previous	   studies	   in	  RORγt-­‐/-­‐	  mice	   showed	  
mild	   EAE	   however,	   illustrating	   that	   RORγt	   is	   not	   required	   for	   EAE	   induction	   but	  more	  
likely	   exacerbates	   it	   (Ivanov	   2006).	   	   IL-­‐6	   transcription	   was	   first	   seen	   at	   score	   2	   and	  
steadily	  increased,	  followed	  by	  IL-­‐17	  expression.	  	  IL-­‐17	  and	  IL-­‐6	  mRNA	  has	  been	  observed	  
in	   lesions	   in	   other	   studies	   (Lock	   2002)	   but	   because	   they	   were	   only	   observed	   in	   post-­‐
mortem	  tissue	  and	  at	  peak	  of	  disease,	  such	  observations	  would	  also	  have	  been	  seen	   in	  
the	  Line7	  if	  the	  earlier	  scoring	  mice	  were	  ignored.	  	  Despite	  high	  IL-­‐23	  expression	  at	  early	  
and	  peak	  disease	  stages,	  however,	  RORγt	  expression	  did	  not	  surpass	  that	  seen	  in	  a	  non-­‐
inflamed	  C57BL/6	  CNS.	  	  Therefore,	  the	  CNS	  cytokine	  environment	  appears	  conducive	  to	  
Th17	   expansion	   but	   not	   differentiation	   until	   peak	   disease	   symptoms.	   	   It	   also	   suggests	  
that	   IL-­‐23	   may	   play	   multiple	   roles	   in	   the	   course	   of	   disease.	   	   In	   the	   initial	   stages	   it	   is	  
upregulated	  in	  an	  attempt	  to	  limit	  infiltration	  (Langowski	  2006)	  whilst	  the	  upregulation	  at	  
peak	  disease	  is	  to	  aid	  in	  the	  expansion	  of	  the	  Th17	  population	  (Stritesky	  2008).	  	  	  
These	   data	   indicated	   that	   the	   failure	   to	   identify	   IL-­‐17+	   cells	   was	   not	   an	   artifact	   but	  
representative	  of	  the	  local	  environment.	  	  Taken	  alongside	  the	  flow	  cytometry	  data,	  they	  
would	  suggest	  a	  mechanism	  whereby	  Th1	  cells	  (T-­‐bet+IFNγ+)	  are	  involved	  in	  the	  initiation	  





progression,	  and	  subsequent	  development	  of	  such	  an	  attack.	  	  Th1	  cells	  have	  been	  shown	  
to	   accumulate	   in	   both	   the	   human	   and	   mouse	   CNS	   (Traugott	   1988,	   Olsson	   1990,	   Link	  
1992,	  Merrill	  1992)	  and	  this	  data	  would	  support	  other	  findings	  concluding	  that	  Th17	  cells	  
require	   Th1	   cells	   to	   infiltrate	   the	   CNS	   (O'Connor	   2008).	   It	   would	   add	   weight	   to	   the	  
argument	  that	  the	  importance	  of	  Th17	  cells	   in	  autoimmunity	   is	  perhaps	  confounded	  by	  
reliance	  on	  the	  immune	  adjuvants	  used	  in	  active	  EAE	  (Chen	  2006)	  and	  the	  impossibility	  of	  
generating	   pure	   Th17	   cell	   cultures	   free	   from	   Th1	   cells	   used	   for	   passive	   EAE	   (Langrish	  
2005,	   McGeachy	   2007).	   	   No	   transcriptional	   predisposition	   towards	   Th1	   or	   Th17	  
phenotypes	  could	  be	  observed	   in	   the	  periphery	   throughout	  disease,	   further	  supporting	  
the	   importance	   and	   relevance	   of	   these	   differences	   within	   the	   target	   organ	   of	  
inflammation.	  	  	  
In	  addition	  to	  the	  dynamics	  of	  pro-­‐inflammatory	  T	  cells	  in	  disease	  development,	  the	  Line	  
7	   model	   is	   supportive	   of	   an	   important	   role	   for	   Tregs	   in	   autoimmunity.	   Whilst	   not	  
investigating	   the	   functionality	   of	   Tregs	   at	   this	   stage,	   the	   observation	   that	   they	  
accumulate	   in	   the	   inflamed	   CNS	   demonstrates	   the	   presence	   of	   an	   anti-­‐inflammatory	  
response	   occurring	   throughout	   the	   lifespan	   of	   the	   mice.	   	   The	   accumulation	   is	  
proportional	   to	   both	   the	   age	   and	   disease	   severity	   score	   of	   the	   mice,	   indicative	   of	   a	  
continual	  migration	  or	  proliferation	  of	  Tregs	  as	  disease	  is	  progressing.	  	  Increases	  in	  Foxp3	  
transcription	   in	   the	   periphery	   are	   not	   seen	   throughout	   disease	   and	   levels	   remain	  
comparable	  to	  unaffected	  C57BL/6	  mice,	  demonstrating	  that	  this	   is	  not	  a	  systemic	  Treg	  
upregulation.	  	  Tregs	  have	  been	  seen	  to	  accumulate	  in	  the	  CNS	  of	  other	  EAE	  models	  and	  
have	   been	   associated	   with	   the	   recovery	   of	   animals	   from	   signs	   of	   disease	   (McGeachy	  





recovery	   is	   not	   seen,	   despite	   the	   increase	   in	   Treg	   numbers.	   	   Tregs	   readily	   infiltrate	  
alongside	   autoreactive	   cells,	   and	   the	   observable	   increase	   in	   CNS	   Foxp3	   expression,	  
implying	  that	  regulation	  is	  occurring	  continually	  throughout	  disease	  progression.	  	  
In	   Line	   7	   mice,	   autoimmunity	   progresses	   without	   an	   adjuvant	   required	   to	   impair	   the	  
function	  of	  Tregs.	  	  This	  would	  suggest	  impaired	  function	  of	  Tregs	  in	  the	  Line	  7,	  especially	  
as	  migration	  does	  not	  appear	  to	  be	  impaired.	  In	  one	  study	  the	  absence	  of	  Tregs	  in	  the	  MS	  
lesion	  was	  attributed	  to	  poor	  migration,	  something	  not	  seen	  in	  this	  model	  (Tzartos	  2008).	  
Without	  direct	  testing	  however,	  it	  would	  be	  premature	  to	  come	  to	  this	  conclusion	  and	  so	  
this	   issue	  will	   be	   addressed	   in	   the	   next	   chapter	   through	   the	   use	   of	   the	   newly	   created	  
L7Fox	   line	   which	   offers	   great	   benefits	   in	   visualisation	   and	   extraction	   of	   Tregs	   over	  













11 Role	  of	  Tregs	  and	  Effector	  Cells	  
11.1 Introduction	  
Previous	   work	   in	   the	   laboratory	   had	   shown	   the	   presence	   of	   abundant	   CD4+CD25+	  
lymphocytes	   in	   the	   CNS	   of	   a	   heavily	   diseased	   Line7	  mice,	   in	   line	  with	   other	   studies	   in	  
both	   mice	   and	   humans	   (Felicity	   Holt,	   MSc	   Thesis	   Imperial	   College	   London),	   and	  
confirmed	   by	   the	   work	   described	   here	   in	   the	   preceding	   chapter.	   	   This	   somewhat	  
paradoxical	   increase	   in	   Treg	   infiltration	   led	   to	   outstanding	   questions	   regarding	   the	  
functionality	   of	   the	   Tregs.	   	   MS	   has	   been	   considered	   a	   disease	   of	   aberrant	   regulation	  
(Viglietta	  2004)	  yet	  considerable	  numbers	  of	  Tregs	  clearly	  enter	  the	  CNS	  during	  disease;	  
are	   they	   inherently	   dysfunctional,	   or	   perhaps	   simply	   fail	   to	   control	   the	   overwhelming	  
force	  of	  pathogenic	  cells?	  
Functionality	   of	   Tregs,	   as	  measured	  by	   in	   vitro	   suppression	   assays	   of	  mitogenesis,	  was	  
impaired	   in	   the	  context	  of	  MS.	   	  Tregs,	  sorted	  as	  CD4+CD25+,	  derived	   from	  MS	  patients’	  
blood	  demonstrated	  a	  reduction	  in	  ability	  to	  suppress	  stimulated	  effector	  cells,	  either	  by	  
myelin	   peptides	  or	  more	   general	   stimulations	   (Viglietta	   2004,	  Haas	   2005,	   Kumar	  2006,	  
Feger	  2007,	  Venken	  2008a,	  Frisullo	  2009).	  Accumulation	  of	  Tregs	  in	  CSF	  (Venken	  2008b),	  
the	  closest	  source	  available	  to	  the	  inflamed	  tissue,	  and	  reduction	  in	  Foxp3	  levels	  on	  a	  per	  
cell	  basis	  (Huan	  2005,	  Venken	  2008b)	  adds	  support	  to	  the	  conclusion	  that	  their	  function	  
may	  be	  impaired.	  
Depletion	   of	   the	   Treg	   population	   in	  mice	   has	   been	   shown	   to	   increase	   disease	   severity	  
(Zhang	  2004b),	  decrease	  the	  threshold	  of	  antigen	  required	  (Stephens	  2005),	  and	  inhibit	  





Tregs	  prior	   to	  EAE	   induction	  prevents	   the	  development	  of	  disease	   (Olivares-­‐Villagomez	  
1998)	   and	   even	   if	   administered	   alongside	   autoreactive	   T	   cell	   blasts,	   reduces	   disease	  
severity	  (Kohm	  2002).	   	  These	  findings	  point	  to	  an	   important	  role	  of	  Tregs	   in	  preventing	  
the	   initiation	   and	   subsequent	   severity	   of	   autoimmune	   reactions,	   but	   direct	   studies	   in	  
human	  patients	  are	  limited	  by	  the	  source	  of	  Tregs.	  	  Findings	  from	  human	  blood-­‐derived	  
Tregs	   are	   not	   directly	   transferable	   to	   the	   situation	   in	   the	   inflamed	   tissue,	   rather	   are	  
suggestive	  of	  a	  more	  general	  context	  of	  autoimmunity.	  	  
The	   limitation	   that	   Tregs	   cannot	   be	   extracted	   from	   the	   site	   of	   inflammation	   during	  
disease	  from	  human	  tissue	  can	  be	  overcome	  through	  the	  use	  of	  mouse	  models.	   	   It	  has	  
already	   been	   demonstrated	   by	   us	   and	   other	   groups	   that	   Tregs	   accumulate	   in	   the	   CNS	  
throughout	   CNS	   autoimmunity	   (McGeachy	   2005,	   Liu	   2006b,	   Korn	   2007b),	   allowing	   the	  
investigation	  of	  these	  cells	  once	  extracted	  from	  the	  inflamed	  CNS.	  	  Tregs	  taken	  during	  the	  
recovery	   phase	   of	   EAE	   were	   shown	   to	   be	   capable	   of	   suppressing	   MOG-­‐specific	  
proliferation	   and	   release	   of	   IFNγ	   in	   vitro	   (O'Connor	   2007),	   however	   another	   group	  
extracted	  Tregs	   from	  peak	  disease	  and	  did	  not	  demonstrate	  any	   suppressive	  action	  on	  
CNS-­‐derived	   effector	   T	   cells	   (Korn	   2007b).	   	   Therefore	   Tregs	   have	   been	   implicated	   in	  
bringing	  about	  the	  natural	   recovery	  seen	   in	  some	  EAE	  models,	  whilst	   the	   inflamed	  CNS	  
has	   been	   shown	   to	   drive	   the	   proliferation	   of	   Treg	   cells	   (Korn	   2007b,	   O'Connor	   2007),	  
likely	  in	  an	  attempt	  to	  control	  the	  inflammation.	  	  	  
Up	   until	   now,	   the	   investigation	   into	   Treg	   function	   has	   been	   limited	   by	   the	   ability	   to	  
specifically	   identify	   and	   extract	   Tregs	   from	   desired	   samples.	   	   Initially	   Tregs	   were	  
identified	   as	   being	   CD4+CD25+	   until	   the	   discovery	   of	   Foxp3	   as	   the	   characteristic	  





cells	   and	   exclusion	   of	   contaminating	   populations.	   	   However,	   the	   limitation	   of	   Foxp3	   is	  
that	   it	  resides	   in	  the	  nucleus	  and	  so	   it	   is	  unavailable	  to	  use	  as	  a	  marker	  for	  sorting	  and	  
then	   further	  culture	  of	  Tregs.	   	  CD25	   (IL-­‐2Rα)	   is	  not	  present	  solely	  on	  Tregs	  but	  also	  on	  
activated	   T	   cells	   (Leonard	   1985,	   Thèze	   1996)	   meaning	   that	   the	   sorted	   populations	   of	  
Tregs	  could	  include	  effector	  cells,	  compromising	  suppression	  studies	  and	  leading	  to	  false	  
conclusions.	   	   Studies	   aiming	   to	   deplete	   Tregs	   also	   had	   to	   rely	   on	   CD25,	   and	   used	   a	  
depleting	   antibody,	   PC61	   to	   remove	   any	   CD25+	   cells.	   	   There	   is	   debate	   as	   to	   the	  
effectiveness	  of	  PC61	  in	  depleting	  Treg	  populations	  (Kohm	  2006,	  Stephens	  2006,	  Zelenay	  
2006),	   as	   despite	   the	   removal	   of	   CD25hi	   cells,	   cells	   that	  were	   Foxp3+	   remained	   (Kohm	  
2006).	  	  In	  addition,	  the	  contribution	  of	  removal	  of	  activated	  cells	  could	  not	  be	  excluded	  
from	   the	   reduction	   in	   disease	   signs	   and	   prevention	   of	   autoimmunity	   observed.	   	   There	  
have	   also	   been	   recent	   attempts	   to	   deplete	   Tregs	   through	   the	   use	   of	   a	   depleting	  GITR	  
antibody	  (Coe	  2010).	  	  These	  provide	  a	  potential	  depleting	  mechanism	  in	  place	  of	  the	  use	  
of	  anti-­‐CD25	  antibodies.	   	  The	  suppressive	  function	  of	  Tregs	   is	  unaffected	  whilst	   ligation	  
with	   DTA-­‐1	   antibody	   simply	   selects	   Tregs	   for	   depletion	   but	   this	   protocol	   still	   relies	   on	  
surface	  markers	  and	  GITR,	  similar	  to	  CD25,	  is	  not	  restricted	  to	  Treg	  cells.	  
Therefore	   the	   L7Fox	   strain	   was	   created	   in	   order	   to	   allow	   targeted	   depletion	   of	   Tregs	  
without	   affecting	   any	   other	   cell	   populations.	   	   The	   administration	   of	   diphtheria	   toxin	  
depletes	   the	   Treg	   population	   and	   allows	   direct	   observation	   of	   the	   progression	   of	  
autoimmunity	  in	  these	  animals	  without	  the	  regulatory	  component	  of	  the	  immune	  system	  
present	  (Kim	  2009).	  	  The	  added	  advantage	  of	  using	  these	  mice	  is	  the	  GFP	  expression	  from	  
the	   disrupted	   Foxp3	   locus	   (Kim	   2007).	   	   This	   allows	   ease	   of	   identification	   of	   Tregs	   and	  





populations.	   	   The	   added	   advantage	   to	   using	   this	   protocol	   is	   the	   absence	   of	   immune	  
adjuvants	   required	   to	   initiate	   disease.	   	   The	   use	   of	   such	   adjuvants	   has	   been	   shown	   to	  
impair	  Treg	   function	   (Cassan	  2006,	  Chen	  2006)	  and	   so	   the	  aim	  of	   such	  work	  will	  be	   to	  
identify	   whether	   the	   impairment	   of	   function	   at	   peak	   EAE	   was	   a	   result	   of	   the	  
immunization	  protocol	  or	  a	  representative	  state	  of	  autoimmunity.	  	  	  
In	  addition	  to	  observations	  of	  the	  impact	  of	  Tregs	  on	  the	  course	  of	  disease,	  the	  removal	  
of	   Tregs	  will	   highlight	  which	   effector	   cells	   are	   under	   the	   strongest	   Treg	   control	   in	   the	  
autoimmune	  context.	  	  This	  will	  implicate	  protective	  or	  pathogenic	  roles	  for	  these	  cells	  in	  
the	   development	   of	   paralysis	   in	   the	   Line7	   model.	   	   In	   addition,	   the	   use	   of	   depleting	  
antibodies	  will	  be	  used	  to	  specifically	  remove	  CD8	  or	  NK	  cells	  to	  add	  additional	  data	  with	  
regard	   to	   their	   roles.	   	  Mixed	   results	  have	  been	  generated	   from	  previous	  depletion	  and	  
knockout	  studies	  in	  EAE.	  	  Depletion	  of	  NK	  cells	  has	  been	  shown	  to	  exacerbate	  EAE	  (Zhang	  
1997a,	  Matsumoto	  1998,	  Xu	  2005)	  or	  reduce	  severity	  (Winkler-­‐Pickett	  2008)	  whilst	  use	  of	  
CD8-­‐/-­‐	  mice	  has	  lead	  to	  a	  reduction	  in	  CNS	  inflammation	  (Abdul-­‐Majid	  2003).	   	  Therefore	  
the	  results	  generated	  in	  the	  Line7	  model	  would	  contribute	  to	  the	  debate	  regarding	  their	  
roles.	  
Identification	   of	   Treg	   control	   on	   either	   population	   combined	   with	   less	   severe	   disease	  
upon	   cellular	   depletion	  would	   implicate	   a	   pathogenic	   role	   in	   disease	   initiation.	   	   In	   this	  
way,	   the	   degree	   of	   Treg	   control	   over	   disease	   initiation	   and	   progression	   can	   be	  
determined	  and	  combined	  with	  data	  highlighting	  the	  relative	  importance	  of	  effector	  cell	  






11.2.1 Unabated	  Development	  of	  Paralysis	  without	  the	  presence	  of	  Tregs	  
In	  order	  to	  look	  at	  the	  role	  that	  Tregs	  might	  play	  in	  limiting	  spontaneous	  disease	  in	  the	  
Line7	  mice,	  a	  new	  line	  was	  created	  called	  L7Fox.	  	  This	  was	  created	  by	  crossing	  Line7	  with	  
Foxp3DTR	  mice	  generated	  by	  Alexander	  Rudensky	  (University	  of	  Washington).	  	  Line7	  mice	  
were	   mated	   with	   Foxp3DTR	   mice	   for	   at	   least	   three	   generations	   to	   provide	   mice	  
homozygous	   for	   both	   the	   Line7	   and	   Foxp3DTR	   transgenes.	   	   The	   presence	   of	   transgenes	  
was	  confirmed	  by	  PCR	  analysis	  as	  outlined	  in	  the	  materials	  and	  methods.	  	  	  
Foxp3DTR	  mice	  express	  GFP	  in	  the	  presence	  of	  Foxp3,	  under	  the	  control	  of	  a	  repressible	  
promoter.	   	   The	  promoter	   is	   reactive	   to	   the	  presence	  of	  diphtheria	   toxin,	   such	   that	   the	  
addition	  of	  DT	  depletes	  the	  Treg	  population.	  	  L7Fox	  mice	  share	  the	  characteristics	  of	  both	  
founder	  lines	  and	  allow	  investigation	  of	  Treg	  dynamics	  within	  a	  model	  of	  autoimmunity.	  	  	  
DT	  was	  administered	  every	  other	  day	  in	  young	  (8	  week	  old)	  L7Fox	  mice,	  beginning	  on	  day	  
0.	  	  3	  male	  and	  6	  female	  mice	  were	  used	  in	  both	  the	  DT	  and	  PS	  control	  group.	  	  This	  age	  of	  
mice	   is	   before	   they	   present	   signs	   of	   disease	   under	   normal	   circumstances,	   and	   the	  
regimen	   of	   DT	   administration	   was	   to	   maintain	   complete	   depletion	   of	   the	   Treg	  
population.	   	  Previous	  work	  had	  shown	  that	  depletion	  of	  Tregs	  was	  achieved	   for	  2	  days	  
after	   the	   initial	   dose	   of	   DT,	   (Kim	   2007)	   and	   after	   consideration	   of	   other	   depletion	  
experiments	  investigating	  Treg	  return	  that	  were	  carried	  out	  in	  the	  lab,	  regular	  doses	  very	  
other	  day	  were	  administered	  to	  allow	  this	  depletion	  to	  be	  extended.	   	  Ablation	  of	  Tregs	  
was	  near	   complete	  with	   less	   than	  0.3%	  of	   total	   lymphocytes	   remaining	  Foxp3+	   in	  mice	  





progress	  unabated	  in	  100%	  of	  mice	  compare	  to	  0%	  of	  control	  mice	  of	  this	  age	  given	  PBS	  
(Figure	  11A).	  
	  
Figure	  11.	   	  Complete	   removal	  of	  Tregs	   leads	   to	  acute	  progression	  of	   cellular	   infiltration	  
and	  disease	  symptoms.	  	  	  
A	   –	   Percentage	   of	   mice	   affected	   in	   the	   three	   groups;	   L7Fox	   administered	   DT,	   L7Fox	  
administered	  PBS,	  L7	  administered	  DT,	  through	  the	  length	  of	  the	  study.	  	  B	  –	  Scores	  of	  all	  
mice	   in	   the	  study	  averaged	  within	  groups	   to	  generate	  mean	  disease	  progression.	   (n=22	  
total).	  	  C	  –	  Counts	  of	  CNS	  infiltrating	  cells	  taken	  when	  mice	  were	  removed	  from	  the	  study.	  	  
CNS	   infiltrating	   cells	   were	   extracted	   following	   perfusion,	   enzymatic	   digestion	   of	   CNS	  





taken	   at	   the	   same	   time	   as	   affected	   mice	   and	   DT	   control	   mice	   were	   taken	   at	   the	  
conclusion	   of	   the	   study.	   (n=10	   total).	   	   D	   –	   Counts	   of	   splenic	   Foxp3+	   lymphocytes	   based	  
upon	   GFP	   expression	   in	   spleen	   of	   DT	   treated	   (black)	   and	  matched	   PBS	   control	   (white)	  
L7Fox	   mice	   when	   they	   were	   removed	   from	   the	   study.	   	   Asterisks	   denote	   statistical	  
significance	   between	   cell	   populations	   of	   indicated	   disease	   scores;	   	   *	   p<0.05,	   **	   p<0.01	  
(two-­‐tailed	  T	  test).	  
	  
	  
Mice	  were	  observed	  everyday	  and	  their	  score	  recorded.	  	  An	  average	  score	  for	  mice	  in	  the	  
study	  was	  calculated	  by	  adding	  the	  scores	  of	  all	  mice	  and	  dividing	  by	  the	  number	  of	  mice	  
in	   the	   study.	   	   Mice	   were	   culled	   and	   samples	   taken	   at	   the	   point	   where	   full	   hind	   limb	  
paralysis	   had	   been	   achieved	   and	   the	   paralysis	   was	   serious	   enough	   to	   risk	   the	   animals	  
survival.	  	  	  Upon	  removal	  from	  the	  study,	  the	  final	  score	  of	  the	  mouse	  was	  used	  for	  each	  
subsequent	  day	  to	  calculate	  the	  average	  for	  the	  study.	  	  This	  was	  necessary	  to	  provide	  a	  
realistic	  average	  score	  for	  the	  study,	  not	  assuming	  that	  disease	  scores	  would	  increase	  but	  
not	   losing	   the	   impact	   of	   a	  mouse	   that	   had	   progressed	   through	   to	   full	   disease	   on	   the	  
average	  for	  the	  colony.	  	  The	  first	  signs	  of	  disease	  were	  seen	  after	  as	  few	  as	  2	  days	  after	  
the	  initial	  dose	  of	  DT,	  but	  all	  mice	  had	  presented	  within	  a	  week	  and	  by	  day	  9,	  all	  mice	  had	  
progressed	   through	   to	   full	   hind	   limb	   paralysis	   (B).	   	   As	   a	   further	   control,	   DT	   was	  
administered	  to	  4	  Line7	  mice	  (2	  male,	  2	  female)	  lacking	  the	  Foxp3DTR	  construct,	  to	  control	  
for	  any	  effects	  of	  DT	  itself.	  	  These	  mice	  were	  4	  months	  of	  age,	  at	  the	  time	  when	  signs	  of	  
disease	  would	  be	  expected	  to	  be	  presented.	  	  In	  these	  circumstances,	  no	  presentation	  or	  





to	   PBS	   controls.	   	   Removal	   of	   Tregs	   led	   to	   mass	   infiltration	   of	   cells	   into	   the	   CNS	   at	  
significantly	  higher	  levels	  than	  compared	  to	  both	  the	  PBS	  and	  DT	  controls	  (Figure	  11C).	  
	  
	  
Figure	  12.	  	  Peripheral	  cell	  dynamics	  after	  Treg	  depletion.	  	  	  
Surface	   and	   intracellular	   cytokine	   staining	   of	   peripheral	   lymphocytes	   extracted	   from	  
spleens	   of	   affected	   DT	   treated	   mice	   (black)	   and	   matched	   PBS	   controls	   (white)	   after	  





they	   were	   removed	   from	   the	   study.	   	   A	   –	   surface	   staining	   of	   total	   spleen-­‐derived	  
lymphocytes.	   IFNγ	  and	   IL-­‐17	  secreting	  cells	  as	  shown	  as	  percentage	  of	  total	   lymphocyte	  
(B),	  CD4	  (C),	  CD8	  (D),	  NK	  (E),	  and	  γδ	  (F)	  cell	  populations.	  	  (n=3	  per	  group).	  	  Lymphocytes	  
were	  gated	   initially	   according	   to	   cell	   surface	  markers	   and	  positive	   cells	   interrogated	   to	  
determine	   the	   size	   of	   cytokine	   positive	   populations.	   	   Asterisks	   denote	   statistical	  
significance	   between	   cell	   populations	   of	   indicated	   disease	   scores;	   	   *	   p<0.05,	   **	   p<0.01	  
(two-­‐tailed	  T	  test).	  
	  
The	   functional	  effect	  of	  Treg	  ablation	  was	   then	  assessed	  by	   flow	  cytometric	  analysis	  of	  
splenic	  and	  CNS-­‐infiltrating	  lymphocytes,	  looking	  for	  any	  resulting	  changes	  in	  intracellular	  
cytokine	   staining	   from	   CD4,	   CD8,	   NK	   and	   γδ	   cells.	   	   The	   same	   extraction	   protocol	   was	  
utilised	  as	  described	  before,	  allowing	  individual	  mice	  to	  be	  investigated	  separately.	  	  Upon	  
removal	   of	   an	   affected	   DT	   administered	   mouse,	   a	   sex	   matched	   corresponding	   PBS	  
control	  mouse	  was	  also	  removed.	  	  This	  was	  to	  control	  for	  both	  the	  reagents	  used	  and	  the	  
time	  since	  the	  last	  injection	  had	  been	  administered.	  	  Lymphocyte	  populations	  were	  non-­‐
specifically	   stimulated	   with	   PMA	   and	   ionomycin	   in	   the	   presence	   of	   BFA.	   	   They	   were	  
stained	   with	   fluorescently	   conjugated	   antibodies	   for	   cell	   surface	   markers	   and	  
permeabilised	   to	   allow	   the	   use	   of	   antibodies	   for	   intracellularly	   sequestered	   cyokine	  
production.	  	  Two-­‐tailed	  t	  tests	  were	  used	  with	  Welch’s	  correction	  for	  unequal	  variances	  
to	  compare	  means	  between	  cellular	  populations.	   	  After	  removal	  of	  Tregs,	  there	  was	  no	  
significant	   variation	   in	   the	   proportion	   of	   CD4,	   CD8,	   γδ	   and	   NK	   cell	   populations	   in	   the	  
periphery	  (Figure	  12A)	  although	  there	  is	  a	  slight	  decrease	  in	  the	  proportion	  of	  CD4	  cells	  





the	   CD4	   population	   could	   be	   explained	   as	   the	   removal	   of	   Tregs	   whilst	   the	   other	  
proportions	   will	   adjust	   in	   reaction.	   	   At	   a	   functional	   level,	   as	   expected,	   control	   was	  
released	  on	   cytokine	   production.	   	   IFNγ	   and	   IL-­‐17	   secreting	   cell	   populations	   increase	   in	  
the	   absence	   of	   Tregs,	   but	   only	   the	   increase	   in	   IFNγ	   population	   shows	   statistical	  
significance	  (Figure	  12B).	  	  The	  IFNγ	  response	  shows	  a	  larger	  increase	  than	  IL-­‐17,	  reaching	  
around	   a	   third	   of	   lymphocytes	   producing	   IFNγ,	   and	   is	   represented	   in	   the	   statistical	  
analysis.	   	  By	  analyzing	   the	  cytokine	  positive	  cells	  after	  selection	  of	  populations	  positive	  
for	  each	  cell	  surface	  marker,	  it	  could	  be	  seen	  that	  the	  CD4,	  CD8	  and	  NK	  cell	  populations	  
all	  demonstrated	  a	  similar	  significant	   increase	   in	   IFNγ	  production	  although	  due	  to	  small	  
sample	  numbers,	  only	  CD8	  reached	  significance.	  	  γδ	  cells	  demonstrated	  a	  trend	  towards	  
an	   increase	   of	   IFNγ	   production	   but	   this	   did	   not	   achieve	   statistical	   significance	   (Figure	  
12F).	   	  Greater	  proportions	  of	  positive	   cells	   can	  be	   seen	   in	  all	   analyzed	  cell	  populations	  
with	   respect	   to	   release	   of	   IFNγ	   as	   compared	   to	   IL-­‐17.	   	   There	   is	   a	   trend	   towards	  
enhancement	   of	   IL-­‐17	   in	   both	   the	   CD4	   and	   γδ	   populations	   although	   not	   statistically	  
significant	  (Figure	  12C,F).	  	  With	  respect	  to	  the	  peripheral	  response,	  the	  findings	  appeared	  
to	  suggest	  that	  the	  impact	  of	  Treg	  ablation	  on	  disease	  exacerbation	  was	  to	  a	  far	  greater	  
extent	   attributable	   to	   the	   release	   from	   regulation	   of	   IFNγ	   than	   IL-­‐17	   responses.	   	   Note	  
that,	  in	  this	  model,	  since	  the	  TCR	  is	  carried	  on	  a	  RAG-­‐sufficient	  background	  there	  is	  a	  full	  
repertoire	  of	  HLA-­‐DR15-­‐restricted	  responses	  to	  other	  antigens	  apart	  from	  MBP,	  including	  







Figure	  13.	  	  Characteristics	  of	  CNS	  lymphocyte	  infiltrates	  after	  Treg	  depletion.	  	  	  
Surface	  and	  intracellular	  cytokine	  staining	  of	  CNS	  infiltrating	  lymphocytes	  in	  affected	  DT	  
treated	   mice	   (black)	   and	   matched	   PBS	   controls	   (white)	   after	   stimulation	   for	   4h	   with	  
PMA/ionomycin	   and	   BFA.	   Infiltrating	   lymphocytes	   were	   extracted	   from	   the	   CNS	   of	  





gradients	  when	  mice	  were	   removed	   from	   the	   study.	   	   A	   –	   surface	   staining	   of	   total	   CNS	  
infiltrating	   lymphocytes.	   IFNγ	  and	  IL-­‐17	  secreting	  cells	  are	  shown	  as	  percentage	  of	  total	  
lymphocyte	   (B),	   CD4	   (C),	   CD8	   (D),	   and	   NK	   (E)	   cell	   populations.	   	   (n=3	   per	   group).	  
Lymphocytes	   were	   gated	   initially	   according	   to	   cell	   surface	   markers	   and	   positive	   cells	  
interrogated	   to	   determine	   the	   size	   of	   cytokine	   positive	   populations.	   	   Asterisks	   denote	  
statistical	  significance	  between	  cell	  populations	  of	  indicated	  disease	  scores;	  	  *	  p<0.05,	  **	  
p<0.01	  (two-­‐tailed	  T	  test).	  
	  
This	  regulation	  appears	  to	  be	  relevant	  to	  cytokine	  production	  from	  CD4,	  CD8	  and	  NK	  cell	  
populations	  but	  not	  cellular	  proliferation,	  as	  this	  was	  not	  seen	  to	  increase	  in	  the	  absence	  
of	   regulation.	   	   In	   the	   CNS,	   ablation	   of	   Foxp3+	   cells	   can	   be	   seen	   to	   impact	   on	   cellular	  
infiltration	  across	  the	  BBB.	   	  Both	  CD4	  and	  CD8	  cell	   infiltration	  were	  seen	  to	   increase	   in	  
the	  absence	  of	  Tregs,	  each	  reaching	  close	  to	  20%	  of	  the	  total	  infiltrating	  population.	  	  Only	  
the	  increase	  in	  CD4	  cells	  showed	  statistical	  significance	  although	  the	  increase	  in	  CD8	  cells	  
approached	   significance	   (Figure	   13A).	   	   The	   rate	   at	   which	   this	   increase	   in	   proportion	  
occurs	   makes	   it	   unlikely	   that	   it	   is	   simply	   an	   increase	   in	   proliferation	   of	   resident	  
lymphocytes	  but	  rather	  migration	  across	  the	  BBB.	  	  However,	  in	  this	  experiment	  such	  an	  
explanation	   cannot	   be	   ruled	   out	   and	   investigations	   using	   tracking	   of	   peripheral	   cells	  
would	  be	  required	  to	  differentiate	  between	  these	  two	  possibilities.	  	  	  	  
NK	  cells	  still	  make	  up	  the	  largest	  population	  of	  infiltrating	  cells	  but	  they	  do	  not	  show	  any	  
increase	  in	  proportion	  upon	  removal	  of	  Tregs.	  	  This	  consistency	  is	  mirrored	  by	  the	  γδ	  cell	  
population,	   and	   neither	   cell	   population	   demonstrate	   significantly	   different	   proportions	  





IFNγ+	  cells	  can	  be	  readily	  identified	  in	  the	  infiltrate	  and	  are	  present	  at	  significantly	  higher	  
levels	  than	  in	  Treg	  competent	  mice.	  	  There	  are	  very	  few	  IL-­‐17+	  cells	  observed	  in	  the	  CNS,	  
in	   contrast	   to	   the	   peripheral	   picture,	   and	   even	   upon	   removal	   of	   Tregs,	   there	   is	   no	  
significant	  increase	  in	  cytokine	  production	  as	  measured	  by	  number	  of	  IL-­‐17+	  cells	  (Figure	  
13B).	  	  No	  evidence	  was	  therefore	  found	  that	  triggering	  of	  disease	  exacerbation	  through	  
loss	   of	   Tregs	   had	   correlated	   either	   with	   increased	   infiltration	   by	   IL-­‐17+	   cells	   or	   by	  
increased	   activation	   to	   secrete	   IL-­‐17	   by	   those	   cells	   present.	   	   In	   the	   absence	   of	   Tregs,	  
there	   is	   a	   trend	   towards	   control	   of	   IFNγ	  production	   from	  both	  CD8	  and	  NK	   cells	   being	  
released,	   as	   the	   proportion	   of	   cytokine	   positive	   cells	   increased,	   although	   neither	  
observation	  was	  statistically	  significant.	  	  Very	  little	  production	  of	  IL-­‐17	  could	  be	  observed	  
from	  either	  CD8	  or	  NK	  cell	  populations	  irregardless	  of	  Treg	  presence	  or	  absence	  (Figure	  
13D,E).	  	  CD4	  cells	  were	  seen	  to	  secrete	  both	  IFNγ	  and	  IL-­‐17,	  although	  at	  low	  total	  levels	  
and	   not	   in	   significantly	   different	   proportions	   compared	   to	   when	   Tregs	   were	   present	  
(Figure	  13C,D,E).	   	  Trends	  towards	   increases	   in	  activation	  were	  seen	  but	  these	  were	  not	  
statistically	  significant.	  	  	  
Analysis	  of	   the	  cell	   surface	  markers	  within	   the	   IFNγ+	  cell	  population	  was	  carried	  out	   to	  
determine	   whether	   the	   removal	   of	   Tregs	   affected	   the	   source	   of	   the	   released	   IFNγ	  
observed.	  	  The	  proportion	  of	  cytokine	  release	  increases	  significantly	  by	  around	  20%,	  from	  
the	  CD8	  cell	  population	  (Figure	  14A)	  in	  response	  to	  the	  removal	  of	  Tregs	  and	  progression	  
of	  symptoms.	  	  Smaller	  proportions	  of	  IFNγ	  release	  were	  observed	  from	  the	  γδ	  and	  NK	  cell	  
populations.	   	   The	  γδ	   cell	   observation	   shows	  a	   statistically	   significant	  decrease	  whereas	  





proportion	  of	  IFNγ	  derived	  from	  CD4	  cells	  was	  observed	  and	  this	  remained	  around	  10%	  
of	  the	  cytokine	  release.	  	  
	  
Observation	  of	  double	   cytokine	  positive	   cells	   as	   a	  proportion	  of	   each	   cytokine	  positive	  
population	  shows	  a	  significant	  decrease	  in	  the	  number	  of	  IFNγ+	  cells	  also	  producing	  IL-­‐17	  
after	   removal	   of	   Tregs	   (Figure	   14B).	   	   This	   is	   in	   contrast	   to	   results	   at	   similar	   disease	  
severities	   in	   Line7	  mice	   that	   progressed	   through	   disease	  without	   any	   interference.	   	   In	  
these	  mice,	  IFNγ+	  cells	  began	  to	  release	  IL-­‐17	  at	  high	  disease	  scores.	  	  These	  observations	  
show	  no	  evidence	  that	  that	  release	  was	  due	  to	  Treg	  control	  however,	  and	  it	  is	  more	  likely	  
that	   other	   factors	   influenced	   the	   phenotypic	   development	   of	   those	   cells.	   	   The	   same	  
analysis	  of	  the	   IL-­‐17+	  cell	  population	  shows	  an	   increase	   in	  the	  proportion	  of	   IL-­‐17+	  cells	  
also	  releasing	  IFNγ	  but	  this	  was	  not	  statistically	  significant.	  	  It	  should	  be	  noted	  that	  there	  
are	  very	  few	  of	  these	  cells	  to	  put	  this	  in	  context	  (Figure	  14B)	  but	  supports	  evidence	  that	  








Figure	  14.	  CNS	  IFNγ	  derived	  from	  infiltrating	  CD8+	  cells.	  	  	  
Composition	  of	  cytokine	  positive	  cells	  extracted	   from	  the	  CNS	  of	  DT	   treated	   (black)	  and	  





Infiltrating	   lymphocytes	  were	  extracted	   from	  the	  CNS	  of	  perfused	  animals	  by	  enzymatic	  
digestion	   followed	  by	  separation	  on	  percoll	  density	  gradients	  when	  mice	  were	   removed	  
from	   the	   study.	   	   A	   –	   Surface	   markers	   as	   shown	   as	   percentage	   of	   IFNγ+	   population.	  	  
Lymphocytes	  were	  gated	   initially	  on	   IFNγ	  and	  positive	  cells	   interrogated	  for	  presence	  of	  
cell	  surface	  markers.	   	  B	  –	  Proportion	  of	  cytokine	  positive	   infiltrating	  cells	  also	  producing	  
the	  other	  cytokine	  (IFNγ	  and	  IL-­‐17	  only).	  	  Lymphocytes	  were	  gated	  on	  IFNγ	  and	  IL-­‐17	  and	  
positive	   cells	   interrogated	   for	   production	   of	   the	   other	   cytokine.	   	   Asterisks	   denote	  
statistical	  significance	  between	  cell	  populations	  of	  indicated	  disease	  scores;	  	  *	  p<0.05,	  **	  
p<0.01	  (two-­‐tailed	  T	  test).	  
	  
	  
11.2.2 Return	  of	  Tregs	  Halts	  Disease	  Progression	  
Through	  work	  with	  another	  PhD	  student	  in	  the	  lab	  (Deborah	  Chong)	  we	  had	  clear	  data	  on	  
the	  kinetics	  of	  Treg	  reconstitution	  following	  the	  DT	  administration.	  	  To	  assess	  the	  impact	  
of	  Tregs	  returning	  to	  an	  inflamed	  CNS	  following	  a	  period	  of	  ablation,	  Tregs	  were	  depleted	  
through	  use	  of	  DT	  but	  only	  one	  or	  two	  doses	  (day	  0	  and	  day	  2)	  were	  given	  to	  allow	  the	  
Treg	  population	  to	  reconstitute	  as	  the	  DT	  was	  processed	  and	  removed	  from	  the	  mice.	  	  4,	  
6-­‐8	  week	  old	  L7Fox	  mice	  were	  used	  per	  group	  (3	  male,	  1	  female).	  	  Age	  matched	  Foxp3DTR	  
mice	  were	  used	  to	  quantify	  Treg	  depletion	  and	  repletion	  following	  the	  protocol	  used	  to	  
treat	  L7Fox	  mice.	   	  DT	  was	  administered	  to	  48	  mice,	  split	   into	  2	  equal	  groups,	   receiving	  
either	  one	  dose	  of	  DT	  or	   two	  doses	  on	  alternate	  days.	   	  Untreated	  mice	  were	   taken	   to	  
provide	  a	  baseline	  and	  3	  mice	  removed	  from	  each	  DT	  treated	  group	  on	  alternate	  days.	  	  





spleen	  and	  an	  average	  taken	  from	  the	  three	  mice	  at	  each	  time	  point.	  	  From	  this	  it	  could	  
be	  shown	  that	  two	  doses	  of	  DT	  were	  sufficient	  to	  maintain	  a	  depleted	  Treg	  population	  
until	  day	  6	  (Figure	  15A).	  	  By	  this	  time	  3	  out	  of	  4	  mice	  had	  already	  progressed	  through	  to	  
full	   hind	   limb	   paralysis	   in	   a	   similar	   way	   to	   the	   previous	   continual	   Treg	   depletion	  
experiment.	  	  
	  
Only	  one	  mouse	  survived	  and	  managed	  to	  limit	  paralysis	  scores	  (Figure	  15A).	  	  In	  contrast,	  
one	  administration	  of	  DT	  was	  sufficient	  to	  deplete	  Treg	  cells	  but	  by	  day	  4,	  they	  began	  to	  
return	  and	  had	  returned	  to	  baseline	  levels	  by	  day	  8	  (Figure	  15B).	  	  In	  these	  mice	  receiving	  
one	   dose	   of	   DT,	   the	   removal	   of	   Treg	   population	   allowed	   disease	   to	   initiate,	   with	  
symptoms	   presented	   between	   days	   4	   and	   6.	   	   Disease	   progressed	   until	   further	  
presentation	  of	  disease	  signs	  halted	  by	  day	  9	  (Figure	  15B)	  and	  after	  this	  point	  mice	  were	  
stable	  albeit	  with	  mild	   to	  heavy	   impairment.	   	  The	  progression	  of	  disease	  and	   return	  of	  
the	  Treg	  population	  overlapped	  almost	  perfectly	  (Figure	  15B).	  	  
	  
Age	   and	   sex-­‐matched	   controls	   were	   administered	   PBS	   according	   to	   the	   same	  
immunization	  regime	  as	  a	  control	   for	  both	  disease	  development	  and	  cellular	  dynamics.	  	  
As	  with	  the	  previous	  Treg	  depletion	  experiment,	  mice	  were	  removed	  from	  the	  study	  and	  
samples	   taken	  when	  the	  development	  of	  paralysis	   threatened	  their	   survival.	   	  Upon	  the	  
removal	  of	  an	  affected	  mouse,	  a	  matched	  control	  was	  also	  taken	  to	  control	  for	  reagents	  
and	  duration	  since	  the	   last	   injection	  had	  been	  administered.	   	   Infiltrating	  and	  peripheral	  
cells	  were	  extracted	  from	  the	  CNS	  and	  spleen	  respectively	  following	  the	  earlier	  described	  





haemocytometer	  and	  cells	  stimulated	  and	  stained	  with	  antibodies	  in	  the	  same	  manner	  as	  
previous	  experiments.	  	  Comparison	  of	  mean	  cell	  populations	  was	  done	  using	  two-­‐tailed	  t	  
tests	  with	  Welch’s	  correction	  for	  unequal	  variances	  in	  this	  experiment.	  
	  
	  





L7Fox	  mice	  received	  either	  two	  doses	  (A)	  or	  one	  dose	  (B)	  of	  DT	  to	  limit	  Treg	  numbers,	  (as	  
illustrated	   in	   the	   periphery	   by	   the	   red	   line	   tracking	   their	   recovery	   (n=3	   per	   point)).	  	  
Individual	   score	   progressions	   of	   each	   mouse	   in	   the	   study	   are	   shown	   in	   the	   respective	  
graphs.	   	   All	   PBS	   control	   L7Fox	   mice	   receiving	   the	   same	   dosing	   regimen	   remained	  
unaffected	  (not	  shown	  on	  graph).	  	  Infiltrating	  lymphocytes	  were	  extracted	  from	  the	  CNS	  
of	   perfused	   animals	   by	   enzymatic	   digestion	   followed	   by	   separation	   on	   percoll	   density	  
gradients	   when	  mice	   were	   removed	   from	   the	   study.	   	   Counts	   of	   infiltrating	   cells	   made	  
when	   each	   mouse	   was	   removed	   from	   the	   study,	   matched	   PBS	   control	   mice	   taken	  
alongside	  affected	  DT	  treated	  mice	  (C)	  and	  shown	  as	  mean	  with	  SEM.	  	  Count	  of	  GFP+	  cells	  
shown	  as	  percentage	  of	   the	  total	   lymphocytic	   infiltrate	  shown	   	   (D).	   	  n=4	  per	  group.	   	  P1	  
and	  P2	  grouping	  signifies	  control	  L7Fox	  mice	   receiving	  1	  or	  2	  doses	  of	  PBS	   respectively,	  
DT1	  and	  DT2	  grouping	   signifies	   L7Fox	  mice	   receiving	  1	  or	  2	  doses	  of	  DT	   respectively	   to	  
deplete	   Tregs.	   	   Asterisks	   denote	   statistical	   significance	   between	   cell	   populations	   of	  
indicated	  disease	  scores;	  	  *	  p<0.05	  (two-­‐tailed	  T	  test).	  
	  	  
	  
Maintaining	  a	  low	  Treg	  population	  allowed	  a	  significantly	  higher	  infiltration	  of	  cells	   into	  
the	  CNS	  (Figure	  15C)	  compared	  to	  respective	  PBS	  treated	  controls.	   	  The	  infiltration	  was	  
higher	  in	  mice	  receiving	  two	  doses	  of	  DT	  demonstrating	  that	  the	  period	  of	  time	  without	  a	  
Treg	   presence	   affects	   the	   level	   of	   cellular	   infiltration	   allowed.	   	   However,	   upon	   their	  
return,	  Tregs	  readily	  infiltrated	  into	  the	  CNS	  as	  measured	  by	  FACS	  analysis	  of	  GFP+	  cells	  in	  





potential	  upon	  the	  reconstitution	  of	  the	  Treg	  population	  and	  that	  this	  infiltration	  may	  be	  
an	  important	  factor	  in	  the	  deceleration	  of	  disease	  progression.	  	  	  
As	  with	  continual	  depletion	  of	  Tregs,	  CD4	  and	  CD8	  infiltration	   into	  the	  CNS	  significantly	  
increased	  in	  the	  absence	  of	  Tregs	  (Figure	  16F).	  	  In	  mice	  receiving	  either	  dosing	  regime	  of	  
DT	   the	   proportion	   of	   the	   infiltrating	   population	   increased.	   	  Whilst	   the	   CD8	   proportion	  
increased	   significantly	   in	   response	   to	   any	   duration	   of	   Treg	   depletion,	   in	   the	   longer	  
depletion	   protocol,	   the	   proportion	   of	   CD4	   cells	   in	   the	   infiltrate	   was	   not	   significantly	  
increased	  compared	  to	  control	  mice.	   	  This	  significance	   is	   likely	   representative	  of	  a	  high	  
variance	   in	   the	   control	   mice	   as	   the	   limited	   size	   of	   this	   population	   means	   a	   greater	  
influence	   for	   individual	   cells.	   	   	   There	   was	   no	   change	   in	   γδ	   T	   cell	   infiltration	   but	   a	  
significant	  increase	  was	  observed	  in	  NK	  cell	  infiltration	  after	  only	  one	  dose	  of	  DT.	  	  Similar	  
to	  CD4,	  there	  was	  no	  significant	  increase	  in	  infiltration	  seen	  after	  two	  doses	  of	  either	  DT	  
compared	  to	  PBS	   (Figure	  16F)	  but	  as	   the	  spread	  of	   results	  was	  small	  and	  no	  difference	  
was	  observed	  in	  NK	  cell	  infiltration	  in	  response	  to	  complete	  Treg	  ablation	  (Fig	  13A),	  this	  
result	  is	  supported	  by	  other	  results.	  	  
In	  response	  to	  the	  depletion	  of	  Tregs	  by	  two	  doses	  of	  DT,	  control	  of	  both	  IFNγ	  and	  IL-­‐17	  
production	   from	   splenocytes	   was	   released	   (Figure	   16A).	   	   Reconstitution	   of	   the	   Treg	  
population,	   after	   only	   one	   dose	   of	   DT,	   allowed	   a	   regain	   of	   control	   over	   peripheral	  
cytokine	  release	  demonstrating	  the	  functionality	  of	  Tregs	  upon	  their	  return	  (Figure	  16A).	  	  
In	   the	   CNS,	   control	   over	   cytokine	   release	   was	   limited	   to	   IFNγ	   with	   significantly	   more	  
cytokine	  positive	  cells	  seen	  infiltrating	  after	  any	  depletion	  of	  the	  Treg	  population.	  	  
No	   change	   was	   observed	   in	   the	   IL-­‐17+	   cell	   population	   after	   a	   depletion	   of	   the	   Treg	  





(Figure	   13B).	   	  Mice	   receiving	   two	   doses	   of	   DT	   that	   progressed	   through	   to	   full	   disease	  
showed	  a	  significantly	  higher	  number	  of	  IFNγ+	  cells	  than	  those	  with	  stable	  disease	  after	  
only	  one	  dose	  of	  DT	  (Figure	  16B)	  showing	  evidence	  for	  a	  partial	  recovery	  of	  control.	  	  	  
Within	  the	  CD4	  and	  CD8	  infiltrating	  cell	  populations,	  there	  were	  significant	   increases	  of	  
IFNγ	  production	  after	  Treg	  depletion,	  regardless	  of	  dosing	  strategy	  and	  a	  trend	  towards	  
an	  increase	  was	  observed	  in	  the	  NK	  cell	  population	  (Figure	  16C,D,E).	  	  No	  differences	  were	  
observed	  between	  DT	  dosing	  regimes	  in	  any	  of	  these	  cell	  types.	  	  In	  these	  populations,	  no	  
change	   was	   observed	   in	   IL-­‐17	   production,	   demonstrating	   no	   evidence	   for	   their	  







Figure	  16.	  	  Altered	  cell	  dynamics	  after	  temporal	  Treg	  depletion.	  	  	  
Intracellular	  cytokine	  staining	  of	  peripheral	  (A)	  and	  infiltrating	  (B)	  lymphocytes	  extracted	  
from	   affected	   DT	   treated	  mice	   (one	   dose	   -­‐	   DT1,	   2	   doses	   -­‐	   DT2)	   after	   stimulation	   with	  
PMA/ionomycin	  and	  BFA	  with	  matched	  PBS	  controls	  (P1,	  P2).	  	  Shown	  as	  percentages	  from	  
the	  total	  lymphocyte	  (A,B),	  infiltrating	  CD4	  (C),	  infiltrating	  CD8	  (D),	  	  and	  infiltrating	  NK	  (E)	  
cell	   populations.	   	   Surface	   staining	   of	   total	   infiltrating	   lymphocyte	   population	   (F)	   also	  





animals	  by	  enzymatic	  digestion	  followed	  by	  separation	  on	  percoll	  density	  gradients	  when	  
mice	   were	   removed	   from	   the	   study.	   	   Peripheral	   lymphocytes	   were	   extracted	   from	   the	  
spleen	  of	  mice	   removed	   from	  the	  study.	   	   Lymphocytes	  were	  gated	   initially	  according	   to	  
cell	   surface	   markers	   and	   positive	   cells	   interrogated	   to	   determine	   the	   size	   of	   cytokine	  
positive	  populations.	  	  Asterisks	  denote	  statistical	  significance	  between	  cell	  populations	  of	  
indicated	  disease	  scores;	  	  *	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001	  (two-­‐tailed	  T	  test).	  
	  
Analysis	  within	   the	   IFNγ+	   cell	   population	   showed	   that	   as	  with	   a	   continual	   depletion	   of	  
Tregs,	  an	  increase	  was	  observed	  in	  the	  proportion	  of	  these	  cells	  positive	  for	  CD8+	  (Figure	  
17A)	  which	   reached	   significance	   after	   2	  doses	  of	  DT	   and	   approached	   significance	   after	  
only	  one	  dose	  compared	   to	   their	   controls.	   	  A	   significant	  decrease	  was	  observed	  within	  
the	  NK	  cell	  population	  and	  a	  trend	  within	  the	  γδ	  cell	  population,	  although	  not	  from	  both	  
dosing	   regimens.	   	   The	   decrease	   in	   γδ	   cell	   derived	   IFNγ	   was	   from	   only	   one	   dose	   of	   DT	  
whereas	  a	  decrease	  in	  NK	  cell	  derived	  IFNγ	  after	  two	  doses	  was	  likely	  a	  result	  of	  sample	  
size,	  as	  very	  high	  proportions	  were	  derived	  from	  small	  IFNγ+	  cell	  populations	  within	  small	  
total	  infiltrating	  populations	  in	  the	  CNS	  of	  unaffected	  PBS	  control	  mice	  (Figure	  17A).	  	  No	  
difference	  was	  observed	   in	   the	  proportion	  of	  CD4+	  cells	  producing	   IFNγ	   (Figure	  17A)	  as	  
seen	  in	  the	  previous	  depletion	  experiment	  (Figure	  14A).	  	  	  
	  
No	  significant	  difference	  was	  observed	  in	  the	  proportion	  of	  double	  cytokine	  positive	  cells	  
within	   the	   IFNγ+	   population	   in	   contrast	   to	   the	   previous	   depletion	   experiment	   (Figure	  
17B).	   	   There	   was	   however,	   a	   significant	   increase	   in	   the	   proportion	   of	   IL-­‐17+	   cells	   also	  





cells	  significantly	  increased	  but	  as	  with	  the	  previous	  experiment,	  these	  results	  were	  from	  
very	  small	  cytokine	  positive	  cell	  populations	  and	  so	  should	  be	  treated	  with	  caution.	  	  
	  
	  





Composition	  of	  cytokine	  positive	  cells	  extracted	   from	  the	  CNS	  of	  DT	  treated	   (one	  dose	   -­‐	  
DT1,	  2	  doses	  -­‐	  DT2)	  	  and	  matched	  PBS	  control	  (P1,	  P2)	  mice	  after	  stimulation	  for	  4h	  with	  
PMA/ionomycin	  and	  BFA.	   	  n=4	  per	  group.	   	   Infiltrating	   lymphocytes	  were	  extracted	  from	  
the	   CNS	   of	   perfused	   animals	   by	   enzymatic	   digestion	   followed	   by	   separation	   on	   percoll	  
density	   gradients	   when	   mice	   were	   removed	   from	   the	   study.	   	   A	   –	   Surface	   markers	   as	  
shown	  as	  percentage	  of	  IFNγ+	  population.	  	  Lymphocytes	  were	  gated	  initially	  on	  IFNγ	  and	  
positive	  cells	  interrogated	  for	  presence	  of	  cell	  surface	  markers.	  	  B	  –	  Proportion	  of	  cytokine	  
positive	   infiltrating	   cells	   also	   producing	   the	   other	   cytokine	   (IFNγ	   and	   IL-­‐17	   only).	  	  
Lymphocytes	  were	  gated	  on	  IFNγ	  and	  IL-­‐17	  and	  positive	  cells	  interrogated	  for	  production	  
of	  the	  other	  cytokine.	  	  Asterisks	  denote	  statistical	  significance	  between	  cell	  populations	  of	  
indicated	  disease	  scores;	  	  *	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001	  (two-­‐tailed	  T	  test).	  
	  
	  
11.2.3 Tregs	  Remain	  Functional	  Throughout	  Disease	  Development	  
The	  main	   issue	  unresolved	  at	   this	  point	  was	  whether	   the	  Tregs	  were	  acting	  directly	  on	  
the	   effector	   cells	   or	  whether	   the	   stopping	   of	   disease	   progression	  was	   associated	  with	  
other	   indirect	   factors	   related	   to	   the	   return	   of	   the	   Tregs.	   	   It	   was	   also	   of	   interest	   to	  
determine	  whether	  Tregs	  retained	  their	  functionality	  throughout	  disease	  progression	  or	  
whether	   progression	   under	   normal	   circumstances	   occurred	   because	   of	   aberrant	  
regulation.	  	  	  
In	  order	  to	  assess	  Treg	  functionality,	  cells	  were	  extracted	  from	  both	  the	  spleen	  and	  CNS	  
from	   3	   (1	   male,	   2	   female)	   high	   scoring	   mice	   (2-­‐3)	   and	   sorted	   on	   the	   basis	   of	   Foxp3	  





were	   pooled	   together	   to	   provide	   sufficient	   cells	   for	   the	   experiment.	   	   The	   sorting	   was	  
carried	  out	  using	  a	  BD	  FACS	  Aria	  II	  running	  FACSDiva	  software	  and	  high	  purity	  mask.	  	  The	  
sort	  generated	  99%	  pure	  populations	  of	  Tregs	  and	  effector	  T	  cells	  as	  can	  be	  seen	  by	  the	  
FACS	  plots	  of	  cell	  populations	  pre	  and	  post-­‐sorting	  (Figure	  18D,E,F,G,H).	  	  There	  is	  no	  CNS	  
post-­‐sort	  GFP+	  plot	  as	  this	  population	  was	  limited	  in	  number	  and	  no	  cells	  could	  be	  spared	  
from	  the	  suppression	  experiment.	  	  
	  
Effector	   cells	   were	   cultured	   either	   with	   or	   without	   Tregs	   in	   the	   presence	   of	   2.5µg/ml	  
MBP85-­‐99,	  and	  cellular	  proliferation	  was	  assessed	  by	  thymidine	  incorporation	  after	  3	  days.	  	  
Media	  only	   and	  unstimulated	  effector	   cell	   cultures	   are	   shown	  on	   the	  graph	   to	  provide	  
illustration	   that	   proliferation	   and	   cytokine	   release	   was	   significantly	   higher	   than	  
background	   levels.	   	   Two-­‐tailed	   t	   tests	  were	   used	   to	   compare	  means	   derived	   from	   this	  
experiment.	  	  Significant	  proliferation	  was	  observed	  upon	  stimulation	  with	  MBP85-­‐99	  with	  
effectors	  derived	   from	  both	   the	   spleen	  and	  CNS	   (Figure	  18A).	   	  Upon	  addition	  of	  Tregs,	  
effector	   cell	   proliferation	   was	   significantly	   reduced	   in	   all	   combinations	   tested	  
demonstrating	   the	   functionality	   of	   Tregs	   even	   at	   high	   disease	   scores	   (Figure	   18A).	  	  
Effector	  cells	  were	  cultured	  with	  Tregs	  derived	  from	  the	  same	  organ	  (spleen	  or	  CNS)	  to	  
demonstrate	  functionality	   in	  vivo.	   	   In	  addition,	  peripherally	  derived	  Tregs	  were	  cultured	  
with	  effector	  T	  cells	  from	  the	  CNS	  to	  show	  that	  these	  cells	  have	  not	  escaped	  regulation	  






Figure	  18.	  	  Tregs	  retain	  suppressive	  ability	  throughout	  the	  mouse	  even	  at	  high	  disease.	  	  	  
GFP+	  Tregs	  and	  GFP-­‐	  T	  effector	  cells	  were	  sorted	  using	  a	  BD	  FACS	  Aria	   II	   from	  extracted	  





extracted	  from	  the	  CNS	  of	  perfused	  score	  2-­‐3	  L7Fox	  mice	  by	  enzymatic	  digestion	  followed	  
by	  separation	  on	  percoll	  density	  gradients,	  peripheral	   lymphocytes	  were	  extracted	   from	  
the	   spleens	   of	   the	   same	   L7Fox	   mice.	   	   Effector	   cells	   were	   cultured	   in	   the	   presence	   or	  
absence	   of	  MBP85-­‐99	   peptide	   stimulation	   (2.5µg/ml)	   and	   regulatory	   cells	   at	   a	   1:1	   ratio.	  	  
Origin	   of	   cells	   outlined	   beneath	   each	   figure.	   	   Proliferation	   was	   assessed	   by	   thymidine	  
incorporation	   (A)	   (30,000	   effector	   cells	   per	  well)	   and	   cytokine	   secretion	   by	   ELISA	   (B,C).	  	  
Bars	   indicate	   mean	   from	   triplicate	   cultures	   ±	   SEM.	   	   Asterisks	   denote	   statistical	  
significance	  between	  cell	  populations	  of	   indicated	  disease	   scores;	   	   *	  p<0.05,	  **	  p<0.01,	  
***	  p<0.001	  (two-­‐tailed	  T	  test).	   	  Purity	  of	  sorting	  was	  very	  high	  with	  mixed	  populations	  
(D,G)	   at	   the	   start	   and	   pure	   effector	   cell	   (E,H)	   and	   regulatory	   (F)	   populations	   after.	  	  	  
Percentages	  are	  from	  total	  cell	  population.	  
	  
Cytokine	  release	  from	  these	  cell	  cultures	  was	  also	  measured	  by	  ELISA.	  	  After	  stimulation,	  
only	  IFNγ	  was	  released	  with	  no	  IL-­‐17	  detectable	  (Figure	  18B,C).	  	  There	  was	  a	  significantly	  
lower	   production	   of	   IFNγ	   from	  CNS	   effector	   cells	   than	   peripheral	   effector	   cells	   (Figure	  
18B)	   upon	   stimulation	  with	  MBP85-­‐99,	   although	   the	   release	   of	   cytokine	   from	   both	  was	  
significantly	  reduced	  to	  undetectable	  levels	  upon	  culture	  in	  the	  presence	  of	  Tregs	  (Figure	  
18B).	   	  This	  demonstrated	   that	   in	  addition	   to	  suppression	  of	  cellular	  proliferation,	  Tregs	  
were	   able	   to	   suppress	   activation	   of	   effector	   cells,	   as	   measured	   by	   pro-­‐inflammatory	  
cytokine	   production	   and	   these	   mechanisms	   together	   explain	   the	   halting	   of	   disease	  





11.2.4 Role	  of	  CD8	  and	  NK	  Cells	  
An	  attempt	  was	  made	  to	  shed	  light	  on	  the	  role	  that	  CD8	  and	  NK	  cells	  may	  play	  in	  disease	  
initiation	  and	  progression.	  	  Depleting	  antibodies	  for	  CD8	  and	  NK1.1	  were	  given	  to	  mice	  in	  
order	  to	  remove	  these	  cell	  populations	  and	  assess	  the	  impact	  on	  disease	  progression.	  	  5,	  
6-­‐8	  week	   old	   L7Fox	  mice	  were	   included	   in	   each	   group	   (2	  male,	   3	   female).	   	   Antibodies	  
were	   administered	   alongside	   a	   regimen	  of	  DT	   in	   order	   to	   increase	   the	   speed	   at	  which	  
signs	   of	   disease	   developed.	   	   CD8	   cells	   showed	   increased	   cytokine	   production	   and	  
increase	   infiltration	   upon	   removal	   of	   Tregs	   implicating	   a	   pathogenic	   role	   in	   disease	  
progression.	   	   If	   these	   results	   represent	   the	   true	   function,	   disease	   initiation	   or	   severity	  
should	  expect	  to	  be	  reduced	  compared	  to	  controls.	  	  The	  infiltration	  of	  NK	  cells	  however,	  
did	   not	   increase	   in	   response	   to	   Treg	   depletion,	   despite	   showing	   increased	   cytokine	  
production.	  	  They	  make	  up	  the	  largest	  proportion	  of	  the	  cellular	  infiltrate	  but	  so	  far	  there	  
is	  no	  conclusive	  evidence	  as	  to	  whether	  they	  fulfill	  a	  protective	  or	  pathogenic	  role.	  	  If	  NK	  
cells	   are	   merely	   bystander	   cells	   then	   no	   difference	   would	   be	   expected	   in	   disease	  
progression	  whereas	  roles	  promoting	  or	  preventing	  disease	  should	  appear	  in	  relation	  to	  
controls.	  	  A	  group	  receiving	  an	  isotype	  control	  antibody	  in	  place	  of	  a	  depleting	  antibody	  
was	  included	  in	  the	  study	  to	  act	  as	  a	  control	  for	  antibody	  administration.	   	   In	  this	  group	  
only	   one	   dose	   of	   DT	   was	   administered	   and	   the	   second	   dose	   isotype	   control	   antibody	  
alone.	  
The	  regimens	  of	  depleting	  antibody	  and	  DT	  were	  selected	  to	  provide	  movement	  to	  both	  
accelerate	  or	  delay	   the	  development	  of	  disease	   signs.	   	   They	  are	  described	   for	  CD8	  but	  
apply	   identically	   for	  NK	  cells.	   	  Three	  combinations	  of	  dosing	  were	  designed,	  with	  every	  





both	  DT	  and	  the	  αCD8	  to	  remove	  Tregs	  and	  the	  CD8+	  cells.	  	  The	  second	  dose	  contained	  
either	  αCD8	  alone,	  DT	  alone,	  or	  both	  together.	  	  This	  would	  generate	  mice	  in	  which	  cells	  
returned	  at	  different	  times,	  hopefully	  impacting	  on	  the	  development	  of	  disease.	  	  If	  CD8+	  
cells	   played	   a	   pathogenic	   role	   then	   a	   delay	   in	   development	   of	   disease	   signs	  would	   be	  
expected	   in	  mice	  receiving	  two	  doses	  of	  αCD8	  in	  which	  CD8	  cells	  were	  absent	  past	  the	  
return	  of	  Tregs.	  	  If	  however	  they	  were	  protective,	  then	  development	  of	  disease	  would	  be	  
expected	   to	  be	  accelerated	   in	   these	  mice.	   	  Statistical	   significances	  were	  determined	  by	  
comparison	  of	  means	  by	  a	  two-­‐tailed	  T	  test	  with	  Welch’s	  correction	  for	  unequal	  variance.	  
In	   order	   to	   determine	   the	   extent	   of	   depletion	   and	   rate	   of	   return	   of	   CD8	   or	   NK	   cells,	  
depleting	  antibodies	  were	  administered	  to	  Foxp3DTR	  mice	  as	  either	  a	  single	  dose,	  or	  two	  
doses	  on	  two	  days	  apart.	  	  24	  (12	  male,	  12	  female)	  mice	  received	  αCD8	  split	  between	  the	  
two	  dosing	  regimes	  and	  24	  	  (12	  male,	  12	  female)	  received	  αNK1.1.	  	  3	  mice	  receiving	  the	  
single	   dose	   were	   culled	   on	   days	   2,	   6,	   11	   and	   16	   after	   immunization,	   whilst	   3	   mice	  
receiving	  two	  doses	  were	  culled	  on	  days	  4,	  8,	  12	  and	  16	  after	  the	  initial	  immunization.	  	  3	  
mice	  that	  did	  not	  receive	  an	  injection	  were	  taken	  to	  provide	  a	  baseline	  reading.	  	  Spleen	  
cells	  were	  extracted	   from	   these	  mice	  and	   stained	  with	  antibodies	   to	  determine	   size	  of	  
the	   originally	   depleted	   cell	   populations.	   	   Mice	   receiving	   αCD8	   were	   identified	   using	  
another	  CD8	  antibody,	  specific	  for	  a	  different	  epitope	  whilst	  NK	  cells	  were	   identified	  as	  
being	  CD3-­‐NKp46+	  as	  the	  αNK1.1	  antibody	  used	  in	  other	  experiments	  was	  specific	  for	  the	  
same	  epitope	  as	  the	  depleting	  antibody.	  	  Results	  are	  displayed	  in	  Figure	  19C	  and	  D,	  and	  
showed	  that	  despite	  a	  reduction	  in	  proportion	  of	  both	  cell	  types,	  neither	  was	  completely	  
depleted.	   	  CD8	  cells	   showed	  around	  a	  75%	  reduction,	  whilst	   the	  population	  of	  NK	  cells	  





experiment,	  and	  neither	  cell	  phenotype	  was	  observed	  to	  return	  to	  baseline	  levels	  by	  the	  
end	   of	   the	   study	   (Figure	   19C,D).	   	   There	   was	   no	   discernable	   difference	   in	   depletion	  
efficiency	   between	   one	   and	   two	   dose	   regimes,	   meaning	   the	   intended	   difference	   in	  
temporal	  repletion	  did	  not	  occur.	  	  
The	   disease	   curves	   reflect	   the	   incomplete	   depletion	   and	   no	   obvious	   change	  was	   seen	  
between	  mice	  administered	  one	  or	  two	  doses	  of	  either	  depleting	  antibody	  or	  the	  isotype	  
control	   (Figure	   19A,B).	   	   Average	   scores	   for	   mice	   in	   each	   group	   were	   calculated	   by	  
addition	  of	  the	  scores	  of	  mice	  within	  each	  group	  divided	  by	  the	  total	  mice	  still	  alive	  on	  
each	  day.	  	  Mice	  were	  taken	  for	  samples	  as	  in	  previous	  experiments	  when	  their	  paralysis	  
threatened	   their	   survival	   but	   their	   scores	   were	   not	   included	   in	   the	   generation	   of	   an	  
average	  score	  after	  their	  removal.	  	  No	  significant	  delay	  in	  development	  of	  symptoms	  was	  
observed	   in	   any	   group	  and	   there	  was	  no	   significant	   reduction	   in	   severity	  of	   symptoms	  








Figure	   19.	   	   Partial	   depletion	   of	   CD8	   or	   NK	   cells	   does	   not	   affect	   disease	   initiation	   or	  
severity.	  	  	  
Administration	   of	   depleting	   antibodies	   to	   L7Fox	   mice	   alongside	   depletion	   of	   Treg	  
populations.	   	  Mice	  were	  observed	  and	   scored	  daily	  and	  disease	   scores	  averaged	  within	  





cellular	   depletion	   and	   recovery	   of	   cell	   populations	   tracked	   (C,D)	   	   (n=3	   per	   point).	  	  
Peripheral	  lymphocytes	  were	  extracted	  from	  the	  spleen	  of	  L7Fox	  mice	  administered	  either	  
one	   or	   two	   doses	   of	   either	   αCD8	   or	   αNK1.1	   depleting	   antibody.	   	   Cells	  were	   stained	   to	  
determine	   level	   of	   depletion,	   CD8+	   cells	   measured	   using	   an	   antibody	   for	   a	   different	  
epitope,	  NK	  cells	  measured	  as	  CD3-­‐	  NKp46+.	  	  Stained	  cells	  were	  read	  using	  a	  BD	  FACS	  Aria	  
II.	  	  Number	  of	  mice	  affected	  in	  each	  group	  and	  progressing	  to	  score	  4	  or	  above	  shown	  in	  
E.	  
	  
In	   this	   experiment,	   the	   dose	   regime	   of	   DT	   was	   the	   largest	   correlate	   with	   disease	  
outcome,	   such	   that	   as	   seen	   in	   previous	   experiments,	   mice	   receiving	   two	   doses	   of	   DT	  
progressed	   through	   to	   full	  disease	  at	  a	  higher	   frequency	   than	   those	  only	   receiving	  one	  
dose	   (Figure	   19E).	   The	   small	   sample	   size	  of	   each	   group	   limits	   the	   significance	  of	   these	  
frequencies,	   and	   larger	   groups	   would	   be	   required	   to	   gain	   statistical	   power	   in	   this	  
observation.	  	  Some	  mice	  receiving	  two	  doses	  of	  DT	  managed	  to	  resist	  progression	  to	  full	  
disease	   as	  previously	   seen	  and	   in	   this	   case	   two	  mice	   receiving	   the	   isotype	   control	   and	  
only	  one	  dose	  of	  DT	  also	  progressed	  fully	  (Figure	  19E).	  
	  
Because	   of	   the	   failure	   of	   differential	   doses	   of	   depleting	   antibody	   to	   provide	   different	  
rates	  of	  repletion,	  and	  the	  limited	  survival	  of	  mice	  receiving	  two	  doses	  of	  DT,	  meaningful	  
conclusions	  are	  only	  going	  to	  be	  found	  through	  comparison	  of	  groups	  receiving	  one	  dose	  
of	  DT.	   	   Through	  comparison	  of	   the	  disease	   course	  of	   these	  groups,	   it	   appears	   that	   the	  
depletion	   of	   CD8	   cells	  may	   cause	   later	   onset	   and	  milder	   signs	   of	   disease	  whereas	   the	  





effect	   is	   very	   marginal	   and	   would	   need	   to	   be	   confirmed	   by	   complete	   depletion	  
experiments	  or	  much	  larger	  sample	  sizes.	   	  No	  statistical	  significance	  can	  be	  determined	  
but	  development	  of	  disease	   signs	  appear	   to	  be	  delayed	  by	   two	  days	   in	   the	  absence	  of	  
CD8+	  cells	  and	  scores	  fail	  to	  achieve	  an	  average	  greater	  than	  2.	  	  	  
The	   depleting	   antibodies	   used	   in	   this	   study	   had	   previously	   shown	   reliable	   efficacy	   at	  
depleting	   their	   respective	   populations	   in	   previous	   work	   done	   in	   the	   lab	   and	   in	   other	  
published	  studies	  so	  the	  only	  partial	  depletions	  were	  not	  expected.	   	  YTS169,	  developed	  
in	   the	   laboratory	   of	   Herman	   Waldmann,	   has	   been	   used	   successfully	   by	   many	   other	  
groups	  to	  deplete	  CD8	  T	  cells	  (Cobbold	  1990)	  and	  the	  αNK1.1	  antibody	  used	  in	  this	  study	  
is	   commercially	   available	   and	   has	   been	   used	   widely	   to	   deplete	   NK	   cells	   in	   previous	  






Figure	   20.	   	   Variations	   in	   lymphocyte	   cell	   proportions	   after	   administration	   of	   depleting	  
antibodies.	  	  	  
A	  -­‐	  Average	  disease	  progression	  shown	  for	  each	  group	  receiving	  only	  one	  dose	  of	  DT	  to	  





in	  the	  periphery	  and	  infiltrating	  the	  CNS	  as	  measured	  in	  the	  whole	  lymphocyte	  population	  
at	   that	   location	   (n=29	   total).	   	   Infiltrating	   lymphocytes	  were	   extracted	   from	   the	   CNS	   of	  
perfused	   animals	   by	   enzymatic	   digestion	   followed	   by	   separation	   on	   percoll	   density	  
gradients	   when	   mice	   were	   removed	   from	   the	   study.	   	   Peripheral	   lymphocytes	   were	  
extracted	   from	   the	   spleen	   of	   mice	   removed	   from	   the	   study.	   	   Dosing	   regime	   outlined	  
beneath	   figure.	   	   Asterisks	   denote	   statistical	   significance	   between	   administration	  
protocols.	  	  An	  asterisk	  above	  individual	  bars	  denotes	  statistical	  significance	  with	  regard	  to	  
the	   isotype	   contol	   group	   (centre).	   	   Asterisks	  with	   associated	   lines	   between	   two	   groups	  
denotes	  statistical	  significance	  between	  the	  two	  groups;	  *	  p<0.05,	  **	  p<0.01	  (two-­‐tailed	  T	  
test).	  	  
	  
Reflecting	  the	  poor	  depletions,	  there	  are	  still	  substantial	  populations	  of	  cells	  targeted	  for	  
depletion	   present	   in	   the	   periphery	   and	   infiltrating	   the	   CNS	   from	   both	   groups	   (Figure	  
20B,C,D,E).	  	  The	  lower	  numbers	  of	  CD8	  cells	  illustrate	  that	  the	  depletion	  had	  some	  effect	  
on	  the	  CNS	  infiltrate,	  with	  the	  two	  groups	  showing	  significant	  reductions	  relative	  to	  the	  
isotype	  control	  (Figure	  20C).	  	  However	  CD8+	  cells	  still	  make	  up	  over	  5%	  of	  infiltrating	  cells	  
even	  in	  the	  mice	  that	  progressed	  very	  fast	  through	  to	  complete	  disease	  (Figure	  20C).	  	  In	  
the	   periphery	   only	   one	   group	   showed	   a	   significant	   reduction	   in	   size	   of	   the	   CD8	  
population,	  and	  this	  was	  the	  group	  receiving	  only	  one	  dose	  of	  depleting	  antibody	  rather	  
than	  the	  expected	  groups	  receiving	  two	  doses	  (Figure	  20B).	  	  No	  change	  was	  observed	  in	  
the	  size	  of	   the	   infiltrating	  NK	  cell	  population	  after	  CD8	  depletion	   (Figure	  20E)	  although	  
the	   administration	   of	   two	   doses	   of	   αCD8	   did	   lead	   to	   a	   significant	   increase	   in	   the	  






Figure	   21.	   	   Changes	   in	   cytokine	   dynamics	   of	   peripheral	   and	   CNS	   infiltrating	   cells	   after	  
administration	  of	  depleting	  antibodies.	  	  	  
Intracellular	  cytokine	  staining	  of	   infiltrating	  and	  peripheral	   lymphocytes	  extracted	  when	  
each	  mouse	  was	  removed	  from	  the	  study.	   	  Stimulated	  with	  PMA/ionomycin	   for	  4h	  with	  
BFA.	   	   Infiltrating	   lymphocytes	   were	   extracted	   from	   the	   CNS	   of	   perfused	   animals	   by	  





removed	  from	  the	  study.	  	  Peripheral	  lymphocytes	  were	  extracted	  from	  the	  spleen	  of	  mice	  
removed	  from	  the	  study.	  	  IFNγ	  (A,B),	  IL-­‐17	  (C,D)	  secreting	  cells,	  and	  Foxp3+	  (gfp+)	  cells	  (E)	  
measured	  as	  proportion	  of	  total	  lymphocyte	  population.	  	  Dosing	  regime	  outlined	  beneath	  
figure	   (n=29	   total).	   	   Asterisks	   denote	   statistical	   significance	   between	   administration	  
protocols.	  	  An	  asterisk	  above	  individual	  bars	  denotes	  statistical	  significance	  with	  regard	  to	  
the	   isotype	   contol	   group	   (centre).	   	   Asterisks	  with	   associated	   lines	   between	   two	   groups	  




The	  administration	  of	  αNK1.1	  antibody	  significantly	  increased	  the	  proportion	  of	  CD8	  cells	  
in	  the	  periphery	  relative	  to	  the	  isotype	  control	  as	  would	  be	  expected	  with	  a	  reduction	  in	  
the	   NK	   cell	   population	   (Figure	   20B).	   	   However,	   significant	   increases	   could	   also	   be	  
observed	  in	  the	  peripheral	  NK	  cell	  population	  after	  administration	  of	  2	  doses	  of	  αNK1.1	  
(Figure	  20D)	  making	  the	  derivation	  of	  this	  result	  unclear.	  No	  significant	  changes	  in	  either	  
infiltrating	  CD8	  or	  NK	  cell	  populations	  were	  observed	  after	  attempted	  NK	  cell	  depletion	  
(Figure	  20C,E).	   	  Both	   the	  detection	  and	  depleting	  αNK1.1	  antibodies	   react	   to	   the	  same	  
epitope	  of	  NK1.1.	  	  This	  further	  emphasizes	  the	  poor	  efficacy	  of	  depletion	  as	  any	  depleting	  
antibody	   remaining	   in	   the	  mouse	  would	  be	  expected	   to	  block	  binding	  of	   the	  detection	  
antibody	   and	   so	   yield	   lower	   proportions.	   	   The	   ability	   to	   detect	   NK1.1+	   populations	  






The	  severity	  of	  symptoms,	  measured	  by	  the	  number	  of	  mice	  still	  being	  alive	  at	  the	  end	  of	  
the	   run	   was	   correlated	   with	   higher	   Treg	   infiltrates	   (Figure	   21E).	   	   This	   was	   seen	  
irrespective	  of	  which	  depleting	  antibody	  had	  been	  administered	  and	  demonstrated	  the	  
overriding	   importance	   of	   Tregs	   on	   controlling	   disease	   initiation	   and	   progression.	   	   In	  
groups	  receiving	  αCD8	  and	  two	  doses	  of	  DT	  there	  were	  significantly	  lower	  Treg	  infiltrates	  
in	  the	  CNS	  of	  mice	  compared	  to	  the	  isotype	  control	  group.	  	  In	  these	  groups,	  all	  but	  one	  
mouse	  progresses	  through	  to	  full	  disease	  (Figure	  19E).	  	  This	  pattern	  was	  recapitulated	  in	  
the	   corresponding	   groups	   receiving	  αNK1.1	   although	   it	   was	   not	   statistically	   significant	  
(Figure	   21E).	   	   Interestingly	   a	   trend	   towards	   a	   different	   proportion	   of	   infiltrating	   Tregs	  
were	  observed	  in	  mice	  receiving	  the	  second	  dose	  of	  DT	  alone	  with	  groups	  receiving	  αCD8	  
showing	  lower	  Treg	  infiltration	  than	  those	  receiving	  αNK1.1	  (Figure	  21E).	  	  	  
Irrespective	  of	  which	  depleting	   antibody	  had	  been	  administered,	  higher	   levels	  of	   IFNγ+	  
cells	   infiltrating	   the	  CNS	  were	   seen	   in	  groups	  with	   low	  Treg	   infiltration,	   all	   significantly	  
different	  to	  the	  isotype	  control	  (Figure	  21A).	  	  Both	  groups	  receiving	  depleting	  antibodies	  
but	  only	  one	  dose	  of	  DT	  showed	  lower	  levels	  of	  IFNγ+	  cell	  infiltration,	  more	  comparable	  
to	  that	  seen	  in	  the	  isotype	  control,	  although	  it	  was	  still	  significantly	  higher	  in	  the	  group	  
receiving	  αCD8	  (Figure	  21A).	  	  	  
There	  was	   however	   a	   noticeable	   increase	   in	   peripheral	   levels	   of	   IFNγ+	   cells	   from	  mice	  
administered	   αCD8	   compared	   to	   those	   receiving	   isotype	   control	   in	   contrast	   to	   a	  
consistent	  proportion	  in	  those	  mice	  receiving	  αNK1.1.	  	  This	  increase	  was	  significant	  in	  the	  
group	   administered	   αCD8,	   apart	   from	   those	   receiving	   two	   doses	   of	   DT	   which	   only	  






No	   variation	   in	   infiltration	   or	   peripheral	   presence	   of	   IL-­‐17+	   cells	   was	   observed	   (Figure	  
21C,D)	  after	  administration	  of	  any	  depleting	  antibody	  and	  DT	  combination.	  	  There	  was	  no	  
change	   in	   IL-­‐17+	   cell	   infiltration	   replicating	   results	   from	   earlier	   Treg	   depletion	  
experiments.	   	   In	   the	  periphery	   lower	  proportions	  of	   IL-­‐17+	   cells	  were	  observed	   in	  mice	  
receiving	  two	  doses	  of	  αNK1.1	  and	  those	  within	  groups	  receiving	  αCD8	  and	  DT	  followed	  
by	   either	   DT	   or	   αCD8	   alone	   although	   none	   of	   these	   differences	   showed	   statistical	  
significance	  when	  compared	  to	  the	  isotype	  control	  group.	  	  This	  was	  likely	  due	  to	  the	  high	  
variation	  of	  the	  isotype	  control	  group	  but	  as	  IL-­‐17+	  cells	  only	  represented	  2%	  of	  the	  total	  
lymphocytes	  at	  their	  maximum,	  the	  sample	  sizes	  are	  relatively	  small.	  	  	  
Despite	  the	  incomplete	  depletion	  of	  CD8	  or	  NK	  cells	  in	  this	  protocol,	  the	  partial	  removal	  
of	  CD8	  or	  NK	  cells	  highlighted	  some	  properties	  of	  these	  cells	  that	  can	  help	  to	  shed	  light	  
on	   their	   role	   in	   autoimmunity.	   	   Consideration	  of	   groups	   receiving	  only	  one	  dose	  of	  DT	  
and	  two	  doses	  of	  either	  depleting	  or	  isotype	  control	  antibody,	  allows	  comparisons	  to	  be	  
made	  between	  mice	  without	  the	  added	  variable	  of	  DT	  dose	  and	  therefore	  Treg	  dynamics.	  	  
Under	   partial	   depletion	   of	   CD8	   cells,	   IFNγ	   production	   showed	   a	   trend	   towards	   an	  
increase	  in	  the	  spleen	  in	  contrast	  to	  IL-­‐17	  which	  did	  not	  vary	  (Figure	  22A,B).	  	  The	  release	  
of	   IFNγ	   from	   the	   CD4+	   population	   was	   also	   increased	   relative	   to	   the	   isotype	   control	  
(Figure	   22D),	   despite	   the	   overall	   CD4	   population	   remaining	   stable	   (Figure	   22D).	   	   The	  
proportion	  of	  IFNγ	  and	  IL-­‐17	  coming	  from	  the	  CD8	  population	  was	  significantly	  decreased	  
in	   both	   the	   peripheral	   (Figure	   22F,H)	   and	   infiltrating	   cell	   populations	   Figure	   22E,G)	  
reflecting	   the	   partial	   depletion	   but	   as	   no	   major	   difference	   in	   symptoms	   had	   been	  
observed	   it	   is	  not	  possible	   to	  say	   that	   this	  was	  a	  major	   factor.	   	  These	  results	  suggest	  a	  





This	  is	  limited	  to	  IFNγ	  and	  not	  IL-­‐17	  although	  the	  importance	  of	  this	  result	  is	  questionable	  
as	   the	   same	   increases	  were	   not	   observed	   in	   the	   infiltrating	   cell	   populations	   (data	   not	  
shown).	  	  	  
	  
The	  partial	  depletion	  of	  NK	  cells	   increased	  the	  proportion	  of	  CD8+	  cells	   in	  the	  periphery	  
(Figure	   23E)	   and	   as	   there	  were	   consistent	   proportions	   of	   CD4	   cells	   (Figure	   23D)	   and	   a	  
significant	  increase	  in	  NK	  cells	  despite	  the	  depleting	  antibody	  (Figure	  23F),	  this	  is	  unlikely	  
to	   be	   just	   an	   artifact	   of	  measuring	   percentages	   but	   actually	   an	   increase	   in	   number	   of	  
cells.	  	  There	  is	  also	  an	  increase	  in	  infiltrating	  CD8	  cells	  that	  produce	  IFNγ+	  (Figure	  23B)	  but	  
not	  a	  similar	  pattern	  for	  IL-­‐17+	  cells	  (Figure	  23C).	  	  This	  is	  not	  simply	  due	  to	  an	  increase	  in	  
CD8	  cell	  population	  (Figure	  23A)	  but	  likely	  reflects	  increased	  activation.	  	  Therefore	  these	  
results	  would	  lead	  to	  there	  being	  a	  regulatory	  role	  for	  NK	  cells.	  	  They	  may	  act	  to	  suppress	  
CD8	  proliferation	  and	  cytokine	  release,	  which	  could,	  if	  completely	  removed,	  lead	  to	  more	  







Figure	  22.	  	  Cellular	  dynamics	  after	  administration	  of	  depleting	  antibodies.	  	  	  
Intracellular	   cytokine	   staining	   of	   peripheral	   and	   infiltrating	   lymphocytes	   from	   groups	  





stimulation	  with	  PMA/ionomycin	  and	  BFA	  for	  4h.	  	  Infiltrating	  lymphocytes	  were	  extracted	  
from	   the	   CNS	   of	   perfused	   animals	   by	   enzymatic	   digestion	   followed	   by	   separation	   on	  
percoll	   density	   gradients	   when	   mice	   were	   removed	   from	   the	   study.	   	   Peripheral	  
lymphocytes	  were	  extracted	  from	  the	  spleen	  of	  mice	  removed	  from	  the	  study.	  	  Peripheral	  
IFNγ	   (A),	   IL-­‐17	   (B)	   and	   CD4	   (C)	   positive	   cells	   as	   measured	   as	   proportion	   of	   total	  
lymphocyte	  population	  and	  IFNγ	  positive	  cells	  as	  a	  proportion	  of	  peripheral	  CD4	  positive	  
cells	  (D).	  	  The	  proportion	  of	  cytokine	  positive	  cells	  that	  are	  CD8+	  is	  measured	  in	  both	  the	  
periphery	   and	   cellular	   infiltrate	   for	   IFNγ+	   cells	   (E,F)	   and	   IL-­‐17	   (G,H).	   	   (n=4	   per	   group).	  	  
Asterisks	   denotes	   statistical	   significance	   in	   the	   size	   of	   cell	   population	   between	   the	   two	  
groups;	  *	  p<0.05,	  **	  p<0.01	  (two-­‐tailed	  T	  test).	  
	  
	  
It	  was	  noticeable	  that	  in	  the	  isotype	  control	  group,	  2	  of	  the	  mice	  progressed	  fully	  through	  
disease	   compared	   to	  3	   that	  did	  not.	   	  Observation	  of	   the	   cellular	   infiltrate	   showed	   that	  
whether	   a	   mouse	   progressed	   to	   full	   disease	   was	   determined	   by	   the	   success	   of	   Treg	  
infiltration	  into	  the	  CNS	  and	  peripheral	  recovery	  after	  DT	  administration	  (Figure	  24A,B).	  	  
A	   significantly	   higher	   Treg	   infiltrate	  was	   seen	   in	   the	  mice	   resisting	   disease	   progression	  
compared	  to	  those	  which	  developed	  full	  hind	  limb	  paralysis	  (Figure	  24A)	  but	  only	  a	  trend	  
towards	  an	   increase	   in	  peripheral	  Treg	  numbers	  was	  seen	  as	   this	  was	  not	  shown	  to	  be	  
statistically	  significant.	  
With	   larger	   sample	   sizes	   it	   should	   be	   possible	   to	   determine	   whether	   this	   is	   a	   true	  
relationship	   or	   not.	   	   Taken	   with	   previous	   results	   however,	   these	   further	   illustrate	   the	  






Figure	  23.	  	  Comparison	  of	  cellular	  dynamics	  groups	  receiving	  one	  dose	  DT	  and	  two	  doses	  
of	  isotype	  control	  or	  αNK1.1	  antibodies.	  	  	  
Surface	   and	   intracellular	   staining	   after	   PMA/ionomycin	   stimulation	   with	   BFA	   for	   4h.	  	  
Infiltrating	   lymphocytes	  were	  extracted	   from	  the	  CNS	  of	  perfused	  animals	  by	  enzymatic	  
digestion	   followed	  by	  separation	  on	  percoll	  density	  gradients	  when	  mice	  were	   removed	  
from	  the	  study.	  	  Peripheral	  lymphocytes	  were	  extracted	  from	  the	  spleen	  of	  mice	  removed	  





lymphocyte	  population	  (A)	  and	  percentage	  of	  these	  that	  were	  also	  secreting	   IFNγ	  (B)	  or	  
IL-­‐17	   (C).	   	   Lymphocytes	   were	   first	   gated	   on	   CD8	   and	   positive	   cells	   interrogated	   to	  
determine	  the	  size	  of	  the	  cytokine	  positive	  population.	   	  Peripheral	  CD4	  (D),	  CD8	  (E),	  and	  
NK	   (F)	   cell	   populations	  measured	  as	   proportion	  of	   total	   lymphocytes.	   	   (n=4	  per	   group).	  	  
Asterisks	   denotes	   statistical	   significance	   in	   the	   size	   of	   cell	   population	   between	   the	   two	  













Figure	   24.	   	   Higher	   Treg	   numbers	   in	   mice	   from	   isotype	   control	   that	   did	   not	   progress	  
through	  to	  full	  disease.	  	  	  
Infiltrating	   lymphocytes	  were	  extracted	   from	  the	  CNS	  of	  perfused	  animals	  by	  enzymatic	  
digestion	   followed	  by	  separation	  on	  percoll	  density	  gradients	  when	  mice	  were	   removed	  
from	  the	  study.	  	  Peripheral	  lymphocytes	  were	  extracted	  from	  the	  spleen	  of	  mice	  removed	  
from	  the	  study.	  	  GFP+	  cells	  shown	  as	  proportion	  of	  total	  lymphocytes	  in	  the	  infiltrating	  (A)	  
and	  peripheral	  (B)	  cells.	  	  (n=2	  per	  group).	  	  Asterisks	  denotes	  statistical	  significance	  in	  the	  






Investigations	   into	   the	   functionality	   of	   Tregs	   in	  MS	   have	   been	   hampered	   by	   both	   the	  
source	  if	  using	  human	  tissue	  samples,	  and	  the	  nature	  of	  the	  EAE	  model	  if	  concerned	  with	  
mouse	  studies.	  	  Human	  Tregs	  are	  not	  derived	  from	  inflammation	  and	  the	  use	  of	  immune	  
adjuvants	   in	  EAE	  may	  artificially	   impair	   Treg	   function	   to	  generate	  disease	   (Chen	  2006).	  	  
Previous	   studies	   depleting	   Tregs	   have	   relied	   on	  αCD25	   antibodies,	   but	   the	   degree	   of	  
success	  of	  these	  depletions	  is	  debatable,	  impacting	  on	  the	  relevance	  of	  any	  conclusions	  
drawn	  (Kohm	  2006,	  Stephens	  2006,	  Zelenay	  2006).	  	  In	  the	  L7Fox	  model,	  it	  is	  possible	  to	  
completely	   deplete	   mice	   of	   Tregs,	   without	   affecting	   any	   other	   cell	   type	   by	   targeting	  
Foxp3	   (Kim	  2007),	   and	  under	   those	   circumstances	   autoimmunity	   progresses	   unabated.	  	  
Disease	   develops	   in	   all	   mice	   at	   a	   very	   rapid	   rate	   at	   an	   age	   where	   development	   of	  
symptoms	  is	  not	  expected	  for	  at	  least	  another	  2	  months.	  	  Mass	  infiltration	  is	  associated	  
with	   the	   removal	   of	   Tregs,	   upon	   DT	   administration,	   suggesting	   an	   additional	   role	   in	  
limiting	  cell	  migration	  and	  supported	  by	  Treg	  control	  of	  infiltration	  observed	  in	  adoptive	  
transfer	  experiments	  (Kohm	  2002).	  	  There	  has	  been	  debate	  as	  to	  the	  role	  DT	  plays	  in	  the	  
mouse,	   and	   whether	   the	   fatal	   autoimmunity	   observed	   in	   Foxp3	   knockout	   mice	   is	  
attributable	  to	  breakdown	  of	  epithelial	  barriers	  (Chen	  2008,	  Kim	  2009).	  	  In	  this	  study,	  DT	  
was	  administered	  to	  Line7	  mice	  and	  did	  not	  lead	  to	  breakdown	  of	  the	  BBB.	  	  Depletion	  of	  
the	  Treg	  population	  could	  be	  observed	  however,	  demonstrating	  the	  effectiveness	  of	  this	  
treatment.	   	  No	  extra	  cellular	   infiltration	  was	  observed	   illustrating	  that	  the	  BBB	  was	  still	  
intact,	  preventing	  the	  infiltration	  of	  T	  cells,	  and	  paralysis	  to	  develop,	  confirming	  that	  the	  





A	  significant	  advantage	  in	  using	  the	  L7Fox	  mice	  is	  that	  Tregs	  can	  be	  allowed	  to	  return	  in	  
the	  face	  of	  an	  autoimmune	  attack	  without	  requiring	  adoptive	  transfer	  of	  in	  vitro	  purified	  
Treg	  populations	  (Kim	  2009).	   	  There	  is	  no	  sudden	  burst	  of	  Tregs	  into	  the	  system,	  rather	  
they	   return	  at	  a	   rate	  determined	  by	  each	  mouse’s	  physiology,	  but	  what	   is	   clear	   is	   that	  
upon	  return	  they	  are	  able	  to	  prevent	  any	  further	  development	  of	  autoimmunity.	  	  	  
Even	  one	  dose	  of	  DT,	  with	  Tregs	  depleted	  for	  2	  days	  was	  sufficient	  for	  autoimmunity	  to	  
initiate	   and	   reach	  peak	   severities.	   	   Such	   an	  observation	  demonstrates	   the	   cliff-­‐edge	   at	  
which	  the	  mice	  live,	  only	  requiring	  a	  small	  lapse	  in	  regulation	  to	  fall	  off	  the	  edge.	  	  Disease	  
develops	  at	  an	  alarming	  rate	  without	  regulation	  such	  that	  if	  Tregs	  have	  not	  returned	  by	  
day	  6	  then	  it	  is	  too	  late.	  	  This	  further	  underlines	  their	  importance	  but	  also	  demonstrates	  
their	  effectiveness	  under	  normal	  circumstances	  in	  preventing	  disease	  progression	  in	  the	  
Line7	   base-­‐strain.	   	   A	   competent	   Treg	   population	   is	   able	   to	   prevent	   progression	   to	   full	  
signs	  of	  disease	  for	  near	  a	  year,	  and	  in	  some	  cases	  completely.	  	  They	  limit	  inflammation	  
in	  a	  mouse	   line	  primed	  for	  development	  of	  autoimmunity,	  both	   in	  only	  allowing	  a	  slow	  
accumulation	  of	  cells	  into	  the	  CNS	  but	  also	  limiting	  their	  activation	  once	  they	  infiltrate.	  	  	  
Removal	  of	  the	  Treg	  population	  allows	  recognition	  of	  which	  cell	  populations	  were	  under	  
Treg	  control.	  	  It	  could	  be	  seen	  that	  only	  peripheral	  activation	  of	  cells	  was	  released,	  Tregs	  
usually	  acting	  to	  limit	  both	  IFNγ	  and	  IL-­‐17	  production.	  	  It	  has	  been	  thought	  that	  Tregs	  are	  
unable	   to	   control	   Th17	   activation	   and	   only	   act	   on	   Th1	   (O'Connor	   2007)	   and	   although	  
statistical	   significance	   and	   as	   large	   an	   increase	   as	   from	   IFNγ+	   cells	   were	   not	   achieved,	  
there	  was	  a	  noticeable	   increase	   in	   IL-­‐17+	  cells	   from	  CD4+	  spleen	  cells	   in	   this	   study.	   	  No	  
peripheral	  cell	  populations	  varied	  demonstrating	  that	  aside	  from	  the	  removal	  of	  the	  Treg	  





Tregs	  appear	  to	  exhibit	  control	  over	  CD4	  and	  CD8	  infiltration	  as	  these	  cells	   increased	  in	  
much	  higher	  proportions	  and	  lead	  to	  disease	  development.	  	  Such	  control	  does	  not	  seem	  
to	  be	  present	   for	  NK	   cells	   or	   γδ	   cells	   as	   neither	  differed	   in	   infiltrating	  proportion	   after	  
Treg	  depletion.	  	  The	  high	  proportion	  of	  the	  infiltrate	  that	  was	  NK1.1+	  remained	  constant	  
suggesting	  that	  their	   infiltration	  was	  not	   linked	  to	  Tregs.	   	  Their	  activation	  however	  was	  
released	  and	  greater	  levels	  of	  IFNγ	  were	  observed	  from	  the	  CNS	  infiltrating	  populations,	  
mirrored	  also	  by	  CD4	  and	  CD8	  cells,	  demonstrating	  a	   level	  of	   control	  of	   Tregs	  over	  NK	  
cells,	  an	  observation	  seen	  in	  other	  circumstances	  (Ghiringhelli	  2005).	  	  	  
Most	  noticeable	  was	  that	  the	  severe	  disease	  was	  initiated	  and	  developed	  in	  the	  absence	  
of	   IL-­‐17	   in	   the	   CNS.	   	   Cytokine	   positive	   cells	   were	   almost	   exclusively	   IFNγ+	   and	   this	  
proportion	   increased	  greatly	  upon	   removal	  of	   Tregs.	   	  Any	  doubts	   that	   IFNγ+	   cells	  were	  
most	   important	   in	  disease	   initiation	  were	  dispelled,	  and	   it	  suggests	   that	   IL-­‐17+	  cells	  are	  
not	   required	   to	  move	   to	   full	   blown	  disease	  but	   rather	  differentiate	   after	   inflammation	  
has	   been	   established	   for	   a	   prolonged	   period	   of	   time	   in	   contrast	   to	   the	   many	   studies	  
insistent	  on	  Th17	  cells	  mediating	  autoimmunity.	  
These	  results	  highlight	  two	  roles	  that	  Tregs	  play,	  both	  the	  inhibition	  of	  activated	  effector	  
T	   cells	   and	   the	   control	   of	   infiltration	   into	   the	   CNS.	   	  Most	   noticeable	   in	   the	   temporary	  
depletion	  experiment	  was	  the	  correlation	  between	  cellular	  infiltration	  and	  period	  of	  time	  
without	  Tregs.	   	   It	   appears	   therefore	   that	   Tregs	   can	  act	   as	   the	  gatekeepers	  of	   the	  BBB,	  
preventing	  infiltration	  of	  autoreactive	  cells	  into	  the	  CNS.	  	  	  
In	   addition	   the	   demonstration	   in	   vitro	   that	   Tregs	   retain	   functionality	   at	   peak	   disease,	  
reinforces	   the	   important	   role	   Tregs	   play	   in	   suppressing	   effector	   T	   cell	   activity.	  	  





At	  a	  disease	  stage	  when	  IL-­‐17+	  cells	  can	  be	  identified	  in	  the	  infiltrating	  population,	  it	  may	  
suggest	  that	  they	  are	  responding	  to	  other	  stimuli,	  rather	  than	  direct	  myelin	  stimulation	  
itself.	   	   The	   limitation	   of	   cellular	   proliferation	   and	   secretion	   of	   pro-­‐inflammatory	  
cytokines,	   irrespective	   of	   extracted	   origin,	   are	   in	   direct	   contrast	   to	   previous	   studies	  
showing	  that	  Tregs	  extracted	  at	  peak	  EAE	  lack	  ability	  to	  suppress	  CNS	  derived	  effector	  T	  
cells	   (Korn	   2007a).	   	   There	   are	   no	   localised	   effects	   impairing	   Treg	   function	   from	   the	  
inflamed	  organ	  observed	  that	  could	  be	  used	  to	  explain	  the	  progression	  of	  autoimmunity	  
in	  this	  model.	  The	  use	  of	  pertussis	  toxin	   in	  the	   induction	  protocol	  of	  other	  studies	  may	  
responsible	   for	   this	   inhibition	   of	   function,	   and	   also	   for	   the	   importance	   of	   Tregs	   in	   the	  
recovery	  phase	  of	  EAE	  (McGeachy	  2005).	  	  Once	  the	  pertussis	  toxin	  had	  been	  excreted	  by	  
the	  mouse,	  Tregs	  would	  be	  able	  to	   function	  normally,	  and	  this	  could	   lead	  to	  either	  the	  
recovery	  from	  symptoms,	  or	  stabilization	  of	  symptoms	  as	  seen	  in	  other	  EAE	  models.	  	  The	  
ability	   of	   Tregs	   to	   curtail	   further	   disease	   progression	   upon	   return	   from	   DT-­‐mediated	  
depletion	  acts	  as	  an	  example	  of	  such	  a	  mechanism.	  	  Once	  the	  mouse	  has	  processed	  the	  
DT,	   competent	   Treg	   populations	   begin	   to	   return	   and	   limit	   both	   cytokine	   release	   and	  
further	   proliferation.	   	   Tregs	   readily	   traffic	   to	   the	   CNS	   to	   in	   this	   context	   and	   suppress	  
inflammation	  in	  a	  similar	  way	  that	  they	  migrate	  in	  EAE.	  	  Therefore,	  EAE	  could	  simply	  be	  
seen	   as	   an	   acute	  model	   utilising	   a	   forced	   impairment	   in	   T	   cell-­‐mediated	   regulation	   to	  
allow	   neuroinflammation	   rather	   than	   an	   accurate	   model	   of	   longer-­‐standing	   disease	  
where	  inflammation	  progresses	  despite	  a	  competent	  regulatory	  cell	  subset.	  	  
Tregs	   have	   been	   shown	   to	   demonstrate	   ability	   to	   suppress	   cytokine	   release,	   both	   by	  
direct	   in	  vitro	  measurement	  after	  cell	  culture,	  and	   implied	  cytokine	   increase	  upon	  their	  





IFNγ	   and	   IL-­‐17	  secretion	   in	   the	  peripheral	   cells,	  but	  only	   IFNγ	  was	  observed	   in	   the	  CNS	  
infiltrating	   populations.	   	   This	   provides	   evidence	   that	   Tregs	   are	   capable	   of	   suppressing	  
Th17	  cells,	  whilst	  reinforcing	  the	  idea	  that	  Th1	  cells	  are	  most	  important	  in	  the	  initiation	  
of	  disease.	  	  	  
In	   addition	   to	   observation	   of	   those	   cell	   populations	   under	   Treg	   control,	   it	   is	   also	  
noticeable	  which	  cells	  do	  not	  appear	  to	  be	  under	  Treg	  control	  and	  are	  not	  deregulated	  
upon	  removal	  of	  the	  Treg	  population.	  	  The	  consistent	  NK	  and	  γδ	  cell	  infiltration	  into	  the	  
CNS	  demonstrates	  that	  their	  infiltration	  is	  not	  influenced	  by	  Tregs	  but	  could	  be	  a	  steady	  
traffic	   across	   the	   BBB,	   representative	   of	   different	   roles	   in	   the	   CNS.	   	   	   γδ	   cells	   show	   no	  
evidence	   of	   being	   under	   Treg	   control	   as	   neither	   their	   infiltration	   or	   activation	   status	  
increases	  upon	  depletion	  of	  Tregs.	  	  The	  activation	  of	  NK	  cells	  as	  measured	  by	  IFNγ	  release	  
shows	   Treg	   control	   but	   this	   is	   not	   representative	   of	   an	   increase	   in	   proportion	   of	   total	  
IFNγ	  production,	  as	  the	  proportion	  of	  IFNγ	  derived	  from	  the	  NK	  cell	  population	  does	  not	  
vary.	  	  The	  variable	  levels	  of	  control	  exhibited	  by	  Tregs	  over	  different	  cell	  types	  highlights	  
a	   range	   of	   roles	   that	   each	   play	   in	   the	   development	   of	   autoimmunity.	   	   The	   large	  
infiltration	  of	  NK	  cells	  implicates	  them	  in	  disease	  progression	  but	  the	  observation	  that	  it	  
is	   only	   their	   release	   of	   pro-­‐inflammatory	   cytokines	   and	   not	   their	   infiltration	   that	   are	  
under	   Treg	   control	   offers	   a	   note	   of	   caution	   when	   assigning	   a	   role	   to	   these	   cell	  
populations.	   	  The	  functions	  of	  NK	  cells	   in	  autoimmunity	  are	  likely	  multi-­‐faceted,	  able	  to	  
exhibit	   their	   own	   regulation	  without	   the	   requirement	   for	   a	   Treg	  presence.	   	   The	  model	  
also	   highlights	   a	   potential	   for	   location	   dependent	   regulation	   as	   IL-­‐17	   production	   was	  






To	  move	  beyond	  Th1	  and	  Th17	  cells,	  an	  attempt	  was	  made	  to	  investigate	  the	  roles	  of	  NK	  
and	  CD8	   cells	   using	   this	  model.	   	   Incorporating	  observations	   from	   the	  base-­‐strain,	   after	  
removal	  of	  Tregs	  in	  L7Fox	  mice	  and	  then	  in	  more	  direct	  antibody	  depletion	  experiments,	  
it	  was	  hoped	  to	  establish	  how	  important	  these	  cells	  were	  to	  disease	  establishment	  and	  
subsequent	  progression.	   	  Upon	  removal	  of	  Tregs,	  NK	  cells	  rapidly	   infiltrate	  the	  CNS	  but	  
the	   lack	   of	   a	   change	   in	   proportion	   compared	   to	   controls	   suggests	   that	   these	   cells	   are	  
more	   likely	   to	   be	   bystanders	   rather	   than	   directly	   involved	   in	  mediating	   inflammation.	  	  
They	  do	  however	  increase	  their	  production	  of	  IFNγ	  upon	  Treg	  depletion	  as	  a	  pathogenic	  
cell	  would,	  and	  also	  upon	  partial	  depletion,	   IFNγ+	  cell	   infiltration	   is	   reduced.	   	  However,	  
under	   the	   partial	   depletion,	   control	   on	   IFNγ	   production	   from	   infiltrating	   CD8+	   cells	  
appears	  to	  be	  released,	  indicative	  of	  removal	  of	  regulation.	  	  	  
In	   response	   to	   Treg	   depletion,	   an	   increased	   infiltration	   of	   CD8	   cells	   and	   most	   of	   the	  
increase	   in	   IFNγ	  production	   is	   indicative	  of	   the	  release	  of	  control	  of	   their	  activation.	   	   It	  
would	   appear	   that	   CD8	   cells	   might	   have	   an	   important	   role	   in	   mediating	  
neuroinflammation	   and	   after	   partial	   depletion	  of	   CD8	   cells,	   lower	   IFNγ+	   cell	   infiltration	  
was	  observed	   to	   support	   this.	   	  However,	   it	   also	   led	   to	   increased	   IFNγ	   production	   from	  
peripheral	   cells	   and	   specifically	   within	   the	   CD4+	   population,	   more	   suggestive	   of	   a	  
regulatory	   role	   and	   supportive	   of	   previous	   studies	   using	   CD8-­‐deficient	   mice	   which	  
showed	  CD8	  cells	  act	  to	  limit	  CD4-­‐mediated	  inflammation	  (Jiang	  1992,	  Koh	  1992).	  	  
Direct	   investigation	   of	   the	   effector	   cell	   dynamics	   in	   the	   model	   was	   not	   completely	  
successful	   and	   so	   limits	   what	   could	   be	   learnt.	   	   Evidence	   could	   be	   taken	   for	   both	  
protective	  and	  pathogenic	  roles	  for	  CD8	  and	  NK	  cells	  in	  this	  autoimmune	  context,	  as	  has	  





Sun	   2001,	   Abdul-­‐Majid	   2003,	   Jiang	   2003,	   Ford	   2005,	   Xu	   2005,	   Winkler-­‐Pickett	   2008)	  
These	  results	  suggest	  that	  likely	  the	  use	  of	  those	  markers	  is	  too	  general	  and	  groups	  many	  
cellular	  subtypes	  together	  (as	  with	  CD4	  including	  Th1,	  Th17	  and	  Treg	  cells)	  that	  should	  be	  
investigated	   individually.	   	   	   It	   may	   be	   more	   informative	   to	   try	   and	   deplete	   simply	   the	  
regulatory	  or	  pathogenic	  subset	  of	  CD8	  cells	  to	  ascertain	  whether	  they	  play	  an	  important	  
role	   (Najafian	   2003,	   Rifa'i	   2004,	   Endharti	   2005).	   	   Hampered	   by	   incomplete	   depletions	  
however	  makes	  it	  additionally	  hard	  to	  draw	  definite	  conclusions	  from	  this	  study	  although	  
further	   investigations	   should	   be	   a	   high	   priority.	   	   In	   this	   vein,	   knockout	  mice	  would	   be	  
more	   relevant	   than	   the	   use	   of	   depleting	   antibodies	   in	   the	   context	   of	   Line7	   disease.	  	  
Therefore	   a	   breeding	   strategy	   has	   been	   initiated	   between	   Line7	   mice	   and	   recently	  
described	  NK	  cell	  knockout	  mice	   (Gascoyne	  2009)	  although	   it	  will	  be	  some	  time	  before	  
results	  from	  this	  cross	  become	  clear.	  
In	  conclusion,	  a	  model	  of	  disease	  could	  therefore	  be	  proposed	  whereby	  the	  presence	  of	  
autoreactive	  T	  cells	  in	  the	  periphery	  of	  a	  Line7	  predicates	  it	  towards	  the	  development	  of	  
autoimmunity.	  	  Tregs	  function	  to	  prevent	  activation	  of	  these	  cells	  and	  infiltration	  across	  
the	  BBB	  into	  the	  CNS.	  	  In	  a	  constant	  battle	  between	  effector	  and	  regulatory	  cells,	  there	  is	  
a	   slow	  accumulation	  of	  effector	   cells	   through	   the	  BBB	   leading	   to	  autoimmunity.	   	   Tregs	  
infiltrate	   the	   CNS	   in	   reaction	   and	   act	   to	   inhibit	   their	   activity	   although	   the	   slow	  
progression	  of	  symptoms	  demonstrates	  the	  gradual	  accumulation	  of	  neurodegeneration.	  	  
In	  mice	  able	  to	  maintain	  strong	  regulation,	  minimal	  effector	  cells	   infiltrate	  the	  CNS	  and	  
autoimmunity	   does	   not	   develop.	   	   The	   main	   requirement	   for	   regulation	   to	   prevent	  





maintenance	  of	  the	  impermeability	  of	  the	  BBB,	  to	  control	  the	  inflammatory	  cell	  presence	  
in	  the	  CNS.	  
This	   could	   be	   parallel	   to	   the	  mechanism	   of	   human	   disease,	   whereby	   individual	   genes	  
impact	   on	   the	   strength	   of	   the	   autoreactive	   or	   regulatory	   T	   cells.	   	   Isolated	   incidents	   of	  
environmental	  stress	  could	  tip	  the	  balance	  temporarily	  in	  favour	  of	  effector	  cells	  leading	  



















12 Innate	  activation	  through	  toll-­‐like	  receptors	  and	  spontaneous	  
autoimmunity	  
12.1 Introduction	  
A	  remaining	  question	  to	  be	  investigated	  with	  the	  L7	  mice	  is	  with	  regard	  to	  the	  triggering	  
event	  that	  leads	  to	  the	  development	  of	  autoimmunity.	  	  As	  signs	  of	  disease	  develop	  in	  the	  
L7	  mice	   spontaneously	   with	   a	   variable	   time	   to	   first	   signs	   and	   40%	   of	   L7	  mice	   do	   not	  
develop	   any	   signs	   of	   disease,	   autoimmunity	   does	   not	   develop	   simply	   as	   a	   result	   of	  
genetic	   pre-­‐determining	   factors,	   in	   a	   similar	   way	   to	   human	   MS.	   	   There	   is	   likely	   an	  
environmental	   influence	   leading	   to	   the	   triggering	   of	   disease	   and	   manipulation	   of	   this	  
event	  by	  small	  environmental	  changes	  is	  possible	  in	  the	  L7	  model	  where	  it	  is	  impossible	  
in	  the	  EAE	  model	  as	  the	  small	  changes	  are	  overwhelmed	  by	  the	  large	  immune	  adjuvants	  
in	  the	  induction	  protocol.	  	  	  
The	  uneven	  worldwide	  distribution	  of	  MS	  points	  towards	  an	  impact	  of	  the	  environment	  
on	   the	   development	   and	   progression	   of	   MS.	   	   Concordance	   rates	   of	   only	   30%	  
demonstrate	   that	   while	   there	   is	   a	   tangible	   genetic	   component	   (Ebers	   1986,	   Dyment	  
2004a),	  there	  is	  a	  great	  deal	  left	  to	  explain	  as	  to	  why	  the	  disease	  initiates.	  	  Whilst	  latitude	  
is	   the	  most	   closely	   correlated	   factor	   with	  MS	   distribution	   (Skegg	   1987,	   Fawcett	   1988,	  
Ebers	   1993),	   such	   a	   description	   is	   used	   purely	   to	   group	   together	   a	   series	   of	  
environmental	   factors	   that	   all	   vary	   in	   a	   similar	   gradient.	   	   Sunshine	   exposure	   and	  
conversely	  vitamin	  D	  levels	  will	  vary	  (Goldberg	  1986)	  but	  so	  will	  local	  temperatures	  and	  





exposed	   to	   on	   a	   daily	   basis.	   	   There	  will	   also	   be	   variation	   in	   the	  microorganisms,	   some	  
pathogenic	  and	  others	  not	  whose	  distribution	  will	  align	  similar	  to	  latitude.	  	  	  
In	  the	  same	  way	  that	  there	  is	  not	  one	  ‘MS	  gene’	  responsible	  for	  disease	  but	  rather	  it	  is	  a	  
polygenic	   condition	   (Kemppinen	   2011),	   each	   environmental	   factor	   is	   likely	   to	   convey	  
variation	   in	   susceptibility	   which	   when	   coupled	   with	   other	   genetic	   and	   environmental	  
factors	   lead	   to	   the	   development	   of	   MS.	   	   Being	   able	   to	   exclude	   certain	   factors	   and	  
investigate	   the	   impact	   of	   one	   on	   its	   own	  will	   allow	  dissection	   of	   any	   impact,	   however	  
small,	   it	   may	   have,	   and	   is	   the	   major	   advantage	   of	   using	   animal	   models,	   where	   the	  
genetics	  and	  other	  environmental	  factors	  can	  be	  controlled	  for.	  
Migration	   studies	   have	   suggested	   that	  movement	   from	  high	   to	   low	   risk	   areas	   conveys	  
protection	   from	   acquiring	  MS	   (Kurtzke	   1993),	   although	   at	   what	   critical	   age	   this	   is	   not	  
appropriate	   remains	   debatable	   (Dean	   1997,	   Hammond	   2000).	   	   This	   suggests	   that	  
exposure	   to	   environmental	   factors	   through	   maturity	   impact	   greatly	   to	   determine	  
susceptibility	  with	  infectious	  or	  endemic	  organisms	  an	  attractive	  candidate.	  	  	  
Toll-­‐like	   receptors	   have	   been	   implicated	   in	   the	   development	   of	   MS	   as	   increased	  
expression	  has	  been	  observed	  in	  CSF	  and	  MS	  brain	  lesions	  and	  also	  in	  EAE	  brains	  (Bsibsi	  
2002,	  Hanisch	  2008).	  	  MyD88	  knockout	  mice,	  lacking	  the	  adaptor	  protein	  for	  many	  TLRs	  
have	  been	  shown	  to	  be	  resistant	  to	  EAE	  (Marta	  2008,	  Cohen	  2010b)	  and	  more	  generally,	  
the	  requirement	  for	  adjuvants	  in	  the	  EAE	  protocol	  suggests	  an	  influence	  of	  TLR	  signaling	  
in	  development	  of	  disease.	   	  M.tuberculosis	   in	  CFA	  activates	  TLR4	  and	  activation	  of	  TLRs	  






Previous	  work	   in	   the	   lab	   showed	  an	   increase	   in	  TLR2	  expression	  which	  correlated	  with	  
the	  development	  of	  disease	  signs	  in	  the	  Line7	  CNS	  although	  it	  was	  unclear	  whether	  this	  
played	   a	   causal	   role	   (Thomas	   Alexandris,	   Msc	   Imperial	   College).	   	   Therefore,	   it	   was	   of	  
interest	   to	  see	  whether	  activation	  of	   this	  pathway	  could	  act	  as	  a	   triggering	  mechanism	  
for	  development	  of	  disease	  in	  the	  Line7	  mice.	  	  The	  addition	  of	  individual	  TLR2	  agonists	  in	  
regular	   doses	   was	   used	   to	   mimic	   continual	   environmental	   exposure	   in	   mice	   already	  
primed	  to	  develop	  autoimmunity.	  	  The	  Line7	  model	  is	  ideal	  to	  work	  with	  in	  this	  context	  
as	   they	   are	   genetically	   susceptible	   to	   development	   of	   autoimmunity	   without	   the	  
requirement	   for	   additional	   adjuvants	   (Ellmerich	   2005),	   but	   still	   require	   an	   unknown	  
triggering	  mechanism	  to	  initiate	  disease.	  	  	  
Responses	  to	  the	   introduction	  of	  TLR2	  agonists	  would	  be	  measured	  not	  only	  by	  clinical	  
score	  but	  also	  T	  cell	  proliferation	  and	  cytokine	  release.	  	  It	  was	  reasoned	  that	  whether	  or	  
not	   TLR2	   agonism	   itself	  may	   be	   sufficient	   to	   trigger	   disease,	   there	  was	   evidence	   from	  
other	  studies	  of	  synergistic	  effects	  to	  increase	  the	  reactivity	  of	  T	  cells	  through	  their	  TCRs	  
(Rudd	  2008)	  which	  may	  itself	  impact	  on	  disease	  in	  this	  model.	  	  In	  addition,	  an	  increase	  in	  
release	   of	   pro-­‐inflammatory	   cytokines	   after	   TLR	   ligation	   could	   accelerate	   T	   cell	  
polarization	  and	  lead	  to	  a	  greater	  likelihood	  of	  developing	  symptoms	  (Reynolds	  2010).	  
TLRs	  are	  activated	  in	  the	  induction	  of	  EAE	  (Waldner	  2004)	  but	  activation	  of	  certain	  TLRs	  
may	  be	  more	  or	  less	  important	  in	  MS.	  	  Activation	  of	  TLRs	  would	  offer	  an	  overlap	  between	  
EAE	  and	  MS	  as	  they	  mediate	  the	  reactivity	  to	  pathogens	  by	  the	  innate	  immune	  system.	  	  
Environmental	  factors	  signaling	  through	  TLRs	  may	  influence	  the	  immune	  system	  and	  act	  
as	   triggering	  mechanisms	   for	   the	  development	  of	  MS.	   	  Production	  of	  pro-­‐inflammatory	  





CII	   could	  both	   influence	  autoreactive	  T	  cells	  and	  aid	   in	   their	  activation	  and	  subsequent	  
initial	  autoimmune	  attack	  (Jack	  2007).	  	  	  
If	   TLR	   ligation	   has	   a	   role	   to	   play	   in	   the	   development	   of	   MS,	   there	   would	   likely	   be	   a	  
difference	  in	  reactivity	  between	  MS	  patients	  and	  healthy	  controls.	   	  This	  could	  be	  either	  
over-­‐reaction	   to	   harmless	   ligands,	   which	   could	   lead	   to	   a	   disproportionate	   immune	  
response	  and	  production	  of	  a	   large	  number	  of	  pro-­‐inflammatory	  T	  cells.	   	   In	  contrast,	  a	  
lower	  response	  to	  TLR	  ligation	  may	  be	  representative	  of	  tolerance.	  	  	  
Tolerance	  is	  an	  adaptive	  mechanism	  that	  acts	  to	  limit	  the	  extent	  and	  duration	  of	  immune	  
activation	   to	   further	   challenges	   by	   an	   antigen.	   	   Should	   a	   TLR	   ligation	   event	   have	  been	  
important	   in	   triggering	   the	   autoimmune	   attack,	  MS	   patients	  would	   be	   expected	   to	   be	  
tolerised	  to	  a	  subsequent	  stimulation	  with	  the	  same	  ligand.	  	  Therefore,	  it	  is	  of	  interest	  to	  
investigate	  whether	   reactivity	   to	  TLR	   ligands	   is	   affected	   in	  MS	  patients	  with	   respect	   to	  
controls.	   	  Any	  disparity	  will	   add	   further	   support	   to	   the	   role	  of	  TLR	   ligands	   in	   the	   initial	  
autoimmune	  attack	  in	  MS.	  	  
As	   an	   attempt	   to	   identify	   a	   difference,	   a	   panel	   of	   TLR	   agonists	   was	   used	   to	   stimulate	  
whole	  blood	  derived	   from	  patients	  and	  matched	  healthy	   controls.	   	   The	   release	  of	  pro-­‐
inflammatory	   cytokine	   TNFα	   was	   measured	   by	   ELISA	   to	   determine	   any	   differences	   in	  
stimulation	  in	  response	  to	  each	  of	  the	  stimulants	  in	  the	  panel.	  	  	  	  	  
It	  has	  been	  shown	  that	  systemic	  challenge	  to	  TLR	  ligands	  can	  lead	  to	  cross-­‐tolerance	  to	  
signaling	   through	  other	  TLRs	   (de	  Vos	  2009)	  which	   should	  mean	   that	  where	  a	  person	   is	  
tolerised	   to	   a	   specific	   TLR	   ligand,	   changes	   in	   cytokine	   production	  would	   be	   detectable	  





Whilst	  not	  being	  a	  comprehensive	  study	  into	  environmental	  factors	  in	  the	  development	  
of	  MS,	   these	  experiments	  offer	   indications	  as	   to	  whether	  TLR	  agonism	   is	   an	   important	  
























12.2.1 Introduction	  of	  TLR2	  Agonists	  to	  Line7	  Mice	  
Previous	   observations	   in	   the	   Line7	   mouse	   model	   showed	   that	   TLR2	   expression,	   as	  
measured	   by	   real-­‐time	   PCR,	   correlated	   with	   disease	   progression.	   	   In	   order	   to	   try	   and	  
ascertain	  whether	  this	  was	  a	  causative	  rather	  than	  just	  correlative	  effect,	  TLR2	  agonists	  
were	   introduced	   into	   groups	   of	   4	   (2	  male,	   2	   female)	   Line7	  mice	   to	   see	   whether	   they	  
could	  act	  as	  a	  trigger,	  upregulating	  TLR2	  expression	  and/or	  supplying	  evidence	  for	  a	  role	  
in	   initiating	  disease	   in	   these	  mice.	   	   In	   the	  controlled	  housing	  of	   the	  mouse	   facility,	   the	  
introduction	  of	  these	  agonists	  would	  be	  the	  only	  environmental	  factor	  different	  between	  
highly	  MS-­‐susceptible	  mice.	  	  PBS	  was	  administered	  in	  a	  separate	  group	  to	  control	  for	  the	  
influence	  of	  the	  immunisation	  protocol.	  
3	  TLR2	  agonists	  were	  selected	  based	  upon	  their	  different	  organisms	  of	  origin.	  	  LPS	  derives	  
from	   gram-­‐negative	   bacteria,	   LTA	   from	   gram-­‐positive	   bacteria	   and	   LM-­‐MS	   from	  
mycobacteria.	   	   LPS	   stimulates	   both	   TLR2	   and	   TLR4,	   LM-­‐MS	   induces	   the	   release	   of	  
cytokines	  including	  IL-­‐8	  and	  TNFα	  in	  a	  TLR2	  and	  MyD88	  dependent	  but	  TLR4	  independent	  
manner,	   and	   LTA	   also	   stimulates	   the	   release	   of	   pro-­‐inflammatory	   cytokines	   including	  
TNFα.	   	   It	   was	   therefore	   also	   of	   interest	   to	   see	  whether	   different	   agonists	   could	   show	  
different	  potencies	   for	   triggering	  autoimmunity.	   	   Immunizations	  were	  administered	   i.p.	  
every	  Monday	  and	  Friday	  for	  three	  weeks	  so	  a	  total	  of	  6	  injections	  were	  given	  per	  mouse.	  	  
Mice	   were	   culled	   three	   weeks	   after	   the	   commencement	   of	   the	   study	   as	   this	   was	   the	  
maximum	  length	  of	  time	  permitted	  under	  the	  guidelines	  of	  Professor	  Altmann’s	  project	  
licence	   for	   such	   an	   experiment.	   	   The	   dose	   size	   of	   each	   agonist	   was	   determined	   after	  





to	   likely	   scale	   of	   agonist	   seen	   in	   the	   human	   context.	   	   Dose	   sizes	   were	   selected	   that	  
ensured	   that	   the	   dosing	   regime	   would	   not	   exceed	   the	   lethal	   dose	   but	   as	   there	   were	  
limited	  preceding	  studies	  using	  a	  continual	  exposure	  in	  mice	  as	  in	  this	  investigation,	  the	  
doses	   were	   estimated	   in	   an	   attempt	   to	   try	   and	   model	   small	   non-­‐life	   threatening	  
infections	  similar	  to	  continual	  environmental	  exposure.	  	  A	  lack	  of	  availability	  of	  mice	  and	  
duration	   of	   the	   experiment	   hindered	   detailed	   range-­‐finding	   experiments	   of	   dose	   size,	  
which	  would	  have	  been	  beneficial	  to	  do.	  	  	  	  
The	   CNS	   and	   a	   small	   piece	   of	   spleen	   tissue	   were	   extracted	   from	   all	   mice	   and	  
homogenised	  in	  Trizol	  for	  RNA	  extraction,	  whilst	  cells	  were	  extracted	  from	  the	  remaining	  











TLR2	  agonists	  were	  administered	   to	  mice	  on	  days	   indicated	  by	  arrows	   (A),	  mice	   scored	  
daily	  and	  average	  disease	  scores	  are	  plotted	  for	  each	  group	  (n=4	  per	  group).	  	  mRNA	  was	  
extracted	  from	  spinal	  cord	  tissue	  of	  L7	  mice	  receiving	  TLR2	  agonists	  or	  PBS	  taken	  at	  the	  
end	  of	   the	  study.	   	  Relative	  expression	  of	  spinal	  cord	  mRNA	  transcripts	   from	  each	  group	  
was	  compared	  to	  PBS	  control	  as	  measured	  by	  real-­‐time	  PCR	  using	   individually	  designed	  
hydrolysis	   probe	   based	   assays	   and	   analysed	   using	   REST	   software	   (B)	   n=4	   per	   group,	   *	  
denotes	   significance	   compared	   to	   PBS	   control	   expression	   (p<0.05)	   (randomisation	  
analysis).	   	   Mean	   cellular	   proliferation	   of	   lymphocytes	   extracted	   from	   the	   spleens	   of	  
individual	  mice	   (n=4	  per	   group)	   ±SEM	   in	   response	   to	  25μg/ml	  MBP85-­‐99	   (C),	   50μg/ml	  of	  
other,	   ‘myelin	   spread’	   epitopes	   (D)	   assessed	   after	   4	   day	   stimulation	   by	   thymidine	  
incorporation.	   	   Cytokine	   secretion	   from	   these	   stimulated	   cells	   measured	   by	   ELISA	   (E).	  	  
Asterisks	  denote	   statistical	   significance	  between	   two	  groups;	  *	  p<0.05,	  **	  p<0.01	   (two-­‐
tailed	  T	  test).	  
	  
The	  introduction	  of	  each	  of	  the	  3	  TLR2	  agonists	  had	  no	  effect	  on	  disease	  initiation	  per	  se	  
across	  the	  time	  frame	  of	  the	  study	  and	  no	  mice	  developed	  any	  symptoms	  (Figure	  25A).	  	  
To	   assess	   whether	   any	   pathways	   had	   been	   activated	   by	   the	   introduction	   of	   these	  
agonists,	   the	   transcription	   profile	   of	   the	   spinal	   cord	   and	   spleen	   (data	   not	   shown)	  was	  
examined	   by	   real-­‐time	   PCR	   and	   analysed	   by	   REST	   software.	   	   Genes	   tested	   included	   a	  
range	  of	  TLRs,	  and	  a	  selection	  of	  pro-­‐inflammatory	  cytokines	  thought	  to	  be	  important	  in	  
the	  development	  of	  autoimmunity.	  	  Expression	  levels	  of	  gene	  transcripts	  were	  compared	  
to	   those	   seen	   in	   the	  PBS	   control	  mice	   and	   a	   relative	   expression	   level	   determined.	   	  No	  





spleen	  as	  a	  result	  of	  TLR	  agonist	  immunisation	  (Figure	  25B),	  suggesting	  that	  it	  is	  unlikely	  
that	   the	   introduction	   of	   the	   TLR2	   agonists	   had	   much	   effect	   at	   this	   time	   point.	  	  
Observation	   earlier	   in	   the	   study	   may	   have	   yielded	   different	   results	   but	   if	   sub-­‐clinical	  
autoimmunity	   was	   developing	   then	   transcript	   levels	   would	   still	   be	   expected	   to	   be	  
elevated.	  	  	  
In	   order	   to	   see	  whether	   the	   agonists	   had	   other	   effects	   aside	   from	   stimulation	   of	   pro-­‐
inflammatory	   cytokine	   release,	   lymphocytes	   were	   extracted	   from	   the	   spleen	   and	  
assessed	  for	  their	  proliferative	  potential	  to	  MBP85-­‐99	  and	  other	  myelin	  antigens	  to	  which	  
epitope	  spread	  has	  previously	  been	  reported	  in	  this	  model	  (Ellmerich	  2005).	  	  Line7	  TCRs	  
are	   specific	   for	   MBP85-­‐99	   and	   so	   initial	   autoimmunity	   is	   assumed	   to	   be	   mediated	   by	  
recognition	  of	   this	   antigen	   in	   vivo.	   	   As	  disease	  develops,	  mice	   show	   reactivity	   to	  other	  
myelin	  epitopes	  and	  so	  these	  were	   included	  to	  determine	  whether	  such	  a	  process	  may	  
be	   accelerated	   by	   TLR	   stimulation.	   	   Proliferative	   responses	   of	   T	   cells	   by	   thymidine	  
incorporation	  was	  measured	  after	  cell	   culture	   in	   the	  presence	  of	  myelin	  peptides	   for	  4	  
days	   and	   a	   two-­‐tailed	   t	   test	   used	   to	   determine	   statistical	   significance	   of	   differences	  
between	  means.	   	  This	  showed	  that	  cells	  from	  those	  mice	  receiving	  TLR2	  agonists	  had	  a	  
trend	  towards	  being	  more	  responsive	  to	  MBP85-­‐99.	  	  Significantly	  higher	  responsiveness	  to	  
spread	  epitope	  αBcrystallin161-­‐175	  was	   seen	   from	  mice	   receiving	   LTA	  and	   LM-­‐MS.	   	  Mice	  
receiving	  LTA	  also	  showed	  	  a	  trend	  towards	  higher	  proliferation	  in	  response	  to	  MOG82-­‐96	  
but	  no	  other	  increased	  responses	  were	  observed	  from	  mice	  receiving	  any	  TLR2	  agonist	  to	  
any	  of	   the	  spread	  epitopes	  of	  myelin	  antigens	   (Figure	  25C,D).	   	   	  Addition	  of	  LM-­‐MS	  and	  
LTA	   lead	   to	   a	   trend	   towards	   upregulated	   proliferative	   responses	   to	   αBcrystallin161-­‐175	  





towards	   increased	   proliferation	   in	   response	   to	  MBP38-­‐59	   (Figure	   25D).	   	   LPS	   elicited	   no	  
significant	  change	  in	  proliferative	  potential	  to	  any	  peptide	  tested.	  
In	   contrast	   to	   the	   proliferation	   data,	   when	   the	   cytokine	   profiles	   of	   responding	   T	   cells	  
were	  compared	  between	  Line7	  mice	   in	  the	  presence	  of	  absence	  of	  TLR2	  agonists,	  clear	  
differences	  were	  found	  in	  the	  nature	  of	  the	  autoimmune	  response.	  	  Cytokine	  release	  was	  
measured	   by	   cytokine-­‐specific	   ELISA	   on	   cell	   culture	   supernatants	   extracted	   from	   the	  
MBP85-­‐99	  stimulated	  cell	  cultures.	  	  	  
Levels	  of	  IL-­‐17	  were	  barely	  detectable	  from	  any	  culture,	  either	  from	  those	  mice	  that	  had	  
received	   a	   TLR2	   agonist	   or	   the	   PBS	   control,	   demonstrating	   that	   this	   cytokine	   was	   not	  
produced	   in	   response	   to	   MBP85-­‐99	   stimulation.	   	   Cells	   from	   all	   mice	   receiving	   a	   TLR2	  
agonist	   released	   a	   comparable	   amount	  of	   IFNγ	   to	   those	   receiving	   the	  PBS	   control,	   but	  
there	   was	   a	   trend	   towards	   reduced	   IFNγ	   release	   from	  mice	   receiving	   LPS	   and	   LM-­‐MS	  
which	   did	   not	   achieve	   statistical	   significance	   (Figure	   25E).	   	   This	   would	   suggest	   an	  
impaired	  response	  to	  MBP85-­‐99	  which	  may	  be	  responsible	  for	  the	  lack	  of	  disease	  initiation	  
observed.	   	   In	   support	   of	   this	   theory,	   somewhat	   surprisingly,	   higher	   amounts	   of	   IL-­‐10	  
were	   released	   in	   mice	   that	   received	   LM-­‐MS	   and	   LTA	   compared	   to	   the	   PBS	   control	  
whereas	   mice	   receiving	   LPS	   released	   comparable	   levels	   of	   IL-­‐10	   to	   the	   control	   mice	  
(Figure	  25E).	   	  Taken	  together,	   the	  reduction	   in	   IFNγ	  and	   increase	   in	   IL-­‐10	  released	  may	  
suggest	  that	  after	  the	  immunisation	  regime	  and	  subsequent	  re-­‐stimulation,	  the	  agonists	  
may	   not	   be	   stimulating	   the	   cells	   towards	   a	   pro-­‐inflammatory	   pathway	   anymore.	  	  
Cytokine	   release	   from	   cultures	   stimulated	  with	   spread	   epitopes	  was	   not	   detectable	   at	  





Despite	   the	   failure	   of	   mice	   to	   develop	   signs	   of	   disease,	   and	   the	   limited	   variation	  
generated	   in	  gene	  transcription,	  the	   increased	  proliferative	  responses,	  especially	  to	  the	  
spread	   epitopes	   were	   encouraging	   as	   this	   is	   only	   usually	   seen	   in	   mice	   that	   have	  
progressed	  through	  to	  full	  paralysis.	  	  	  
Working	  on	  the	  hypothesis	  that	  the	  doses	  of	  TLR	  agonist	  used	  had	  been	  too	  low	  to	  elicit	  
sufficiently	   large	   immune	   responses	   in	   the	   mouse,	   the	   agonist	   showing	   the	   strongest	  
proliferative	  responses,	  LTA,	  was	  selected	  and	  administered	  to	  5	  (2	  male,	  3	  female)	  Line7	  
mice	   at	   a	   higher	   dose.	   	   The	   same	  dosing	   regime	  was	   used,	   so	   that	  mice	   received	   two	  
doses	  per	  week	  and	  were	  culled	  three	  weeks	  after	  the	  first	  dose.	  	  PBS	  was	  administered	  
to	   a	   matched	   group	   of	   mice	   under	   the	   same	   protocol	   to	   act	   as	   a	   control	   for	   regular	  








Figure	  26.	  	  Administration	  of	  a	  higher	  dose	  of	  one	  TLR2	  agonist	  has	  no	  effect	  on	  disease	  
initiation.	  	  	  
LTA	  was	  administered	   to	  mice	  on	  days	   indicated	  by	  arrows	   (A),	  mice	   scored	  daily	   	   and	  





from	  spinal	  cord	  tissue	  of	  L7	  mice	  receiving	  TLR2	  agonists	  or	  PBS	  taken	  at	  the	  end	  of	  the	  
study.	   	   Relative	   expression	   of	   spinal	   cord	   derived	   mRNA	   transcripts	   from	   the	   group	  
receiving	  LTA	  compared	   to	  PBS	  control	  as	  measured	  by	   real-­‐time	  PCR	  using	   individually	  
designed	   hydrolysis	   probe	   based	   assays	   and	   analysed	   using	   REST	   software	   (B)	   n=5	   per	  
group,	   *	   denotes	   significance	   compared	   to	   PBS	   control	   expression	   (p<0.05)	  
(randomisation	  analysis).	  
	  
Despite	  the	  increase	  in	  dose	  of	  TLR2	  agonist,	  no	  disease	  initiation	  was	  observed	  (Figure	  
26A).	  	  Samples	  from	  the	  CNS	  and	  spleen	  were	  taken	  as	  before	  for	  both	  analysis	  of	  mRNA	  
production	  and	  cellular	  proliferation	  responses.	   	  Measurement	  of	  gene	  transcription	  by	  
real-­‐time	  PCR	  was	  carried	  out	  for	  pro	  and	  anti-­‐inflammatory	  cytokines,	  as	  well	  as	  TLR2,	  
Foxp3	  and	  Clusterin,	  a	  protein	  involved	  in	  amyloid	  formation	  and	  clearance	  that	  has	  been	  
linked	  to	  the	  development	  of	  multiple	  sclerosis	  as	  well	  as	  an	  association	  with	  Alzheimer’s	  
disease,	  another	  neurodegenerative	  condition	  (Stoop	  2009,	  Thambisetty	  2010).	  	  Analysis	  
was	   done	   using	   REST	   software	   which	   also	   calculated	   statistical	   significance.	   	   No	  
significant	  change	  in	  gene	  expression	  was	  observed	  between	  the	  mice	  administered	  LTA	  
and	   those	   administered	   PBS	   (Figure	   26B)	   that	   would	   suggest	   early	   stages	   of	   disease	  
initiation.	  	  iNOS	  was	  included	  in	  this	  analysis,	  as	  it	  is	  known	  to	  be	  produced	  by	  microglia	  
in	  response	  to	  MBP-­‐specific	  T	  cells	  (Dasgupta	  2002)	  but	  it	  showed	  no	  variable	  expression	  
which	  would	  have	  been	  expected	  if	  autoimmunity	  had	  been	  triggered.	  	  Extracted	  spleen	  
cells	   were	   stimulated	   with	   the	   same	   panel	   of	   myelin	   peptides	   as	   in	   the	   previous	  
experiment	   for	   4	   days	   and	   supernatants	   collected	   for	   analysis	   of	   cytokine	   release.	  	  





The	   failure	  of	  any	  signs	  of	  disease	   to	  develop	  or	   there	   to	  be	  any	  significant	  changes	   in	  
gene	  expression	  meant	  that	  the	  experiment	  was	  not	  repeated	  to	  generate	  this	  data.	  	  Cell	  
culture	  supernatants	  were	  also	  not	  analyzed	  as	  there	  was	  no	  evidence	  that	  they	  would	  
show	  results	  different	  to	  the	  previous	  observations.	  
12.2.2 Responses	  to	  TLR	  Ligation	  in	  MS	  Patients	  
An	  environmental	   trigger	   for	  MS	   is	  an	  attractive	  hypothesis	  as	   this	  might	  open	  options	  
for	   therapeutic	   intervention	   or	   lifestyle	  modification	   interventions,	   and	   could	   go	   some	  
way	   to	   explaining	   the	   geographical	   distribution	  of	   the	  disease	  observed.	   	   TLR	   signaling	  
could	   provide	   mediation	   for	   the	   initial	   immune	   insult	   that	   could	   trigger	   the	   first	  
autoimmune	  attack.	   	  Evidence	  for	  such	  an	  event	  may	  be	  detected	  through	  tolerance	  to	  
TLR	   ligands,	   suggestive	   of	   previous	   stimulation	   at	   a	   level	   above	   that	   seen	   in	   healthy	  
controls.	  
In	  an	  attempt	  to	  investigate	  whether	  previous	  TLR	  agonism	  could	  play	  a	  role	  as	  triggers	  
for	   disease	   initiation,	   a	   panel	   of	   TLR	   and	   NBOD	   agonists	   (Table	   14)	   was	   created	   to	  
stimulate	  whole	  blood	  extracted	  from	  10	  MS	  patients.	  	  By	  comparing	  their	  responses	  to	  
those	  of	  8	  age	  and	  sex	  matched	  healthy	  controls,	   it	  would	  be	  possible	  to	  see	  there	  are	  
any	   differences	   in	   the	   innate	   immune	   responses	   that	   could	   be	   characteristic	   of	   MS	  
patients	  and	  suggestive	  of	  over-­‐reaction	  or	  tolerance	  to	  innate,	  environmental	  activation.	  
In	   particular,	   the	   hypothesis	   was	   that,	   it	   may	   be	   possible	   to	   uncover	   a	   footprint	   of	  
ongoing	  TLR	  agonism	  through	  the	  detection	  of	  functional	  down-­‐modulation	  of	  particular	  
pathways,	  as	  has	  been	  described	  in	  other	  diseases	  (Biswas	  2009,	  De	  Nardo	  2009,	  de	  Vos	  
2009).	   	   TNFα	   ELISA	   was	   chosen	   as	   a	   read-­‐out	   as	   it	   has	   been	   shown	   to	   be	   a	   pro-­‐







Figure	  27.	  	  Lower	  reactivity	  to	  TLR	  agonists	  by	  MS	  patients.	  	  	  
Whole	  blood	  from	  MS	  patients	  and	  healthy	  controls	  diluted	  1/10	  and	  stimulated	  with	  TLR	  
and	   NBOD	   agonist	   panel.	   	   Supernatants	   aspirated	   after	   24hr	   stimulation	   and	   TNFα	  
secretion	   measured	   by	   ELISA.	   	   Differential	   responses	   recorded	   for	   MS	   patients	   (white)	  
(n=10)	   and	   age	   and	   sex	   matched	   healthy	   controls	   (black)	   (n=8).	   	   Bars	   show	   average	  
response	   for	   each	   group	  with	   the	   SEM.	   	   *	   shows	   significance	   between	   groups	   (p<0.05	  







When	   the	   relative	   responses	   of	   MS	   patients	   are	   compared	   to	   those	   seen	   from	   the	  
healthy	  controls,	   it	   is	  clear	   that	   the	  MS	  patients’	   response	  to	  the	  TLR	  agonists	  was	   less	  
than	   that	  of	   the	  healthy	   controls.	   	  Not	   all	   of	   the	  agonists	   in	   the	  panel	   elicited	  positive	  
responses,	   and	   cytokine	   release	   could	   not	   be	   detected	   after	   stimulation	   with	   some	  
agonists	   from	   both	   the	   MS	   patient	   and	   healthy	   control	   groups	   (data	   not	   shown	   on	  
graph).	   	   It	  was	  possible	  to	  detect	  cytokine	  release	  after	  stimulation	  with	  8	  TLR	  agonists	  
alongside	  the	  positive	  control	  and	  using	  these,	  compare	  the	  relative	  responses	  between	  
MS	  patients	  and	  healthy	  controls.	  	  The	  only	  significantly	  different	  responses	  between	  MS	  
patients	  and	  controls	  were	  to	  HKLM	  (TLR2),	  PGN-­‐SA	  (TLR2)	  and	  Flagellin	  (TLR5).	  	  The	  MS	  
patients’	  response	  to	  these	  agonists	  were	  lower	  than	  the	  healthy	  controls	   in	  each	  case.	  	  
In	  a	  similar	  way,	  there	  were	  trends	  towards	  weaker	  responses	  to	  LPS	  (TLR2),	  PGN-­‐EColi	  
(TLR2),	   Pam3CSK4	   (TLR1/2)	   and	  MDP	   (NBOD2)	   (Figure	  27)	   in	  MS	  patients	   compared	   to	  
healthy	   controls	   but	   none	  of	   these	   reached	   statistical	   significance.	   	   The	  other	   agonists	  
(not	  shown)	  did	  not	  elicit	   responses	  higher	   than	   the	  baseline	  samples	   in	  either	   the	  MS	  
patient	   or	   healthy	   control	   groups	   and	   so	   were	   not	   considered	   to	   have	   successfully	  
stimulated	  the	  blood	  samples.	  	  No	  response	  from	  the	  MS	  patients	  to	  any	  TLR	  agonist	  was	  
in	   excess	   of	   that	   by	   the	   healthy	   controls	   showing	   a	   dampened	   innate	   activation	   as	   a	  
result	  of	  MS	  disease.	  	  	  
The	   absolute	   size	   of	   the	   response	   to	   each	   agonist	   can	   be	   misleading	   in	   this	   context	  
however	  as	  the	  doses	  for	  each	  agonist	  were	  not	  uniform	  to	  each	  other	  so	  it	   is	  only	  the	  
relative	  responses	  between	  patient	  and	  HC	  samples	  that	  are	  worth	  comparing.	  	  This	  data	  
does	  not	  demonstrate	  an	  over-­‐reactive	   response	   to	  TLR	  stimulation	   that	  could	  act	  as	  a	  





whether	   the	   lower	   responses	   are	   due	   to	   a	   systemic	   suppression	   or	   previous	   over-­‐

























Incomplete	   concordance	   of	   MS	   between	   monozygotic	   twins	   among	   other	   factors	  
illustrates	   an	   important	   environmental	   influence	   in	   the	   development	   of	   MS	   (Bulman	  
1991).	   	  Mirroring	   that,	  a	  percentage	  of	   Line7	  mice	   that	   fail	   to	  develop	   signs	  of	  disease	  
demonstrating	   that	   there	   must	   be	   a	   triggering	   point	   for	   disease	   initiation.	   	   Bringing	  
together	  the	  geographical	  distribution	  of	  MS	  and	  the	  success	  of	  EAE	  as	  a	  model	  for	  MS,	  
TLR	   ligation	   is	   an	   attractive	   target	   to	   influence	   the	   immune	   system	   and	   provide	   the	  
metaphorical	  straw	  that	  broke	  the	  camel’s	  back.	   	   It	   is	  difficult	  to	   investigate	  the	  role	  of	  
TLR	   ligation	   in	   the	  development	  of	   EAE	  because	   the	  method	  of	   induction	   requires	   TLR	  
ligation	  to	  break	  tolerance,	  often	  using	  M.tuberculosis	  in	  CFA	  that	  acts	  to	  stimulate	  TLR4.	  	  
In	   support,	   MyD88-­‐/-­‐	   mice,	   lacking	   the	   adaptor	   protein	   for	   almost	   all	   TLRs	   have	   been	  
shown	   to	   be	   resistant	   to	   EAE	   induction	   (Prinz	   2006).	   	   Therefore,	   models	   with	  
spontaneous	  disease	  would	  offer	  better	  and	  more	  relevant	  situations	  in	  which	  to	  assess	  
the	  importance	  of	  TLR	  ligation	  without	  the	  large	  effect	  of	  inducing	  adjuvants.	  	  
Attempts	   using	   other	   TCR	   transgenic	   mice,	   that	   exhibit	   low	   levels	   of	   spontaneous	  
disease,	   appear	   to	   have	   identified	   a	   role	   for	   TLR	   ligands	   in	   disease	   initiation	   (Waldner	  
2004).	  	  However,	  these	  studies	  have	  been	  limited	  as	  they	  still	  rely	  on	  the	  concept	  of	  EAE	  
to	   initiate	  disease.	   	   In	   these	  cases,	  different	  TLR	   ligands	  were	   immunized	  alongside	   IFA	  
(lacking	   M.	   tuberculosis)	   and	   followed	   with	   a	   protocol	   of	   Pertussis	   toxin	   injection.	  	  
Therefore	  they	  have	  simply	  substituted	  one	  TLR	   ligand	  for	  another	   in	  the	  protocol,	  and	  
rather	   than	  prove	   the	   requirement	   for	  TLR	   ligands	   in	  MS,	  have	   simply	  proved	   they	  are	  





Using	  the	  Line7	  mice,	  which	  does	  not	  require	  any	  adjuvants	  to	  initiate	  disease	  in	  a	  high	  
percentage	  of	  mice	  provides	  a	  more	  attractive	  and	  realistic	  experimental	  model.	  	  In	  this	  
situation,	  the	  introduction	  of	  TLR	  ligands	  should	  appear	  as	  small	  environmental	  insults	  to	  
which	   mice	   can	   respond	   with	   competent	   immune	   systems.	   	   However,	   initiation	   of	  
disease	  was	  not	  seen	  after	  such	  an	   introduction	  of	  TLR	   ligands.	   	  Mice	  appeared	  normal	  
with	   no	   signs	   of	   sub-­‐clinical	   disease	   after	   the	   course	   of	   immunisations	  when	   CNS	   and	  
peripheral	  transcriptional	  profiles	  were	  measured.	  	  	  Trends	  towards	  greater	  reactivity	  to	  
MBP85-­‐99	  hinted	  at	  possible	  activation	  but	  with	  higher	  IL-­‐10	  release	  from	  this	  stimulation,	  
it	   is	   likely	   not	   generating	   the	   pro-­‐inflammatory	   responses	   required	   to	   initiate	  
neuroinflammation.	   	   Indeed,	   the	   regular	  doses	  may	  have	  acted	   to	   tolerize	  mice	   to	   the	  
TLR	  ligands	  and	  a	  variable	  dosing	  regime	  would	  lead	  to	  more	  success.	  	  A	  higher	  dose	  of	  
LTA	  did	  not	  increase	  disease	  initiation	  suggesting	  either	  that	  it	  was	  still	  not	  high	  enough	  
or	  that	  it	  was	  too	  high	  and	  tolerance	  was	  once	  again	  induced.	  
This	  experiment	  was	  an	  attempt	  to	  investigate	  the	  role	  played	  by	  TLR2	  in	  Line7	  disease	  
progression.	  	  Previous	  observations	  that	  TLR2	  expression	  increased	  in	  the	  CNS	  as	  disease	  
severity	  increased	  did	  not	  provide	  a	  clear	  evidence	  to	  distinguish	  between	  a	  causative	  or	  
simply	  correlative	  relationship.	  	  This	  study	  would	  lend	  support	  to	  the	  expression	  increase	  
being	   a	   simple	   correlation	   of	   disease	   severity.	   	   The	   increased	   expression	   could	   be	  
attributed	   to	   an	   increase	   in	   cellular	   infiltrate	   rather	   than	  upregulation	  of	   the	   receptor.	  	  
Activation	   through	   TLR2	   does	   not	   appear	   directly	   responsible	   for	   initiation	   of	   disease	  
although	  a	  role	  in	  further	  development	  once	  disease	  is	  established	  cannot	  be	  ruled	  out.	  	  	  
The	  triggering	  mechanism	  itself	  may	  also	  be	  more	  complicated.	  	  As	  with	  the	  development	  





disease,	   it	  would	  be	   logical	   to	   conclude	   that	   in	   Line7	  and	  human	  disease,	  a	  number	  of	  
insults	  would	  be	  present,	  and	  their	  timing	  relevant,	  to	  trigger	  autoimmunity	  to	  develop	  in	  
an	  otherwise	  healthy	  individual.	  	  	  
Despite	   not	   achieving	   its	   original	   aim,	   an	   intriguing	   observation	   was	   the	   increased	  
proliferation	   in	   response	   to	   myelin	   spread	   epitopes.	   	   Reactivity	   to	   these	   epitopes	   is	  
usually	  associated	  with	  progression	  through	  disease	  (Ellmerich	  2004,	  Davies	  2005)	  and	  so	  
it	   may	   be	   that	   TLR	   activation	   aids	   to	   widen	   the	   scope	   of	   reactivity	   for	   T	   cells.	  	  
Extrapolating	   this	   could	   provide	   a	   mechanism	   for	   generation	   of	   relapses	   following	  
environmental	  insults,	  although	  this	  would	  need	  to	  be	  studied	  much	  more	  specifically.	  	  	  
Data	   from	   the	   MS	   patients	   indicated	   a	   lower	   response	   to	   TLR	   ligands	   compared	   to	  
healthy	   controls.	   	  Whether	   this	   is	   directly	   relevant	   to	   the	   development	   of	   the	   human	  
condition	   is	   still	   unclear.	   	   Previous	   stimulation	   through	   TLRs	   has	   been	   shown	   to	   be	  
sufficient	   to	  drive	  development	  of	  TLR	   tolerance,	   through	  mechanisms	   including	  down-­‐
regulation	   of	   receptors,	   immune	   cell	   apotopsis	   and	   alterations	   of	   signaling	   pathways	  
(Biswas	   2009,	   De	   Nardo	   2009,	   de	   Vos	   2009).	   	   Tolerance	   to	   previously	   encountered	  
pathogens	  is	  of	  benefit	  to	  prevent	  disproportionate	  immune	  responses	  that	  could	  lead	  to	  
endotoxin	   shock	  and	  substantial	   tissue	  damage.	   	   Such	   tolerance	   to	  TLR	   ligands	  may	  be	  
characteristic	   of	   previous	   signaling	   through	   these	   receptors	   and	   the	   lower	   responses	  
demonstrating	   greater	   exposure	   to	   TLR	   ligands	   in	   earlier	   life.	   	  Whether	   such	   exposure	  
and	   the	   subsequent	   reaction	   is	   reflective	   of	   local	   environments	   or	   genetic	   differences	  
between	  individuals	  can	  not	  be	  determined.	  	  How	  an	  individual	  reacts	  to	  insults	  early	  in	  
life	   is	   likely	   determined	   by	   their	   genetics	   and	   so	   could	   offer	   a	   link	   between	   genetic	  





Most	   of	   the	   patients	   who	   donated	   blood	   were	   on	   treatment	   or	   had	   previously	   been	  
receiving	   treatment.	   	  This	   could	  mean	   that	   the	   immune	  dampening	  observed	   is	  due	   to	  
immune	   suppression	   elicited	   by	   these	   therapies	   or	   their	   own	   body	   in	   response	   to	   a	  
relapse.	  	  Whether	  the	  patients	  were	  currently	  experiencing	  a	  relapse	  or	  had	  recently	  was	  
not	   consistently	   recorded	   and	   so	   unfortunately	   hinders	   use	   of	   this	   factor	   for	  
interpretation	  of	  the	  results.	  	  It	  would	  be	  more	  interesting	  to	  test	  blood	  donated	  from	  a	  
cohort	  of	  MS	  patients	  before	  treatment	  strategies	  are	  started,	  as	  these	  responses	  would	  
be	  more	  relevant	  to	  control	  for	  the	  effect	  of	  the	  disease	  alone.	  	  	  
A	  lower	  overall	  innate	  response	  could	  be	  indicative	  of	  compromised	  immune	  responses,	  
rather	   than	   induced	   tolerance	   to	   previous	   exposure.	   However,	   even	   both	   could	   have	  
implications	  for	  the	  development	  of	  MS	  as	  general	  immune	  suppression	  would	  be	  a	  poor	  
way	  to	  fight	  autoimmunity	  and	  would	  suggest	  that	  the	  function	  of	  regulatory	  pathways	  is	  
impaired.	   	  Distinguishing	  between	  these	  two	  hypotheses	  would	  determine	  whether	  TLR	  
ligation	   had	   a	   role	   to	   play	   in	   the	   initial	   development	   of	   MS.	   	   The	   difficulty	   of	   such	  
experiments	  is	  that	  measurement	  is	  done	  after	  disease	  is	  established	  and	  so	  may	  not	  be	  
directly	   relevant	   to	   the	   early	   stages	   of	   disease.	   	  Without	   relying	   on	   animal	   studies,	   it	  
would	   be	   interesting	   to	   compare	   reactivity	   of	   individuals	   to	   TLR	   ligands	   over	   a	  
longitudinal	   time	   frame	   or	   those	   suffering	   from	   initial	   neurological	   attacks	   (clinically	  
isolated	   syndrome	   (CIS)	   patients).	   	   These	   samples	   would	   be	   more	   relevant	   to	   early	  






13 Final	  Discussion	  
13.1 Usefulness	  of	  Animal	  Models	  
Findings	  in	  animal	  models	  hold	  great	  impact	  it	  the	  research	  community	  as	  they	  are	  much	  
faster	  to	  do,	  with	  higher	  reproducibility	  than	  work	  in	  humans.	  	  Our	  understanding	  of	  MS	  
pathogenesis	  is	  much	  greater	  with	  their	  use	  but	  because	  of	  the	  relatively	  small	  number	  
of	  widely	  used	  models,	  the	  question	  has	  to	  be	  asked	  whether	  we	  are	  actually	  finding	  out	  
relevant	   details	   for	   human	  disease	   or	   just	   investigating	   nuances	   in	   the	   animal	  models.	  	  
TCR	  transgenic	  models	  have	  provided	  much	  greater	  specificity	  to	  disease	  and	  tolerance	  
research,	   but	   despite	   the	   first	   model	   being	   described	   23	   years	   ago	   (Kisielow	   1988a),	  
there	  are	  still	  only	  a	  handful	  being	  used	  as	  pre-­‐clinical	  models	  for	  any	  given	  condition.	  	  In	  
MS	  research,	  there	  considerable	  reliance	  on	  EAE,	  and	  the	  adjuvants	  used	  in	  the	  protocol,	  
to	   induce	   inflammation	  and	  autoreactivity	   in	  the	  CNS.	   	  The	  disease	  course	   is	  very	  short	  
and	  synchronous,	  unlike	  that	  of	  human	  MS,	  and	  it	  is	  unlikely	  that	  in	  this	  short	  window,	  all	  
of	   the	   important	  events	   in	  MS	  pathology	  take	  place.	   	  The	  resolution	  of	  disease	  signs	   in	  
many	   EAE	   protocols	   is	   a	   weakness	   in	   terms	   of	   relevance	   to	   a	   chronic	   long-­‐standing	  
human	   disease	   and	   is	  more	   reminiscent	   of	   an	   acute	   brain	   infection.	   	   A	  more	   relevant	  
model	  would	  therefore	  be	  spontaneous,	  having	  the	  disease	  initiate	  without	  the	  need	  for	  
large	   immune	   adjuvants	   to	   overwhelm	   the	   inbuilt	   regulatory	   mechanisms	   and	   so	  
introduce	   in-­‐built	  biases.	   	  TMEV	  has	  been	  regarded	   in	  some	  respects	  to	  fulfill	   this	  need	  
and	   be	  more	   accurate	   at	   predicting	   therapeutic	   potential	   than	   EAE	   (Nelson	   2004)	   but	  
until	   MS	   is	   proved	   to	   have	   a	   viral	   cause,	   the	   direct	   relevance	   of	   this	   model	   will	   be	  





The	   advantage	   of	   a	   humanized	   TCR	   transgenic	   mouse	   in	   this	   context	   would	   be	   that	  
findings	   in	   each	   HLA-­‐restricted	   epitope	   could	   be	   transferable	   to	   the	   human	   disease,	  
especially	  if	  the	  mouse	  also	  possessed	  both	  sides	  of	  the	  TCR-­‐MHC	  interaction.	  	  The	  Line7	  
mouse	   model	   fulfils	   these	   criteria,	   having	   a	   TCR	   from	   an	   MS-­‐derived	   T	   cell	   clone	  
(Ob1A12),	   seeing	   antigen	   presented	   by	   human	   HLA-­‐DR15,	   the	   strongest	   genetic	  
susceptibility	   locus	   implicated	   in	   caucasian	   disease	   and	   functionally	   implicated	   in	   the	  
causality	   of	   MS.	   	   This	   mouse	   model	   was	   recently	   adopted	   by	   the	   GlaxoSmithKline	  
Neuroscience	   institute	   in	   Shanghai	   as	   their	   key	   pre-­‐clinical	  model	   for	  MS	   research.	   	   In	  
previously	  published	  work,	  it	  has	  been	  shown	  that	  these	  mice	  are	  pathologically	  relevant	  
to	  human	  disease	  and	  exhibit	  epitope	  spread	  to	  other	  myelin	  antigens	  (Ellmerich	  2005).	  	  
The	  disease	  course	  shows	  a	  slow	  progression	  of	  disease	  signs	  across	  the	  life-­‐time	  of	  the	  
mice	  rather	  than	  one	  acute	  attack	  and	  does	  not	  present	  signs	  until	  around	  4	  months	  of	  
age.	   	   There	   is	   also	   a	   female	   propensity,	   as	   it	   is	   only	   male	   mice	   that	   can	   remain	  
unaffected,	   partially	   reflecting	   the	   situation	   in	   humans.	   	   The	   disease	   presentation	   and	  
subsequent	  progression	  of	  disease	  signs	  could	   therefore	  be	  a	  model	   for	   the	  underlying	  
neuropathology	  of	  RR-­‐MS	  patients,	  and	  in	  some	  cases	  show	  PP	  and	  SP	  disease	  courses.	  	  
Relapses	  are	  not	  seen	  in	  the	  same	  way	  as	  in	  human	  MS	  and	  although	  the	  mice	  do	  show	  
some	  variability	  day	   to	  day,	   it	   rarely	   shows	  up	   in	   the	  scoring	  protocol	  and	   they	  do	  not	  
obviously	  resolve	  in	  between	  attacks.	  	  Relapses	  have	  been	  reported	  to	  be	  associated	  with	  
T	  cell	  reactivity	  to	  new	  epitopes	  (McCarron	  1990)	  and	  also	  to	  the	  presence	  of	  anti-­‐MOG	  
antibodies	  from	  studies	  with	  RR-­‐EAE	  models	  (Amor	  1994,	  Zhang	  2004a,	  Pollinger	  2009).	  	  
The	  reactivity	  to	  new	  myelin	  epitopes	  offers	  an	  attractive	  hypothesis	  for	  development	  of	  





the	  different	  myelin	  epitopes	  used	  to	  initiate	  EAE	  (Greer	  2008).	  	  The	  lack	  of	  a	  consistent	  
region	   of	   the	   CNS	   being	   attacked	   could	   be	   responsible	   for	   the	   observed	   relapses	   and	  
would	   explain	   why	   relapses	   were	   not	   seen	   in	   Line7	  mice,	   as	   the	   immune	   response	   is	  
dominantly	   directed	   to	   MBP85-­‐99	   until	   later	   disease	   (Ellmerich	   2004).	   	   	   The	   use	   of	   a	  
combination	   of	   myelin	   epitopes	   (MOG	   and	   PLP)	   have	   been	   shown	   to	   be	   capable	   of	  
inducing	   RR-­‐EAE	   (Zhang	   2004a)	   so	   it	   would	   be	   attractive	   to	   hypothesise	   that	   the	  
incorporation	   of	   a	   second	   transgenic	   TCR	   into	   the	   Line7	   mice,	   or	   ability	   to	   speed	   up	  
epitope	   spread	   may	   lead	   to	   the	   development	   of	   relapses	   and	   transformation	   of	   the	  
chronic	  progressive	  model	  into	  one	  with	  a	  relapsing-­‐remitting	  profile.	  	  	  
The	   presence	   of	   MBP-­‐specific	   B	   cells	   and	   generation	   of	   antibodies	   have	   not	   been	  
investigated	   in	   the	   Line7	   model	   but	   would	   offer	   another	   explanation	   for	   the	   lack	   of	  
relapses	  observed.	   	   In	  a	  MOG	  transgenic	  mouse	  model,	  MOG	  specific	  B	  cells	  have	  been	  
shown	   to	   be	   responsible	   for	   development	   of	   spontaneous	   RR-­‐EAE	   and	   their	   removal	  
suppressed	  the	  development	  of	  RR-­‐EAE	  when	  started	  at	  a	  young	  age	  (Pollinger	  2009).	  	  B	  
cells	  can	  also	  work	  in	  the	  opposite	  direction,	  aiding	  Treg	  function	  and	  releasing	  IL-­‐10	  to	  
limit	   inflammation	   (Fillatreau	  2002,	  Mann	  2007).	   	  An	  autoreactive	  polarization	  of	   the	  B	  
cells	  in	  the	  Line7	  mice	  would	  offer	  a	  simple	  hypothesis	  for	  the	  progressive	  disease	  seen	  
although	  whether	  this	  is	  the	  case	  will	  only	  be	  borne	  out	  by	  further	  experiments.	  	  	  
	  
These	  progressive	  signs	  of	  disease	  however	  allow	  a	  great	  advantage	  not	  present	  in	  other	  
EAE	  models,	  that	  of	  the	  availability	  and	  consistency	  of	  samples	  across	  the	  development	  
of	   disease.	   	   Samples	   can	   be	   taken	   before	   and	   during	   disease	   development,	   at	   all	   the	  





than	  simply	  which	  ones	  are	  there	  at	  the	  peak	  of	  disease	  as	  observed	  from	  EAE	  studies	  or	  
post-­‐mortem	  human	  tissue.	  	  T	  cells	  have	  been	  shown	  to	  be	  present	  in	  the	  CNS	  of	  normal	  
mice	   (Brabb	   2000)	   and	   they	   can	   be	   extracted	   from	  pre-­‐disease	   presenting	   Line7	  mice,	  
allowing	  a	  baseline	  to	  be	  determined.	  	  	  
The	  Line7	  model	  overcomes	  some	  of	  the	   limitations	  presented	  by	  other	  TCR	  transgenic	  
mice	   and	   reduces	   the	   gap	   between	   animal	   models	   (EAE)	   and	   MS.	   	   Other	   humanized	  
mouse	  models	   have	  been	  developed	  using	   the	   same	  TCR-­‐MHC	   restriction	   as	   the	   Line7	  
(Madsen	  1999)	  but	   in	   this	   case,	   the	  TCR	   repertoire	  was	   close	   to	  normal	   and	  very	   little	  
spontaneous	  disease	  was	  observed.	   	  These	  mice	  more	  closely	   resemble	   the	  Line8	  mice	  
(Ellmerich	  2004),	  a	  sister	  line	  of	  the	  Line7s.	  	  The	  higher	  proportion	  of	  TCR+CD4+	  T	  cells	  in	  
the	   Line7	   allows	   spontaneous	   disease	   to	   progress	   without	   the	   need	   for	   adjuvants,	  
crossing	   onto	   a	   RAG-­‐/-­‐	   background	   or	   limiting	   the	   B	   cell	   repertoire	   (Bettelli	   2006a).	  	  
Limitations	   in	   obtaining	   funding	   for	   large	   numbers	   of	   new	   transgenic	   lines	   and	   the	  
tendency,	   once	   a	  model	   is	   published	   and	   accepted	   to	   share	   it	   between	   labs	   as	   a	   ‘safe	  
option’	   can	   have	   the	   effect	   that	   inferences	   from	   individual	   models	   are	   given	  
disproportionate	   weight	   in	   extrapolations	   to	   human	   disease.	   	   There	   should	   be	  
consideration	   of	   many	   models	   alongside	   recognition	   of	   the	   limitations	   of	   each	   when	  
developing	  ideas	  and	  theories	  about	  human	  conditions	  from	  animal	  models.	  	  Only	  a	  small	  
number	  of	  mouse	  and	  human	  TCRs	  relevant	  to	  MS	  or	  EAE	  have	  thus	  far	  been	  explored	  in	  
transgenic	  models;	   even	   this	   small	   number	  offers	   clues	   that	   a	  wider	   application	  of	   the	  
approach	  might	  help	  to	  illuminate	  the	  enormous	  diversity	  of	  symptoms,	  CNS	  localization,	  
PNS	  involvement	  and	  severity	  seen	  in	  the	  human	  disease.	  	  For	  example,	  a	  TCR	  transgenic	  





unpredicted	   optic	   neuritis	   pattern	   that	   had	   not	   been	   seen	   in	   other	   TCR	   transgenics	  
(Bettelli	   2003).	   	  Wider	   application	   of	   this	   approach	   to	   explore	   the	   specific	   pathogenic	  
correlates	  of	  TCRs	  against	  commonly	  identified	  HLA/peptide	  combinations	  in	  human	  MS	  
patients	  may	  thus	  be	  beneficial.	  	  	  
	  
13.2 More	  complicated	  picture	  than	  Th17?	  
EAE	   has	   highlighted	   a	   role	   for	   Th17	   in	   mediating	   autoimmune	   attacks.	   	   However,	  
evidence	  from	  the	  Line7	  model	  challenges	  that	  assumption	  and	  prompts	  questions	  to	  be	  
asked	  about	  whether	   the	  results	  generated	  were	  true	  representations	  of	  MS,	  or	   rather	  
artifacts	  of	  the	  model	  itself.	  	  Adjuvants	  (CFA	  and	  pertussis	  toxin)	  in	  the	  EAE	  immunisation	  
protocol	   introduce	   biases;	  Mycobacterium	   tuberculosis,	   present	   in	   CFA,	   and	   pertussis	  
toxin	  have	  been	  shown	  to	  stimulate	  IL-­‐17	  release	  (Veldhoen	  2006a,	  Chen	  2007)	  providing	  
a	  compelling	  argument	  that	  the	  propensity	  of	  Th17	  cells	  is	  a	  result	  of	  polarization	  by	  the	  
immunization	  protocol.	  	  Whilst	  the	  intention	  is	  not	  to	  challenge	  the	  involvement	  of	  Th17	  
cells	  in	  EAE,	  the	  relevance	  of	  findings	  in	  EAE	  to	  MS	  should	  not	  be	  assumed.	  	  In	  addition,	  
the	  ability	  to	  generate	  pure	  T	  cell	  polarised	  cultures	   for	  the	  adoptive	  transfer	  model	  of	  
EAE	   is	   always	   questioned	   (O'Connor	   2008,	   Jager	   2009),	   and	   the	  presence	  of	   a	   residual	  
negative	  cytokine-­‐expressing	  population	  leaves	  the	  door	  open	  for	  arguments.	  	  	  
The	  spontaneous	  nature	  of	  the	  Line7	  model	  allows	  investigation	  of	  disease	  without	  these	  
introduced	  biases,	  with	  no	  T	  helper	  subset	  favoured	  by	  the	  method	  of	  disease	  induction.	  	  
The	   TCR	   is	   in	   vitro	   Th0,	   with	   both	   IFNγ	   and	   IL-­‐4	   produced	   in	   response	   to	   MBP85-­‐99	  
(Ellmerich	   2004).	   	   The	   MS-­‐derived	   TCR	   and	   immunogenetically	   human	   status	   of	   the	  





demonstration	  that	  Th17	  cells	  are	  not	  important	  in	  early	  stages	  of	  disease	  should	  restrain	  
unabated	   enthusiasm	   for	   the	   importance	   of	   Th17	   cells	   in	   human	   disease.	   	   Findings	  
regarding	   the	  encephalitogenicity	  of	  T-­‐bet-­‐expressing	  cells	  are	   reaffirmed	   (Gocke	  2007,	  
Yang	  2009b),	  and	  noticeably,	  the	  source	  of	  pro-­‐inflammatory	  cytokine	  is	  not	  restricted	  to	  
the	  CD4+	  T	  cells.	  	  CD8+	  T	  cells	  are	  seen	  in	  MS	  lesions	  (Babbe	  2000,	  Junker	  2007)	  and	  their	  
presence	   in	   Line7,	   despite	   the	   model	   being	   an	   HLA	   class	   II	   transgenic,	   underline	   the	  
importance	  of	  these	  often	  overlooked	  cells	  in	  neuropathology.	  	  Whether	  these	  cells	  are	  
protective	   or	   pathogenic	   is	   not	   clear	   from	   this	   work	   and	   would	   require	   further	  
investigation.	  	  
Immunologists	   have	   dug	   themselves	   into	   a	   corner	   with	   their	   over-­‐classification	   of	  
immune	  cells.	   	  The	   largest	  example	  of	  this	   is	   in	  the	  division	  of	  helper	  T	  cells	  where	  the	  
consideration	  of	  which	  cells	  are	   important	   in	  autoimmunity	  overshadows	  consideration	  
of	   the	   factors	   that	   are	  mediating	   the	   damage	   observed.	   	   Experiments	   are	   interpreted	  
with	   the	  view	  that	  T	  cell	  polarization	   is	   crucial	   to	   their	   function,	  and	  plasticity	   is	  a	   side	  
effect,	  characteristic	  of	  certain	  helper	  cell	  commitments.	  	  An	  ideal	  immune	  system	  would	  
be	  one	  that	  could	  react	  to	  unexpected	   insults	  and	  so	  terminally	  polarized	  T	  cells	  would	  
not	  be	  an	  advantage	  to	  such	  a	  system.	  	  	  	  	  
The	  classification	  criteria	  has	  led	  to	  studies	  being	  considered	  contradictory	  to	  each	  other	  
whereas	   the	   focus	  of	  each	  study	  may	  have	  been	  misdirected	  at	   factors	  unimportant	   in	  
development	  of	  autoimmunity	   instead	  of	   those	  more	  relevant.	   	  An	  example	  of	   this	   is	  a	  
recent	  paper	  by	  Hirota	  et	  al	  (Hirota	  2011).	  	  In	  this	  the	  production	  of	  IL-­‐17	  caused	  T	  cells	  
to	   express	   YFP	   for	   their	   lifespan	   and	   allowed	   tracking	   of	   ‘ex-­‐Th17’	   cells.	   	   The	  





important	   than	   the	  observation	   that	   IFNγ	  was	   the	  dominant	   cytokine	  expressed	   in	   the	  
inflamed	  organ.	  	  The	  importance	  of	  plasticity	  of	  helper	  T	  cells	  was	  given	  more	  emphasis	  
to	  the	  detriment	  of	  the	  T	  cell	  function	  in	  the	  autoimmune	  context.	  	  IL-­‐23	  was	  also	  shown	  
to	   promote	   T-­‐bet,	   a	   finding	   which	   in	   the	   guise	   of	   Th1	   and	   Th17	   classification	   adds	  
confusion.	  	  This	  was	  interpreted	  as	  further	  support	  for	  the	  role	  of	  the	  Th17	  phenotype	  in	  
autoimmunity,	  but	  this	  is	  simply	  one	  of	  many	  interpretations.	  	  T-­‐bet	  has	  been	  shown	  to	  
define	  the	  encephalitogenicity	  of	  T	  cells	  in	  other	  studies	  and	  IL-­‐23	  KO	  mice	  are	  resistant	  
to	  EAE,	  meaning	  these	  results	  go	  some	  way	  to	  explaining	  the	  seminal	  experiments	  of	  Cua	  
et	  al	  in	  2003	  (Cua	  2003)	  without	  the	  requirement	  to	  exclude	  an	  important	  role	  for	  IFNγ.	  	  
It	  could	  be	  argued	  that	  factors	  assigned	  to	  Th1	  and	  Th17	  cells	  play	  a	  role	  in	  autoimmunity	  
together,	  and	  such	  a	  hypothesis	  would	  be	  supported	  by	  observations	  in	  Line7	  mice.	  	  The	  
importance	   of	   T-­‐bet	   and	   IFNγ	   in	   development	   of	   autoimmunity	   are	   seen	   in	   the	   Line7	  
model	  as	  well	  as	  the	  study	  by	  Hirota	  et	  al.	  	  Therefore	  whilst	  classification	  is	  a	  useful	  tool	  
to	  compare	  results	  and	  further	  our	  understanding,	  it	  can	  be	  adding	  layers	  of	  complexity	  
and	   preconceptions	   that	   hinder	   accurate	   consideration	   of	   which	   factors	   are	   the	  most	  
important	  in	  a	  given	  context.	  	  	  
	  
13.3 Controlling	  role	  for	  Tregs	  
Whilst	  Th1	  cells	  appear	  to	  be	   involved	   in	  the	   initiation	  of	  neuroinflammation,	   the	  most	  
valuable	   observation	   is	   with	   regard	   to	   the	   importance	   of	   Tregs.	   	   EAE	   studies	   have	  
demonstrated	  autoimmunity	  progressing	  because	  of	  impairments	  in	  regulation,	  linked	  to	  





that	  Tregs	  are	  functional	  and	  autoimmunity	  can	  progress	  despite	  this	  regulation.	  	  This	  is	  
more	   in	   keeping	   with	   the	   human	   condition,	   as	   MS	   patients	   do	   not	   suffer	   systemic	  
autoimmune	   attacks	   in	   much	   the	   same	   way	   as	   patients	   with	   immunodysregulation	  
polyendocrinopathy	   enteropathy	   X-­‐linked	   syndrome	   (IPEX)	   and	   neurodegeneration	  
occurs	   progressively	   over	   long	  periods	  of	   time	   in	  most	   cases.	   	   In	   fact	   Tregs	   have	  been	  
shown	   to	   have	   normal	   suppressive	   function	   and	   Foxp3	   expression	   in	   secondary	  
progressive	  MS	  as	  compared	  to	  RR-­‐MS	  (Venken	  2006).	  
Origins	  for	  the	  results	  from	  EAE	  can	  be	  derived	  from	  the	  use	  of	  pertussis	  toxin	  in	  the	  EAE	  
protocol.	   	   Pertussis	   toxin	   acts	   to	   inhibit	   Tregs	   (Cassan	   2006,	   Chen	   2006)	   alongside	  
increasing	  the	  permeability	  of	  the	  BBB	  (Brabb	  1997)	  although	  the	  BBB	  permeability	  could	  
be	   derived	   from	   the	   Treg	   inhibition	   as	   demonstrated	   in	   the	   L7Fox	   Treg	   depletion	  
experiments.	  	  	  
The	  significant	  role	  for	  Tregs	  demonstrated	  in	  this	  work	  highlights	  a	  limitation	  of	  EAE	  for	  
studying	   regulation	   of	   autoimmunity.	   	   In	   EAE	   models,	   regulatory	   pathways	   are	  
overwhelmed	   in	   the	   induction	   protocol,	   rendering	   investigation	   of	   Treg	   dynamics	  
difficult.	   	  Roles	  for	  Tregs	  have	  been	  reserved	  for	  the	  recovery	  phase	  of	  EAE	  where	  they	  
have	  been	   shown	   to	  be	   capable	   to	   suppress	  MOG-­‐specific	   T	   cells	   and	   in	   their	   absence	  
recovery	  is	  prevented	  (McGeachy	  2005).	  	  	  
Tregs	   are	   present	   in	   abundance	   under	   normal	   circumstances	   and	   are	   very	   effective	   at	  
suppressing	  activated	  T	  cells.	  	  This	  model	  demonstrates	  that	  autoimmunity	  can	  progress	  
despite	   tight	   regulation	   and	   autoreactive	   T	   cells	   can	   slowly	   accumulate	   and	   function	  
under	   such	   circumstances.	   	   The	   slow	   rate	   of	   progression	   through	   autoimmunity	   is	   a	  





This	  is	  why	  when	  they	  are	  removed	  such	  large-­‐scale	  devastation	  in	  the	  CNS	  is	  observed.	  	  
Function	  is	  retained	  throughout	  the	  progression	  of	  autoimmunity	  in	  contrast	  to	  findings	  
in	   EAE,	   but	   likely	   more	   representative	   of	   MS	   where	   the	   disease	   is	   not	   a	   large-­‐scale	  
impairment	   of	   regulation	   but	   a	   continuous	   battle	   to	   regain	   control	   over	   cells	   whose	  
function	  is	  detrimental	  to	  the	  whole	  organism.	  	  	  
	  
The	   chronic	   progression	   of	   symptoms	   in	   the	   Line7	   allows	   study	   of	   competent	   Treg	  
responses	   rather	   than	   observing	   autoimmunity	   resulting	   from	   Treg	   impairment.	   	   It	  
supports	  the	  idea	  that	  development	  of	  MS	  is	  associated	  with	  a	  breakdown	  in	  regulation	  
allowing	   the	   initial	   attack	   and	   explains	   why	   there	   is	   an	   observable	   incomplete	  
concordance	   rate	   in	   monozygotic	   twins	   (Ebers	   1986,	   Dyment	   2004a).	   	   Environmental	  
factors	  play	  an	  important	  role	   in	  the	  development	  of	  MS,	  but	  most	   likely	   in	  modulating	  
the	  ability	  of	  Tregs	   to	   limit	  activation	  and	   infiltration	  of	  autoreactive	  cells.	   	  Many	  small	  
factors	  could	  influence	  the	  functionality	  of	  Tregs	  throughout	  a	  patient’s	  life.	  	  In	  this	  way,	  
temporary	   breakdowns	   in	   regulation	   could	   lead	   to	   relapses,	  with	   remission	   associated	  
with	   recovery	  of	   Treg	   functionality.	   	   Breakdowns	   in	   regulation	  would	   lead	   to	  boosts	   in	  
pro-­‐inflammatory	   cytokine	   production,	   and	   enhancement	   of	   IFNγ	   alone	   has	   been	  
associated	  with	   relapses	   in	  MS	  patients	   (Frisullo	  2008).	   	   In	   the	  Line7	  model	   the	   lack	  of	  
relapses	  could	  be	  explained	  by	  the	  consistently	  high	  level	  of	  IFNγ	  transcription,	  indicative	  
perhaps	  of	  the	  presence	  of	  a	  constant	  relapse.	  	  	  
Breakdowns	   in	  regulation	  may	  be	  mediated	  through	  environmental	   insults	   that	  may	  be	  
detected	   through	   TLR	   ligation.	   	   TLRs	   are	   present	   on	  many	   cells	   including	   Tregs	   and	   so	  





regulation.	  	  TLR	  ligation	  has	  been	  shown	  to	  both	  promote	  and	  suppress	  Treg	  function,	  for	  
example	   in	  the	  presence	  of	  a	  TLR2	  agonist,	  Treg	  numbers	  expand	  but	  their	  suppressive	  
function	   is	   temporarily	  abrogated	   (Liu	  2006a)	  but	  Tregs	  could	  be	  activated	  through	  the	  
administration	  of	  lipopolysaccharide,	  a	  TLR4	  ligand	  (Caramalho	  2003).	  	  The	  focus	  of	  this	  
study	  is	  not	  to	  ascertain	  a	  specific	  factor	  responsible	  for	  temporary	  Treg	  impairment	  but	  
it	   is	  not	  beyond	  comprehension	   that	   such	  a	   factor	  or	  combination	  of	   factors	  may	  have	  
influenced	  Treg	  cells	  in	  an	  MS	  patient	  and	  promoted	  the	  initial	  autoimmune	  attack.	  	  	  
Exposure	  to	  TLR	  ligands	  could	  in	  this	  way	  impair	  Tregs	  so	  that	  an	  opportunity	  would	  arise	  
for	   autoreactive	   cells	   to	   infiltrate	   the	   CNS	   leading	   to	   the	   development	   of	   MS.	  	  
Extrapolating	   this	   hypothesis,	   subsequent	   spikes	   in	   autoreactive	   T	   cell	   activity	  
corresponding	  with	  temporary	  hindrance	  of	  Tregs	  could	  manifest	  themselves	  as	  relapses	  
but	  further	  extensive	  research	  would	  be	  required	  to	  test	  this	  theory.	  
The	  percentage	  of	  mice	  not	  developing	  symptoms	  is	  reminiscent	  of	  non-­‐concordant	  MS	  
monozygotic	   twins.	   	   	   Studying	   these	   provides	   an	   invaluable	   comparison	   to	   affected	  
animals	   that	   is	   lacking	   from	   EAE	   research.	   	   The	   resistance	   of	   these	  mice	   to	   allow	   CNS	  
infiltration	   and	   development	   of	   autoimmunity	   despite	   being	   highly	   susceptible	  
demonstrates	  that	  a	  breakdown	  in	  regulation	  is	  likely	  to	  be	  the	  important	  factor	  leading	  
to	   the	   initiation	   of	   autoimmunity.	   	   Diversity	   of	   Treg	   function	  was	   demonstrated	   upon	  
their	  depletion	  when	  production	  of	  pro-­‐inflammatory	  cytokines	  was	  increased	  from	  CD8	  
cells.	   	  The	   increase	   in	  activation	  and	   infiltration	  of	  CD8+	  T	  cells	   in	   the	  absence	  of	  Tregs	  
suggests	   a	   mechanism	   for	   their	   involvement	   and	   identification	   in	   MS	   lesions	   in	  
association	  not	  contradiction	  to	  those	  mechanisms	  implicating	  CD4+	  T	  cells.	  	  Impairments	  





regulation	   as	   the	   key	   step	   to	   prevention	   of	   autoimmunity.	   	   This	   idea	   could	   be	   further	  
extended	   as	   NK	   cell	   activation,	   as	  measured	   by	   pro-­‐inflammatory	   cytokine	   production	  
was	   increased	  upon	  Treg	  depletion,	  although	   infiltration	  was	  unaffected.	   	  An	  additional	  
role	   for	   Tregs	   at	   controlling	   inflammation	   in	   the	   local	   environment	   broadens	   the	  
importance	  of	  these	  cells	  in	  managing	  autoimmune	  progression.	  	  More	  detailed	  analysis	  
of	   the	   regulatory	   cells	   derived	   from	   these	   mice	   would	   demonstrate	   how	   these	   mice	  
retain	   functional	   regulation	  over	   the	  wide	   range	  of	   immune	   cells,	   highlighting	   possible	  
avenues	   for	   therapies.	   	   It	   would	   be	   an	   interesting	   experiment	   to	   see	   if	   autoimmunity	  
could	  be	  prevented	  by	  boosting	  Treg	  cells	   in	  early	  age.	   	   It	  could	  be	  as	  simple	  as	  regular	  
administration	  of	   recombinant	   IL-­‐2	   to	  boost	   Treg	  populations	  and	  allow	   the	   regulatory	  
pathways	   to	  prevent	  autoreactivity	   rather	   than	  targeting	  one	  distinct	  pro-­‐inflammatory	  
cytokine	  in	  the	  myriad	  of	  redundant	  pathways.	  	  
	  
13.4 Future	  use	  of	  Line7	  
The	  spontaneous	  nature	  of	  disease	   in	  Line7	  mice	  makes	   it	  a	  perfect	  model	   in	  which	   to	  
test	   therapeutics.	   	   The	   immune	   system	  of	   the	  mice	   is	   not	   influenced	  by	   any	   adjuvants	  
and	   the	  disease	   is	  a	   slow	  progression,	  more	   in	  keeping	  with	   the	  human	  condition	   than	  
acute	   EAE	  models.	   	   It	   has	   previously	   been	   shown	   to	   be	   pathologically	   relevant	   to	  MS	  
(Ellmerich	  2005)	  and	  dosing	  regimes	  could	  be	  tailored	  to	  mimic	  those	  expected	  when	  the	  
therapy	   is	   trialed	   in	   patients.	   	   Therapeutic	   copolymers	   have	   been	   trialed	   in	   the	   sister	  
Line8	  mice	  previously	  with	   success	   (Illes	  2004)	  and	   further	   similar	   studies	  are	  ongoing.	  	  
Doses	   could	  be	   given	  over	   long	  periods	  of	   time	  and	  once	  disease	   is	   established	   rather	  





predicting	  therapeutic	  potential	  in	  MS	  treatment	  highlight	  the	  need	  for	  a	  better	  model	  in	  
with	  to	  test	  long-­‐term	  exposure	  to	  drugs	  (Steinman	  2005b).	  	  The	  mechanistic	  differences	  
between	   Line7	   and	   EAE	   in	   initiation	   of	   disease	   also	   open	   the	   door	   to	   a	   new	   range	   of	  
potential	  therapeutic	  targets	  for	  MS,	  and	  offer	  possible	  explanations	  for	  the	  contrasting	  
efficacies	  of	  treatments	  seen	  between	  EAE	  and	  MS.	  	  	  
However,	  the	  limitation	  of	  the	  Line7	  lies	  in	  its	  genetic	  specificity.	  	  Whilst	  DR15	  shows	  the	  
largest	   association	   of	   any	   gene	   with	   MS,	   evidence	   of	   epitope	   spread	   in	   MS	   and	   no	  
consensus	   antigen	   for	   every	   clinical	   profile	  make	   the	   consideration	   of	   different	  myelin	  
epitopes	   a	  high	  priority.	   	   The	   generation	  of	   similar	  models	  with	  other	  MS	  derived	  TCR	  
clones	  specific	  for	  other	  myelin	  epitopes	  and	  their	  cognate	  HLA	  class	  II	  alleles	  should	  be	  
explored.	  	  	  Comparison	  of	  the	  clinical	  profile	  and	  immunological	  dynamics	  of	  such	  models	  
would	   inform	   whether	   mechanisms	   are	   TCR-­‐dependent	   as	   this	   could	   provide	   one	  
explanation	   for	   the	   high	   prevalence	   of	   Th17	   cells	   seen	   in	   the	   MOG35-­‐55	   EAE	   models	  
relative	  to	  the	  seemingly	  Th1	  dominated	  MBP85-­‐99	  associated	  autoimmunity.	  	  
Findings	  in	  single	  models	  of	  disease	  should	  always	  be	  treated	  with	  caution.	  	  The	  tendency	  
to	   overvalue	   findings	   in	   one	   model	   over	   another	   does	   not	   further	   our	   knowledge	  
regarding	  the	  human	  conditions.	  	  Sometimes	  it	  appears	  as	  if	  this	  final	  aim	  of	  animal	  work	  
is	   lost,	  with	  model	   selection	  based	  upon	   the	   likelihood	  of	   generating	   successful	   results	  
and	  in	  whichever	  model	  is	  currently	  fashionable.	  	  The	  importance	  of	  cellular	  subsets	  can	  
be	  overstated	  leading	  to	  wasted	  money	  and	  time	  in	  clinical	  trials.	  	  	  Improving	  the	  life	  of	  
patients	   through	   development	   of	   effective	   treatments	   should	   be	   the	   ultimate	   aim	   of	  
most	  disease	  related	  research	  and	  in	  this	  vein,	  the	  Line7	  model	  and	  findings	  in	  it	  should	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